

## Colorectal cancer (update)

[C3] Optimal surgical technique for rectal cancer

*NICE guideline NG151*

*Evidence reviews*

*January 2020*

*Final*

*Developed by the National Guideline  
Alliance part of the Royal College of  
Obstetricians and Gynaecologists*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2020. All rights reserved. Subject to Notice of rights.

ISBN: 978-1-4731-3657-1

# Contents

<b>Contents</b> .....	<b>4</b>
<b>Optimal surgical technique for rectal cancer</b> .....	<b>6</b>
Review question .....	6
Introduction .....	6
Summary of the protocol .....	6
Methods and process .....	7
Clinical evidence .....	7
Summary of clinical studies included in the evidence review .....	8
Quality assessment of clinical studies included in the evidence review .....	15
Economic evidence .....	15
Economic model.....	15
Evidence statements .....	19
The committee’s discussion of the evidence.....	26
References.....	29
<b>Appendices</b> .....	<b>34</b>
<b>Appendix A – Review protocols</b> .....	<b>34</b>
Review protocol for review question: What is the optimal surgical technique for rectal cancer? .....	34
<b>Appendix B – Literature search strategies</b> .....	<b>38</b>
Literature search strategies for review question: What is the optimal surgery for rectal cancer? .....	38
<b>Appendix C – Clinical evidence study selection</b> .....	<b>41</b>
Clinical study selection for review question: What is the optimal surgery for rectal cancer? .....	41
<b>Appendix D – Clinical evidence tables</b> .....	<b>42</b>
Clinical evidence tables for review question: What is the optimal surgery for rectal cancer? .....	42
<b>Appendix E – Forest plots</b> .....	<b>137</b>
Forest plots for review question: What is the optimal surgery for rectal cancer?	137
<b>Appendix F – GRADE tables</b> .....	<b>162</b>
GRADE tables for review question: What is the optimal surgery for rectal cancer? .....	162
<b>Appendix G – Economic evidence study selection</b> .....	<b>182</b>
Economic evidence study selection for review question: What is the optimal surgical technique for rectal cancer?.....	182
<b>Appendix H – Economic evidence tables</b> .....	<b>183</b>
Economic evidence study selection for review question: What is the optimal surgical technique for rectal cancer? .....	183
<b>Appendix I – Economic evidence profiles</b> .....	<b>184</b>

Economic evidence profiles for review question: What is the optimal surgical technique for rectal cancer? .....	184
<b>Appendix J – Economic analysis .....</b>	<b>185</b>
Economic evidence analysis for review question: What is the optimal surgical technique for rectal cancer? .....	185
<b>Appendix K – Excluded studies .....</b>	<b>199</b>
Excluded clinical studies for review question: What is the optimal surgical technique for rectal cancer? .....	199
<b>Appendix L – Research recommendations .....</b>	<b>226</b>
Research recommendations for review question: What is the optimal surgical technique for rectal cancer? .....	226

# 1 Optimal surgical technique for rectal 2 cancer

3 This evidence review supports recommendations 1.3.6 to 1.3.9.

## 4 Review question

5 What is the optimal surgical technique for rectal cancer?

## 6 Introduction

7 The NICE technology appraisal on laparoscopic surgery for colorectal cancer published in  
8 2006 covers colorectal cancer in general, with evidence largely based on mixed (colon and  
9 rectal cancer) populations or colon cancer populations. Over time, the clinical community has  
10 started to treat surgery for colon and rectal cancer as separate entities with rectal cancer  
11 surgery being considered more challenging. In the last couple of decades, laparoscopic  
12 surgery, a minimally invasive surgical technique, has become more and more common in  
13 rectal cancer surgery, offering an alternative to the conventional open surgical technique. In  
14 recent years manual laparoscopic surgery has been challenged by robotic surgery and  
15 transanal total mesorectal excision (TaTME) has been suggested as a surgical technique  
16 when performing anterior resection. The aim of this review is to compare the clinical and cost  
17 effectiveness of different surgical techniques in treating non-metastatic rectal cancer.

## 18 Summary of the protocol

19 Please see Table 1 for a summary of the population, intervention, comparison and outcomes  
20 (PICO) characteristics of this review.

21 **Table 1: Summary of the protocol (PICO) table**

<b>Population</b>	Adults with non-metastatic rectal cancer <ul style="list-style-type: none"><li>• T1-2 N1-2</li><li>• T3 N any</li><li>• T4 N any</li><li>• M0</li></ul>
<b>Intervention</b>	Surgical resection (for example abdominoperineal resection [APR] or low anterior resection [LAR]) <ul style="list-style-type: none"><li>• Open</li><li>• Laparoscopic</li><li>• Robotic</li><li>• Transanal total mesorectal excision (TaTME; only anterior resection)</li></ul>
<b>Comparison</b>	Surgical techniques compared to each other
<b>Outcomes</b>	<b>Critical</b> <ul style="list-style-type: none"><li>• Overall survival</li><li>• Quality of life<ul style="list-style-type: none"><li>○ Overall</li><li>○ Sexual function</li><li>○ Bladder function</li></ul></li><li>• Resection margins</li></ul> <b>Important</b> <ul style="list-style-type: none"><li>• Local recurrence</li></ul>

- Length of hospital stay
- 90-day mortality
- Treatment-related complications:
  - Anastomotic leak (only relevant in anterior resection)
  - Surgical site infection
  - Blood loss

1 *APR: abdominoperineal resection; LAR: lower anterior resection; TNM: cancer classification system, standing for*  
2 *tumour, nodal and metastasis stages.*

3 For further details see the review protocol in appendix A.

## 4 **Methods and process**

5 This evidence review was developed using the methods and process described in  
6 [Developing NICE guidelines: the manual 2014](#). Methods specific to this review question are  
7 described in the review protocol in appendix A.

8 Declarations of interest were recorded according to NICE's 2014 conflicts of interest policy  
9 until 31 March 2018. From 1 April 2018, declarations of interest were recorded according to  
10 NICE's 2018 [conflicts of interest policy](#). Those interests declared until April 2018 were  
11 reclassified according to NICE's 2018 conflicts of interest policy (see Register of Interests).

## 12 **Clinical evidence**

### 13 **Included studies**

14 Thirty-nine publications from 19 RCTs and 9 cohort studies were included in this review  
15 (ACOSOG Z6051 trial [Fleshman 2015; Fleshman 2018]; ALaCaRT trial [Stevenson 2015;  
16 Stevenson 2018]; Arteaga Gonzalez 2006; Baik 2008; Bordeaux trial [Denost 2018;  
17 Pontallier 2016]; Braga 2007; Buonpane 2017; CLASICC trial [Green 2013; Guillou 2005;  
18 Jayne 2005; Jayne 2010; Quah 2002]; COLOR II trial [Andersson 2014; Andersson 2013;  
19 Bonjer 2015; van der Pas 2013]; Corbellini 2016; COREAN trial [Jeong 2014; Kang 2010];  
20 Ielpo 2017; Ishibe 2017; Kim 2016; Kim 2017a; Kim 2017b; Law 2017; Liang 2011; Lujan  
21 2011; Ng 2008; Ng 2009; Ng 2014; Park 2015; ROLARR trial [Jayne 2017]; Rouanet 2018;  
22 Wang 2017; Yoo 2015; Zhou 2004).

23 The included studies are summarised in Table 2.

24 Fourteen RCTs (24 publications) compared laparoscopic surgery to open surgery in people  
25 with rectal cancer (comparison 1) (ACOSOG Z6051 trial [Fleshman 2015; Fleshman 2018];  
26 ALaCaRT trial [Stevenson 2015; Stevenson 2018]; Arteaga Gonzalez 2006; Braga 2007;  
27 CLASICC trial [Green 2013; Guillou 2005; Jayne 2005; Jayne 2010; Quah 2002]; COLOR II  
28 trial [Andersson 2014; Andersson 2013; Bonjer 2015; van der Pas 2013]; COREAN trial  
29 [Jeong 2014; Kang 2010]; Ishibe 2017; Liang 2011; Lujan 2011; Ng 2008; Ng 2009; Ng 2014;  
30 Zhou 2004)).

31 Three cohort studies compared robotic surgery to open surgery in people with rectal cancer  
32 (comparison 2) (Buonpane 2017; Corbellini 2016; Kim 2016).

33 Four RCTs and 8 cohort studies compared robotic surgery to laparoscopic surgery in people  
34 with rectal cancer (comparison 3) (Baik 2008; Corbellini 2016; Ielpo 2017; Kim 2016; Kim  
35 2017a; Kim 2017b; Law 2017; Park 2015; ROLARR trial [Jayne 2017]; Rouanet 2018; Wang  
36 2017; Yoo 2015).

37 One RCT (3 publications) compared TaTME to laparoscopic anterior resection in people with  
38 rectal cancer (comparison 4) (Bordeaux' trial [Denost 2017; Denost 2018; Pontallier 2016]).

39 See the literature search strategy in appendix B and study selection flow chart in appendix C.

1

2 **Excluded studies**

3 Studies not included in this review with reasons for their exclusions are provided in appendix  
4 K.

5 **Summary of clinical studies included in the evidence review**

6 Summaries of the studies that were included in this review are presented in Table 2.

7 **Table 2: Summary of included studies**

Study	Population	Intervention/Comparison	Outcomes
<b>Comparison 1: Laparoscopic versus open surgery</b>			
ACOSOG Z6051 trial  (Fleshman 2015; Fleshman 2018)  RCT  USA	N=486  Adenocarcinoma of the rectum within 12 cm of the anal verge; clinical stage II, IIA, or IIB; ≥18 years of age; BMI <34; ECOG performance score <3	Everyone received preoperative therapy.  Laparoscopic surgery included 17% hand-assisted laparoscopic surgery and 14% robot-assisted laparoscopic surgery.  ~75-80% LAR ~20-25% APR	<ul style="list-style-type: none"> <li>• Positive resection margins</li> <li>• Local or locoregional recurrence</li> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Anastomotic leak</li> <li>• Blood loss</li> </ul>
ALaCaRT trial  (Stevenson 2015; Stevenson 2018)  RCT  Australia	N=475  Adenocarcinoma of the rectum within 15 cm of the anal verge; ≥18 years of age; life expectancy of >12 weeks; adequate performance status; no comorbidity or condition that would preclude the use of either form of surgery	~50% received preoperative radiotherapy  ~90% LAR ~10% APR	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Positive resection margins</li> <li>• Local or locoregional recurrence</li> </ul>
Arteaga Gonzalez 2006  RCT  Spain	N=40  Rectal carcinoma <15 cm from the anal verge  ~25% TNM stage I	Preoperative radiotherapy: T3 or T4 middle and lower third tumours or mesorectal adenopathy without distant metastases  ~50% LAR ~25% APR ~25% Hartmann	<ul style="list-style-type: none"> <li>• Positive resection margins</li> <li>• Length of hospital stay</li> <li>• Anastomotic leak</li> <li>• Blood loss</li> </ul>
Braga 2007  RCT  Italy	N=168  Adenocarcinoma of the rectum; ≥18 years of age; suitable for elective surgery	Preoperative chemoradiotherapy: preoperative T3 cancers  ~90% LAR	<ul style="list-style-type: none"> <li>• Positive resection margins</li> <li>• Local or locoregional recurrence</li> </ul>



Study	Population	Intervention/Comparison	Outcomes
	~30% Duke's stage I	~10% APR	<ul style="list-style-type: none"> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Anastomotic leak</li> <li>• Surgical site infection</li> <li>• Blood loss</li> </ul>
CLASICC trial  (Green 2013; Guillou 2005; Jayne 2005; Jayne 2010; Quah 2002)  RCT  UK	N=381  Rectal or colon cancer suitable for right melicectomy, left hemicolectomy, sigmoid colectomy, anterior resection, or abdominoperineal resection  (only data on people with rectal cancer were considered for this review)  Proportion of the population with T1-2N0M0 cancer (exact proportion not clear)	Not clear how many received preoperative therapy.  ~65% AR ~25% APR ~10% other  4% of laparoscopic surgery and 17% of open surgery was palliative surgery	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Quality of life</li> <li>• Positive resection margins</li> <li>• Operative mortality</li> <li>• Surgical site infection</li> </ul>
COLOR II trial  (Andersson 2013; Andersson 2014; Bonjer 2015; van der Pas 2013)  RCT  Belgium, Canada, Denmark, Germany, the Netherlands, Poland, South Korea, Spain, Sweden	N=1,103  A single rectal cancer within 15 cm of the anal verge; no evidence of distant metastases; candidate for elective surgery  ~30% clinical stage I	Preoperative radiotherapy: ~60% Preoperative chemotherapy: ~30%  ~60% resection with TME ~10% resection with partial mesorectal excision ~25% APR ~5% Hartmann	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Quality of life</li> <li>• Positive resection margins</li> <li>• Local or locoregional recurrence</li> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Anastomotic leak</li> <li>• Surgical site infection</li> </ul>
COREAN trial  (Jeong 2014; Kang 2010)  RCT  South Korea	N=340  Mid- or low-rectal cancer; T3N0-2M0; previous preoperative chemoradiotherapy; 18-80 years of age	Everyone received preoperative chemoradiotherapy.  ~85-90% LAR ~10-15% APR	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Positive resection margins</li> <li>• Local or locoregional recurrence</li> <li>• Operative mortality</li> <li>• Anastomotic leak</li> </ul>

Study	Population	Intervention/Comparison	Outcomes
Ishibe 2017  RCT  Japan	N=58  Colorectal adenocarcinoma; ≥75 years of age; clinical stage of up to T4a tumours; any N stage; no evidence of metastasis; elective surgery (only data on people with rectal cancer was considered for this review)  Note that this study was among people 75 years or older.	No one received preoperative therapy.  ~65% LAR ~20% high AR ~10% APR	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Local or locoregional recurrence</li> </ul>
Liang 2011  RCT  China	N=343  Rectal cancer; without lung or liver metastases; BMI ≤30; no preoperative therapy  ~5% T1-2N0M0	No one received preoperative therapy.  ~50% LAR ~50% APR	<ul style="list-style-type: none"> <li>• Operative mortality</li> <li>• Anastomotic leak</li> <li>• Surgical site infection</li> </ul>
Lujan 2009  RCT  Spain	N=204  Mid and low rectal adenocarcinoma  ~10-15% stage I	Preoperative therapy: ~75%  ~75-80% AR ~20-25% APR	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Positive resection margins</li> <li>• Local or locoregional recurrence</li> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Anastomotic leak</li> <li>• Surgical site infection</li> <li>• Blood loss</li> </ul>
Ng 2008  RCT  Hong Kong	N=99  Low rectal cancer within 5cm from the anal verge  ~17-19% AJCC stage I	No one received preoperative therapy.  100% APR	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Positive resection margins</li> <li>• Local or locoregional recurrence</li> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Surgical site infection</li> <li>• Blood loss</li> </ul>

Study	Population	Intervention/Comparison	Outcomes
Ng 2009  RCT  Hong Kong	N=153  Adenocarcinoma in the upper rectum (12-15cm from the anal verge)  ~14-17% AJCC stage I	Preoperative therapy: not reported  100% AR	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Positive resection margins</li> <li>• Local or locoregional recurrence</li> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Anastomotic leak</li> <li>• Surgical site infection</li> <li>• Blood loss</li> </ul>
Ng 2014  RCT  Hong Kong	N=80  Mid and low rectal cancer, lowest margin of tumour located between 5 and 12 cm from the anal verge  ~13% AJCC stage I	No one received preoperative therapy.  100% sphincter-preserving surgery	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Positive resection margin</li> <li>• Local or locoregional recurrence</li> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Surgical site infection</li> <li>• Anastomotic leak</li> <li>• Blood loss</li> </ul>
Zhou 2004  RCT  China	N=171  Rectal adenocarcinoma with the lowest margin of tumour located under the peritoneal reflection and 1.5 cm above the dentate line  ~6% Duke's stage A	Preoperative therapy: not reported  Laparoscopic surgery: anal sphincter-preserving resection Open surgery: type of surgery not clear	<ul style="list-style-type: none"> <li>• Positive resection margins</li> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Anastomotic leak</li> <li>• Surgical site infection</li> </ul>
<b>Comparison 2: Robotic versus open surgery</b>			
Buonpane 2017  Retrospective cohort study  This is a 3-arm study comparing robotic versus laparoscopic	N=16,672  Surgically resected rectal cancer  Data obtained from a national oncology database.	Preoperative radiotherapy: ~60% Preoperative chemotherapy: ~60%  Type of surgery not reported.	<ul style="list-style-type: none"> <li>• Positive resection margins</li> </ul>

Study	Population	Intervention/Comparison	Outcomes
versus open surgery but only robotic versus open surgery is considered in this review.  USA	A proportion of the population with T1-2N0M0 (not clear how many)  ~6-10% metastatic disease		
Corbellini 2016  Prospective cohort study  This is a 3-arm study comparing robotic versus laparoscopic versus open surgery.  Italy	N=120  A single rectal cancer within 12 cm of the anal verge; without evidence of distant metastases; candidates for elective, good-chance surgeries  ~20-25% pathologic stage I (clinical stage not reported)	Preoperative therapy recommended to locally advanced cancers.  ~80-90% AR ~10-20% APR	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Positive resection margins</li> </ul>
Kim 2016  Prospective cohort study  This is a 3-arm study comparing robotic versus laparoscopic versus open surgery.  South Korea	N=1,628  Curatively resected adenocarcinoma of the rectum; stage ≤ III; ECOG performance status of 0-3; ≤75 years of age  ~25% AJCC clinical stage 0-I	Preoperative chemoradiotherapy: 32% robotic surgery, 51% open surgery  ~85-95% LAR ~1-3% AR ~5-10% APR	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Quality of life</li> <li>• Positive resection margins</li> </ul>
<b>Comparison 3: Robotic versus laparoscopic surgery</b>			
Baik 2008  RCT  South Korea	N=34 Rectal adenocarcinoma; without distant metastasis; within 15cm of anal verge; T4 excluded  28% were T1-2N0M0	Preoperative chemoradiotherapy: NR  100% LAR	<ul style="list-style-type: none"> <li>• Length of stay</li> </ul>
Corbellini 2016  Prospective cohort study  This is a 3-arm study comparing robotic versus laparoscopic versus open surgery.	N=105  A single rectal cancer within 12cm from the anal verge; without evidence of distant metastases; candidates for elective, good-chance surgeries  ~25-35% pathologic stage I (clinical stage not reported)	Preoperative therapy recommended to locally advanced cancers.  ~90-95% AR ~3-10% APR	<ul style="list-style-type: none"> <li>• Overall survival</li> </ul>

Study	Population	Intervention/Comparison	Outcomes
Italy			
Lelpo 2017  Retrospective cohort study  Spain	N=198  Rectal cancer; underwent laparoscopic or robotic surgery; not T4 cancer  Proportion of population with T1-2N0M0 not clear.	Preoperative therapy: ~77%  ~65-70% LAR ~25-30% APR ~5% colo-anal anastomosis	<ul style="list-style-type: none"> <li>Overall survival</li> </ul>
Kim 2016  Prospective cohort study  This is a 3-arm study comparing robotic versus laparoscopic versus open surgery  South Korea	N=1,628  Curatively resected adenocarcinoma of the rectum; stage ≤ III; ECOG performance status of 0-3; ≤75 years of age  ~25% AJCC clinical stage 0-I	Preoperative chemoradiotherapy: 32% robotic surgery, 51% open surgery  ~85-95% LAR ~1-3% AR ~5-10% APR	<ul style="list-style-type: none"> <li>Overall survival</li> <li>Quality of life</li> <li>Positive resection margins</li> </ul>
Kim 2017a  RCT  South Korea	N=163  Rectal adenocarcinoma within 9 cm from the anal verge; without distant metastasis  Proportion of population with T1-2N0M0 not clear.	Preoperative chemoradiotherapy: ~80%  ~95-99% LAR ~1-3% APR	<ul style="list-style-type: none"> <li>Quality of life</li> <li>Positive resection margins</li> </ul>
Kim 2017b  Retrospective cohort study  South Korea	N=448  Rectal adenocarcinoma within 15cm of the anal verge; underwent minimally invasive surgery for rectal cancer  28% pathologic TNM stage I (clinical stage was not reported)	Preoperative chemoradiotherapy: ~20%  ~75% LAR ~2% AR ~15% intersphincteric resection ~5% APR	<ul style="list-style-type: none"> <li>Overall survival</li> <li>Quality of life</li> <li>Positive resection margins</li> <li>Length of hospital stay</li> <li>Anastomotic leak</li> <li>Blood loss</li> </ul>
Law 2017	N=391	Preoperative radiotherapy: ~30-40%	<ul style="list-style-type: none"> <li>Overall survival</li> </ul>

Study	Population	Intervention/Comparison	Outcomes
Retrospective cohort study  Hong Kong	Rectal cancer within 12cm from the anal verge; underwent elective radical resection  ~30% stage 0-I	~90-95% LAR ~5-8% APR ~1-3% Hartmann	
Park 2015  Prospective cohort study  South Korea	N=217  Rectal adenocarcinoma; underwent low anterior resection by robotic or conventional laparoscopic approach  ~30% postoperative pathologic stage I (preoperative/clinical stage not reported)	Preoperative chemoradiotherapy: ~11%  100% AR	<ul style="list-style-type: none"> <li>• Overall survival</li> </ul>
ROLARR trial  (Jayne 2017)  RCT  Australia, Denmark, Finland, France, Germany, Italy, Singapore, South Korea, UK, US	N=471  Adenocarcinoma of the rectum; fit for resectional surgery  Proportion of population with T1-2N0M0 not clear.	Preoperative radiotherapy or chemoradiotherapy: ~46%  ~65-70% LAR ~10% high AR ~20% APR	<ul style="list-style-type: none"> <li>• Quality of life</li> <li>• Positive resection margins</li> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Anastomotic leak</li> <li>• Surgical site infection</li> </ul>
Rouanet 2018  Retrospective cohort study  France	N=400  Histologically proven adenocarcinoma located 12 cm from the anal verge who underwent minimally invasive surgery (laparoscopic or robotic TME), with no previous or concurrent malignancy and no evidence of distant metastasis at time of surgery.	Laparoscopic TME (n=200) vs robotic TME (n=200)	<ul style="list-style-type: none"> <li>• Overall survival</li> </ul>
Wang 2017  RCT  China	N=137 male patients with rectal adenocarcinoma within 12 cm from the anal verge;  22% were T1-2N0M0	Perioperative radiotherapy: ~25%  ~96-97% LAR	<ul style="list-style-type: none"> <li>• Sexual function</li> <li>• Urinary function</li> </ul>
Yoo 2015  Retrospective cohort study  South Korea	N=70  Rectal cancer <5 cm from the anal verge; treated via laparoscopic or robotic intersphincteric resection	Preoperative chemoradiotherapy: 54% robotic, 27% laparoscopic  100% intersphincteric resection	<ul style="list-style-type: none"> <li>• Overall survival</li> </ul>

Study	Population	Intervention/Comparison	Outcomes
	Proportion of the population with T1-2N0M0 not clear.  ~10% with metastatic disease  South Korea		
<b>Comparison 4: TaTME versus laparoscopic surgery</b>			
Bourdeaux' Trial  (Denost 2018; Pontallier 2016)  RCT  France	N=100  Rectal cancer <6 cm from the anal verge; suitable for laparoscopic sphincter-saving resection  Small proportion possibly with T1-2N0M0 but not clear (~80% T3-4 and ~60% N+)	Preoperative radiotherapy: ~80-90% Preoperative chemotherapy: ~80%  Laparoscopic surgery: sphincter-preserving resection	<ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Quality of life</li> <li>• Positive resection margins</li> <li>• Local recurrence</li> <li>• Length of hospital stay</li> <li>• Operative mortality</li> <li>• Anastomotic leak (and/or abscess)</li> </ul>

1 AJCC: American Joint Committee on Cancer; APR: abdominoperineal resection; AR: anterior resection; BMI:  
2 body mass index; ECOG: Eastern Cooperative Oncology Group; LAR: lower anterior resection; N: number; RCT:  
3 randomised controlled trial; T: tumour stage; TaTME: transanal total mesorectal excision; TME: total mesorectal  
4 excision; TNM: tumour, node, metastasis staging system

5 See the full evidence tables in appendix D and the forest plots in appendix E.

## 6 **Quality assessment of clinical studies included in the evidence review**

7 See the clinical evidence profiles in appendix F.

## 8 **Economic evidence**

### 9 **Included studies**

10 A systematic review of the economic literature was conducted but no economic studies were  
11 identified which were applicable to this review question.

### 12 **Excluded studies**

13 A global search of economic evidence was undertaken for all review questions in this  
14 guideline. See Supplement 2 for further information.

### 15 **Economic model**

16 An economic analysis was undertaken to estimate the cost-effectiveness of surgical  
17 techniques for rectal cancer (see appendix J for the full report of the economic analysis).

### 18 **Methods**

19 The analysis was developed in Microsoft Excel® and was conducted from the perspective of  
20 the NHS and Personal Social Services (PSS) as outlined in the NICE Reference Case (see  
21 [Developing NICE guidelines: the manual](#)). The model considered a lifetime horizon with

1 future costs and benefits discounted at a rate of 3.5% (as recommended in the NICE  
2 reference case).

### 3 ***Clinical data and model approach***

4 The economic analysis was based on clinical effectiveness data for each of the surgical  
5 techniques, which was sourced from the clinical evidence review. However, only the  
6 comparison between the open and laparoscopic approach provided sufficient data for all the  
7 key outcomes of interest for the economic analysis (overall survival, local recurrence and  
8 complications). As a result, a decision was made to separately consider two comparisons in  
9 the analysis. In the first, a comparison is made between the open and laparoscopic approach  
10 based on evidence from the clinical evidence review. In the second, all four surgical  
11 approaches are considered using available data from the clinical evidence review in  
12 combination with assumptions to fill in the missing data. The second analysis was therefore  
13 considered to be more speculative and the conclusions that can be drawn from the analysis  
14 were limited.

### 15 **Costs**

16 The costs considered in the model reflect the perspective of the analysis, thus only costs that  
17 are relevant to the UK NHS & PSS were included. Where possible, all costs were estimated  
18 in 2016/17 prices.

19 The majority of costs were sourced from NHS reference costs 2016/17 by applying tariffs  
20 associated with the appropriate Healthcare Resource Groups (HRG) code. However, note  
21 that the cost of the surgical procedure in NHS reference costs (FF31: complex large intestine  
22 procedures, 19 years and over) is the same regardless of the approach taken. Therefore, this  
23 cost was not estimated using the procedure code from NHS reference costs and an  
24 alternative approach was adopted in order to differentiate the various surgical techniques.

25 Surgical equipment costs were estimated using data from a cost-effectiveness analysis of  
26 surgical approaches in prostate cancer (Ramsay 2012), with costs inflated to 2016 prices.  
27 Equipment costs were estimated to be £1,502, £1,605, £4,628 and £1,815 for the open,  
28 laparoscopic, robotic and TaTME approaches, respectively. Operative time costs were  
29 estimated using average theatre time estimates reported in Ramsay 2012. A cost for an hour  
30 of operating theatre time was sourced from the cost-effectiveness analysis from Ramsay  
31 2012 and inflated to 2016 prices (£1,266). Length of stay costs were estimated using data on  
32 the length of stay in hospital following each procedure from the studies included in the clinical  
33 evidence review combined with the cost of an excess bed day from NHS reference costs  
34 2016/17.

35 Complication costs were estimated using the different costs associated with complication and  
36 co-morbidity (CC) scores for the surgical procedure from NHS reference costs. The  
37 difference between CC score 0-2 and an average of the other CC scores associated with  
38 complex large intestine procedures (FF31) was used as an estimate of complication costs.

39 Systemic chemotherapy costs were estimated assuming that patients would be treated with 6  
40 cycles of FOLFIRI or FOLFOX. The chemotherapy delivery costs were sourced from NHS  
41 Reference Costs 2015/16 (assuming day case delivery) and drug costs were sourced from  
42 eMit.

43 The cost of palliative care was estimated using estimates from a costing report by the  
44 Nuffield Trust (Georghiou 2014). A cost of £7,287 was applied based on the average  
45 resource use of patients with cancer in the last three months of life.



## 1 **Health-related quality of life**

2 As recommended in the NICE reference case, the model estimates effectiveness in terms of  
3 quality adjusted life years (QALYs). These are estimated by combining life year estimates  
4 with quality of life (QoL) values associated with being in a particular health state.

5 QoL data for all comparisons were sourced from Rao 2017, a cost-effectiveness analysis that  
6 estimated QoL for recurrences (0.78) and for being recurrence free (0.86).

## 7 **Base case results**

8 The base case results of the analysis, based on the point estimates of the model inputs, are  
9 shown in Table 15 and Table 16 for the two-way and four-way comparison respectively. The  
10 results of the two-way comparison show the laparoscopic approach to be more effective  
11 (1.26 QALYs) and less costly than the open approach (£921) and it is therefore dominant.  
12 These results are driven by improvements in overall survival which are clinically significant.

13 In the four-way comparison, alternative approaches were compared using a net monetary  
14 benefit approach assuming a threshold of £20,000 per QALY. The results show the TaTME  
15 approach to be the least costly approach. All other strategies are found to be more costly and  
16 less effective than TaTME and are therefore dominated. Consequently, net monetary benefit  
17 was negative for all other interventions. However it should be noted for TaTME that the  
18 results are driven by improvements in overall survival and recurrence which were based on a  
19 hazard ratio for which the 95% confidence interval passed the line of no effect. It is therefore  
20 plausible that TaTME may result in lower QALYs and higher costs (through increased  
21 recurrence) compared to alternative approaches. These results should therefore be  
22 considered speculative.

23 **Table 3: Base case results for two-way comparison**

Strategy	Cost		QALYs		ICER (cost per QALY)
	Total	Incremental	Total	Incremental	
Open	£11,963	-	9.08	-	-
Laparoscopic	£11,042	-£921	10.34	1.26	<b>Dominant</b>

24 *ICER: incremental cost-effectiveness ratio; QALYs: quality adjusted life years*

25 **Table 4: Base case results for four-way comparison**

Strategy	Cost		QALYs		ICER (cost per QALY)	NMB
	Total	Incremental	Total	Incremental		
TaTME	£9,812	-	11.15	-	-	
Laparoscopic	£11,042	£1,230	10.34	-0.81	<b>Dominated</b>	-£17,395
Open	£11,963	£2,151	9.08	-2.07	<b>Dominated</b>	-£43,575
Robotic	£15,612	£5,800	9.92	-1.24	<b>Dominated</b>	-£30,503

26 *ICER: incremental cost-effectiveness ratio; QALYs: quality adjusted life years NMB Net monetary benefit*

## 27 **Deterministic sensitivity results**

28 A series of deterministic sensitivity analyses were conducted, whereby an input parameter is  
29 changed, the model is re-run and the new cost-effectiveness result is recorded. This is a  
30 useful way of estimating uncertainty and determining the key drivers of the model result. The  
31 results of the deterministic sensitivity analyses are presented in Table 5 and Table 6 for the  
32 two-way and four-way comparison, respectively.

33 In the two way comparison, it can again be seen that the conclusion of the analysis remains  
34 unchanged in the majority of modelled scenarios with the laparoscopic approach found to be  
35 cost-effective. Notably this includes a scenario in which only statistically significant effects

1 are modelled. The conclusion of the analysis was found to change when the upper hazard  
2 ratio (HR) for overall survival was applied (meaning that overall survival is better with the  
3 open approach).

4 In the four way comparison, it can again be seen that the conclusion of the analysis remains  
5 unchanged in the majority of modelled scenarios with TaTME found to be cost-effective.  
6 However, notably, this does not includes a scenario in which only statistically significant  
7 effects are modelled (in which the laparoscopic approach is found to be cost-effective). The  
8 laparoscopic approach was also found to be cost-effective when the upper HR for overall  
9 survival for TaTME was applied or when overall survival was assumed to be equivalent with  
10 laparoscopic and TaTME. The open approach was found to be cost-effective when the upper  
11 HR for overall survival for TaTME and the laparoscopic approach was applied.

12 **Table 5: Deterministic sensitivity results for two-way comparison**

Modelled scenario	Optimal strategy
Base case	Laparoscopic
Overall survival – lower HR	Laparoscopic
Overall survival – upper HR	Laparoscopic
Local recurrence – lower RR	Laparoscopic
Local recurrence – upper RR	Laparoscopic
Complications – lower RR	Laparoscopic
Complications – upper RR	Laparoscopic
Statistically significant changes only	Laparoscopic
Number of robotic procedures per year = 50	Laparoscopic
Number of robotic procedures per year = 100	Laparoscopic
Number of robotic procedures per year = 200	Laparoscopic
Complication costs + 50%	Laparoscopic
Complication costs - 50%	Laparoscopic
No systemic chemotherapy costs	Laparoscopic
No palliative care costs	Laparoscopic
No recurrence disutility	Laparoscopic

13 *HR: hazard ratio; RR: relative risk*

14 **Table 6: Deterministic sensitivity results for four-way comparison**

Modelled scenario	Optimal strategy
Base case	TaTME
Overall survival – lower HR for laparoscopic	TaTME
Overall survival – upper HR for laparoscopic	TaTME
Overall survival – lower HR for TaTME	TaTME
Overall survival – upper HR for TaTME	<b>Laparoscopic</b>
Overall survival with TaTME equivalent to laparoscopic	<b>Laparoscopic</b>
Overall survival – upper HR for TaTME and laparoscopic	<b>Open</b>
Absolute overall survival with robotic 10% higher	TaTME
Absolute overall survival with robotic 10% lower	TaTME
Local recurrence – lower RR for laparoscopic	TaTME
Local recurrence – upper RR for laparoscopic	TaTME
Absolute local recurrence with TaTME 10% higher	TaTME
Absolute local recurrence with TaTME 10% lower	TaTME
Local recurrence with TaTME equivalent to laparoscopic	TaTME

Modelled scenario	Optimal strategy
Complications – lower RR	TaTME
Complications – upper RR	TaTME
Statistically significant changes only	<b>Laparoscopic</b>
Number of robotic procedures per year = 50	TaTME
Number of robotic procedures per year = 100	TaTME
Number of robotic procedures per year = 200	TaTME
Complication costs + 50%	TaTME
Complication costs - 50%	TaTME
No systemic chemotherapy costs	TaTME
No palliative care costs	TaTME
No recurrence disutility	TaTME

1 *HR: hazard ratio; RR: relative risk; TaTME: transanal total mesorectal excision*

## 2 Evidence statements

### 3 Clinical evidence statements

#### 4 Comparison 1: Laparoscopic versus open surgery

##### 5 Critical outcomes

##### 6 Overall survival

- 7 • Moderate quality evidence from 9 RCTs (N=2731; median follow-up 3.2 to 9.2 years)  
8 showed a clinically important improvement in the overall survival of people who underwent  
9 laparoscopic surgery for non-metastatic rectal cancer when compared to those who had  
10 open surgery.

##### 11 Quality of life

- 12 • Very low quality evidence from 1 RCT (N=338) showed no clinically important difference in  
13 global quality of life at 4 weeks, 6 months or 12 months after surgery (self-assessed using  
14 QLQ-C30) between people who underwent laparoscopic or open surgery for non-  
15 metastatic rectal cancer.
- 16 • Very low quality evidence from 1 RCT (N=336) showed no clinically important difference in  
17 global health status at 4 weeks, 6 months or 12 months after surgery (self-assessed using  
18 EQ-VAS) between people who underwent laparoscopic or open surgery for non-  
19 metastatic rectal cancer.
- 20 • Very low quality evidence from 1 RCT (N=168) showed a clinically importantly higher  
21 general health score at 12 months after surgery (self-assessing using SF-36) in people  
22 who underwent laparoscopic surgery compared to those who underwent open surgery for  
23 non-metastatic rectal cancer. However, at 24 months after surgery there was no  
24 difference in the same general health score.
- 25 • Very low quality evidence from 1 RCT (N=1,103) showed no clinically important difference  
26 in sexual functioning at 4 weeks, 6, 12 or 24 months after surgery (self-assessed using  
27 QLQ-CR38) between people who underwent laparoscopic or open surgery for non-  
28 metastatic rectal cancer.
- 29 • Very low quality evidence from 1 RCT (N=1,103) showed no clinically important difference  
30 in sexual enjoyment at 6, 12 or 24 months after surgery (self-assessed using QLQ-CR38)  
31 between people who underwent laparoscopic or open surgery for non-metastatic rectal  
32 cancer.

- 1 • Very low quality evidence from 1 RCT (N=1,103) showed no clinically important difference  
2 in sexual problems at 6, 12 or 24 months after surgery (self-assessed using QLQ-CR38)  
3 between women who underwent laparoscopic or open surgery for non-metastatic rectal  
4 cancer.
- 5 • Very low quality evidence from 1 RCT (N=46) showed no clinically important difference in  
6 overall sexual dysfunction after surgery (self-assessed using FSFI) between women who  
7 underwent laparoscopic or open surgery for non-metastatic rectal cancer.
- 8 • Very low quality evidence from 1 RCT (N=1,103) showed no clinically important difference  
9 in sexual problems at 4 weeks, 6, 12 or 24 months after surgery (self-assessed using  
10 QLQ-CR38) between men who underwent laparoscopic or open surgery for non-  
11 metastatic rectal cancer.
- 12 • Very low quality evidence from 1 RCT (N=37) showed a clinically important increased risk  
13 of overall sexual dysfunction at median 3 years after surgery (self-assessed using IIEF) in  
14 previously sexually active men who underwent laparoscopic surgery compared to those  
15 who underwent open surgery for non-metastatic rectal cancer.
- 16 • Very low quality evidence from 1 RCT (N=82) showed no clinically important difference in  
17 perceived severe change in overall level of sexual function after surgery (self-assessed  
18 using IIEF) in men who underwent laparoscopic or open surgery for non-metastatic rectal  
19 cancer.
- 20 • Very low quality evidence from 1 RCT (N=1,103) showed no clinically important difference  
21 in micturitional symptoms at 4 weeks, 6, 12, or 24 months after surgery (self-assessed  
22 using QLQ-CR38) between people who underwent laparoscopic or open surgery for non-  
23 metastatic rectal cancer.
- 24 • Very low quality evidence from 1 RCT (N=148) showed “no differences in bladder  
25 function, either in overall score or in individual symptom scores” at 2 weeks, 3, 6, and 18  
26 months after surgery (self-assessed using IPSS and QLQ-CR38) between people who  
27 underwent laparoscopic or open surgery for non-metastatic rectal cancer (reported  
28 narratively only).

## 29 **Resection margins**

- 30 • Moderate quality evidence from 9 RCTs (N=2,246) showed no clinically important  
31 difference in positive CRM (defined as <1 mm, ≤1 mm or not defined) between people  
32 who underwent laparoscopic or open surgery for non-metastatic rectal cancer.
- 33 • Low quality evidence from 1 RCT (N=888) showed no clinically important difference in  
34 positive CRM (defined as <2 mm) between people who underwent laparoscopic or open  
35 surgery for non-metastatic rectal cancer.
- 36 • Low quality evidence from 5 RCTs (N=1,347) showed no clinically important difference in  
37 positive distal resection margin between people who underwent laparoscopic or open  
38 surgery for non-metastatic rectal cancer.
- 39 • Moderate quality evidence from 1 RCT (N=462) showed no clinically important difference  
40 in positive radial resection margin (defined as ≤1 mm) between people who underwent  
41 laparoscopic or open surgery for non-metastatic rectal cancer.
- 42 • Very low quality evidence from 1 RCT (N=40) showed no clinically important difference in  
43 positive radial resection margin (defined as ≤2 mm) between people who underwent  
44 laparoscopic or open surgery for non-metastatic rectal cancer.
- 45 Low quality evidence from 1 RCT (N=171) showed that 0 people who underwent either  
46 laparoscopic or open surgery for non-metastatic rectal cancer had positive resection  
47 margins (defined as “cancer cell found in the cut margins”).

1 **Important outcomes**

2 **Local recurrence**

- 3 • Moderate quality evidence from 3 RCTs (N=701; median follow-up ranging from 3.2 to 4  
4 years) showed no clinically important difference in local recurrence free survival between  
5 people who underwent laparoscopic or open surgery for non-metastatic rectal cancer.
- 6 • Low quality evidence from 9 RCTs (N=2,520; median follow-up ranging from 3 to 7.5  
7 years) showed no clinically important difference in local or locoregional recurrence rates  
8 between people who underwent laparoscopic or open surgery for non-metastatic rectal  
9 cancer.

10 **Length of hospital stay**

- 11 • Meta-analysis of length of hospital stay showed considerable heterogeneity, therefore,  
12 subgroup analysis according to type of surgical resection was done.
- 13 • Very low quality evidence from 4 RCTs (N=1,750) showed no clinically important  
14 difference in mean length of hospital stay between people who underwent laparoscopic or  
15 open anterior resection or abdominoperineal resection for non-metastatic rectal cancer.  
16 Low quality evidence from one 1 RCT (N=381) showed no clinically important difference in  
17 median length of hospital stay between people who underwent laparoscopic or open  
18 anterior resection or abdominoperineal resection for non-metastatic rectal cancer.
- 19 • Low quality evidence from 4 RCTs (N=572) showed a clinically important lower mean  
20 length of hospital stay in people who underwent laparoscopic sphincter-preserving surgery  
21 compared to open sphincter-preserving surgery for non-metastatic rectal cancer.  
22 Moderate quality evidence from 2 RCTs (N=815) showed no clinically important difference  
23 in median length of hospital stay in people who underwent laparoscopic or open sphincter-  
24 preserving surgery for non-metastatic rectal cancer.
- 25 • Low quality evidence from 1 RCT (N=99) showed no clinically important difference in  
26 mean length of hospital stay in people who underwent laparoscopic or open  
27 abdominoperineal surgery for non-metastatic rectal cancer.

28 **90-day mortality**

- 29 • Low quality evidence from 4 RCTs (N=2,053) showed no clinically important difference in  
30 30-day mortality between people who underwent laparoscopic or open surgery for non-  
31 metastatic rectal cancer.
- 32 • Moderate quality evidence from 1 RCT (N=340) showed no deaths within 90 days of  
33 surgery in people who underwent either laparoscopic or open surgery for non-metastatic  
34 rectal cancer.
- 35 • Low quality evidence from 6 RCTs (N=1,408) showed no clinically important difference in  
36 operative mortality (timeframe not defined) between people who underwent laparoscopic  
37 or open surgery for non-metastatic rectal cancer.

38 **Treatment-related complications: anastomotic leak**

- 39 • Low quality evidence from 10 RCTs (N=2,616) showed no clinically important difference in  
40 anastomotic leak between people who underwent laparoscopic or open surgery for non-  
41 metastatic rectal cancer.

42 **Treatment-related complications: surgical site infection**

- 43 • Low quality evidence from 10 RCTs (N=2,678) showed no clinically important difference in  
44 surgical site infection between people who underwent laparoscopic or open surgery for  
45 non-metastatic rectal cancer.

1 **Treatment-related complications: blood loss**

- 2 • Meta-analysis of blood loss showed considerable heterogeneity, therefore, subgroup  
3 analysis according to type of surgical resection was done.
- 4 • Moderate quality evidence from 3 RCTs (N=695) showed a clinically important lower  
5 mean blood loss in people who underwent laparoscopic anterior resection or  
6 abdominoperineal resection compared to those who underwent open anterior resection or  
7 abdominoperineal resection for non-metastatic rectal cancer. Moderate quality evidence  
8 from 1 RCT (N=1,044) showed that the median blood loss was significantly lower in  
9 people who underwent laparoscopic anterior resection or abdominoperineal resection  
10 compared to those who underwent open anterior resection or abdominoperineal resection  
11 for non-metastatic rectal cancer.
- 12 • Moderate quality evidence from 4 RCTs (N=572) showed a clinically important lower  
13 mean blood loss in people who underwent laparoscopic sphincter-preserving surgery  
14 compared to those who underwent open sphincter-preserving surgery for non-metastatic  
15 rectal cancer. Moderate quality evidence from 2 RCTs (N=815) showed that the median  
16 blood loss was significantly lower in people who underwent laparoscopic sphincter-  
17 preserving surgery compared to those who underwent open sphincter-preserving surgery  
18 for non-metastatic rectal cancer.
- 19 • Low quality evidence from 1 RCT (N=99) showed no difference in mean blood loss  
20 between people who underwent laparoscopic or open abdominoperineal resection for  
21 non-metastatic rectal cancer.

22 **Comparison 2: Robotic versus open surgery**

23 **Critical outcomes**

24 **Overall survival**

- 25 • Very low quality evidence from 1 prospective and 1 retrospective cohort study (N=1,691)  
26 showed no clinically important difference in overall survival at 3 years between people  
27 who underwent robotic surgery compared to those who underwent open surgery for non-  
28 metastatic rectal cancer.

29 **Quality of life**

- 30 • Very low quality evidence from 1 prospective cohort study (N=473) showed a clinically  
31 important lower risk of moderate or severe sexual dysfunction in men 65 years or younger  
32 (self-assessed using VAS) who underwent robotic surgery compared to those who  
33 underwent open surgery for non-metastatic rectal cancer. When looking at severe and  
34 moderate sexual dysfunction separately, there was no difference in severe sexual  
35 dysfunction (VAS 4-5) between the groups but a clinically important lower risk of moderate  
36 sexual dysfunction (VAS 2-3) in men 65 years or younger who underwent robotic surgery  
37 compared to those who underwent open surgery.

38 **Resection margins**

- 39 • Very low quality evidence from 1 retrospective cohort study (N=16,672) showed a  
40 clinically important lower risk of positive resection margin (not defined) in people who  
41 underwent robotic surgery compared to those who underwent open surgery for non-  
42 metastatic rectal cancer.
- 43 • Very low quality evidence from 1 prospective cohort study (N=1,628) showed no clinically  
44 important difference in positive CRM (defined as  $\leq 1$  mm) between people who underwent  
45 robotic or open surgery for non-metastatic rectal cancer.
- 46 • Very low quality evidence from 1 prospective cohort study (N=120) showed no clinically  
47 important difference in R1 resection between people who underwent robotic or open  
48 surgery for non-metastatic rectal cancer.

- 1 • Very low quality evidence from 1 prospective cohort study (N=1,628) showed no clinically  
2 important difference in positive distal resection margin (defined as  $\leq 5$  mm) between  
3 people who underwent robotic or open surgery for non-metastatic rectal cancer.

4 **Important outcomes**

5 **Local recurrence**

6 No RCT evidence was identified to inform this outcome.

7 **Length of hospital stay**

8 No RCT evidence was identified to inform this outcome.

9 **90-day mortality**

10 No RCT evidence was identified to inform this outcome.

11 **Treatment-related complications: anastomotic leak**

12 No RCT evidence was identified to inform this outcome.

13 **Treatment-related complications: surgical site infection**

14 No RCT evidence was identified to inform this outcome.

15 **Treatment-related complications: blood loss**

16 No RCT evidence was identified to inform this outcome.

17 **Comparison 3: Robotic versus laparoscopic surgery**

18 **Critical outcomes**

19 **Overall survival**

- 20 • Very low quality evidence from 2 prospective and 6 retrospective cohort studies (N=2,771)  
21 with median follow-up 3 to 5 years showed no clinically important difference in overall  
22 survival between people who underwent robotic or laparoscopic surgery for non-  
23 metastatic rectal cancer.

24 **Quality of life**

- 25 • Very low quality evidence from 1 RCT (N=139) showed no clinically important difference in  
26 global health status at 3 weeks, 3 and 12 months after surgery (self-assessed using QLQ-  
27 C30) between people who underwent robotic or laparoscopic surgery for non-metastatic  
28 rectal cancer.
- 29 • Very low quality evidence from 1 RCT (N=139) showed a clinically important better sexual  
30 function score at 12 months (self-assessed using QLQ-CR38) in people who underwent  
31 robotic surgery compared to those who underwent laparoscopic surgery for non-  
32 metastatic rectal cancer.
- 33 • Very low quality evidence from 1 RCT (N=471) showed no clinically important difference in  
34 female sexual function at 6 months (self-assessed using FSFI) between women who  
35 underwent robotic or laparoscopic surgery for non-metastatic rectal cancer.
- 36 • Very low quality evidence from 2 RCTs (N=608) showed no clinically important difference  
37 in male sexual function at 6 months (self-assessed using IIEF) between men who  
38 underwent robotic or laparoscopic surgery for non-metastatic rectal cancer.

- 1 • Very low quality evidence from 2 RCTs (N=608) showed no clinically important difference  
2 in bladder function at 6 months (self-assessed using IPSS) between people who  
3 underwent robotic or laparoscopic surgery for non-metastatic rectal cancer.
- 4 **Resection margins**
- 5 • Very low quality evidence from 2 RCTs (N=598) showed no clinically important difference  
6 in positive CRM (defined as  $\leq 1$  mm) between people who underwent robotic or  
7 laparoscopic surgery for non-metastatic rectal cancer.
- 8 • Very low quality evidence from 1 RCT (N=471) showed no clinically important difference in  
9 positive distal resection margin between people who underwent robotic or laparoscopic  
10 surgery for non-metastatic rectal cancer. In the same trial, no positive proximal resection  
11 margins were observed.
- 12 **Important outcomes**
- 13 **Local recurrence**
- 14 No RCT evidence was identified to inform this outcome.
- 15 **Length of hospital stay**
- 16 • Very low quality evidence from 3 RCTs (N=644) showed no clinically important difference  
17 in length of hospital stay between people who underwent robotic or laparoscopic surgery  
18 for non-metastatic rectal cancer.
- 19 **90-day mortality**
- 20 • Very low quality evidence from 1 RCT (N=471) showed no clinically important difference in  
21 30-day mortality between people who underwent robotic or laparoscopic surgery for non-  
22 metastatic rectal cancer.
- 23 **Treatment-related complications: anastomotic leak**
- 24 • Very low quality evidence from 2 RCTs (N=500) showed no clinically important difference  
25 in anastomotic leak between people who underwent robotic or laparoscopic surgery for  
26 non-metastatic rectal surgery.
- 27 **Treatment-related complications: surgical site infection**
- 28 • Very low quality evidence from 1 RCT (N=471) showed no clinically important difference in  
29 surgical site infection within 30 days from the operation or between 30 days and 6 months  
30 from the operations between people who underwent robotic or laparoscopic surgery for  
31 non-metastatic rectal cancer.
- 32 **Treatment-related complications: blood loss**
- 33 • Low quality evidence from 1 RCT (N=139) showed a clinically important higher blood loss  
34 in people who underwent robotic surgery compared to those who underwent laparoscopic  
35 surgery for non-metastatic rectal cancer.
- 36 **Comparison 4: Transanal total mesorectal excision versus laparoscopic surgery**
- 37 **Critical outcomes**
- 38 **Overall survival**
- 39 • Low quality evidence from 1 RCT (N=100) showed no clinically important difference in  
40 overall survival at 5 years between people who underwent TaTME or laparoscopic  
41 anterior resection for non-metastatic rectal cancer.



1 **Quality of life**

- 2 • Very low quality evidence from 1 RCT (N=51) showed a clinically important higher rate of  
3 maintained sexual activity at median 3.2 years after treatment in previously sexually active  
4 people who underwent TaTME compared to those who underwent laparoscopic anterior  
5 resection for non-metastatic rectal cancer.
- 6 • Very low quality evidence from 1 RCT (N=39) showed no clinically important difference in  
7 erectile function at median 3.2 years after treatment (self-assessed using IIEF) between  
8 men who underwent TaTME or laparoscopic anterior resection for non-metastatic rectal  
9 cancer.
- 10 • Very low quality evidence from 1 RCT (N=37) showed no clinically important difference in  
11 ejaculatory function at median 3.2 years after treatment (self-assessed using IIEF)  
12 between previously sexually active men who underwent TaTME or laparoscopic anterior  
13 resection for non-metastatic rectal cancer.
- 14 • Very low quality evidence from 1 RCT (N=8) showed no clinically important difference in  
15 female sexual function after treatment (self-assessed using FSFI) between previously  
16 sexually active female who underwent TaTME or laparoscopic anterior resection for non-  
17 metastatic rectal cancer.
- 18 • Very low quality evidence from 1 RCT (N=72) showed no clinically important difference in  
19 median urinary function quality of life score or median urinary function total score after  
20 treatment (self-assessed using IPSS) in people who underwent TaTME or laparoscopic  
21 anterior resection for non-metastatic rectal cancer.

22 **Resection margins**

- 23 • Low quality evidence from 1 RCT (N=100) showed a clinically important lower risk of R1  
24 resection (defined as positive CRM) in people who underwent TaTME compared to those  
25 who underwent laparoscopic anterior resection for non-metastatic rectal cancer.
- 26 • Low quality evidence from 1 RCT (N=100) showed no clinically important difference in  
27 positive distal margin between people who underwent TaTME or laparoscopic anterior  
28 resection for non-metastatic rectal cancer.

29 **Important outcomes**

30 **Local recurrence**

- 31 • Low quality evidence from 1 RCT (N=100) showed no clinically important difference in  
32 local recurrence at 5 years between people who underwent TaTME or laparoscopic  
33 anterior resection for non-metastatic rectal cancer.

34 **Length of hospital stay**

- 35 • Low quality evidence from 1 RCT (N=100) showed no clinically important difference in  
36 median length of hospital stay between people who underwent TaTME or laparoscopic  
37 anterior resection for non-metastatic rectal cancer.

38 **90-day mortality**

- 39 • Low quality evidence from 1 RCT (N=100) showed no clinically important difference in  
40 postoperative mortality between people who underwent TaTME or laparoscopic anterior  
41 resection for non-metastatic rectal cancer.

42 **Treatment-related complications: anastomotic leak**

- 43 • Low quality evidence from 1 RCT (N=100) showed no clinically important difference in  
44 anastomotic leak and/or abscess between people who underwent TaTME or laparoscopic  
45 anterior resection for non-metastatic rectal cancer.

1 **Treatment-related complications: surgical site infection**

2 No RCT evidence was identified to inform this outcome.

3 **Treatment-related complications: blood loss**

4 No RCT evidence was identified to inform this outcome.

5 **Comparison 5: Transanal total mesorectal excision versus open surgery**

6 No evidence was identified for this comparison.

7 **Comparison 6: Transanal total mesorectal excision versus robotic surgery**

8 No evidence was identified for this comparison.

9 **Economic evidence statements**

10 One bespoke economic model developed for this review question taking a UK NHS and PSS  
11 perspective and using clinical parameters from the accompanying clinical evidence review  
12 suggested that a laparoscopic approach was both cost saving and health improving  
13 compared to an open approach. Probabilistic sensitivity analysis concluded this result was  
14 robust with a 93% probability of laparoscopic approach being cost effective when QALYs are  
15 valued at £20,000 each. A speculative analysis gave very favourable results for TaTME  
16 compared to an open, laparoscopic and robotic approaches. However, there was great  
17 uncertainty around the inputs for this model and consequently the conclusions with results  
18 sensitive to assumptions around overall survival.

19 **The committee's discussion of the evidence**

20 **Interpreting the evidence**

21 ***The outcomes that matter most***

22 Overall survival, quality of life and resection margins were considered critical outcomes for  
23 decision making. Overall survival was considered a critical outcome because ultimately the  
24 aim of cancer treatment is to improve survival. From the patient's perspective it is also critical  
25 to consider the effect on quality of life. Quality of life in terms of sexual function and bladder  
26 function were of particular interest to this review because of the potential effects that the  
27 different surgical techniques might have on these. Impaired sexual function and bladder  
28 function can both have a significant impact on a person's quality of life. Resection margins  
29 were considered a critical outcome because a cancer-positive resection margin is a predictor  
30 for cancer recurrence.

31 Local recurrence, length of hospital stay, mortality within 90 days of surgery and treatment-  
32 related complications were considered important outcomes.

33 ***The quality of the evidence***

34 Evidence was available for the comparison of laparoscopic versus open surgery (comparison  
35 1), robotic versus open surgery (comparison 2), robotic versus laparoscopic surgery  
36 (comparison 3), and transanal total mesorectal excision (TaTME) versus laparoscopic  
37 surgery (comparison 4). No evidence was identified for the comparison of TaTME versus  
38 open surgery or of TaTME versus robotic surgery.

39 Evidence was available for all of the outcomes for comparison 1. The quality of the clinical  
40 evidence was assessed using GRADE and varied from low to moderate quality. For  
41 comparison 2, evidence was available for all critical outcomes but no evidence was available  
42 for important outcomes (local recurrence, length of hospital stay, 90-day mortality, and  
43 treatment-related complications). The quality of the evidence was assessed using GRADE

1 and was of very low quality. For comparison 3 evidence was available for all outcomes  
2 except local recurrence and for comparison 4 evidence was available for all outcomes except  
3 surgical site infection and blood loss. The quality of the evidence for these comparisons was  
4 assessed using GRADE: for comparison 3 the evidence was mostly of very low quality and  
5 varied from very low to low and for comparison 4 it was mostly of low quality, varying from  
6 very low to low quality.

7 The main reasons for downgrading the quality of evidence were population indirectness,  
8 imprecision of the effect estimate, and risk of bias due to lack of blinding.

9 Some of the studies included a proportion of participants with early rectal cancer (T1-2, N0,  
10 M0) or metastatic rectal cancer which were out of the scope for this review and the quality of  
11 evidence was therefore downgraded for population indirectness.

12 For some outcomes, there was considerable uncertainty in the effect estimate due to the  
13 small number of participants or low number of events, in which case the evidence was  
14 downgraded for imprecision.

15 Blinding of personnel, patients and outcome assessors was generally not done or not  
16 possible to do. Lack of blinding might influence outcome measurement, particularly for  
17 outcomes that are subjective in nature. Therefore, for subjective outcomes such as quality of  
18 life, the quality of evidence was downgraded due to risk of detection bias.

### 19 ***Benefits and harms***

20 Over time, minimally invasive surgical techniques, including laparoscopic surgery, have been  
21 developed in order to lower operative complications and adverse events and speeding up  
22 recovery without compromising the long-term effectiveness of surgery on survival and  
23 disease recurrence. Laparoscopic surgery for rectal cancer is commonly used in current  
24 practice alongside open surgery and the choice of technique is sometimes dependent on the  
25 skills and experience of the surgeon rather than the clinical effectiveness or appropriateness  
26 of either technique.

27 Clinical evidence on the long-term effectiveness of laparoscopic surgery compared to open  
28 surgery indicated an overall survival benefit with laparoscopic surgery with no clinically  
29 important difference in local recurrence rates.

30 The committee also considered the short-term effectiveness of laparoscopic surgery  
31 compared to open surgery. No overall difference was observed in positive resection margins.  
32 However, the committee discussed that there can be a long learning curve for laparoscopic  
33 surgery, which might be reflected in the results for resection margin and operative  
34 complications seen in some of the trials. The expectation is that the clinical effectiveness and  
35 safety of laparoscopic technique is now better than when most of the trials were conducted.

36 In general, there was no difference in length of hospital stay; however, a clinically important  
37 lower mean length of hospital stay was observed in people who underwent laparoscopic  
38 compared to open sphincter-preserving surgery for non-metastatic rectal cancer. No clinically  
39 important difference was observed in respect of quality of life, operative mortality, or  
40 anastomotic leak. As the committee expected, mean or median blood loss was lower in the  
41 laparoscopic group compared to the open group.

42 However, the committee agreed that in some cases open surgery is the most appropriate  
43 approach because of clinical or technical reasons. For example, scarring from previous  
44 abdominal or pelvic surgeries might make open surgery more feasible. Open surgery might  
45 also be more appropriate for technically demanding resection of adjacent organs or  
46 structures in locally advanced tumours.

47 In recent years robotic surgery has been introduced as another way of performing  
48 laparoscopic surgery. The robots are expensive but their technical advantages compared to

- 1 the manual laparoscopic surgery include, for example, better visualisation, better freedom of  
2 movement, lack of tremor, and better ergonomics. Some clinical evidence was available  
3 comparing the robotic technique to either open or laparoscopic technique in rectal cancer  
4 surgery.
- 5 Low quality observational evidence was available comparing robotic surgery to open surgery.  
6 No difference was observed in overall survival. One study suggested a lower risk of positive  
7 resection margin with robotic approach, although two other studies found no difference  
8 between the groups. One study found less sexual dysfunction in men who underwent robotic  
9 surgery.
- 10 Robotic technique was compared to manual laparoscopic technique in four RCTs and a few  
11 low quality observational studies. Overall, the evidence did not show the robotic approach to  
12 be better than manual laparoscopic approach. There was no difference in overall survival,  
13 overall quality of life, bladder function, resection margins, length of hospital stay, operative  
14 mortality, or anastomotic leak. Two studies showed better sexual function in the robotic  
15 group compared to manual laparoscopic group at 1 year after surgery, however the pooled  
16 results did not show a clinically important difference.
- 17 TaTME is another relatively novel surgical approach to treat rectal cancers. TaTME has been  
18 suggested as a particularly useful approach in cancers in the low rectum in male patients  
19 because of the anatomical challenges of open or laparoscopic technique in this area,  
20 however, the evidence on this is lacking. The evidence base for this technique is small and  
21 the findings were statistically underpowered, therefore, the committee was not able to  
22 determine if TaTME is a clinically effective surgical technique to treat rectal cancer.
- 23 The committee was aware of the NICE interventional procedures guidance on [transanal total  
24 mesorectal excision of the rectum \(IPG514\)](#). The committee was also aware that TaTME has  
25 been suspended in Norway due to increased local recurrence rates. Increased complication  
26 rates have also been attributed to TaTME, however, it is not impossible that these  
27 complications could happen in any operation in the pelvis. There is currently not enough  
28 evidence to show neither benefit nor harm from TaTME compared to more established  
29 techniques. COLOR III trial is currently recruiting patients to compare TaTME to laparoscopic  
30 technique.
- 31 After reviewing the clinical evidence on the different surgical techniques, the committee  
32 concluded that the clinical short- and long-term outcomes of laparoscopic technique were  
33 similar or better than of the open technique (although as discussed in certain cases the open  
34 approach is better) and that there seemed to be no difference between manual laparoscopic  
35 and robotic laparoscopic techniques. The committee agreed that in addition to the clinical  
36 effectiveness it is important to consider the costs of these difference techniques in order to  
37 assess which technique is the most cost effective approach in rectal cancer surgery.
- 38 The evidence showed no clinical benefit, clinically important higher blood loss but no other  
39 clinically important differences in complications no clinically important difference in  
40 complications (length of hospital stay, 90-day mortality, anastomotic leak, and surgical site  
41 infection) from the robotic technique. The committee recognised, however, that the robotic  
42 technique is already being used by certain centres in the UK. The committee would not want  
43 those centres with established programmes to stop performing robotic surgery but in the  
44 absence of clinical and cost effectiveness evidence in favour of robotic technique, the  
45 committee would only recommend robotic surgery to be considered within these established  
46 programmes. It was also considered important that audit data is collected within these  
47 programmes to assess the effectiveness and safety of robotic technique in clinical practice.  
48 The techniques and equipment of robotic surgery develop rapidly and more evidence on its  
49 usefulness will be available in the future.
- 50 Similarly, TaTME is used in some of centres in the UK. It was agreed that TaTME should be  
51 considered as a treatment option only within proctored programmes. These structured and

1 supervised programmes should also collect outcome data for the national TaTME registry in  
2 order to enable assessment of the safety and effectiveness of TaTME in clinical practice.

### 3 **Cost effectiveness and resource use**

4 Bespoke economic modelling for this review question suggested that a laparoscopic  
5 approach to surgery would be both cost saving and health improving compared to an open  
6 approach. These increases in QALYs and cost savings were largely driven by survival  
7 parameters, which were clinically significant in the clinical evidence review favouring the  
8 laparoscopic approach. The deterministic and probabilistic sensitivity analysis results  
9 suggested that results were robust to alternative assumptions. The committee were therefore  
10 confident that recommending laparoscopic surgery was both cost effective and cost saving.

11 Whilst the bespoke economic analysis suggested that robotic surgery was not cost effective,  
12 the committee highlighted that this was a fast moving and expanding area and as volumes  
13 increase (across all disease areas), costs of robotic surgery would decrease and, potentially,  
14 outcomes will also improve. For these reasons the committee thought that conclusions  
15 around cost effectiveness would become more favourable to robotic surgery potentially within  
16 a short period of time and recommending against it, based on current efficiency grounds,  
17 would be inappropriate. Given the above the committee recommended robotic surgery  
18 should only be considered in centres where there are already established programmes.

19 A speculative analysis as part of the bespoke economic analysis suggested that TaTME  
20 could be both cost saving and health improving compared to all other potential approaches.  
21 The committee however acknowledge that this was a new technique and that it was difficult  
22 to place a large amount of confidence in the results given the evidence to inform the model.  
23 The committee therefore only recommended its use in centres with structured and  
24 supervised programmes with appropriate auditing allowing for evaluation of the technique in  
25 future.

26 The committee were of the opinion that all recommendations were cost effective and all  
27 would potentially be cost saving within a short period of time compared to current practice.  
28 This would be largely driven by reducing the number of more intensive, expensive and  
29 potentially less effective procedures.

### 30 **References**

#### 31 **ACOSOG Z6051 trial**

32 Fleshman J, Branda M, Sargent DJ, et al. (2015) Effect of laparoscopic-assisted resection vs  
33 open resection of stage II or III rectal cancer on pathologic outcomes the ACOSOG Z6051  
34 randomized clinical trial. *Journal of the American Medical Association* 314(13): 1346-55

35 Fleshman J, Branda ME, Sargent DJ et al. (2019) Disease-free Survival and Local  
36 Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III  
37 Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial.  
38 *Annals of Surgery* 269(4): 589-95

#### 39 **ALaCaRT trial**

40 Stevenson ARL, Solomon MJ, Lumley JW et al. (2015) Effect of laparoscopic-assisted  
41 resection vs open resection on pathological outcomes in rectal cancer: The ALaCaRT  
42 randomized clinical trial. *Journal of the American Medical Association* 314(13): 1356-63

43 Stevenson ARL, Solomon MJ, Brown CSB et al. (2019) Disease-free Survival and Local  
44 Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer:  
45 The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial. *Annals of*  
46 *Surgery* 269(4): 596-602

- 1     **Arteaga Gonzalez 2006**
- 2     Arteaga Gonzalez I, Diaz Luis H, Martin Malagon A et al. (2006) A comparative clinical study  
3     of short-term results of laparoscopic surgery for rectal cancer during the learning curve.  
4     International Journal of Colorectal Disease 21(6): 590-5
- 5     **Baik 2008**
- 6     Baik SH, Ko YT, Kang CM, et al. (2008) Robotic tumor-specific mesorectal excision of rectal  
7     cancer: short-term outcome of a pilot randomized trial. Surgical Endoscopy 22: 1601 - 1608
- 8     **Bordeaux' trial**
- 9     Denost Q, Loughlin P, Chevalier R et al. (2018) Transanal versus abdominal low rectal  
10    dissection for rectal cancer: long-term results of the Bordeaux' randomized trial. Surgical  
11    Endoscopy 32(3): 486-94
- 12    Pontallier A, Denost Q, Van Geluwe B et al. (2016) Potential sexual function improvement by  
13    using transanal mesorectal approach for laparoscopic low rectal cancer excision. Surgical  
14    Endoscopy and Other Interventional Techniques 30(11): 4924-33
- 15    **Braga 2007**
- 16    Braga M, Frasson M, Vignali A et al. (2007) Laparoscopic resection in rectal cancer patients:  
17    Outcome and cost-benefit analysis. Diseases of the Colon and Rectum 50(4): 464-71
- 18    **Buonpane 2017**
- 19    Buonpane C, Efiog E, Hunsinger M et al. (2017) Predictors of utilization and quality  
20    assessment in robotic rectal cancer resection: A review of the national cancer database.  
21    American Surgeon 83(8): 918-24
- 22    **CLASICC trial**
- 23    Green B, Marshall H, Collinson F et al. (2013) Long-term follow-up of the Medical Research  
24    Council CLASICC trial of conventional versus laparoscopically assisted resection in  
25    colorectal cancer, British Journal of Surgery 100: 75-82
- 26    Guillou PJ, Quirke P, Thorpe H et al. (2005) Short-term endpoints of conventional versus  
27    laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial):  
28    multicentre, randomised controlled trial. Lancet 365(9472): 1718-26
- 29    Jayne DG, Brown JM, Thorpe H et al. (2005) Bladder and sexual function following resection  
30    for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. British  
31    Journal of Surgery 92(9): 1124-32
- 32    Jayne DG, Thorpe HC, Copeland J et al. (2010) Five-year follow-up of the Medical Research  
33    Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer.  
34    British Journal of Surgery 97(11): 1638-45
- 35    Quah HM, Jayne DG, Eu KW et al. (2002) Bladder and sexual dysfunction following  
36    laparoscopically assisted and conventional open mesorectal resection for cancer. British  
37    Journal of Surgery 89(12): 1551-6
- 38    **COLOR II trial**
- 39    Andersson J, Abis G, Gellerstedt M et al. (2014) Patient-reported genitourinary dysfunction  
40    after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II). British  
41    Journal of Surgery 101(10): 1272-9

- 1 Andersson J, Angenete E, Gellerstedt M et al. (2013) Health-related quality of life after  
2 laparoscopic and open surgery for rectal cancer in a randomized trial. *British Journal of*  
3 *Surgery* 100(7): 941-9
- 4 Bonjer HJ, Deijen CL, Abis GA et al. (2015) A randomized trial of laparoscopic versus open  
5 surgery for rectal cancer. *New England Journal of Medicine* 372, 1324-32
- 6 van der Pas MH, Haglind E, Cuesta MA et al. (2013) Laparoscopic versus open surgery for  
7 rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet*  
8 *Oncology* 14(3): 210-8
- 9 **Corbellini 2016**
- 10 Corbellini C, Biffi R, Luca F et al. (2016) Open, laparoscopic, and robotic surgery for rectal  
11 cancer: medium-term comparative outcomes from a multicenter study. *Tumori* 102(4): 414-  
12 21
- 13 **COREAN trial**
- 14 Jeong SY, Park JW, Nam BH et al. (2014) Open versus laparoscopic surgery for mid-rectal  
15 or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): Survival  
16 outcomes of an open-label, non-inferiority, randomised controlled trial. *Lancet Oncology*  
17 15(7): 767-74
- 18 Kang SB, Park JW, Jeong SY et al. (2010) Open versus laparoscopic surgery for mid or low  
19 rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): Short-term outcomes of  
20 an open-label randomised controlled trial. *Lancet Oncology* 11(7): 637-45
- 21 **Ielpo 2017**
- 22 Ielpo B, Duran H, Diaz E et al. (2017) Robotic versus laparoscopic surgery for rectal cancer:  
23 a comparative study of clinical outcomes and costs. *International Journal of Colorectal*  
24 *Disease* 32(10): 1423-9
- 25 **Ishibe 2017**
- 26 Ishibe A, Ota M, Fujii S et al. (2017) Midterm follow-up of a randomized trial of open surgery  
27 versus laparoscopic surgery in elderly patients with colorectal cancer. *Surgical Endoscopy*  
28 *and Other Interventional Techniques* 31(10): 3890-7
- 29 **Kim 2016**
- 30 Kim J, Yu C, Lim S, et al. (2016) Comparative analysis focusing on surgical and early  
31 oncological outcomes of open, laparoscopy-assisted, and robot-assisted approaches in  
32 rectal cancer patients. *International Journal of Colorectal Disease* 31(6): 1179-87
- 33 **Kim 2017a**
- 34 Kim M, Park S, Park J, et al. (2017a) Robot-assisted Versus Laparoscopic Surgery for Rectal  
35 Cancer: A Phase II Open Label Prospective Randomized Controlled Trial. *Annals of Surgery*  
36 25
- 37 **Kim 2017b**
- 38 Kim J, Baek S, Kang D, et al. (2017b) Robotic Resection is a Good Prognostic Factor in  
39 Rectal Cancer Compared with Laparoscopic Resection: Long-term Survival Analysis Using  
40 Propensity Score Matching. *Diseases of the Colon and Rectum* 60(3): 266-73
- 41 **Law 2017**

- 1 Law W and Foo D (2017) Comparison of short-term and oncologic outcomes of robotic and  
2 laparoscopic resection for mid- and distal rectal cancer. *Surgical Endoscopy and Other*  
3 *Interventional Techniques* 31(7): 2798-807
- 4 **Liang 2011**
- 5 Liang X, Hou S, Liu H, et al. (2011) Effectiveness and safety of laparoscopic resection versus  
6 open surgery in patients with rectal cancer: a randomized, controlled trial from China. *Journal*  
7 *of Laparoendoscopic Advanced Surgical Techniques A* 21(5): 381-5
- 8 **Lujan 2011**
- 9 Lujan J, Valero G, Hernandez Q et al. (2009) Randomized clinical trial comparing  
10 laparoscopic and open surgery in patients with rectal cancer. *British Journal of Surgery*  
11 96(12): 982-9
- 12 **Ng 2008**
- 13 Ng S, Leung K, Lee J, et al. (2008) Laparoscopic-assisted versus open abdominoperineal  
14 resection for low rectal cancer: A prospective randomized trial. *Annals of Surgical Oncology*  
15 15(9): 2418-25
- 16 **Ng 2009**
- 17 Ng S, Leung K, Lee J, et al. (2009) Long-term morbidity and oncologic outcomes of  
18 laparoscopic-assisted anterior resection for upper rectal cancer: ten-year results of a  
19 prospective, randomized trial. *Diseases of the Colon and Rectum* 52(4): 558-66
- 20 **Ng 2014**
- 21 Ng S, Lee J, Yiu R, et al. (2014) Laparoscopic-assisted versus open total mesorectal  
22 excision with anal sphincter preservation for mid and low rectal cancer: a prospective,  
23 randomized trial. *Surgical Endoscopy* 28(1): 297-306
- 24 **Park 2015**
- 25 Park E, Cho M, Baek S, et al. (2015) Long-term oncologic outcomes of robotic low anterior  
26 resection for rectal cancer. *Annals of Surgery* 261(1): 129-37
- 27 **ROLARR trial**
- 28 Jayne D, Pigazzi A, Marshall H, et al. (2017) Effect of robotic-assisted vs conventional  
29 laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing  
30 resection for rectal cancer: the ROLARR randomized clinical trial. *Journal of the American*  
31 *Medical Association* 318(16): 1569-1580
- 32 **Rouanet 2018**
- 33 Rouanet P, Bertrand M, Jarlier M, et al. (2018) Robotic Versus Laparoscopic Total  
34 Mesorectal Excision for Sphincter-Saving Surgery: Results of a Single-Center Series of 400  
35 Consecutive Patients and Perspectives. *Annals of Surgical Oncology* 25(12): 3572-9.
- 36 **Wang 2017**
- 37 Wang G, Wang Z, Jiang Z, et al. (2017) Male urinary and sexual function after robotic pelvic  
38 autonomic nerve-preserving surgery for rectal cancer. *International Journal of Medical*  
39 *Robotics and Computer Assisted Surgery* 13: e1725
- 40 **Yoo 2015**



- 1 Yoo B, Cho J, Shin J, et al. (2015) Robotic Versus Laparoscopic Intersphincteric Resection
- 2 for Low Rectal Cancer: Comparison of the Operative, Oncological, and Functional
- 3 Outcomes. *Annals of Surgical Oncology* 22(4): 1219-25
- 4 **Zhou 2004**
- 5 Zhou Z, Hu M, Li Y, et al. (2004) Laparoscopic versus open total mesorectal excision with
- 6 anal sphincter preservation for low rectal cancer. *Surgical Endoscopy* 18(8): 1211-5

# 1 Appendices

## 2 Appendix A – Review protocols

### 3 Review protocol for review question: What is the optimal surgical technique for 4 rectal cancer?

5 **Table 7: Review protocol for optimal surgical technique for rectal cancer**

Field (based on PRISMA-P)	Content
Review question	What is the optimal surgical technique for rectal cancer?
Type of review question	Intervention
Objective of the review	To determine the optimal surgical technique for rectal cancer.
Eligibility criteria – population/disease/condition/issue/domain	<p>Adults with non-metastatic rectal cancer based on TNM classification system:</p> <ul style="list-style-type: none"> <li>• T1-2 N1-2</li> <li>• T3 N any</li> <li>• T4 N any</li> <li>• M0.</li> </ul> <p>Staging determined by ultrasound, MRI, computed tomography scan.</p> <p>Rectal cancer defined as any tumour within 15 cm from anal verge excluding anal canal.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> <li>• bowel obstruction, metastatic cancer</li> </ul>
Eligibility criteria – intervention(s)/exposure(s)/prognostic factor(s)	<p>Surgical resection (for example abdominoperineal resection or low anterior resection)</p> <ul style="list-style-type: none"> <li>• Open</li> <li>• Laparoscopic</li> <li>• Robotic</li> <li>• Transanal total mesorectal excision (TaTME; only anterior resection)</li> </ul>
Eligibility criteria – comparator(s)/control or reference (gold) standard	Surgical techniques compared to each other
Outcomes and prioritisation	<p><b>Critical outcomes:</b></p> <ul style="list-style-type: none"> <li>• Overall survival (MID: statistical significance)</li> <li>• Quality of life measured using validated scales only (MID: from literature, see further down this document) <ul style="list-style-type: none"> <li>○ Overall</li> <li>○ Sexual function</li> <li>○ Bladder function</li> </ul> </li> <li>• Resection margins (positive/negative; MID: statistical significance)</li> </ul>

Field (based on PRISMA-P)	Content
	<p><b>Important outcomes:</b></p> <ul style="list-style-type: none"> <li>• Local recurrence (MID: statistical significance)</li> <li>• Length of hospital stay (MID: statistical significance)</li> <li>• 90-day mortality (MID: statistical significance)</li> <li>• Treatment-related complications (MID: statistical significance):               <ul style="list-style-type: none"> <li>○ Anastomotic leak (only relevant in anterior resection)</li> <li>○ Surgical site infection</li> <li>○ Blood loss</li> </ul> </li> </ul> <p>Quality of life MID from the literature:</p> <ul style="list-style-type: none"> <li>• EORTC QLQ-C30: 5 points</li> <li>• EORTC QLQ-CR29: 5 points</li> <li>• EORTC QLQ-CR38: 5 points</li> <li>• EQ-5D: 0.09 to 0.10 using FACT-G quintiles</li> <li>• FACT-C: 5 points</li> <li>• FACT-G: 5 points</li> <li>• SF-12: &gt;3.77 for the mental component summary and &gt; 3.29 for the physical component summary of the Short Form SF-12 (SF-12)</li> <li>• SF-36: &gt;7.1 for the physical functioning scale, &gt;4.9 for the bodily pain scale, and &gt;7.2 for the physical component summary</li> </ul>
Eligibility criteria – study design	<ul style="list-style-type: none"> <li>• Systematic reviews of (RCTs</li> <li>• RCTs</li> <li>• If eligible RCTs are not available for critical outcomes: comparative observational studies</li> </ul>
Other inclusion exclusion criteria	<p>Inclusion:</p> <ul style="list-style-type: none"> <li>• English-language</li> <li>• Published full texts</li> <li>• All settings will be considered that consider medications and treatments available in the UK</li> <li>• Studies published since 2000</li> </ul> <p>Studies published 2000 onwards will be considered for this review question, as the GC felt that surgical techniques have evolved and evidence prior to 2000 would not be relevant any longer.</p>
Proposed sensitivity/sub-group analysis, or meta-regression	<p>In case of high heterogeneity in meta-analysis, the following subgroups will be considered:</p> <ul style="list-style-type: none"> <li>• People who underwent abdominoperineal resection</li> <li>• People who underwent (low) anterior resection</li> <li>• People who received preoperative radiotherapy or chemoradiotherapy</li> <li>• People who did not receive preoperative radiotherapy or chemoradiotherapy</li> </ul>
Selection process – duplicate screening/selection/analysis	<p>Sifting, data extraction, appraisal of methodological quality and GRADE assessment will be performed by the systematic reviewer. Resolution of any disputes will be with the senior systematic reviewer and the Topic Advisor. Quality control will be performed by the senior systematic reviewer.</p> <p>Dual sifting will be undertaken for this question for a random 10% sample of the titles and abstracts identified by the search.</p>

Field (based on PRISMA-P)	Content
Data management (software)	<p>Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).</p> <p>'GRADEpro' will be used to assess the quality of evidence for each outcome.</p> <p>NGA STAR software will be used for study sifting, data extraction, recording quality assessment using checklists and generating bibliographies/citations.</p>
Information sources – databases and dates	<p>Potential sources to be searched: Medline, Medline In-Process, CCTR, CDSR, DARE, HTA, Embase</p> <p>Limits (e.g. date, study design):</p> <ul style="list-style-type: none"> <li>• Apply standard animal/non-English language exclusion</li> <li>• Limit to RCTs and systematic reviews in first instance, but download all results</li> <li>• Dates: from 2000</li> </ul>
Identify if an update	Not an update
Author contacts	<p><a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10060">https://www.nice.org.uk/guidance/indevelopment/gid-ng10060</a></p> <p>Developer: NGA</p>
Highlight if amendment to previous protocol	For details please see section 4.5 of <a href="#">Developing NICE guidelines: the manual</a>
Search strategy – for one database	For details please see appendix B.
Data collection process – forms/duplicate	A standardised evidence table format will be used, and published as appendix D (clinical evidence tables) or H (economic evidence tables).
Data items – define all variables to be collected	For details please see evidence tables in appendix D (clinical evidence tables) or H (economic evidence tables).
Methods for assessing bias at outcome/study level	<p>Standard study checklists were used to critically appraise individual studies. For details please see section 6.2 of <a href="#">Developing NICE guidelines: the manual</a></p> <p>Appraisal of methodological quality: The methodological quality of each study will be assessed using an appropriate checklist:</p> <ul style="list-style-type: none"> <li>• ROBIS for systematic reviews</li> <li>• Cochrane risk of bias tool for RCTs</li> <li>• ROBINS-I tool for non-randomised studies (if applicable)</li> </ul> <p>The quality of the evidence for an outcome (i.e. across studies) will be assessed using GRADE.</p> <p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/">http://www.gradeworkinggroup.org/</a></p>
Criteria for quantitative synthesis	For details please see section 6.4 of <a href="#">Developing NICE guidelines: the manual</a>
Methods for quantitative analysis – combining studies and	<p>Synthesis of data: Pairwise meta-analysis of randomised trials will be conducted where appropriate.</p>

Field (based on PRISMA-P)	Content
exploring (in)consistency	When meta-analysing continuous data, final and change scores will be pooled if baselines are comparable. If any studies reports both, the method used in the majority of studies will be analysed.  MIDs: The guideline committee identified statistically significant differences as appropriate indicators for clinical significance for all outcomes except quality of life for which published MIDs from literature will be used (see outcomes section for more information).
Meta-bias assessment – publication bias, selective reporting bias	For details please see section 6.2 of <a href="#">Developing NICE guidelines: the manual</a> . If sufficient relevant RCT evidence is available, publication bias will be explored using RevMan software to examine funnel plots.
Confidence in cumulative evidence	For details see sections 6.4 and 9.1 of <a href="#">Developing NICE guidelines: the manual</a> .
Rationale/context – what is known	For details please see the introduction to the evidence review.
Describe contributions of authors and guarantor	A multidisciplinary committee developed the guideline. The committee was convened by The National Guideline Alliance and chaired by Peter Hoskin in line with section 3 of <a href="#">Developing NICE guidelines: the manual</a> . Staff from The National Guideline Alliance undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the guideline in collaboration with the committee. For details please see Supplement 1: methods.
Sources of funding/support	The National Guideline Alliance is funded by NICE and hosted by the Royal College of Obstetricians and Gynaecologists
Name of sponsor	The National Guideline Alliance is funded by NICE and hosted by the Royal College of Obstetricians and Gynaecologists
Roles of sponsor	NICE funds the National Guideline Alliance to develop guidelines for those working in the NHS, public health, and social care in England
PROSPERO registration number	Not registered

1  
2  
3

## 1 Appendix B – Literature search strategies

### 2 Literature search strategies for review question: What is the optimal surgery for 3 rectal cancer?

4 A combined search was conducted for the following three review questions:

- 5 • What is the most effective treatment for early rectal cancer?
- 6 • What is the effectiveness of preoperative radiotherapy or chemoradiotherapy for rectal  
7 cancer?
- 8 • What is the optimal surgical technique for rectal cancer?

### 9 Database: Embase/Medline

10 Last searched on: 12/02/2019

#	Search
1	exp Rectal Neoplasms/ use prmz
2	*rectum cancer/ or *rectum tumor/
3	2 use oemez
4	exp Adenocarcinoma/
5	(T1 or T2 or N0 or M0).ti,ab.
6	1 or 3
7	4 or 5
8	6 and 7
9	((rectal or rectum) adj3 (cancer* or neoplas* or malignan* or tumo?r* or carcinom* or adeno*)).ti,ab.
10	early rect* cancer.ti,ab.
11	6 or 8 or 9 or 10
12	exp radiotherapy/ or exp radiation oncology/ or exp external beam radiotherapy/ or exp Brachytherapy/ or exp preoperative care/ or exp neoadjuvant therapy/ or exp multimodality cancer therapy/ or exp chemotherapy/ or exp antineoplastic agent/ or exp drug therapy/ or exp chemoradiotherapy/ or exp fluorouracil/ or exp folinic acid/ or exp capecitabine/ or exp oxaliplatin/ or exp bevacizumab/ or exp methotrexate/ or exp radiation dose fractionation/ or exp tumor recurrence/
13	12 use oemez
14	exp Radiotherapy/ or exp Radiation Oncology/ or exp Radiotherapy, Computer-Assisted/ or exp Brachytherapy/ or exp Preoperative Care/ or exp Neoadjuvant Therapy/ or exp Combined Modality Therapy/ or exp Chemoradiotherapy/ or exp Antineoplastic Combined Chemotherapy Protocols/ or exp Drug Therapy/ or exp Antineoplastic Agents/ or exp Fluorouracil/ or exp Leucovorin/ or exp Capecitabine/ or exp Bevacizumab/ or exp Methotrexate/ or exp Dose Fractionation/
15	14 use prmz
16	((radiotherap* or chemoradio* or radiation or brachytherapy* or chemotherapy*) adj (pre?op* or preop* or periop* or neoadjuvant)).ti,ab.
17	(5-fluorouracil or 5-FU or leucovorin or folinic acid or capecitabine or oxaliplatin or bevacizumab or methotrexate or dose* or fraction* or recurren*).ti,ab.
18	13 or 15 or 16 or 17
19	exp Laparoscopy/ or exp Transanal Endoscopic Microsurgery/ or exp Minimally Invasive Surgical Procedures/ or exp Endoscopy/ or exp Endoscopic Mucosal Resection/ or exp Surgical Procedures, Operative/ or exp Robotic Surgical Procedures/ or exp Surgery, Computer-Assisted/ or exp Dissection/
20	19 use prmz
21	exp laparoscopy/ or exp endoscopic surgery/ or exp transanal endoscopic microsurgery/ or exp endoscopy/ or exp minimally invasive surgery/ or exp endoscopic mucosal resection/ or exp surgery/ or exp robotic surgical procedure/ or exp computer assisted surgery/ or exp dissection/ or exp total mesorectal excision/ or exp excision/ or exp rectum resection/ or exp endoscopic polypectomy/ or exp polypectomy/ or exp endoscopic submucosal dissection/
22	21 use oemez
23	(laparoscop* or endoscop* or transanal excision* or TAE or transanal endoscopic microsurger* or TEM or TEMS or transanal resection or TART or transanal minimally invasive surger* or TAMIS or total mesorectal excision* or TaTME or transanal total mesorectal excision* or TME or anterior resection* or abdominoperineal resection* or endoscopic resection* or polypectomy or endoscopic submucosal dissection* or ESD or endoscopic mucosal resection* or EMR or surger* or surgic* or operat*).ti,ab.
24	20 or 22 or 23
25	11 and 18
26	11 and 18 and 24
27	25 or 26
28	limit 27 to english language
29	limit 28 to yr="1997 -Current"
30	(conference abstract or letter).pt. or letter/ or editorial.pt. or note.pt. or case report/ or case study/ use oemez
31	Letter/ or editorial/ or news/ or historical article/ or anecdotes as topic/ or comment/ or case report/ use prmz
32	(letter or comment* or abstracts).ti.

#	Search
33	or/30-32
34	randomized controlled trial/ use pmz
35	randomized controlled trial/ use omezdz
36	random*.ti,ab.
37	or/34-36
38	33 not 37
39	(animals/ not humans/) or exp animals, laboratory/ or exp animal experimentation/ or exp models, animal/ or exp rodentia/ use pmz
40	(animal/ not human/) or nonhuman/ or exp animal experiment/ or exp experimental animal/ or animal model/ or exp rodent/ use omezdz
41	(rat or rats or mouse or mice).ti.
42	38 or 39 or 40 or 41
43	29 not 42
44	clinical Trials as topic.sh. or (controlled clinical trial or pragmatic clinical trial or randomized controlled trial).pt. or (placebo or randomi#ed or randomly).ab. or trial.ti.
45	44 use pmz
46	crossover procedure/ or double blind procedure/ or randomized controlled trial/ or single blind procedure/ or (assign* or allocat* or crossover* or cross over* or ((doubl* or singl*) adj blind*) or factorial* or placebo* or random* or volunteer*).ti,ab.
47	46 use omezdz
48	or/45,47
49	43 and 48
50	epidemiologic studies/ or observational study/ or case control studies/ or retrospective studies/ or cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or cross-sectional studies/
51	50 use pmz
52	exp observational study/ or exp case control study/ or exp retrospective study/ or exp cohort analysis/ or exp longitudinal study/ or exp follow up/ or exp prospective study/ or exp cross-sectional study/
53	52 use omezdz
54	((retrospective* or cohort* or longitudinal or follow?up or prospective or cross section*) adj3 (stud* or research or analys*)).ti.
55	51 or 53 or 54
56	43 and 55
57	49 or 56
58	57 not 56
59	56 or 58

## 1 Database: Cochrane Library

2 Last searched on: 12/02/2019

#	Search
1	MeSH descriptor: [Rectal Neoplasms] explode all trees
2	MeSH descriptor: [Adenocarcinoma] explode all trees
3	T1 or T2 or N0 or M0
4	#2 or #3
5	#1 and #4
6	(rectal or rectum) near (cancer* or neoplas* or malignan* or tumo?r* or carcinom* or adeno*)
7	early rect* cancer
8	#1 or #5 or #6 or #7
9	MeSH descriptor: [Radiotherapy] explode all trees
10	MeSH descriptor: [Radiation Oncology] explode all trees
11	MeSH descriptor: [Radiotherapy, Computer-Assisted] explode all trees
12	MeSH descriptor: [Brachytherapy] explode all trees
13	MeSH descriptor: [Preoperative Care] explode all trees
14	MeSH descriptor: [Neoadjuvant Therapy] explode all trees
15	MeSH descriptor: [Combined Modality Therapy] explode all trees
16	MeSH descriptor: [Chemoradiotherapy] explode all trees
17	MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] explode all trees
18	MeSH descriptor: [Drug Therapy] explode all trees
19	MeSH descriptor: [Antineoplastic Agents] explode all trees
20	MeSH descriptor: [Fluorouracil] explode all trees
21	MeSH descriptor: [Capecitabine] explode all trees
22	MeSH descriptor: [Bevacizumab] explode all trees
23	MeSH descriptor: [Methotrexate] explode all trees
24	MeSH descriptor: [Dose Fractionation] explode all trees
25	(radiotherap* or chemoradio* or radiation or brachytherapy* or chemotherapy*) near (pre?op* or preop* or periop* or neoadjuvant)
26	5-fluorouracil or 5-FU or leucovorin or folinic acid or capecitabine or oxaliplatin or bevacizumab or methotrexate or dose* or fraction* or recurren*
27	#9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26

#	Search
28	MeSH descriptor: [Laparoscopy] explode all trees
29	MeSH descriptor: [Transanal Endoscopic Microsurgery] explode all trees
30	MeSH descriptor: [Minimally Invasive Surgical Procedures] explode all trees
31	MeSH descriptor: [Endoscopy] explode all trees
32	MeSH descriptor: [Endoscopic Mucosal Resection] explode all trees
33	MeSH descriptor: [Surgical Procedures, Operative] explode all trees
34	MeSH descriptor: [Robotic Surgical Procedures] explode all trees
35	MeSH descriptor: [Surgery, Computer-Assisted] explode all trees
36	MeSH descriptor: [Dissection] explode all trees
37	laparoscop* or endoscop* or transanal excision* or TAE or transanal endoscopic microsurger* or TEM or TEMS or transanal resection or TART or transanal minimally invasive surger* or TAMIS or total mesorectal excision* or TME or anterior resection* or abdominoperineal resection* or endoscopic resection* or polypectomy or endoscopic submucosal dissection* or ESD or endoscopic mucosal resection* or EMR or surger* or surgic* or operat*
38	#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37
39	#8 and #27
40	#8 and #27 and #38
41	#39 or #40 Publication Year from 1997 to 2017


1



## 1 Appendix C – Clinical evidence study selection

### 2 Clinical study selection for review question: What is the optimal surgery for rectal 3 cancer?

#### 4 Figure 1: Study selection flow chart



5  
6 \*The literature search was done for 3 review questions at once including the current review and review questions:  
7 'What is the most effective treatment for early rectal cancer?' and 'What is the effectiveness of preoperative  
8 radiotherapy and chemoradiotherapy for rectal cancer?'. The number of titles and abstracts identified applies for  
9 all three reviews but all the other numbers are applicable to this specific review only. In addition, possibly relevant  
10 studies were added from systematic reviews.

1 **Appendix D – Clinical evidence tables**

2 **Clinical evidence tables for review question: What is the optimal surgery for rectal cancer?**

3 **Table 8: Clinical evidence tables**

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<b>Full citation</b> Andersson, J., Abis, G., Gellerstedt, M., Angenete, E., Angeras, U., Cuesta, M. A., Jess, P., Rosenberg, J., Bonjer, H. J., Haglind, E., Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II), Br J Surg, 103, 1746, 2016  <b>Ref Id</b> 810630  <b>Country/ies                      where the study                      was carried out</b>	<b>Sample size</b> See Bonjer 2015 (COLOR II trial).  <b>Characteristics</b>  <b>Inclusion criteria</b>  <b>Exclusion criteria</b>	<b>Interventions</b>	<b>Details</b>	<b>Results</b>	<b>Limitations</b>  <b>Other information</b>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<b>Study type</b>  <b>Aim of the study</b>  <b>Study dates</b>  <b>Source of funding</b>					
<b>Full citation</b> Andersson, J., Angenete, E., Gellerstedt, M., Angeras, U., Jess, P., Rosenberg, J., Furst, A., Bonjer, J., Haglind, E., Health-related quality of life after laparoscopic and open surgery for rectal cancer in a randomized trial, Br J Surg, 100, 941-9, 2013  <b>Ref Id</b> 810631  <b>Country/ies where the study was carried out</b>  <b>Study type</b>	<b>Sample size</b> See Bonjer 2015 (COLOR II trial).  <b>Characteristics</b>  <b>Inclusion criteria</b>  <b>Exclusion criteria</b>	<b>Interventions</b>	<b>Details</b>	<b>Results</b>	<b>Limitations</b>  <b>Other information</b>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<b>Aim of the study</b>					
<b>Study dates</b>					
<b>Source of funding</b>					
<b>Full citation</b> Arteaga Gonzalez, I., Diaz Luis, H., Martin Malagon, A., Lopez-Tomassetti Fernandez, E. M., Arranz Duran, J., Carrillo Pallares, A., A comparative clinical study of short-term results of laparoscopic surgery for rectal cancer during the learning curve, International Journal of Colorectal Disease, 21, 590-595, 2006  <b>Ref Id</b> 745480  <b>Country/ies where the study was carried out</b>	<b>Sample size</b> N=40 randomised; n=20 laparoscopic surgery; n=20 open surgery  <b>Characteristics</b> Age in years, mean±SD: Laparoscopic 66.6±12.6 Open 70.7±9.2  Male sex, n/n: Laparoscopic 11/20 Open 8/20  BMI, mean±SD Laparoscopic 26.0±2.9 Open 27.9±5.1  Tumour distance to anal verge, n/n: 0-5 cm Laparoscopic 9/20 Open 7/20 6-11 cm	<b>Interventions</b> Laparoscopic surgery versus open surgery  Type of surgery, n/n: Haartmann Laparoscopic 5/20 Open 6/20 Lower anterior resection Laparoscopic 9/20 Open 10/20 Abdominoperineal resection Laparoscopic 6/20 Open 4/20  Total mesorectal excision (TME) was performed on all tumours located in the middle or lower thirds of the rectum.	<b>Details</b> Randomisation and allocation concealment No details provided.  Blinding No blinding.  Follow-up/outcomes Clinical and anatomopathological data were prospectively collected into a database.  Statistical analysis Continuous variables compared using Student's t-test and categorical variables compared using Chi-squared or Fisher's exact test.	<b>Results</b> Outcome: Radial margin >2 mm Laparoscopic 20/20 Open 16/20  Outcome: Tumour-free distal margin Laparoscopic 20/20 Open 20/20  Outcome: Length of hospital stay in days, mean±SD Laparoscopic 9.1±5.7 (n=20) Open 15.6±6.1 (n=20)  Outcome: Anastomotic leak Laparoscopic 0/20 Open 2/20	<b>Limitations</b> Cochrane risk of bias tool  Selection bias Random sequence generation: unclear risk (Details not reported.) Allocation concealment: unclear risk (Details not reported.)  Performance bias Blinding of participants and personnel: high risk (No blinding.)  Detection bias Blinding of outcome assessment: high risk (No blinding.)  Attrition bias Incomplete outcome data: low risk (It is not clear if the <b>Sample size</b> reported)

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Spain</p> <p><b>Study type</b> RCT</p> <p><b>Aim of the study</b> To assess reliability and efficiency of laparoscopy in the curative treatment of rectal carcinoma.</p> <p><b>Study dates</b> Enrolment between January 2003 and April 2004.</p> <p><b>Source of funding</b> None reported.</p>	<p>Laparoscopic 6/20 Open 7/20 11-15 cm Laparoscopic 5/20 Open 6/20</p> <p>TNM staging, n/n: I Laparoscopic 4/20 Open 7/20 II Laparoscopic 7/20 Open 5/20 III Laparoscopic 7/20 Open 3/20 IV Laparoscopic 2/20 Open 5/20</p> <p><b>Inclusion criteria</b> Carcinomas located less than 15 cm from the anal verge (determined with a flexible endoscope).</p> <p><b>Exclusion criteria</b> Tumours with obstruction or perforation symptoms; preoperatively diagnosed T4 staging; tumours larger than 7 cm;</p>	<p>Laparoscopic surgery was performed with 4-6 ports.</p> <p>Patients with preoperatively staged T3 or T4 middle and lower third tumours or mesorectal adenopathy without distant metastases received a regimen of preoperative radiotherapy (45 Gy in 4 weeks).</p>		<p>Outcome: Wound infection Laparoscopic 3/20 Open 6/20</p> <p>Outcome: Blood loss in ml, mean±SD Laparoscopic 243.4±129.6 (n=20) Open 405.0±151.2 (n=20)</p>	<p>is the original sample randomised. However, this paper only reports short-term outcomes and no one was lost to follow-up.)</p> <p>Reporting bias Selective reporting: low risk</p> <p>Other bias N/A</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	candidates for local surgery.				
<p><b>Full citation</b> Baik, S.H., Ko, Y.T., Kang, C.M. et al. (2008) Robotic tumor-specific mesorectal excision of rectal cancer: short-term outcome of a pilot randomized trial. <i>Surg Endosc</i> 22: 1601</p> <p><b>Ref Id</b> 1118085</p> <p><b>Country/ies where the study was carried out</b> Korea</p> <p><b>Study type</b> RCT</p> <p><b>Aim of the study</b> To report on the use of the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) for tumour-specific mesorectal</p>	<p><b>Sample size</b> N=36 randomised.</p> <p>Robotic tumor-specific mesorectal excision n=18; laparoscopic tumor-specific mesorectal excision n=18.</p> <p>Rectal adenocarcinoma; without distant metastasis; within 15cm of anal verge; T4 excluded</p> <p>28% were T1-2N0M0.</p> <p><b>Characteristics</b> Age, years, median (range): Robotic tumor-specific mesorectal excision 57.3 ± 6.3, 60 (37–79); laparoscopic tumor-specific mesorectal excision 62.0 ± 9.0, 60 (47–78); <i>p</i> = 0.079. Sex, n (%): Male - Robotic tumor-specific mesorectal excision 14 (77.8); laparoscopic</p>	<p><b>Interventions</b> Robotic tumor-specific mesorectal excision versus laparoscopic tumor-specific mesorectal excision.</p> <p>Preoperative chemoradiotherapy: NR</p> <p>100% LAR</p> <p>Robotic tumor-specific mesorectal excision: “A standard mechanical bowel preparation was performed 24 h before the operation, and pneumatic compression stockings were applied 1 h beforehand. The patient was placed supine with the legs apart in a 30° Trendelenburg position and 15° right side down. For the first three cases, a 12-mm trocar was placed through an incision just above the umbilicus after achievement of pneumoperitoneum.</p>	<p><b>Details</b> Randomisation Computer generated. No further details provided.</p> <p>Allocation concealment Allocation concealed through use of Independent scheduling nurse.</p> <p>Blinding Not reported</p> <p>Attrition Not reported</p> <p>Statistical analysis Fishers’s exact tests for categorical variables; Mann-Whitney for continuous variables. Power calculations were not conducted as the purpose of the trial was to generate estimates for sample size calculations. All <i>p</i> values of 0.05 or less were considered statistically significant.</p> <p>Follow up Follow-up took place in immediate aftermath – perioperative, postoperative and pathologic outcomes.</p>	<p><b>Results</b> Length of stay (days): robotic tumor-specific mesorectal excision 6.9 ± 1.3, 7 (5–10); laparoscopic tumor-specific mesorectal excision 8.7 ± 1.3, 9 (6–12); <i>p</i> &lt; 0.001.</p>	<p><b>Limitations</b> Risk of bias assessed using Cochrane risk of bias tool</p> <p>Selection bias Random sequence generation: Low risk of bias.</p> <p>Allocation concealment: Low risk of bias.</p> <p>Performance bias Blinding of participants and personnel: Unclear risk of bias. No details reported.</p> <p>Detection bias Blinding of outcome assessment: Low risk of bias. No details reported however lack of blinding is unlikely to have had an effect on length of stay estimates.</p> <p>Attrition bias Incomplete outcome data: Low risk of bias.</p> <p>Reporting bias</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>excision based on total mesorectal excision compared to conventional laparoscopic surgery in rectal cancer patients.</p> <p><b>Study dates</b> April 2006 to February 2007</p> <p><b>Source of funding</b> Faculty research grant of the Yonsei University College of Medicine for 2006 (6-2006-0111).</p>	<p>tumor-specific mesorectal excision 14 (77.8); <math>p = 1.000</math>.</p> <p>Mean height (cm), median (range): Robotic tumor-specific mesorectal excision <math>166.9 \pm 8.7</math>, 160 (145–174); laparoscopic tumor-specific mesorectal excision <math>163.8 \pm 8.1</math>, 163 (144–177); <math>p = 0.296</math>.</p> <p>Mean weight (kg), median (range): Robotic tumor-specific mesorectal excision <math>63.6 \pm 8.2</math>, 60 (46–85); laparoscopic tumor-specific mesorectal excision <math>64.5 \pm 9.4</math>, 60.8 (50–94); <math>p = 0.765</math></p> <p>Mean BMI (kg/m<sup>2</sup>), median (range): Robotic tumour-specific mesorectal excision <math>22.8 \pm 1.8</math>, 23.6 (19.4–31.7); laparoscopic tumour-specific <math>24.0 \pm 2.5</math>, 23.7 (18.6–31.0); <math>p = 0.122</math>.</p> <p>American Society of Anesthesiologists Score, n(%): 1 = Robotic tumour-specific mesorectal excision 12</p>	<p>Then a 30° standard 12-mm robotic laparoscope was inserted through the 12-mm trocar. The other two 8-mm da Vinci trocars were replaced under direct vision, respectively, in the left McBurney area on the lateral margin of the abdominal rectus muscle and in the right McBurney area. A 5-mm trocar was placed in the right midabdomen lateral to the umbilicus in the midaxillary line to allow assistant access for mobilization of the left colon. An additional 12-mm trocar was placed on the right, lateral to the right 8-mm da Vinci trocars, to allow the initial mobilization of the left colon and the use of an endoscopic stapler. After the third case, we changed the trocar locations to allow for the use of four robotic arms. One additional 8-mm da Vinci trocar was used on the left lateral to the previous da Vinci trocar</p>	<p><b>Outcomes</b></p> <p>Perioperative – haemoglobin change (g/dl); days to peristalsis; length of stay (days); conversion n (%).</p> <p>Postoperative – intraluminal bleeding; intraabdominal bleeding; back pain; scrotal swelling.</p> <p>Pathologic – harvested lymph nodes, mean proximal resection margin; mean distal resection margin.</p>		<p>Selective reporting: Low risk of bias.</p> <p>Other bias: N/A</p> <p><b>Other information</b> 28% were T1-2N0M0.</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	<p>(66.7); laparoscopic tumor-specific mesorectal excision 9 (52.9); 2 = Robotic tumor-specific mesorectal excision 6 (33.3); laparoscopic tumor-specific mesorectal excision 6 (35.3); 3 = Robotic tumor-specific mesorectal excision 0 (0.0); laparoscopic tumor-specific mesorectal excision 1 (5.9); 4 = Robotic tumor-specific mesorectal excision 0 (0.0); laparoscopic tumor-specific mesorectal excision 1 (5.9); <math>p = 0.493</math>.</p> <p>Tumour, node, metastasis staging n (%): I = Robotic tumor-specific mesorectal excision 5 (27.8); laparoscopic tumor-specific mesorectal excision 5 (27.8); II = Robotic tumor-specific mesorectal excision 4 (22.2); laparoscopic tumor-specific mesorectal excision 4 (22.2); <math>p = 1.000</math>.</p>	<p>in the left McBurney area, and we removed the 12-mm trocar on the right lateral to the right da Vinci trocar. An 11-mm trocar was placed in the right mid abdomen lateral to the umbilicus in the midaxillary line to allow access for mobilization of the left colon and to allow use of a 10-mm endoclip. In combinations with these five trocar locations, one da Vinci trocar in the right McBurney area was replaced with a 12-mm trocar to allow use of an endoscopic stapler. After the inferior mesenteric artery and vein had been divided proximally using clips, the left colon was mobilized using standard laparoscopic instruments. Next, the robotic instrument was positioned between the legs. The rectum was suspended using an atraumatic grasper through the left port, and rectal dissection in the mesorectal plane</p>			



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	<p>Mean distance from anal verge (cm), median (range): Robotic tumor-specific mesorectal excision 11.3 ± 2.5 10.5 (5–15); laparoscopic tumor-specific mesorectal excision 11.0 ± 2.5 10.0 (6–15); <math>p = 0.645</math>.</p> <p>Previous adominal surgery n (%) - Open radical subtotal gastrectomy: Robotic tumor-specific mesorectal excision 0 (0.0); laparoscopic tumor-specific mesorectal excision 1 (5.6); <math>p = 1.000</math>.</p> <p>The authors report narratively that the two groups did not differ significantly in relation to pathologic outcomes (harvested lymph nodes, mean proximal resection margin; mean distal resection margin).</p> <p><b>Inclusion criteria</b> Patients were consecutive colorectal cabncer patients in one</p>	<p>proceeded using a cautery hook in accordance with TSME principles. The mesorectum was divided precisely beyond the tumor using both robotic arms. The rectum itself was divided using an Endo-GIA (Tyco U.S. Surgical, Norwalk, Conneticut). The robotic instrument then was disengaged. The specimen was extracted though the left lower trocar incision, which was enlarged to approximately 3 to 4 cm after protection with a polyurethane retrieval bag. An endto- end anastomosis (EEA) anvil then was inserted into the proximal colon after tumor resection and secured with a purse-string suture. The colon was placed back into the abdomen, and the port site was closed. Pneumoperitoneum was restored, and an EEA stapler was used to create an end-to-end anastomosis. The</p>			

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	<p>hospital. No inclusion criteria are reported.</p> <p><b>Exclusion criteria</b> Based on preoperative workup patients were excluded on the basis of T4 or M1 clinical stage, significant lateral pelvic nodes, tumour infiltration into anal sphincter complex.</p> <p>Preoperative workup consisted of physical examination, complete blood count, electrolytes, liver function test, chest x-rays, and electrocardiogram. Colonoscopies were performed routinely to obtain tissue diagnosis and to evaluate the entire colon. Abdominopelvic computed tomography was performed to assess distant metastasis and the status of local disease infiltration. Pelvic magnetic resonance imaging was used to evaluate the</p>	<p>anastomosis was tested with air inflation.”</p> <p>Laparoscopic tumor-specific mesorectal excision: “Bowel preparation, application of pneumatic compression stockings, and patient positioning were the same as for the robotic procedures. An 11-mm trocar was placed through an incision just above the umbilicus after achievement of pneumoperitoneum. Then a 30° standard laparoscope was inserted through the 11-mm trocar. The other four trocars were used in the left McBurney area, right McBurney area, and the left and right midabdomen lateral to the umbilicus along the midaxillary line. A 12-mm trocar was used in the left McBurney area to facilitate use of an Endo-GIA. Left colon mobilization was performed in a medial to lateral fashion. The</p>			

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	degree of local infiltration and nodal metastasis. Tumor location was measured using rigid proctoscopy.	inferior mesenteric artery (IMA) was divided at the root of the IMA using an endoclip, and rectal dissection in the mesorectal plane was performed using conventional laparoscopic instruments in accordance with TSME principles. The mesorectum was divided precisely beyond the tumor with an ultrasonic device, after which the rectum itself was divided with an Endo-GIA. Specimen extraction and reconstruction were the same as with the robotic procedure."			
<b>Full citation</b> Bonjer, H. J., Deijen, C. L., Abis, G. A., Cuesta, M. A., Van Der Pas, M. H. G. M., De Lange-De Klerk, E. S. M., Lacy, A. M., Bemelman, W. A., Andersson, J., Angenete, E., Rosenberg, J., Fuerst, A.,	<b>Sample size</b> N=1,103 randomised; n=739 allocated to laparoscopic surgery of which 40 were excluded, n=699 included in analysis ; n=364 allocated to open surgery of which 19 were excluded, n=345 included in analysis (main reasons for exclusion were that the	<b>Interventions</b> Laparoscopic surgery versus open surgery  All procedures had to comply with the principles of TME or partial mesorectal excision (PME).  Resection with PME, n (%) Laparoscopic 72 (10)	<b>Details</b> Randomisation and allocation concealment The participants were registered on the trial's website by the local investigator to ensure allocation concealment. Randomisation was done in a 2:1 ratio in accordance with a list of randomisation numbers and treatment allocation. This list was	<b>Results</b> Outcome: Overall survival at 3 years Laparoscopic 86.7% Open 83.6% (No statistical difference between groups, narratively reported. No number of events, no HR, no p-values reported.)	<b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: low risk Allocation concealment: low risk  Performance bias Blinding of participants and personnel: high risk (No blinding.)

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Haglund, E., A randomized trial of laparoscopic versus open surgery for rectal cancer, New England Journal of Medicine, 372, 1324-1332, 2015 <b>Ref Id</b> 745799</p> <p><b>Country/ies where the study was carried out</b> Belgium, Canada, Denmark, Germany, the Netherlands, Poland, South Korea, Spain, Sweden</p> <p><b>Study type</b> RCT (COLOR II trial)</p> <p><b>Aim of the study</b> To compare 3-year rates of cancer recurrence in the pelvic or perineal area (locoregional recurrence) and survival after laparoscopic and</p>	<p>participant had distant metastasis, did not have carcinoma, had T4 tumour, withdrew consent)</p> <p><b>Characteristics</b> Age in years, mean±SD Laparoscopic 66.8±10.5 Open 65.8±10.9 Male sex, (%) Laparoscopic 448 (64) Open 211 (61)</p> <p>BMI, mean±SD Laparoscopic 26.1±4.5 Open 26.5±4.7</p> <p>Tumour distance from the anal verge, n (%) &lt;5 cm Laparoscopic 203 (29) Open 93 (27) 5-&lt;10 cm Laparoscopic 273 (39) Open 136 (39) 10-15 cm Laparoscopic 223 (32) Open 116 (34)</p> <p>Clinical stage, n (%)</p>	<p>Open 35 (10) Resection with TME, n (%) Laparoscopic 418 (60) Open 230 (67) Abdominoperineal resection Laparoscopic 200 (29) Open 80 (23) Hartmann procedure Laparoscopic 36 (5) Open 25 (7)</p> <p>Preoperative radiotherapy, n (%) Laparoscopic 412 (59) Open 199 (58)</p> <p>Preoperative chemotherapy, n (%) Laparoscopic 196/609 (32) Open 99/295 (34)</p>	<p>computer generated by the trial statistician. The randomisation was stratified by centre, tumour location, and preoperative radiotherapy. It was implemented by use of an internet application to allow central randomisation.</p> <p>Blinding No blinding.</p> <p>Follow-up/outcomes Minimal required follow-up included annual clinical examinations for 5 years after surgery. Three years after the index surgery, CT or MRI of the pelvis combined with imaging of the liver and the chest were performed. The primary outcome was the proportion of patients with local recurrence at 3 years. For health-related quality of life, validated Swedish, Dutch, Danish, English and German translations of the following instruments were used: EQ-5D, EORTC QLQ-C30 and EORTC QLQ-CR38. (Information on</p>	<p>Outcome: Global quality of life (QLQ-C30; scale 0 to 100, higher score indicating better quality of life)* Baseline score Laparoscopic 72.8±20.18 (n=243) Open 68.6±20.81 (n=109) Mean difference at 4 weeks adjusted for baseline† Laparoscopic (n=230) - open (n=108) 0.3 (95% CI -4.7 to 5.3) Mean difference at 6 months adjusted for baseline† Laparoscopic (n=221) - Open (n=106) -2.2 (95% CI -6.8 to 2.4) Mean difference at 12 months adjusted for baseline† Laparoscopic (n=208) - Open (n=97)</p>	<p>Detection bias Blinding of outcome assessment: low/high risk (No blinding. High risk of bias for subjective outcomes.)</p> <p>Attrition bias Incomplete outcome data: low risk (Around 5% of the randomised were excluded from analysis because of distant metastasis, the patient had no carcinoma, withdrawal of consent etc.)</p> <p>Reporting bias Selective reporting: low risk</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>open resection of rectal cancer.</p> <p><b>Study dates</b> January 2004 to May 2010</p> <p><b>Source of funding</b> Ethicon Endo-Surgery Europe; Swedish Cancer Society; the Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland, and an agreement concerning research and education of doctors, Sahlgrenska University Hospital, Gothenburg, Sweden; the Departments of Surgery and Biostatistics, Erasmus University Medical</p>	<p>I Laparoscopic 201 (29) Open 96 (28)</p> <p>II Laparoscopic 209 (30) Open 107 (31)</p> <p>III Laparoscopic 257 (37) Open 126 (37) Missing Laparoscopic 32 (5) Open 16 (5)</p> <p>Pathological stage, n (%)</p> <p>I Laparoscopic 231 (33) Open 107 (31)</p> <p>II Laparoscopic 180 (26) Open 91 (26)</p> <p>III Laparoscopic 180 (26) Open 125 (36)</p> <p>IV Laparoscopic 4 (1) Open 0 Missing Laparoscopic 18 (3) Open 3 (1)</p>		<p>quality of life scales is extracted from Andersson 2013.)</p> <p>The EQ-5D is a standardised non-disease-specific (generic) instrument for assessing self-reported health status. It comprises a description of the patient's health in five dimensions (mobility, self-care, daily activity, pain/discomfort and anxiety/depression).</p> <p>The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. There are five functional scales (physical, role, emotional, cognitive and social functioning), three symptom scales (fatigue, nausea/vomiting and pain), six single-item questions (about dyspnoea, insomnia, loss of appetite, constipation, diarrhoea and financial difficulties) and a global health/quality-of-life index. The latter assesses overall health and overall quality of life on a 7-point scale (1 indicating very poor and 7 indicating excellent). All other questions have four</p>	<p>-1.8 (95% CI -6.1 to 2.4)</p> <p>Outcome: Global health status (EQ-VAS; scale 0 to 100, higher score indicating better health status)*</p> <p>Baseline score Laparoscopic 77.3±16.6 (n=245) Open 74.9±16.6 (n=107)</p> <p>Mean difference at 4 weeks Laparoscopic (n=232) - Open (n=104) 1.6 (95% CI -3.3 to 6.5)</p> <p>Mean difference at 6 months Laparoscopic (n=219) - Open (n=102) 1.7 (95% CI -2.4 to 5.9)</p> <p>Mean difference at 12 months Laparoscopic (n=206) - Open (n=91)</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
Center, Rotterdam, the Netherlands; the Department of Surgery, Dalhousie University, Halifax, NS, Canada; and the Department of Surgery, VU University Medical Center, Amsterdam	<p><b>Inclusion criteria</b> A single rectal cancer within 15 cm from the anal verge (confirmed at colonoscopy, rigid rectoscopy, or barium enema); no evidence of distant metastases; candidate for elective surgery</p> <p><b>Exclusion criteria</b> T4 tumours or T3 tumours within 2 mm of the endopelvic fascia (as determined on CT scan or MRI); T1 tumour treated with local transanal excision; rectal cancer other than adenocarcinoma; history of other malignancy except basocellular carcinoma of the skin or in-situ carcinoma of the cervix uteri; signs of acute intestinal obstruction; need for synchronous colorectal surgery; familial adenomatous polyposis coli; hereditary non-polyposis colorectal cancer; active Crohn's disease or active ulcerative colitis;</p>		<p>possible answers: 'not at all', 'a little', 'quite a bit' and 'very much'. The time frame was 'during the past week'. The EORTC QLQ-CR38 questionnaire is a 38-item questionnaire used to measure more specific information about quality of life in patients with colorectal cancer. The questions cover 4 functional scales/single items (body image, sexual functioning, sexual enjoyment, future perspective) and eight symptom scales/items (micturition problems, chemotherapy side-effects, gastrointestinal symptoms, male sexual problems, female sexual problems, defaecation problems, stoma-related problems and weight loss). For this review, sexual functioning, sexual enjoyment, micturition problems, male sexual problems and female sexual problems were considered. All questions have four possible responses: 'not at all', 'a little', 'quite a bit' and</p>	<p>0.6 (95% CI -3.4 to 4.7)</p> <p>Outcome: Sexual functioning (QLQ-CR38; scale 0 to 100, higher score indicating better functioning)**</p> <p>Baseline score</p> <p>Laparoscopic 19.9±22.4 (n=224)</p> <p>Open 24.3±24.7 (n=102)</p> <p>Mean difference at 4 weeks adjusted for baseline†</p> <p>Laparoscopic (n=207) - Open (n=98)</p> <p>2.5 (95% CI -0.3 to 6.3)</p> <p>Mean difference at 6 months adjusted for baseline†</p> <p>Laparoscopic (n=206) - Open (n=96)</p> <p>-0.8 (95% CI -5.5 to 3.9)</p> <p>Mean difference at 12 months adjusted for baseline†</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	absolute contraindications to general anaesthesia or prolonged pneumoperitoneum; ASA category >III; pregnancy.		<p>'very much'. The time frame was previous 4 weeks. For both QLQ-30 and QLQ-CR38, the individual scores were converted to a score ranging from 0 to 100. A high score for the symptom/item scales represents a high level of symptoms/problems, whereas a high score for the functional scales and the global health/general quality-of-life index represents a high level of functioning, overall health and quality of life.</p> <p><b>Statistical analysis</b> Kaplan–Meier method to estimate the difference in recurrence rates and survival between the study groups.</p>	<p>Laparoscopic (n=197) - Open (n=89) 3.1 (95% CI -1.7 to 7.9) Mean difference at 24 months adjusted for baseline† Laparoscopic (n=141) - Open (n=64) 4.6 (95% CI -1.7 to 10.9)</p> <p>Outcome: Sexual enjoyment (QLQ-CR38; scale 0 to 100, higher score indicating better enjoyment)** Baseline score Laparoscopic 49.1±33.0 (n=97) Open 61.3±32.5 (n=50) Mean difference at 6 months adjusted for baseline Laparoscopic (n=72) - Open (n=37) 0.7 (95% CI -13.6 to 15.0) Mean difference at 12</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
				<p>months adjusted for baseline</p> <p>Laparoscopic (n=87) - Open (n=38)</p> <p>8.0 (95% CI -5.0 to 21.0)</p> <p>Mean difference at 24 months adjusted for baseline</p> <p>Laparoscopic (n=41) - Open (n=21)</p> <p>-2.1 (95% CI -17.2 to 13.0)</p> <p>Outcome: Female sexual problems (QLQ-CR38; scale 0 to 100, higher score indicating worse problems)**</p> <p>Baseline score</p> <p>Laparoscopic 10.9±15.6 (n=23)</p> <p>Open 12.2±19.4 (n=15)</p> <p>Mean difference at 6 months adjusted for baseline†</p> <p>Laparoscopic (n=19) - Open (n=10)</p> <p>5.1 (95% CI -16.5 to 26.8)</p>	



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
				<p>Mean difference at 12 months adjusted for baseline† Laparoscopic (n=19) - Open (n=14) 0.9 (95% CI -20.8 to 22.7)</p> <p>Mean difference at 24 months adjusted for baseline† Laparoscopic (n=7) - Open (n=5) 11.8 (95% CI -18.9 to 42.5)</p> <p>Outcome: Male sexual problems (QLQ-CR38; scale 0 to 100, higher score indicating worse problems)** Baseline score Laparoscopic 36.2±35.2 (n=124) Open 27.8±29.5 (n=54)</p> <p>Mean difference at 4 weeks adjusted for baseline† Laparoscopic (n=91) - Open (n=41) -6.5 (95% CI -19.9 to 6.8)</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
				<p>Mean difference at 6 months adjusted for baseline†</p> <p>Laparoscopic (n=116) - Open (n=47)</p> <p>-6.9 (95% CI -20.5 to 6.7)</p> <p>Mean difference at 12 months adjusted for baseline†</p> <p>Laparoscopic (n=117) - Open (n=50)</p> <p>-9.8 (95% CI -22.3 to 2.6)</p> <p>Mean difference at 24 months adjusted for baseline†</p> <p>Laparoscopic (n=78) - Open (n=37)</p> <p>1.1 (95% CI -12.2 to 14.4)</p> <p>Outcome: Micturitional symptoms (QLQ-CR38; scale 0 to 100, higher score indicating worse symptoms)**</p> <p>Baseline score</p> <p>Laparoscopic 24.0±18.1 (n=240)</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
				<p>Open 23.3±17.7 (n=110)</p> <p>Mean difference at 4 weeks adjusted for baseline†</p> <p>Laparoscopic (n=219) - Open (n=103)</p> <p>0.9 (95% CI -4.4 to 6.2)</p> <p>Mean difference at 6 months adjusted for baseline†</p> <p>Laparoscopic (n=219) - Open (n=101)</p> <p>-1.0 (95% CI -5.0 to 3.0)</p> <p>Mean difference at 12 months adjusted for baseline†</p> <p>Laparoscopic (n=209) - Open (n=95)</p> <p>2.2 (95% CI -2.0 to 6.4)</p> <p>Mean difference at 24 months adjusted for baseline†</p> <p>Laparoscopic (n=170) - Open (n=79)</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
				<p>2.4 (95% CI -2.4 to 7.2)</p> <p>Outcome: Positive CRM (&lt;2 mm) Laparoscopic 56/588 Open 30/300 (denominator is the number without complete remission)</p> <p>Outcome: Locoregional recurrence at 3 years Laparoscopic 5.0% Open 5.0% No statistical difference between groups, narratively reported.</p> <p>Outcome: Length of hospital stay, mean±SD; median (IQR)*** Laparoscopic 11.9±1.8; 8.0 (6.0-13.0) Open 12.1±10.6; 9.0 (7.0-14.0)</p> <p>Outcome: 28-day mortality*** Laparoscopic 8/699 Open 6/345</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
				<p>Outcome: Anastomotic leak*** Laparoscopic 58/461 Open 25/240</p> <p>Outcome: Blood loss in ml, median (IQR)*** Laparoscopic 200 (100-400) Open 400 (200-700) p&lt;0.0001</p> <p>Outcome: Wound infection*** Laparoscopic 28/697 Open 17/345</p> <p>*Data extracted from Andersson 2013. **Data extracted from Andersson 2014. ***Data extracted from van der Pas 2013. †The analysis of mean difference between groups at a specific time point was adjusted for differing baseline scores and/or</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
				Characteristics, however, it is not clear from the paper what was actually done and why the baseline scores were different even though the groups were randomly assigned.	
<p><b>Full citation</b> Braga, M., Frasson, M., Vignali, A., Zuliani, W., Capretti, G., Di Carlo, V., Laparoscopic resection in rectal cancer patients: Outcome and cost-benefit analysis, Diseases of the Colon and Rectum, 50, 464-471, 2007</p> <p><b>Ref Id</b> 745870</p> <p><b>Country/ies where the study was carried out</b> Italy</p>	<p><b>Sample size</b> N=168 randomised; n=83 allocated to laparoscopic surgery; n=85 allocated to open surgery</p> <p><b>Characteristics</b> Age in years, mean±SD Laparoscopic 62.8±12.6 Open 65.3±10.3</p> <p>Male sex, n/n Laparoscopic 55/83 Open 64/85</p> <p>Obesity, n/n Laparoscopic 9/83 Open 5/85</p> <p>Dukes stage, n/n I Laparoscopic 25/83</p>	<p><b>Interventions</b> Laparoscopic surgery versus open surgery</p> <p>Type of surgery, n/n Low anterior resection Laparoscopic 76/83 Open 74/85 Abdominoperineal resection Laparoscopic 7/83 Open 11/85</p> <p>In both laparoscopy and open groups TME was performed when cancer was located in the middle or low portion of the rectum.</p> <p>Patients with a preoperative diagnosis of T3 stage cancer received preoperative</p>	<p><b>Details</b> Randomisation and allocation concealment Randomization list was generated by a computer program. Assignments were made by means of sealed sequenced masked envelopes, which were opened before the induction of anaesthesia by a nurse unaware of the trial design.</p> <p><b>Blinding</b> No blinding.</p> <p><b>Follow-up/outcomes</b> Follow-up for infectious and noninfectious complications was performed for 30 days after hospital discharge by weekly office visits. Long-term follow-up was performed every six months by office visits.</p>	<p><b>Results</b> Outcome: Quality of life - General health score at 12 months (modified SF-36; scale 0-100, higher indicating better) Laparoscopic 74 (n=83) Open 65 (n=85) p=0.0001</p> <p>Outcome: Quality of life - General health score at 24 months (modified SF-36; scale 0-100, higher indicating better) Laparoscopic 72 (n=83) Open 68 (n=85) (p-value not reported but not significant difference between groups)</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: low risk Allocation concealment: low risk</p> <p>Performance bias Blinding of participants and personnel: high risk (No blinding.)</p> <p>Detection bias Blinding of outcome assessment: high risk (No blinding.)</p> <p>Attrition bias Incomplete outcome data: low risk (Intention-to-treat analysis was done. No losses to follow-up.)</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Study type</b> RCT</p> <p><b>Aim of the study</b> To evaluate the impact of laparoscopic rectal resection on short-term postoperative morbidity and costs.</p> <p><b>Study dates</b> Not reported.</p> <p><b>Source of funding</b> None reported.</p>	<p>Open 24/85 II Laparoscopic 16/83 Open 19/85 III Laparoscopic 31/83 Open 29/85 IV Laparoscopic 11/83 Open 13/85</p> <p>Tumour distance from the anal verge in cm, mean Laparoscopic 9.1 Open 8.6</p> <p>Tumour distance 10-15 cm from the anal verge, n/n Laparoscopic 30/83 Open 24/85</p> <p><b>Inclusion criteria</b> Adenocarcinoma of the rectum; age 18 years or older; suitability to elective surgery.</p> <p><b>Exclusion criteria</b> Cancer infiltrating adjacent organs</p>	<p>chemoradiotherapy: continuous infusion of 5-fluorouracil 20 mg/m<sup>2</sup> daily for 45 days plus 4,500 Gy distributed in 19 days (from day 14) plus oxaliplatin 100 mg/m<sup>2</sup> on days 1, 14, and 28.</p>	<p>Quality of life was assessed by a modified version of the Medical Outcomes Study Short Form 36 (SF-36) questionnaire.</p> <p>Statistical analysis Intention-to-treat analysis was done. Survival curves were constructed with the Kaplan-Meier method and were compared with the log-rank test.</p>	<p>Outcome: Positive distal margin Laparoscopic 0/83 Open 0/85</p> <p>Outcome: Positive circumferential resection margin Laparoscopic 1/83 Open 2/85</p> <p>Outcome: Local recurrence 3 years after surgery Laparoscopic 3/83 Open 4/85</p> <p>Outcome: Length of hospital stay in days, mean±SD Laparoscopic 10±4.9 (n=83) Open 13.6±10 (n=85)</p> <p>Outcome: Operative mortality Laparoscopic 1/83 Open 1/85</p> <p>Outcome: Anastomotic leak</p>	<p>Reporting bias Selective reporting: low risk</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	assessed by CT scan or MRI; cardiovascular dysfunction (New York Heart Association Class > 3); respiratory dysfunction (arterial pO <sub>2</sub> < 70 mmHg); hepatic dysfunction (Child-Pugh Class C); ongoing infection; plasma neutrophil level < 2x10 <sup>9</sup> /L.			Laparoscopic 8/83 Open 9/85  Outcome: Wound infection Laparoscopic 6/83 Open 13/85  Outcome: Blood loss in ml, mean±SD Laparoscopic 213±236 (n=83) Open 396±367 (n=85)	
<b>Full citation</b> Buonpane, C., Efiang, E., Hunsinger, M., Fluck, M., Shabahang, M., Wild, J., Halm, K., Long, K., Buzas, C., Blansfield, J., Predictors of utilization and quality assessment in robotic rectal cancer resection: A review of the national cancer database, American	<b>Sample size</b> N=1,937 robotic surgery; N=7,185 laparoscopic surgery (not considered for this review because RCT data exists on critical outcomes); N=14,735 open surgery  <b>Characteristics</b> Age, % 18-29 years Robotic Not reported (NR) Open 0.7 30-39 Robotic NR Open 3.5	<b>Interventions</b> Robotic surgery versus open surgery  Neoadjuvant radiotherapy, n (%) Robotic 66.2 Open 58.0  Neoadjuvant chemotherapy, n (%) Robotic 64.5 Open 57.4	<b>Details</b> Randomisation and allocation concealment Not a randomised study. The data for this study was received from a national oncology database that captures more than 70% of all newly diagnosed malignancies in the US. Records of all surgically resected rectal cancers were obtained.  Blinding Not applicable.  Follow-up/outcomes	<b>Results</b> Outcome: Positive surgical margin Robotic 106/1,937 Open 1,256/14,735	<b>Limitations</b> ROBINS-I checklist for non-randomised studies of Interventions Pre-intervention Bias due to confounding: Serious risk of bias (This is a retrospective non-randomised observational study. No matching of groups was done. The study did not control for potential confounding in the analysis.) Bias in selection of participants into the study: Low risk of bias



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Surgeon, 83, 918-924, 2017</p> <p><b>Ref Id</b> 745976</p> <p><b>Country/ies where the study was carried out</b> US</p> <p><b>Study type</b> Retrospective cohort study</p> <p><b>Aim of the study</b> To evaluate the use of robotic surgery in rectal cancer resection compared with open and laparoscopic techniques and to assess the quality of resection.</p> <p><b>Study dates</b> 2010 to 2012</p> <p><b>Source of funding</b> None reported.</p>	<p>40-49</p> <p>Robotic 15.2</p> <p>Open 13.1</p> <p>50-59</p> <p>Robotic 30.7</p> <p>Open 27.1</p> <p>60-69</p> <p>Robotic 28.7</p> <p>Open 27.8</p> <p>70-79</p> <p>Robotic 14.6</p> <p>Open 18.6</p> <p>80+</p> <p>Robotic 6.3</p> <p>Open 9.2</p> <p>Male sex, %</p> <p>Robotic 62.7</p> <p>Open 60.2</p> <p>T stage, %</p> <p>In situ</p> <p>Robotic NR</p> <p>Open 1.4</p> <p>x</p> <p>Robotic 15.3</p> <p>Open 21.3</p> <p>T0</p> <p>Robotic NR</p> <p>Open 0.3</p> <p>T1</p>		<p>Data from a database was used.</p> <p><b>Statistical analysis</b> Analysis of outcomes of interest for this review were not adjusted for potential confounders or case-mix.</p>		<p>At intervention Bias in classification of Interventions: Low risk of bias</p> <p>Post-intervention Bias due to deviations from intended Interventions: Low risk of bias Bias due to missing data: Low risk of bias Bias in measurement of outcomes: Low risk of bias Bias in selection of the reported result: Low risk of bias</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	Robotic 9.3 Open 9.4 T2 Robotic 12.6 Open 12.2 T3 Robotic 57.8 Open 48.9 T4 Robotic 3.8 Open 6.5  N stage, n (%) x Robotic 7.7 Laparoscopic 7.7 Open 9.7 N0 Robotic 56.4 Open 57.7 N1 Robotic 29.6 Open 26.7 N2 Robotic 6.3 Open 5.9  Metastatic disease, % Robotic 5.8 Open 9.7				

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	<p><b>Inclusion criteria</b> Surgically resected rectal cancers diagnosed from 2010 through 2012.</p> <p><b>Exclusion criteria</b> If surgical approach for the resection of the primary tumour was not reported or if data required for analysis was missing.</p>				
<p><b>Full citation</b> Corbellini, C, Biffi, R, Luca, F, Chiappa, A, Costa, S, Bertani, E, Bona, S, Lombardi, D, Tamayo, D, Botteri, E, Andreoni, B, Open, laparoscopic, and robotic surgery for rectal cancer: medium-term comparative outcomes from a multicenter study, Tumori, 102, 414-421, 2016</p> <p><b>Ref Id</b> 746335</p>	<p><b>Sample size</b> N=65 patients received robotic surgery; N=40 patients received laparoscopic surgery (only considered for overall survival because for other critical outcomes there is RCT data); N=55 patients received open surgery</p> <p><b>Characteristics</b> Age in years, median (range) Robotic 64 (39-78) Laparoscopic 64 (36-80) Open 62 (40-80)</p> <p>Male sex, n (%) Robotic 35 (54) Laparoscopic 23 (58)</p>	<p><b>Interventions</b> Robotic versus laparoscopic versus open surgery</p> <p>Type of surgery, n (%) Anterior resection Robotic 58 (89) Laparoscopic 38 (95) Open 43 (78) Abdominoperineal resection Robotic 7 (11) Laparoscopic 1 (2.5) Open 11 (20) Hartmann Robotic 0 (0) Laparoscopic 1 (2.5) Open 1 (2)</p>	<p><b>Details</b> Randomisation and allocation concealment This study was not a randomised study. Data was prospectively collected but the choice of surgical technique was done according to preference of the surgeon and the patient.</p> <p>Blinding No blinding.</p> <p>Follow-up/outcomes Follow-up visits were 3 months after surgery and every 6 months for the first 3 years, including a physical examination and tumour marker testing. Colonoscopy was done 1</p>	<p><b>Results</b> Outcome: Overall survival at 3 years Robotic 88.2% Laparoscopic 96.4% Open 93.9% p=0.522</p> <p>Outcome: R1 Robotic 0/65 Open 2/55</p> <p>Outcome: Distal surgical margin &lt;2 cm (Abdominoperineal resection excluded) Robotic 22/58 Open 10/44</p>	<p><b>Limitations</b> ROBINS-I checklist for non-randomised studies of Interventions Pre-intervention Bias due to confounding: Serious risk of bias (This is a non-randomised study, the groups were not matched by any characteristic. The study did not control for potential confounding or case-mix in the analysis.) Bias in selection of participants into the study: Low risk of bias</p> <p>At intervention Bias in classification of Interventions: Low risk of bias</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Country/ies where the study was carried out</b> Italy</p> <p><b>Study type</b> A prospective, multi-centre cohort study.</p> <p><b>Aim of the study</b> To analyse and resolve advantages of robotic surgery with respect to open surgery and laparoscopic surgery in the management of rectal cancer.</p> <p><b>Study dates</b> April 2009 to August 2011</p> <p><b>Source of funding</b>No financial support.</p>	<p>Open 36 (66)</p> <p>BMI, n (%) &lt;25 Robotic 36 (55) Laparoscopic 17 (43) Open 33 (60)</p> <p>25-30 Robotic 23 (35) Laparoscopic 14 (35) Open 13 (24)</p> <p>&gt;30 Robotic 6 (9) Laparoscopic 9 (23) Open 9 (16)</p> <p>Tumour distance from anal margin, n (%) &lt;6 cm Robotic 21 (34) Laparoscopic 9 (23) Open 20 (37)</p> <p>6-9.9 cm Robotic 18 (29) Laparoscopic 13 (33) Open 16 (30)</p>	<p>Choice of surgical technique was carried according to the surgeon's and the patient's preferences. TME with nerve preservation was performed in low and middle rectal cancers and partial mesorectal excision was performed in upper rectal cancers. All robotic-assisted laparoscopic anterior resection surgeries were performed by hybrid technique.</p> <p>Preoperative chemoradiotherapy and postoperative chemotherapy were recommended for patients with locally advanced rectal cancer.</p>	<p>and 3 years after surgery. Chest and abdominopelvic computer tomography was done once a year and abdominal ultrasound examination was done every 6 months.</p> <p><b>Statistical analysis</b> Differences in survival were analysed using the log-rank test. No multivariate analysis was done.</p>		<p>Post-intervention Bias due to deviations from intended Interventions: Low risk of bias Bias due to missing data: Low risk of bias Bias in measurement of outcomes: Low risk of bias Bias in selection of the reported result: Low risk of bias</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	≥10 cm Robotic 23 (37) Laparoscopic 18 (45) Open 18 (33)				
	Pathologic staging, n (%) I Robotic 17 (26) Laparoscopic 15 (38) Open 11 (20)				
	II Robotic 17 (26) Laparoscopic 13 (33) Open 15 (27)				
	III Robotic 31 (48) Laparoscopic 12 (30) Open 29 (53)				
	<b>Inclusion criteria</b> A single rectal cancer within 12 cm from the anal verge; without evidence of distant metastases; candidates for elective, good-chance surgery.				
	<b>Exclusion criteria</b> Tumours treated with				

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	local transanal excision; rectal cancers other than adenocarcinoma; recent history of other malignancies; familial adenomatous polyposis coli; hereditary nonpolyposis colorectal cancer; Crohn disease or ulcerative colitis; preoperative clinical stage IV.				
<b>Full citation</b> Denost, Q., Loughlin, P., Chevalier, R., Celerier, B., Didailler, R., Rullier, E., Transanal versus abdominal low rectal dissection for rectal cancer: long-term results of the Bordeaux' randomized trial, Surgical Endoscopy and Other Interventional Techniques, 1-9, 2017  <b>Ref Id</b> 746561	<b>Sample size</b> N=100 randomised; n=50 allocated to transanal TME (TaTME); n=50 allocated to laparoscopic surgery  <b>Characteristics</b> Age in years, median (range) TaTME 64 (39-82) Laparoscopic 63 (31-90)  Male sex, n/n TaTME 37/50 Laparoscopic 32/50  BMI, median (range) TaTME 25.1 (17.3–33.2) Laparoscopic 25.6 (18.3–38.3)	<b>Interventions</b> TaTME versus laparoscopic TME  Surgery was performed 6 weeks after the end of radiotherapy.  Preoperative radiotherapy, n/n TaTME 40/50 Laparoscopic 44/50  Preoperative chemotherapy, n/n TaTME 39/50 Laparoscopic 42/50	<b>Details</b> Randomisation and allocation concealment The randomization of patients was performed by the assistant researcher the day before surgery, when the investigator has obtained the patient's written informed consent. Randomization was blind for the patient and was stratified by surgeon. No other details reported.  Blinding No blinding.  Follow-up/outcomes Follow-up visits were at 1 month, then every 4 months up to 2 years and 6 months	<b>Results</b> Outcome: Overall survival, median 60.2 months of follow-up TaTME n=50, 7 events* Laparoscopic n=50, 13 events* p=0.135  Outcome: Urinary function median score (range) (IPSS, scale 0 to 35, higher indicating worse urinary function)** TaTME 5.5 (0-23) (n=38) Laparoscopic 3.5 (0-27) (n=34) p=0.821	<b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: unclear risk (Limited details reported.) Allocation concealment: unclear risk (Details not reported.)  Performance bias Blinding of participants and personnel: high risk (No blinding.)  Detection bias Blinding of outcome assessment: low/high risk (No blinding. High risk of bias for subjective outcomes.)

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Country/ies where the study was carried out</b> France</p> <p><b>Study type</b> RCT (Bordeaux' trial)</p> <p><b>Aim of the study</b> To compare outcomes between transanal and laparoscopic rectal dissection in laparoscopic sphincter preservation for low rectal cancer.</p> <p><b>Study dates</b> June 2008 to February 2012</p> <p><b>Source of funding</b> None reported.</p>	<p>Tumour location from the anal verge in cm, median (range) TaTME 4 (2-6) Laparoscopic 4 (2-6)</p> <p>Tumour stage, n/n T1-2 TaTME 10/50 Laparoscopic 9/50 T3-4 TaTME 40/50 Laparoscopic 41/50</p> <p>N1-2, n/n TaTME 30/50 Laparoscopic 33/50</p> <p><b>Inclusion criteria</b> Low rectal cancer (&lt;6 cm from the anal verge); suitable for laparoscopic sphincter-saving resection.</p> <p><b>Exclusion criteria</b> Exclusion criteria for functional outcome assessments were: death; local or recurrent disease; presence of a stoma.</p>		<p>subsequently. Postoperative surveillance included clinical examination, CEA level assessment and computer tomography scan. Colonoscopy was performed 1 year following surgery, then every 5 years.</p> <p>Local recurrence was defined as any recurrence diagnosed or suspected in the pelvis. Recurrences were confirmed with radiological or histological examination. Overall survival was measured from the date of surgery to death.</p> <p>Assessment of urinary and sexual function was performed at least 12 months after stoma closure. (All data relating to urinary and sexual function extracted from Pontallier 2016.)</p> <p>Urinary function was assessed by the International Prostate Symptom score (IPSS). The IPSS questionnaire is based on 7 items</p>	<p>Outcome: Urinary function quality of life median score (range) (IPSS, scale 0 to 6, lower indicating better quality of life)** TaTME 1 (0-6) (n=38) Laparoscopic 1 (0-5) (n=34) p=0.967</p> <p>Outcome: Sexual activity maintained after treatment (in previously sexually active participants)** TaTME 20/28 Laparoscopic 9/23 p=0.02</p> <p>Outcome: Sexual dysfunction at median 3.2 years after treatment (FSFI score ≤19) in previously sexually active female participants TaTME 2/5 Laparoscopic 2/3 p=1.00</p>	<p>Attrition bias Incomplete outcome data: low/high risk (For recurrence, survival and perioperative outcomes intention-to-treat analysis was done. However, for sexual and urinary function only 72/100 participants were included in the analysis.)</p> <p>Reporting bias Selective reporting: low risk</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b> The definition of local recurrence is unclear. The paper reports that local recurrence was defined as diagnosed or suspected recurrence in the pelvis, however, it also reports that all recurrences were confirmed by radiological or histological examination.</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
			<p>(incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia). Each item value is ranged from 0 to 5 (0=not at all; 1=less than one time; 2=less than half the time; 3=about half the time; 4=more than half the time; and 5=almost always). Total IPSS was calculated by adding the score for each item and ranges from 0 (no urinary disorder) to 35 (major urinary disorder). The quality of urinary function was graded in three subgroups according to their IPSS: normal function (IPSS 0–7 points), moderate dysfunction (IPSS 8–19 points) and severe dysfunction (IPSS 20–35 points). The quality of life included in the IPSS questionnaire ranged from 0 (best) to 6 (worst). Male sexual function was assessed by the 5-item version of the International Index of Erectile Function questionnaire (IIEF-5; items included erection confidence, maintenance</p>	<p>Outcome: Erectile function median score (range) in sexually active men (IIEF, scale 5-25, higher indicating better erectile function)**  TaTME 17.5 (5-25) (N not reported)  Laparoscopic 7 (5-21) (N not reported)  p=0.119</p> <p>Outcome: Erectile dysfunction (IIEF score &lt;=21) after treatment**  TaTME 67% (N not reported)  Laparoscopic 93% (N not reported)  p=0.108</p> <p>Outcome: Normal ejaculatory function after treatment among sexually active men before surgery (IIEF)**  TaTME 14/21 (67%) (denominator calculated from percentage reported)</p>	



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
			<p>ability, maintenance frequency, erection firmness, and sexual satisfaction). Each item value is ranged from 0 to 5 (0=did not attempt intercourse; 1=almost never or never; 2=less than half the time; 3=about half the time; 4=more than half the time; and 5=almost always). The IIEF-5 score was calculated by adding the score for each item and ranges from 5 to 25. A total score at or below 21 was considered "abnormal." Erectile function in patients with sexual inactivity (score from 0 to 4) was not analysed. Female sexual function was assessed by the 6-item version of the Female Sexual Function Index (FSFI-6; items included sexual desire, sexual activity, lubrication, dyspareunia, sexual arousal and satisfaction). Each item value is ranged from 0 to 5 (0=did not attempt intercourse; 1=almost never or never; 2=less than half the time; 3=about half the time; 4=more than</p>	<p>Laparoscopic 7/16 (44%) (denominator calculated from percentage reported) p=0.224</p> <p>Outcome: Positive distal margin (not defined) TaTME 1/50 Laparoscopic 4/50</p> <p>Outcome: "R1 resection (positive CRM)" (not defined) TaTME 2/50 Laparoscopic 9/50</p> <p>Outcome: Local recurrence at 5 years TaTME 2.6% (95% CI 2.3% to 7.5%) Laparoscopic 4.8% (95% CI 1.7 to 11.3%) p = 0.300</p> <p>Outcome: Length of hospital stay in days, median (range) TaTME 7 (3-54) (n=50)</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
			<p>half the time; 5=almost always). The FSFI-6 score was calculated by adding the score for each item and ranges from 0 to 30. A total score at or below 19 was considered “abnormal.” Sexual activity in both male and female was assessed before and after treatment. In case of a loss of sexual activity after surgery, patients should report whether this postoperative impairment was due or not to the surgical procedure.</p> <p><b>Statistical analysis</b> Recurrence and survival were evaluated by the Kaplan–Meier method and compared with the log-rank test.</p>	<p>Laparoscopic 8 (2-29) (n=50) p=0.281</p> <p>Outcome: Postoperative mortality TaTME 0/50 Laparoscopic 1/50</p> <p>Outcome: Anastomotic leak and/or abscess TaTME 1/50 Laparoscopic 5/50</p> <p>*Number of events calculated from the Kaplan-Meier curve. **Data extracted from Pontallier 2016.</p>	
<p><b>Full citation</b> Denost Q, Loughlin P, Chevalier R et al. Transanal versus abdominal low rectal dissection for rectal cancer: long-term results of the Bordeaux’ randomized trial.</p>	<p><b>Sample size</b> (See Denost 2017 BORDEAUX trial)</p>	<p><b>Interventions</b> (See Denost 2017 BORDEAUX trial)</p>	<p><b>Details</b> (See Denost 2017 BORDEAUX trial)</p>		<p><b>Limitations</b> (See Denost 2017 BORDEAUX trial)</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Surg Endosc. 2018 Mar;32(3):1486-1494.</p> <p><b>Ref Id</b> 982355</p> <p><b>Country/ies where the study was carried out</b> France</p> <p><b>Study type</b> RCT (Bordeaux' trial)</p> <p><b>Aim of the study</b> To compare outcomes between transanal and laparoscopic rectal dissection in laparoscopic sphincter preservation for low rectal cancer.</p> <p><b>Study dates</b> June 2008 to February 2012.</p> <p><b>Source of funding</b> None reported.</p>					

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Full citation</b> Fleshman, J., Branda, M., Sargent, D. J., Boller, A. M., George, V., Abbas, M., Peters, W. R., Maun, D., Chang, G., Herline, A., Fichera, A., Mutch, M., Wexner, S., Whiteford, M., Marks, J., Birnbaum, E., Margolin, D., Larson, D., Marcello, P., Posner, M., Read, T., Monson, J., Wren, S. M., Pisters, P. W. T., Nelson, H., Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes the ACOSOG Z6051 randomized clinical trial, JAMA - Journal of the American Medical</p>	<p><b>Sample size</b> N=486 randomised; n=243 allocated to laparoscopic surgery but 3 did not receive intervention as randomised, n=240 analysed; n=243 allocated to open surgery but 21 not included in analysis because did not undergo intervention as randomised or problem with consent, n=222 analysed.</p> <p><b>Characteristics</b> Age in years, mean±SD Laparoscopic 57.7±11.5 Open 57.2±12.1</p> <p>Male sex, n (%) Laparoscopic 156 (64.5) Open 158 (66.1)</p> <p>BMI, mean±SD Laparoscopic 26.4±4.0 Open 26.8±4.2</p> <p>Location of tumour in the rectum, n (%) High</p>	<p><b>Interventions</b> Laparoscopic surgery versus open surgery</p> <p>Previous therapy received, n (%) Chemotherapy + radiotherapy Laparoscopic 227 (95.0) Open 217 (91.2) Radiotherapy alone Laparoscopic 8 (3.3) Open 13 (5.5) Chemotherapy alone Laparoscopic 4 (1.7) Open 8 (3.4) Unknown Laparoscopic 3 Open 1</p> <p>Planned surgical approach, n (%) Abdominoperineal resection Laparoscopic 55 (22.7) Open 57 (23.8) Low anterior resection Laparoscopic 187 (77.3) Open 182 (76.2)</p>	<p><b>Details</b> Randomisation and allocation concealment Randomization was performed centrally. Stratification by surgeon, site of primary tumor (high, middle, or low rectum according to the subclassification of the 12 cm of rectum into equal thirds), and planned operative procedure (lowanterior resectionwith anastomosis or abdominoperineal resection with colostomy).</p> <p>Blinding No blinding was done.</p> <p>Follow-up/outcomes Patients were assessed for complications at discharge from the hospital and at 4 to 6 weeks postoperatively.</p> <p><b>Statistical analysis</b> Modified intention-to-treat. Patients who did not receive the randomised intervention were not included in the analysis but patients who had a</p>	<p><b>Results</b> Outcome: Negative distal margin (<math>\geq 1</math> mm) Laparoscopic 234/240 Open 218/222</p> <p>Outcome: CRM <math>&gt; 1</math>mm or distance = not applicable Laparoscopic 211/240 Open 205/222</p> <p>Outcome: Distance to radial margin <math>\leq 1</math> mm Laparoscopic 29/240 Open 17/222</p> <p><math>&gt; 1</math> mm Laparoscopic 211/240 Open 205/222</p> <p>Outcome: Local and regional recurrence* was 4.6% from laparoscopic resection and 4.5% for open resection.</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: low risk Allocation concealment: unclear risk (Details not reported.)</p> <p>Performance bias Blinding of participants and personnel: high risk (No blinding.)</p> <p>Detection bias Blinding of outcome assessment: low/high risk (No blinding. High risk of bias on subjective outcomes.)</p> <p>Attrition bias Incomplete outcome data: unclear risk (Modified intention-to-treat analysis done. 3 in one group and 22 in one group of the originally randomised not analysed.)</p> <p>Reporting bias Selective reporting: low risk</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Association, 314, 1346-1355, 2015</p> <p><b>Ref Id</b> 746895</p> <p><b>Country/ies where the study was carried out</b> US</p> <p><b>Study type</b> RCT (ACOSOG Z6051 trial)</p> <p><b>Aim of the study</b> To determine whether laparoscopic resection is noninferior to open resection.</p> <p><b>Study dates</b> October 2008 to September 2013</p> <p><b>Source of funding</b> The National Cancer Institute; The American Society of Colon and Rectal Surgeons; The</p>	<p>Laparoscopic 33 (13.6) Open 28 (11.7) Middle Laparoscopic 85 (35.1) Open 95 (39.7) Low Laparoscopic 124 (51.2) Open 116 (48.5) Preoperative clinical stage, n (%) I Laparoscopic 2 (0.8) Open 3 (1.3) IIA Laparoscopic 99 (40.9) Open 92 (38.5) IIIA Laparoscopic 11 (4.5) Open 11 (4.6) IIIB Laparoscopic 114 (47.1) Open 114 (47.7) IIIC Laparoscopic 16 (6.6) Open 19 (7.9)</p> <p><b>Inclusion criteria</b> Aged 18 years or older; BMI of 34 or less; Eastern Cooperative Oncology Group performance score less than</p>	<p>Surgical approach used, n (%) Abdominoperineal resection Laparoscopic 58 (24.2) Open 47 (21.2) Low anterior resection Laparoscopic 69 (28.8) Open 73 (32.9) Low anterior resection + coloanal anastomosis Laparoscopic 110 (45.8) Open 96 (43.2) Low Hartmann Laparoscopic 1 (0.4) Open 0 Total proctocolectomy Laparoscopic 2 (0.8) Open 6 (2.7)</p> <p>Surgical technique in the laparoscopic arm, n (%) Laparoscopic 165 (68.8) Hand-assisted 41 (17.1) Robotic assisted 34 (14.2)</p>	<p>conversion to open surgery were included in the analysis as originally allocated.</p>	<p>Outcome: Length of hospital stay in days, mean±SD Laparoscopic 7.3 (5.4) Open 7.0 (3.4)</p> <p>Outcome: 30-day mortality Laparoscopic 2/240 Open 2/222</p> <p>Outcome: Anastomotic leak during postoperative period Laparoscopic 5/240 Open 5/222</p> <p>Outcome: Blood loss in ml, mean±SD (median, IQR) Laparoscopic 256.1±305.8 (150, 100-300) Open 318.4±331.7 (200±100-400)</p> <p>*Data extracted from Fleshman 2019.</p>	<p>Other bias Other sources of bias: -</p> <p><b>Other information</b> Note that "laparoscopic surgery" includes robotic (14%), hand-assisted laparoscopic (17%) and conventional laparoscopic (69%) surgery.</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
Society of American Gastrointestinal and Endoscopic Surgeons	<p>3; histologically proven adenocarcinoma of the rectum at or below 12 cm above the anal verge (by rigid proctoscopy); clinical stage II, IIIA, IIIB (T3N0M0, TanyN1 or 2, M0, and no T4) determined by rectal cancer protocol magnetic resonance imaging or transrectal ultrasonography</p> <p><b>Exclusion criteria</b> History of invasive pelvic malignancy within 5 years; psychiatric or addictive disorders that affected compliance to the protocol; severe incapacitating disease (ASA classification IV or V); systemic disease that would preclude use of a laparoscopic approach (for example cardiovascular, renal, hepatic); conditions that would limit the success of laparoscopic resection (multiple previous laparotomies or severe adhesions).</p>				

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Full citation</b> Fleshman J, Branda ME, Sargent DJ, et al. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. Ann Surg. 2019; 269(4):589-595.</p> <p><b>Ref Id</b> 982405</p> <p><b>Country/ies where the study was carried out</b> US</p> <p><b>Study type</b> RCT (ACOSOG Z6051 trial)</p> <p><b>Aim of the study</b></p>	<p><b>Sample size</b> See Fleshman 2015</p>	<p><b>Interventions</b></p>	<p><b>Details</b></p>	<p><b>Results</b></p>	<p><b>Limitations</b></p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>To determine whether laparoscopic resection is noninferior to open resection.</p> <p><b>Study dates</b> October 2008 to September 2013</p> <p><b>Source of funding</b> The National Cancer Institute; The American Society of Colon and Rectal Surgeons; The Society of American Gastrointestinal and Endoscopic Surgeons.</p>					
<p><b>Full citation</b> Green B, Marshall H, Collinson F et al. (2013) Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically</p>	<p><b>Sample size</b> See Jayne 2010 (CLASICC trial).</p> <p><b>Characteristics</b></p> <p><b>Inclusion criteria</b></p> <p><b>Exclusion criteria</b></p>	<p><b>Interventions</b></p>	<p><b>Details</b></p>	<p><b>Results</b></p>	<p><b>Limitations</b></p> <p><b>Other information</b></p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>assisted resection in colorectal cancer, British Journal of Surgery 100: 75-82</p> <p><b>Ref Id</b> 747298</p> <p><b>Country/ies where the study was carried out</b></p> <p><b>Study type</b> <b>Aim of the study</b></p> <p><b>Study dates</b></p> <p><b>Source of funding</b></p>					
<p><b>Full citation</b> Guillou, P. J., Quirke, P., Thorpe, H., Walker, J., Jayne, D. G., Smith, A. M., Heath, R. M., Brown, J. M., Mrc Clasicc trial group, Short-term endpoints of conventional versus laparoscopic-assisted surgery</p>	<p><b>Sample size</b> See Jayne 2010 (CLASICC trial).</p> <p><b>Characteristics</b></p> <p><b>Inclusion criteria</b></p> <p><b>Exclusion criteria</b></p>	<b>Interventions</b>	<b>Details</b>	<b>Results</b>	<p><b>Limitations</b></p> <p><b>Other information</b></p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial, Lancet, 365, 1718-26, 2005</p> <p><b>Ref Id</b> 809742</p> <p><b>Country/ies where the study was carried out</b></p> <p><b>Study type</b></p> <p><b>Aim of the study</b></p> <p><b>Study dates</b></p> <p><b>Source of funding</b></p>					
<p><b>Full citation</b> Lelpo, B., Duran, H., Diaz, E., Fabra, I., Caruso, R., Malave, L., Ferri, V., Nunez, J., Ruiz-Ocana, A., Jorge, E., Lazzaro, S., Kalivaci, D., Quijano, Y., Vicente, E.,</p>	<p><b>Sample size</b> N=86 robotic surgery; N=112 laparoscopic surgery</p> <p><b>Characteristics</b> Age in years, mean±SD Robotic 63.9±9.5 Laparoscopic 61.6±11.9</p>	<p><b>Interventions</b> Robotic versus laparoscopic surgery Operative procedure, n (%) Lower anterior resection Robotic 62 (72) Laparoscopic 73 (65) Abdominoperineal resection</p>	<p><b>Details</b> Randomisation and allocation concealment This study was not a randomised study. The data was obtained from a prospectively collected database of rectal surgeries in the study institution. No matching of the groups was done.</p>	<p><b>Results</b> Outcome: Overall survival at 3 years Robotic 91% Laparoscopic 94% p=0.7</p>	<p><b>Limitations</b> ROBINS-I checklist for non-randomised studies of Interventions Pre-intervention Bias due to confounding: Serious risk of bias (This is a non-randomised study. No matching of groups was done. The study did</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Robotic versus laparoscopic surgery for rectal cancer: a comparative study of clinical outcomes and costs, International Journal of Colorectal Disease, 32, 1423-1429, 2017</p> <p><b>Ref Id</b> 747778</p> <p><b>Country/ies where the study was carried out</b> Spain</p> <p><b>Study type</b> Retrospective cohort study</p> <p><b>Aim of the study</b> To compare the clinical outcomes and cost differences of robotic versus laparoscopic surgery in the</p>	<p>Male sex, n/n Robotic 48/86 Laparoscopic 67/112</p> <p>BMI, mean±SD Robotic 26.1±4.1 Laparoscopic 25.7±3.4</p> <p>Tumour location from the anal verge, n (%) &lt;5 cm Robotic 25/86 Laparoscopic 32/112 5-9 cm Robotic 30/86 Laparoscopic 39/112 10-15 cm Robotic 31/86 Laparoscopic 41/112</p> <p><b>Inclusion criteria</b> Patients with diagnosed rectal cancer who underwent laparoscopic or robotic surgery.</p> <p><b>Exclusion criteria</b> T4 rectal cancers</p>	<p>Robotic 20 (23) Laparoscopic 32 (29) Colo-anal Robotic 4 (5) Laparoscopic 7 (6)</p> <p>Robotic surgery was performed with da Vinci Robotic Surgical System model Si and Xi.</p> <p>Patients with T3 or N+ cancer received neoadjuvant chemoradiation followed by surgery within 8 weeks. Neoadjuvant therapy, n (%) Robotic 65 (76) Laparoscopic 87 (78)</p>	<p>Blinding No blinding.</p> <p>Follow-up/outcomes Outcome data was obtained retrospectively from a prospectively-collected database. Follow-up assessments were performed at 15 postoperative days, at 1, 3 and 6 months, and every 6 months up to 5 years post-operation. A colonoscopy was performed at the year 1 and 3. A chestabdominal-pelvic CT-scan was used for the detection of locoregional or systemic recurrence at 2 and 6 months after surgery, and every 6 months thereafter, or whenever suspected.</p> <p><b>Statistical analysis</b> No adjustments for potential confounding or case-mix was done.</p>		<p>not control for potential confounding in the analysis.) Bias in selection of participants into the study: Low risk of bias</p> <p>At intervention Bias in classification of <b>Interventions</b>: Low risk of bias</p> <p>Post-intervention Bias due to deviations from intended <b>Interventions</b>: Low risk of bias Bias due to missing data: Low risk of bias Bias in measurement of outcomes: Low risk of bias Bias in selection of the reported result: Low risk of bias</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>treatment of rectal cancer.</p> <p><b>Study dates</b> October 2010 to March 2017</p> <p><b>Source of funding</b> This study has not been funded in whole or in part by any organisation.</p>					
<p><b>Full citation</b> Ishibe, A., Ota, M., Fujii, S., Suwa, Y., Suzuki, S., Suwa, H., Momiyama, M., Watanabe, J., Watanabe, K., Taguri, M., Kunisaki, C., Endo, I., Midterm follow-up of a randomized trial of open surgery versus laparoscopic surgery in elderly patients with colorectal cancer, Surgical Endoscopy and Other</p>	<p><b>Sample size</b> N=200 randomised in total of which 58 were rectal cancer patients; n=29 rectal cancer patients allocated to laparoscopic surgery; n=29 rectal cancer patients allocated to open surgery</p> <p><b>Characteristics</b> <b>Characteristics</b> in the total cohorts (both colon and rectal cancers):</p> <p>Age &gt;=80 years, n (%) Laparoscopic 44 (45) Open 39 (42)</p>	<p><b>Interventions</b> Laparoscopic versus open surgery</p> <p>Medial-to-lateral approach in the laparoscopic surgery was performed in all patients in the laparoscopic group.</p> <p>High anterior resection of rectum, n/n Laparoscopic 5/29 Open 7/29 Low anterior resection of rectum Laparoscopic 19/29 Open 19/29</p>	<p><b>Details</b> Randomisation and allocation concealment Details not reported.</p> <p>Blinding No blinding.</p> <p>Follow-up/outcomes The follow-up schedule was specific to the disease stage. Stage 0 or I: outpatient examinations once a year for 5 years, including tumour marker measurements and computed tomography of the chest, abdomen, and pelvis. Stage II or IIIA: Computed tomography and tumour marker</p>	<p><b>Results</b> Outcome: Overall survival at 3 years (rectal cancer) Laparoscopic 85.7% Open 83.1% p = 0.557</p> <p>Outcome: Local recurrence (median 42.5 months of follow-up) Laparoscopic 0/29 Open 4/29</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: unclear risk (Details not reported.) Allocation concealment: unclear risk (Details not reported.)</p> <p>Performance bias Blinding of participants and personnel: high risk (No blinding.)</p> <p>Detection bias Blinding of outcome assessment: high risk (No blinding, high risk of bias for subjective outcomes.)</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Interventional Techniques, 31, 3890-3897, 2017</p> <p><b>Ref Id</b> 747811</p> <p><b>Country/ies where the study was carried out</b> Japan</p> <p><b>Study type</b> RCT</p> <p><b>Aim of the study</b> To compare open surgery with laparoscopic surgery in elderly patients with colorectal cancer.</p> <p><b>Study dates</b> August 2008 to August 2012</p> <p><b>Source of funding</b> None.</p>	<p>Male sex, n (%) Laparoscopic 49 (50) Open 55 (60)</p> <p>BMI &gt;=25, n (%) Laparoscopic 33 (34) Open 34 (37)</p> <p>Tumour site, n (%) Colon Laparoscopic 69 (70) Open 63 (69) Rectum Laparoscopic 29 (30) Open 29 (32)</p> <p>pStage, n (%) 0 Laparoscopic 5 (5) Open 2 (2) I Laparoscopic 27 (28) Open 24 (26) II Laparoscopic 36 (37) Open 33 (36) III Laparoscopic 30 (31) Open 33 (36)</p>	<p>Abdominoperineal resection Laparoscopic 4/29 Open 2/29 Intersphincteric resection Laparoscopic 1/29 Open 0/29</p> <p>Adjuvant chemotherapy, n (%) (for the total population, including colon and rectal cancers) Laparoscopic 16 (16) Open 10 (11)</p>	<p>measurements every 6 months for the first 2 years, once a year from years 3 to 5. Stage IIIB or IIIC: Computed tomography and tumour marker measurements every 4 months for the first 2 years, and every 6 months from years 3 to 5.</p> <p><b>Statistical analysis</b> Survival was analysed using the Kaplan–Meier method, difference between the groups was determined by log-rank test.</p>		<p>Attrition bias Incomplete outcome data: low risk</p> <p>Reporting bias Selective reporting: low risk</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	<p><b>Inclusion criteria</b> Age of 75 years or older; a histologically confirmed diagnosis of colorectal adenocarcinoma; a clinical stage of up to T4a tumours; any N stage; no evidence of metastasis (M0); elective surgery.</p> <p><b>Exclusion criteria</b> Synchronous or metachronous (within 5 years) malignancy in another organ except carcinoma-in-situ; multiple colorectal cancer needing reconstruction two or more times; acute intestinal obstruction or perforation due to colorectal cancer; bulky tumour &gt;8 cm in diameter; lower rectal cancer that required pelvic side wall lymphadenectomy; history of laparotomy for colorectal resection except appendectomy; pregnancy or breastfeeding; inability to tolerate pneumoperitoneum on</p>				

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	the basis of general condition.				
<b>Full citation</b> Jayne, DG, Brown, J. M., Thorpe, H., Walker, J., Quirke, P., Guillou, P. J., Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique, Br J Surg, 92, 1124-32, 2005  <b>Ref Id</b> 809743  <b>Country/ies where the study was carried out</b>  <b>Study type</b>  <b>Aim of the study</b>  <b>Study dates</b>	<b>Sample size</b> See Jayne 2010 (CLASICC trial).  <b>Characteristics</b>  <b>Inclusion criteria</b>  <b>Exclusion criteria</b>	<b>Interventions</b>	<b>Details</b>	<b>Results</b>	<b>Limitations</b>  <b>Other information</b>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<b>Source of funding</b>					
<b>Full citation</b> Jayne D, Thorpe, Hc, Copeland, J, Quirke, P, Brown, Jm, Guillou, Pj, Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer, British Journal of Surgery, 97, 1638-1645, 2010  <b>Ref Id</b> 747887  <b>Country/ies where the study was carried out</b> UK  <b>Study type</b> RCT (CLASICC trial)  <b>Aim of the study</b> To evaluate the technical and oncological safety and efficacy of	<b>Sample size</b> N=794 randomised (both colon and rectal cancers) of which N=381 were rectal cancer patients; n=253 rectal cancer patients allocated to laparoscopic surgery; n=128 rectal cancer patients allocated to open surgery  <b>Characteristics</b> <b>Characteristics</b> of the total population (both colon and rectal cancers):  Age in years, mean±SD Laparoscopic 69±11 Open 69±12  Female sex, n (%) Laparoscopic 230 (44) Open 123 (46)  BMI, mean±SD Laparoscopic 25±4 Open 26±4	<b>Interventions</b> Laparoscopic versus open surgery  Anterior resection (rectal cancer), n (%) Laparoscopic 167 (66) Open 79 (62) Abdominoperineal resection, n (%) Laparoscopic 63 (25) Open 34 (27)  Surgery with curative intent (rectal cancer), n (%) Laparoscopic 233 (92) Open 99 (77) Palliative surgery (rectal cancer), n (%) Laparoscopic 11 (4) Open 22 (17)	<b>Details</b> Randomisation and allocation concealment Randomisation was done by telephone by the trial coordinator. Randomisation was stratified by surgeon, proposed site of operation, presence of liver metastases, and preoperative radiotherapy administration.  Blinding No blinding.  Follow-up/outcomes Follow-up visits were at 1 and 3 months after surgery, then every 3 months for the first year, every 4 months for the second year, and every 6 months afterwards. Overall survival was calculated from the date of randomisation to the date of death from any cause. The International Prostate Symptom Score (I-PSS), International Index of Erectile Function (IIEF)	<b>Results</b> Outcome: Overall survival at 5 years (rectal cancer) Laparoscopic 62.8% Open 52.9% p=0.247  Outcome: Quality of life - Overall sexual dysfunction at median 3 years after surgery among previously sexually active men (IIEF; rectal cancer only)* Laparoscopic 7/15 Open 1/22  Outcome: Quality of life - A severe change in overall level of sexual function perceived in men (IIEF; rectal cancer only)** Laparoscopic 23/56 Open 6/26  Outcome: Quality of life - Overall level of	<b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: unclear risk (Limited details reported.) Allocation concealment: unclear risk (Limited details reported.)  Performance bias Blinding of participants and personnel: high risk (No blinding.)  Detection bias Blinding of outcome assessment: high risk (No blinding. High risk of bias for subjective outcomes such as quality of life.)  Attrition bias Incomplete outcome data: low risk  Reporting bias Selective reporting: unclear risk (Because this trial included patients with both colon and rectal cancers,



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>laparoscopically assisted surgery in comparison with conventional open surgery for the treatment of colorectal cancer.</p> <p><b>Study dates</b> July 1996 to July 2002</p> <p><b>Source of funding</b> UK Medical Research Council</p>	<p>Tumour site, n (%)</p> <p>Colon</p> <p>Laparoscopic 273 (52)</p> <p>Open 140 (52)</p> <p>Rectum</p> <p>Laparoscopic 253 (48)</p> <p>Open 128 (48)</p> <p>pT stage, n (%)</p> <p>pT1</p> <p>Laparoscopic 26 (6)</p> <p>Open 12 (5)</p> <p>pT2</p> <p>Laparoscopic 68 (15)</p> <p>Open 35 (15)</p> <p>pT3</p> <p>Laparoscopic 261 (56)</p> <p>Open 136 (56)</p> <p>pT4</p> <p>Laparoscopic 70 (15)</p> <p>Open 33 (14)</p> <p>Missing</p> <p>Laparoscopic 33 (7)</p> <p>Open 24 (10)</p> <p>pN stage, n (%)</p> <p>pN0</p> <p>Laparoscopic 244 (53)</p> <p>Open 129 (54)</p>		<p>and Female Sexual Function Index (FSFI) were used as symptom-specific tools to assess bladder and sexual function. A global question was added to each questionnaire to investigate the effect of surgery on sexual and bladder function from the patient's perspective. Quality of life was measured with the European Organization for Research and Treatment of Cancer (EORTC) colorectal module QLQ-CR38 questionnaire, including 10 items relating to sexual and bladder function, with information being collected prospectively before operation, and 2 weeks (bladder function only), 3, 6 and 18 months after surgery.</p> <p>Statistical analysis</p> <p>Differences in survival and recurrences between groups were compared using Kaplan–Meier curves and tested with log-rank test.</p>	<p>sexual function decreased 'quite a lot' or 'severely' as a result of surgery in women (FSFI; rectal cancer only)**</p> <p>Laparoscopic 8/29</p> <p>Open 3/17</p> <p>Outcome: Quality of life - Bladder function (I-PSS; rectal cancer only)**</p> <p>"No differences in bladder function, either in overall score or in individual symptom scores, were detected between the laparoscopic and open rectal resection groups."</p> <p>Outcome: Quality of life - Bladder function (QLQ-CR38; rectal cancer only)**</p> <p>"No differences in bladder function were detected at any time point between the laparoscopic and open rectal groups."</p>	<p>not all outcomes were reported by the site of the tumour.)</p> <p>Other bias</p> <p>Other sources of bias: -</p> <p><b>Other information</b></p> <p>None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	<p>pN1 Laparoscopic 107 (23) Open 52 (22)</p> <p>pN2 Laparoscopic 72 (16) Open 38 (16) Not investigated Laparoscopic 4 (1) Open - Missing Laparoscopic 35 (8) Open 22 (9)</p> <p>pM stage, n (%) pM0 Laparoscopic 167 (36) Open 91 (38)</p> <p>pM1 Laparoscopic 12 (3) Open 7 (3) Not investigated Laparoscopic 229 (50) Open 112 (46)</p> <p>Missing Laparoscopic 54 (12) Open 31 (13)</p>			<p>Outcome: Local recurrence at 5 years (anterior resection for rectal cancer only) Laparoscopic 9.4% Open 7.6% p=0.740</p> <p>Outcome: Length of hospital stay in days (rectal cancer), median (IQR)** Laparoscopic 11 (9-15) Open 13 (9-18)</p> <p>Outcome: in-hospital mortality*** Laparoscopic 17/585 Open: 27/823</p> <p>Outcome: Wound infection (rectal cancer)** Laparoscopic 33/253 Open 15/125</p> <p>*Data extracted from Quah 2002. ** Data extracted from Jayne 2005. ***Data extracted from Guillou 2005.</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	<p><b>Inclusion criteria</b> Patients with cancer of the colon or rectum suitable for right hemicolectomy, left hemicolectomy, sigmoid colectomy, anterior resection, or abdominoperineal resection.</p> <p><b>Exclusion criteria</b> Adenocarcinoma of the transverse colon; contraindications to pneumoperitoneum (chronic cardiac or pulmonary disease); acute intestinal obstruction; malignant disease in the past 5 years; synchronous adenocarcinomas; pregnancy; associated gastrointestinal disease needing surgical intervention.</p>				
<p><b>Full citation</b> Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, Quirke P, West N, Rautio T, Thomassen N,</p>	<p><b>Sample size</b> N=471 randomised; n=237 allocated to robotic surgery; n=234 allocated to laparoscopic surgery</p> <p><b>Characteristics</b></p>	<p><b>Interventions</b> Robotic versus laparoscopic surgery Type of resection, n (%) High anterior resection Robotic 35 (15) Laparoscopic 34 (15) Low anterior resection</p>	<p><b>Details</b> Randomisation and allocation concealment Randomisation was done with stratification for treating surgeon, sex, preoperative radiotherapy or chemoradiotherapy,</p>	<p><b>Results</b> Outcome: Female sexual function at 6 months (FSFI) Adjusted* difference in score Laparoscopic (n=29) minus robotic (n=25)</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: unclear risk (Details not reported.)</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Tilney H, Gudgeon M, Bianchi PP, Edlin R, Hulme C, Brown J. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. JAMA 318(16), 1569-1580, 2017</p> <p><b>Ref Id</b> 839317</p> <p><b>Country/ies where the study was carried out</b> UK, Italy, Denmark, US, Finland, South Korea, Germany, France, Australia and Singapore</p> <p><b>Study type</b> RCT (ROLARR trial)</p>	<p>Age in years, mean±SD Robotic 64.4±11 Laparoscopic 65.5±12</p> <p>Male sex, n (%) Robotic 161 (68) Laparoscopic 159 (68)</p> <p>BMI ≥30, n (%) Robotic 54 (23) Laparoscopic 55 (24)</p> <p>Pathological T stage, n (%) pT0 Robotic 22 (9) Laparoscopic 24 (10) pT1 Robotic 24 (10) Laparoscopic 20 (9) pT2 Robotic 64 (27) Laparoscopic 61 (27) pT3 Robotic 117 (50) Laparoscopic 114 (50) pT4 Robotic 5 (2) Laparoscopic 8 (4) Tx or missing Robotic 4 (2) Laparoscopic 3 (1)</p> <p>Pathological N stage, n (%) pN0 Robotic 146 (62) Laparoscopic 150 (65) pN1</p>	<p>Robotic 159 (67) Laparoscopic 158 (68)</p> <p>Abdominoperineal resection Robotic 43 (18) Laparoscopic 42 (18)</p> <p>Preoperative radiotherapy or chemoradiotherapy Robotic 111 (47) Laparoscopic 108 (46)</p>	<p>intended procedure, and BMI. No other details reported.</p> <p>Blinding No blinding.</p> <p>Follow-up/outcomes Primary endpoint of the trial was conversion to open resection. Secondary endpoints included for example: CRM+ (defined as tumour ≤1 mm), intraoperative and postoperative complications, postoperative 30-day mortality, and patient-reported sexual and bladder function at baseline and at 6 months. Female sexual function was self-assessed by the patients using Female Sexual Function Index (FSFI), with scores ranging from 2 to 36 and higher score indicating better functioning. Male sexual function was self-assessed by the patients using International Index of Erectile Function (IIEF), with scores ranging from 5 to 75 and higher scores</p>	<p>1.23 (95% CI -3.54 to 6.00), p=0.60</p> <p>Outcome: Male sexual function at 6 months (IIEF) Adjusted* difference in score Laparoscopic (n=84) minus robotic (n=97) 0.80 (95% CI -4.10 to 5.70), p=0.75</p> <p>Outcome: Bladder function at 6 months (IPSS) Adjusted* difference in score Laparoscopic (n=176) minus robotic (n=175) 0.743 (95% CI -0.59 to 2.07), p=0.27</p> <p>Outcome: Positive CRM Robotic 12/235 Laparoscopic 14/224</p> <p>Outcome: Positive proximal resection margin Robotic 0/235 Laparoscopic 0/224</p> <p>Outcome: Positive distal resection margin Robotic 0/235 Laparoscopic 1/224</p>	<p>Allocation concealment: unclear risk (Details not reported.)</p> <p>Performance bias Blinding of participants and personnel: high risk (No blinding.)</p> <p>Detection bias Blinding of outcome assessment: high risk (No blinding.)</p> <p>Attrition bias Incomplete outcome data: low risk</p> <p>Reporting bias Selective reporting: low risk</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Aim of the study</b> To compare robotic-assisted versus conventional laparoscopic surgery for risk of conversion to open laparotomy among patients undergoing resection for rectal cancer.</p> <p><b>Study dates</b> January 7th 2011 to September 30th 2014</p> <p><b>Source of funding</b> Efficacy and Mechanism Evaluation Programme, a partnership between Medical Research Council and National Institute for Health Research with contributions from the Chief Scientist Office in Scotland, the National Institute of Social</p>	<p>Robotic 63 (27) Laparoscopic 58 (25) pN2 Robotic 25 (11) Laparoscopic 21 (9) Missing Robotic 2 (1) Laparoscopic 1 (0.4)</p> <p><b>Inclusion criteria</b> Age <math>\geq 18</math> years; able to provide written informed consent; diagnosis of rectal cancer amenable to curative surgery either by low anterior resection, high anterior resection, or abdominoperineal resection i.e. staged T1-3, N0-2, M0 by imaging as per local practice; rectal cancer suitable for resection by either standard or robotic-assisted laparoscopic procedure; fit for robotic-assisted or standard laparoscopic rectal resection; ASA physical status classification less than or equal to 3; capable of completing required questionnaires at time of consent.</p>		<p>meaning better functioning. Bladder function was self-assessed by the patients using International Prostate Symptom Score (IPSS), with scores ranging from 0 to 35, higher score indicating worse symptoms.</p> <p>Statistical analysis Intention-to-treat analysis was done.</p>	<p>Outcome: Length of hospital stay (mean<math>\pm</math>SD days) Robotic 8.0<math>\pm</math>5.85 (n=237) Laparoscopic 8.2<math>\pm</math>6.03 (n=234)</p> <p>Outcome: 30-day operative mortality Robotic 2/236 Laparoscopic 2/230</p> <p>Outcome: Anastomotic leak (within 6 months) Robotic 22/180 Laparoscopic 18/181</p> <p>Outcome: Surgical site infection (within 30 days) Robotic 21/236 Laparoscopic 19/230</p> <p>Outcome: Surgical site infection (between 30 days and 6 months) Robotic 4/236 Laparoscopic 8/230</p> <p>*Adjusted for baseline scores and stratification factors (surgeon, sex, preoperative therapy, intended procedure and BMI)</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Care and Health Research in Wales, and the Health and Social Care Research and Development Division, Public Health Agency in Northern Ireland; National Institute for Health Research; Yorkshire Cancer Research; the Medical Research Council Bioinformatics Initiative.</p>	<p><b>Exclusion criteria</b> Benign lesions of the rectum; benign or malignant diseases of the anal canal; locally advanced cancers not amenable to curative surgery; locally advanced cancers requiring en bloc multi-visceral resection; synchronous colorectal tumours requiring multi-segment surgical resection; co-existent inflammatory bowel disease; clinical or radiological evidence of metastatic spread; concurrent or previous diagnosis of invasive cancer within 5 years that could confuse diagnosis; history of psychiatric or addictive disorder or other medical condition that, in the opinion of the investigator, would preclude the patient from meeting the trial requirements; pregnancy; participation in another rectal cancer clinical trial relating to surgical technique</p>				

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Full citation</b> Jeong S, Park, J. W., Nam, B. H., Kim, S., Kang, S. B., Lim, S. B., Choi, H. S., Kim, D. W., Chang, H. J., Kim, D. Y., Jung, K. H., Kim, T. Y., Kang, G. H., Chie, E. K., Kim, S. Y., Sohn, D. K., Kim, D. H., Kim, J. S., Lee, H. S., Kim, J. H., Oh, J. H., Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): Survival outcomes of an open-label, non-inferiority, randomised controlled trial, The Lancet Oncology, 15, 767-774, 2014</p> <p><b>Ref Id</b> 747902</p>	<p><b>Sample size</b> N=340 randomised; n=170 allocated to laparoscopic surgery; n=170 allocated to open surgery</p> <p><b>Characteristics</b> Age in years, mean±SD Laparoscopic 57.8 (11.1) Open 59.1 (9.9)</p> <p>Male sex, n (%) Laparoscopic 110 (65) Open 110 (65)</p> <p>BMI &gt;25, n (%) Laparoscopic 63 (37) Open 64 (38)</p> <p>Tumour distance from anal verge, n (%) 0-3 cm Laparoscopic 35 (21) Open 46 (27) 3-6 cm Laparoscopic 66 (39) Open 59 (35) 6-9 cm Laparoscopic 69 (41) Open 65 (38)</p>	<p><b>Interventions</b> Laparoscopic surgery versus open surgery</p> <p>Type of surgery, n (%) Abdominoperineal resection Laparoscopic 19 (11) Open 24 (14) Low anterior resection Laparoscopic 151 (89) Open 146 (86)</p> <p>Laparoscopic surgery was done with 5 ports.</p> <p>Surgeries were done 6–8 weeks after completion of preoperative chemoradiotherapy. Radiotherapy was delivered to the whole pelvis at a dose of 45 Gy in 25 fractions, followed by a boost to the primary tumour of 5.4 Gy in three fractions during 5.5 weeks.</p> <p>Type of preoperative chemotherapy, n (%) Fluoropyrimidines alone</p>	<p><b>Details</b> Randomisation and allocation concealment Computer-generated randomisation list was generated through Centre for Clinical Trials with a random permuted block design, 1:1 ratio, randomisation stratified by sex and preoperative chemotherapy regimen. Randomisation was done at the coordinating centre via telephone.</p> <p><b>Blinding</b> Patients and clinicians not blinded. During follow-up, radiologists and pathologists were blinded.</p> <p><b>Follow-up/outcomes</b> Patients were followed-up every 3 months for the first 2 years, every 6 months for the next 3 years, and every 6 months or yearly thereafter. For the postoperative follow-up, a physical examination, complete blood-cell count, liver function tests, serum CEA tests, and chest</p>	<p><b>Results</b> <b>Overall survival</b> Outcome: Overall survival (median 4 years of follow-up; event is death from any cause) Laparoscopic N=170, 20 events Open N=170, 25 events HR 0.8 95% CI 0.44 to 1.45*</p> <p><b>Local recurrence</b> Outcome: Positive CRM (&lt;1 mm) Laparoscopic 5/170 Open 7/170</p> <p><b>Local recurrence</b> Outcome: Local recurrence (median 4 years of follow-up; event is local recurrence) Laparoscopic N=170, 2 events Open N=170, 4 events HR 0.40 95% CI 0.13 to 1.30*</p> <p><b>Length of hospital stay</b> Outcome: Length of hospital stay in days, median (IQR)**</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: low risk Allocation concealment: low risk</p> <p>Performance bias Blinding of participants and personnel: high risk (Patients and clinicians not blinded.)</p> <p>Detection bias Blinding of outcome assessment: low/high risk (Patients and clinicians not blinded but at follow-up radiologists and pathologists were blinded. High risk on subjective outcomes if no blinding done.)</p> <p>Attrition bias Incomplete outcome data: low risk (Intention-to-treat analysis done.)</p> <p>Reporting bias Selective reporting: low risk</p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Country/ies where the study was carried out</b> South Korea</p> <p><b>Study type</b> RCT (COREAN trial)</p> <p><b>Aim of the study</b> To compare survival outcomes of laparoscopic surgery with open surgery for patients with mid-rectal low-rectal cancer.</p> <p><b>Study dates</b> April 4 2006 to August 26 2009</p> <p><b>Source of funding</b> National Cancer Center, (South Korea)</p>	<p>Clinical classification, n (%) cN0 Laparoscopic 59 (35) Open 52 (31) cN+ Laparoscopic 111 (65) Open 118 (69)</p> <p><b>Inclusion criteria</b> Mid-rectal or low-rectal cancer; cT3N0-2M0; previous preoperative chemoradiotherapy; 18–80 years of age</p> <p><b>Exclusion criteria</b> Synchronous distant metastases, another primary malignancy, cardiopulmonary dysfunction, active uncontrolled infection, active uncontrolled psychosis, and intestinal perforation or obstruction.</p>	<p>Laparoscopic 156 (92) Open 156 (92) Capecitabine and irinotecan Laparoscopic 3 (2) Open 1 (1) Capecitabine, irinotecan, and cetuximab Laparoscopic 11 (6) Open 13 (8)</p> <p>Postoperative adjuvant chemotherapy was recommended for all patients, irrespective of the surgical pathology results.</p>	<p>radiography were done every 3 months or 6 months; abdominal and pelvic computer tomography were done every 6 months. Colonoscopic examinations were done 1 year postoperatively and once every 2 years thereafter. The primary outcome was disease-free survival (not of interest to this review). Secondary outcomes were overall survival, local recurrence, and quality of life. Local recurrence was defined as any recurrence within the pelvic cavity or the perineum. Overall survival was defined as time from surgery to death from any cause. A validated Korean version of the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ)–C30 questionnaire (version 3.0) and the colorectal cancer module QLQ–CR38 to assess quality of life preoperatively</p>	<p>Laparoscopic 8 (7-12) Open 9 (8-12) p=0.056</p> <p>Outcome: 90-day mortality** Laparoscopic 0/170 Open 0/170</p> <p>Outcome: Anastomotic leak** Laparoscopic 2/170 Open 0/170</p> <p>Outcome: Blood loss in ml, median (IQR)** Laparoscopic 200.0 (100.0-300.0) Open 217.5 (150.0-400.0) p=0.006</p> <p>*The HR reported in the paper was inverted in order to have open surgery as the reference. **Data extracted from Kang 2010.</p>	<p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
			and at months 3, 12, 24, and 36 after surgery.  Statistical methods All analysis based on intention-to-treat population. Kaplan-Meier method with log-rank test to assess difference between groups.		
<b>Full citation</b> Kang, S. B., Park, J. W., Jeong, S. Y., Nam, B. H., Choi, H. S., Kim, D. W., Lim, S. B., Lee, T. G., Kim, D. Y., Kim, J. S., Chang, H. J., Lee, H. S., Kim, S. Y., Jung, K. H., Hong, Y. S., Kim, J. H., Sohn, D. K., Kim, D. H., Oh, J. H., Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): Short-term outcomes of an open-label randomised controlled trial,	<b>Sample size</b> See Jeong 2014 (COREAN trial).  <b>Characteristics</b>  <b>Inclusion criteria</b>  <b>Exclusion criteria</b>	<b>Interventions</b>	Details	Results	<b>Limitations</b>  <b>Other information</b>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>The Lancet Oncology, 11, 637-645, 2010</p> <p>Ref Id 748017</p> <p>Country/ies where the study was carried out</p> <p>Study type</p> <p>Aim of the study</p> <p>Study dates</p> <p>Source of funding</p>					
<p><b>Full citation</b> Kim, J., Baek, S. J., Kang, D. W., Roh, Y. E., Lee, J. W., Kwak, H. D., Kwak, J. M., Kim, S. H., Robotic Resection is a Good Prognostic Factor in Rectal Cancer Compared with Laparoscopic Resection: Long-term Survival Analysis Using</p>	<p><b>Sample size</b> N=224 robotic TME; N=224 laparoscopic TME (groups matched by sex, age, BMI, comorbidity, ASA score, tumour height from the anal verge, tumour location, preoperative chemoradiotherapy, and TNM stage)</p> <p><b>Characteristics</b> Matched group <b>Characteristics:</b></p>	<p><b>Interventions</b> Robotic versus laparoscopic TME</p> <p>All robotic TME procedures were performed by a single docking totally robotic technique using the da Vinci Surgical System.</p> <p>Type of resection, n (%) Anterior resection Robotic 2 (1)</p>	<p><b>Details</b> Randomisation and allocation concealment This was not a randomised study but a retrospective observational study. Matching of groups were done based on:</p> <p>Blinding Not applicable.</p> <p>Follow-up/outcomes</p>	<p><b>Results</b> Outcome: Overall survival at 5 years Stages I-III Robotic 90.5% Laparoscopic 78.0% p=0.323 Stage II Robotic 91.2% Laparoscopic 87.0% p=0.896 Stage III Robotic 83.1%</p>	<p><b>Limitations</b> ROBINS-I checklist for non-randomised studies of Interventions Pre-intervention Bias due to confounding: Moderate risk of bias (This is a retrospective observational study. Groups were matched.) Bias in selection of participants into the study: Low risk of bias</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Propensity Score Matching, Diseases of the Colon &amp; Rectum, 60, 266-273, 2017</p> <p><b>Ref Id</b> 748152</p> <p><b>Country/ies where the study was carried out</b> South Korea</p> <p><b>Study type</b> Retrospective cohort study</p> <p><b>Aim of the study</b> To evaluate long term oncologic outcomes of robotic TME compared with laparoscopic TME.</p> <p><b>Study dates</b> April 2007 to March 2014</p> <p><b>Source of funding</b></p>	<p>Age in years, mean±SD Robotic 60.7±11.7 Laparoscopic 61.0±11.0</p> <p>Male sex, n (%) Robotic 145 (65) Laparoscopic 141 (63)</p> <p>BMI, mean±SD Robotic 23.3±3.0 Laparoscopic 23.4 (3.3)</p> <p>Tumour location from the anal verge, n (%) Lower Robotic 128 (57) Laparoscopic 136 (61) Middle Robotic 88 (39) Laparoscopic 78 (35) Upper Robotic 8 (4) Laparoscopic 10 (5)</p> <p>Pathologic TNM stage, n (%) I Robotic 62 (28) Laparoscopic 63 (28) II</p>	<p>Laparoscopic 7 (3) Lower anterior resection Robotic 169 (75) Laparoscopic 168 (75) Intersphincteric resection Robotic 41 (18) Laparoscopic 35 (16) Abdominoperineal resection Robotic 12 (5) Laparoscopic 14 (6)</p> <p>Preoperative concurrent chemoradiotherapy was given selectively based on the following indications: T4; CRM positive or threatened; or suggestive metastasis of lateral pelvic lymph node, defined as a lymph node beyond the TME plane such as the iliac and obturator lymph nodes, on preoperative staging.</p> <p>Preoperative chemoradiotherapy, n (%) Robotic 50 (22) Laparoscopic 50 (22)</p>	<p>For those who underwent chemotherapy, laboratory tests including CEA and abdominopelvic computer tomography scan were performed at 3- to 4-cycle intervals during chemotherapy. Other examinations such as chest CT, sigmoidoscopy or total colonoscopy, and positron emission tomography and CT were added when necessary. After chemotherapy, follow-up examinations were performed at 3-month intervals in the first 2 years, at 6-month intervals until 5 years, and annually thereafter, unless there was evidence of recurrence.</p> <p><b>Statistical analysis</b> Propensity score matching was conducted to reduce the bias due to non-randomization of patients, based on: sex, age, BMI, comorbidity, ASA score, tumour height, tumour location, preoperative concurrent chemoradiotherapy, and TNM stage.</p>	<p>Laparoscopic 64.2% p=0.526</p>	<p>At intervention Bias in classification of Interventions: Low risk of bias</p> <p>Post-intervention Bias due to deviations from intended Interventions: Low risk of bias Bias due to missing data: Low risk of bias Bias in measurement of outcomes: Low risk of bias Bias in selection of the reported result: Low risk of bias</p> <p>Other information None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
National Research Foundation of Korea; the Ministry of Science, ICT, and Future Planning (Republic of Korea)	<p>Robotic 59 (26) Laparoscopic 54 (24) III Robotic 75 (34) Laparoscopic 75 (34) IV Robotic 28 (13) Laparoscopic 32 (14)</p> <p><b>Inclusion criteria</b> Primary rectal cancer with pathologically proven adenocarcinoma within 15 cm of the anal verge; underwent minimally invasive surgery for rectal cancer.</p> <p><b>Exclusion criteria</b> Patients with pathological stage IV cancer excluded from survival analysis.</p>	The indications for postoperative radiotherapy were: T4; CRM or distal resection margin positive (CRM <2 mm, distal resection margin <5 mm); or lateral pelvic lymph nodes suspicious on preoperative diagnostic images but not receiving preoperative radiotherapy.	Survival was analysed using the Kaplan-Meier method, and comparison of the survival between the groups was performed by the paired Prentice-Wilcoxon test.		
<b>Full citation</b> Kim, J. C., Yu, C. S., Lim, S. B., Park, I. J., Kim, C. W., Yoon, Y. S., Comparative analysis focusing on surgical and early oncological outcomes of	<b>Sample size</b> N=2,114 consecutive rectal cancer patients; n=533 patients underwent robotic surgery; n=1,095 open surgery (n=486 laparoscopic surgery, not considered for this review because almost	<b>Interventions</b> Robotic versus open surgery  All procedures included TME with at least unilateral pelvic autonomic nerve preservation.	<b>Details</b> Randomisation and allocation concealment This was not a randomised study. Consecutive rectal cancer patients were provided with full information on the three procedures (open, laparoscopic, and robotic	<b>Results</b> Outcome: Overall survival at 3 years Robotic 94.6% Open 91.9% p=0.352  Outcome: Sexual dysfunction in men	<b>Limitations</b> ROBINS-I checklist for non-randomised studies of Interventions Pre-intervention Bias due to confounding: Serious risk of bias (This is a non-randomised study. The outcomes of interest

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>open, laparoscopy-assisted, and robot-assisted approaches in rectal cancer patients, International Journal of Colorectal Disease, 31, 1179-1187, 2016</p> <p><b>Ref Id</b> 748163</p> <p><b>Country/ies where the study was carried out</b> South Korea</p> <p><b>Study type</b> Prospective cohort study</p> <p><b>Aim of the study</b> To compare open, laparoscopic, and robotic TME for rectal cancer in terms of sphincter-saving operation achievement, surgical complications, and early</p>	<p>half of the population in this intervention group with stage 0 or I cancer)</p> <p><b>Characteristics</b> Age in years, mean±SD Robotic 55±9 Open 59±9</p> <p>Male sex, n (%) Robotic 333 (63) Open 700 (64)</p> <p>BMI, mean±SD Robotic 24.1±3 Open 23.8±3</p> <p>Tumour distance from the anal verge, n (%) Lower Robotic 258 (49) Open 429 (39) Middle Robotic 229 (43) Open 554 (51) Upper Robotic 45 (9) Open 112 (10)</p> <p>cStage (AJCC) 0</p>	<p>Type of surgery, n (%) Anterior resection Robotic 4 (1) Open 33 (3) Lower anterior resection Robotic 503 (94) Open 942 (86) Abdominoperineal resection Robotic 26 (5) Open 120 (11)</p> <p>Preoperative chemoradiotherapy was principally indicated for patients with clinical stage III or T4 cancers but was ultimately determined by the surgeon. Postoperative chemoradiotherapy was administered in pathologic stage III patients without preoperative chemoradiotherapy. Patients with preoperative or postoperative chemoradiotherapy received a total of 45–50.4 Gy with fluorouracil + leucovorin or capecitabine.</p>	<p>approaches) and chose one.</p> <p>Blinding No blinding.</p> <p>Follow-up/outcomes Follow-up examinations were done every 6 months for the first 3 years and annually thereafter until five postoperative years. Recurrence was confirmed either by imaging studies or histologic examinations. Male sexual dysfunction was assessed at two postoperative years in ≤65 years old men by evaluating both erectile firmness and ejaculatory frequency using a visual analogue scale (VAS): 0-1 indicating none–mild dysfunction, 2-3 indicating moderate dysfunction, and 4-5 indicating severe dysfunction.</p> <p><b>Statistical analysis</b> Survival outcomes and recurrences were compared using the Kaplan-Meier</p>	<p>≤65 years of age (total; VAS; scale 0-5; 2-3 indicating moderate dysfunction; 4-5 indicating severe dysfunction) Robotic 27/141 Open 108/332</p> <p>Outcome: Severe sexual dysfunction in men ≤65 years of age (VAS 4-5) Robotic 13/141 Open 37/332</p> <p>Outcome: Moderate sexual dysfunction in men ≤65 years of age (VAS 2-3) Robotic 14/141 Open 71/332</p> <p>Outcome: Positive CRM (≤1 mm) Robotic 8/533 Open 26/1,095</p> <p>Outcome: Positive distal resection margin (≤5 mm) Robotic 5/533</p>	<p>were not controlled for potential confounding and case-mix in the analysis.) Bias in selection of participants into the study: Low risk of bias</p> <p>At intervention Bias in classification of Interventions: Low risk of bias</p> <p>Post-intervention Bias due to deviations from intended Interventions: Low risk of bias Bias due to missing data: Low risk of bias Bias in measurement of outcomes: Moderate risk of bias (The clinicians were not blinded to the intervention, therefore, subjective outcomes might be biased.) Bias in selection of the reported result: Low risk of bias</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>oncological outcomes.</p> <p><b>Study dates</b> July 2010 to February 2015</p> <p><b>Source of funding</b> Korea Research Foundation; Ministry of Science, ICT, and Future Planning; the Korea Health 21 R&amp;D Project; Ministry of Health, Welfare, and Family Affairs (Republic of Korea).</p>	<p>Robotic 10 (2) Open 112 (10) I</p> <p>Robotic 137 (26) Open 164 (15) II</p> <p>Robotic 101 (19) Open 197 (18) III</p> <p>Robotic 285 (54) Open 721 (66)</p> <p><b>Inclusion criteria</b> Curatively resected adenocarcinoma of the rectum (<math>\leq</math>stage III); an Eastern Cooperative Oncology Group performance status of 0–3; age <math>\leq</math>75 years.</p> <p><b>Exclusion criteria</b> Previous history of any cancer; hereditary colorectal cancer; inflammatory bowel disease.</p>	<p>Preoperative chemoradiotherapy, n (%)</p> <p>Robotic 172 (32) Laparoscopic 61 (13) Open 553 (51)</p>	<p>method with the log-rank test. Multivariate analysis was not done for the outcomes of interest.</p>	<p>Open 13/1,095</p>	
<p><b>Full citation</b> Kim, M. J., Park, S. C., Park, J. W., Chang, H. J., Kim, D. Y., Nam, B. H., Sohn, D. K., Oh,</p>	<p><b>Sample size</b> N=163 randomised; n=82 allocated to robot-assisted surgery but n=16 dropped before</p>	<p><b>Interventions</b> Robot-assisted surgery versus laparoscopic surgery</p>	<p><b>Details</b> Randomisation and allocation concealment Randomisation was computer-generated, and</p>	<p><b>Results</b> Outcome: Quality of life global health status score at baseline, at 3 weeks, 3 months and 12</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: low risk</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>J. H., Robot-assisted Versus Laparoscopic Surgery for Rectal Cancer: A Phase II Open Label Prospective Randomized Controlled Trial, <i>Annals of Surgery.</i>, 25, 2017</p> <p><b>Ref Id</b> 748185</p> <p><b>Country/ies where the study was carried out</b> South Korea</p> <p><b>Study type</b> RCT</p> <p><b>Aim of the study</b> To compare the outcomes of robotic surgery with those of laparoscopic surgery in patients with rectal cancer.</p>	<p>allocated surgery, in the end n=66 included in analysis; n=81 allocated to laparoscopic surgery but 8 dropped before allocated surgery, in the end n=73 included in analysis</p> <p><b>Characteristics</b> Age in years, mean±SD Robotic 60.4 (9.7) Laparoscopic 59.7 (11.7)</p> <p>Male sex, n (%) Robotic 51 (77) Laparoscopic 52 (71)</p> <p>BMI, mean±SD Robotic 24.1 (3.3) Laparoscopic 23.6 (3.0)</p> <p>Tumour location from the anal verge, n (%) &lt;=5 cm Robotic 33 (50) Laparoscopic 35 (48) &gt;5 cm Robotic 33 (50) Laparoscopic 38 (52)</p>	<p>Robotic surgery was performed with the da Vinci Surgical System.</p> <p>All study participants underwent TME and pelvic autonomic nerve preservation, and the operative extent was the same for both groups.</p> <p>Surgical approach, n (%) Low anterior resection with double stapling anastomosis Robotic 40 (61) Laparoscopic 48 (66) Low anterior resection with hand-sewn anastomosis Robotic 25 (38) Laparoscopic 22 (30) Abdominoperineal resection Robotic 1 (1.5) Laparoscopic 2 (2.7) Hartmann operation Robotic 0 (0) Laparoscopic 1 (1.4)</p> <p>Preoperative chemoradiotherapy received, n (%)</p>	<p>allocation was communicated via telephone by the trial coordinator at the Clinical Trials Research office at the National Cancer Center. Randomisation was stratified according to sex and preoperative chemoradiotherapy administration using a block permutation approach.</p> <p>Blinding No blinding of patients. Pathologists examining the macroscopic quality of the TME were blinded to allocation.</p> <p>Follow-up/outcomes The primary outcome of the trial was completeness of TME. Secondary outcomes included for example resection margins, morbidity and quality of life. Quality of life was evaluated before surgery and 3 weeks, 3 months, and 12 months after surgery using the validated Korean version of the EORTC QLQ-C30 questionnaire (version 3.0) and the colorectal</p>	<p>months after surgery (QLQ-C30) No difference between the two groups. (Reported narratively and in a figure, no mean scores presented.)</p> <p>Outcome: Quality of life - sexual function subscale mean score at 12 months after surgery (QLQ-CR38) (scale 0 to 100, higher indicating better) Robotic 35.2 (95% CI 26.9 to 43.5) SD 33.8 (n=66) Laparoscopic 23.0 (95% CI 15.7 to 30.2) SD 31.1 (n=73)</p> <p>Outcome: Positive CRM (&lt;=1 mm) Robotic 4/66 Laparoscopic 4/73</p> <p>Outcome: Length of hospital stay in days, mean±SD Robotic 10.3±3.4 (n=66)</p>	<p>Allocation concealment: low risk</p> <p>Performance bias Blinding of participants and personnel: high risk (No blinding.)</p> <p>Detection bias Blinding of outcome assessment: low/high risk (Pathologist was blinded but participants were not. High risk of bias for subjective outcomes.)</p> <p>Attrition bias Incomplete outcome data: unclear risk (Per protocol analysis done. 16/82 and 8/81 not included in analysis for robotic and laparoscopic groups, respectively. Reasons for these were reported (main reasons: participants refused the allocated surgery, or distant metastasis was detected).</p> <p>Reporting bias Selective reporting: low risk</p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Study dates</b> February 21 2012 to March 11 2015</p> <p><b>Source of funding</b> National Cancer Center (Republic of Korea)</p>	<p><b>Inclusion criteria</b> People with mid- or low-lying (within 9 cm from the anal verge) rectal adenocarcinoma without distant metastasis.</p> <p><b>Exclusion criteria</b> Cancer invading adjacent organs (T4), distant metastasis (M1), severe concomitant disease that might limit compliance or completion of the protocol, any other malignancy, pregnant or breastfeeding females, hereditary colorectal cancer, and emergency operation.</p>	<p>Robotic 51 (77) Laparoscopic 58 (80)</p>	<p>cancer module QLQ-CR38. Scale was 0 to 100, higher score indication better quality of life for global health status and functioning scores.</p> <p><b>Statistical analysis</b> Per protocol analysis was done.</p>	<p>Laparoscopic 10.8±7.4 (n=73)</p> <p>Outcome: Anastomotic leak Robotic 8/66 Laparoscopic 5/73</p> <p>Outcome: Blood loss in ml, median (range) Robotic 100 (0-1,000) (n=66) Laparoscopic 50 (0-300) (n=73)</p>	<p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>
<p><b>Full citation</b> Law, W. L., Foo, D. C. C., Comparison of short-term and oncologic outcomes of robotic and laparoscopic resection for mid- and distal rectal cancer, Surgical Endoscopy and</p>	<p><b>Sample size</b> N=220 robotic surgery; N=171 laparoscopic surgery</p> <p><b>Characteristics</b> Age in years, median (range) Robotic 65 (34-90) Laparoscopic 67 (23-96)</p>	<p><b>Interventions</b> Robotic versus laparoscopic surgery For robotic surgeries, the Da Vinci surgical robotic system was used. The majority of robotic surgeries were performed with the hybrid technique with left colon mobilisation and division of the inferior mesenteric vessels</p>	<p><b>Details</b> Randomisation and allocation concealment This was not a randomised study. The groups were not matched.</p> <p>Blinding No blinding.</p> <p>Follow-up/outcomes</p>	<p><b>Results</b> Outcome: Overall survival at 5 years Robotic 71.8% Laparoscopic 74.3% p=0.423</p>	<p><b>Limitations</b> ROBINS-I checklist for non-randomised studies of Interventions Pre-intervention Bias due to confounding: Serious risk of bias (This is a non-randomised, observational study, the groups were not matched by any characteristic. The</p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Other Interventional Techniques, 31, 2798-2807, 2017</p> <p><b>Ref Id</b> 748501</p> <p><b>Country/ies where the study was carried out</b> Hong Kong</p> <p><b>Study type</b> Retrospective cohort study</p> <p><b>Aim of the study</b> To compare the short-term operative as well as oncologic outcomes of laparoscopic and robotic rectal resection.</p> <p><b>Study dates</b> January 2008 to June 2015</p>	<p>Male sex, n/n Robotic 148/220 Laparoscopic 97/171</p> <p>BMI, mean Robotic 24.9 Laparoscopic 24.6</p> <p>Tumour distance from the anal verge in cm, median (range) Robotic 7.0 (0-12) Laparoscopic 8.0 (0-12)</p> <p><b>Inclusion criteria</b> People with rectal cancer within 12 cm from the anal verge and underwent elective radical resection.</p> <p><b>Exclusion criteria</b> People who underwent open resection.</p>	<p>using the conventional laparoscopic technique.</p> <p>Type of surgery, n (%) Lower anterior resection Robotic 206 (94) Laparoscopic 152 (88) Abdominoperineal resection Robotic 11 (5) Laparoscopic 14 (8) Hartmann Robotic 3 (1.4) Laparoscopic 5 (3)</p> <p>Neoadjuvant chemoradiation was offered to patients when the mesorectal margin was at risk (&lt;1 mm by MRI) and to those with findings of poor prognosis with distal cancer destined for abdominoperineal resection or low anterior resection with hand- sewn coloanal anastomosis.</p> <p>Preoperative radiotherapy, n (%) Robotic 91 (41)</p>	<p>The patients were followed up at intervals of 2–3 months during the first 2 years and every 4–6 months from 3 to 5 years and annually thereafter. The visits included: history, physical examination, blood tests and serum CEA level. A digital rectal examination was performed at each visit to detect any anastomotic stricture or local recurrence. Colonoscopy was performed regularly for the detection of metachronous lesions. If recurrences were suspected, endoscopic examination, CT scan or other imaging studies were performed to determine whether salvage surgery could be performed.</p> <p>Data, including survival data, were prospectively collected in a database for rectal cancer.</p> <p><b>Statistical analysis</b> Survival was analysed using the Kaplan–Meier method, and the groups were compared with the</p>		<p>study did not control for potential confounding or case-mix in the analysis.) Bias in selection of participants into the study: Low risk of bias</p> <p>At intervention Bias in classification of Interventions: Low risk of bias</p> <p>Post-intervention Bias due to deviations from intended Interventions: Low risk of bias Bias due to missing data: Low risk of bias Bias in measurement of outcomes: Low risk of bias Bias in selection of the reported result: Low risk of bias</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<b>Source of funding</b> None reported.		Laparoscopic 50 (29)  An enhanced recovery care program was adopted for patients following surgery for rectal cancer during the study period.	log-rank test. No matching or adjusting was done.		
<b>Full citation</b> Liang, X., Hou, S., Liu, H., Li, Y., Jiang, B., Bai, W., Li, G., Wang, W., Feng, Y., Guo, J., Effectiveness and safety of laparoscopic resection versus open surgery in patients with rectal cancer: a randomized, controlled trial from China, J Laparoendosc Adv Surg Tech A, 21, 381-5, 2011  <b>Ref Id</b> 809748  <b>Country/ies where the study was carried out</b> China	<b>Sample size</b> N=343 randomised; n=169 allocated to laparoscopic surgery, 2 people lost to follow-up and n=167 included in analysis; n=174 allocated to open surgery, 2 people lost to follow-up and n=172 included in analysis.  <b>Characteristics</b> Age in years, mean±SD Laparoscopic 57.3±14.1 Open 57.4±13.1  Male sex, n/n Laparoscopic 104/169 Open 92/174  BMI, mean (assumed to be mean, not reported) Laparoscopic 21.45 Open 22.31	<b>Interventions</b> Laparoscopic surgery versus open surgery  Surgical approach, n/n Abdominoperineal resection Laparoscopic 83/169 Open 70/174 Lower anterior resection Laparoscopic 86/169 Open 104/174  No one received preoperative (chemo)radiotherapy (in fact that was an exclusion reason).	<b>Details</b> Randomisation and allocation concealment Randomisation was done on the day before surgery through sealed opaque envelopes.  Blinding Short-term complications were reviewed by a single person blinded to treatment allocation. Otherwise no blinding.  Follow-up/outcomes Patients were assessed for complications at the time of hospital discharge by a single reviewer blinded to the treatment assignments. Follow-up visits were at 1 and 3 months after surgery, every 3 months for the first 2 years and every 6 months thereafter. The visits	<b>Results</b> Outcome: Overall survival at 3 years Laparoscopic 76.0% Open 82.8% p=0.462  Outcome: 30-day mortality Laparoscopic 0/169 Open 0/174  Outcome: Anastomotic leak Laparoscopic 4/169 Open 6/174  Outcome: Wound infection Laparoscopic 9/169 Open 8/174  Outcome: Blood transfusion	<b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: unclear risk (No sufficient detail provided.) Allocation concealment: low risk  Performance bias Blinding of participants and personnel: high risk (No blinding.)  Detection bias Blinding of outcome assessment: high risk (No blinding.)  Attrition bias Incomplete outcome data: low risk (2 patients in each group lost to follow-up and not included in survival analysis.)

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Study type</b> RCT</p> <p><b>Aim of the study</b> To assess efficacy and safety of laparoscopic surgery for treatment of rectal cancer.</p> <p><b>Study dates</b> May 2005 to April 2008</p> <p><b>Source of funding</b> None reported.</p>	<p>TNM stage, n/n T1-2N0M0 Laparoscopic 9/169 Open 7/174 T3-4N0M0 Laparoscopic 72/169 Open 84/174 TxN1-2M0 Laparoscopic 88/169 Open 83/174</p> <p><b>Inclusion criteria</b> Rectal cancer diagnosed by pathologic examination; written informed consent.</p> <p><b>Exclusion criteria</b> Liver or lung metastases assessed by computer tomography, magnetic resonance imaging or ultrasonography; BMI of &gt;30 kg/m<sup>2</sup>; acute intestinal obstruction; serious infection; previous abdominal surgery; patients who had received neoadjuvant therapy.</p>		<p>included physical examination, abdominal and pelvic part ultrasonography, chest radiography, examination of alimentary tract tumour markers and colonofiberscope examination. Recurrence was confirmed by imaging or pathological examination.</p> <p><b>Statistical analysis</b> For survival, Kaplan-Meier method was used and log-rank test was used to compare the interventions.</p>	<p>Laparoscopic 4/169 Open 8/174</p>	<p>Reporting bias Selective reporting: low risk</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>
<b>Full citation</b>	<b>Sample size</b> N=204 randomised;	<b>Interventions</b>	Details	Results	<b>Limitations</b> Cochrane risk of bias tool

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Lujan, J., Valero, G., Hernandez, Q., Sanchez, A., Frutos, M. D., Parrilla, P., Randomized clinical trial comparing laparoscopic and open surgery in patients with rectal cancer, British Journal of Surgery, 96, 982-989, 2009</p> <p><b>Ref Id</b> 748829</p> <p><b>Country/ies where the study was carried out</b> Spain</p> <p><b>Study type</b> RCT</p> <p><b>Aim of the study</b> To compare surgical outcomes after laparoscopic and open approaches for mid and low rectal cancers.</p>	<p>n=101 allocated to laparoscopic surgery but n=97 included in analysis (2 excluded due to postoperative deaths and 2 excluded because of tumour persistence); n=103 allocated to open surgery but n=96 included in analysis (3 excluded due to postoperative deaths and 4 excluded because of tumour persistence)</p> <p><b>Characteristics</b> Age in years, mean±SD Laparoscopic 67.8 (12.9) Open 66.0 (9.9)</p> <p>Male sex, n/n Laparoscopic 64/103 Open 62/101</p> <p>Tumour location from the anal verge in cm, mean±SD Laparoscopic 5.49 (3.04) Open 6.24 (2.91)</p> <p>Preoperative stage, n (%) I</p>	<p>Laparoscopic versus open surgery</p> <p>All patients underwent TME with preservation of the hypogastric nerves.</p> <p>The laparoscopic surgery was performed with 4 or sometimes 5 ports.</p> <p>Surgical approach, n (%) Anterior resection Laparoscopic 77 (76) Open 81 (79) Abdominoperineal resection Laparoscopic 24 (24) Open 22 (21)</p> <p>Neoadjuvant therapy, n (%) Laparoscopic 73 (72) Open 77 (75)</p>	<p>Randomisation and allocation concealment Randomisation was computer-generated with the surgical approach concealed in a sealed envelope until the day of operation.</p> <p>Blinding No blinding.</p> <p>Follow-up/outcomes Postoperative complications were regarded as those occurring during admission or up to 30 days after surgery. All patients were followed up as outpatients every 3 months for the first 2 years and every 6 months thereafter. On each visit the participants had a physical examination, general blood tests and determination of the CEA level. Every 6 months they alternated between thoracic and abdominal computer tomography or abdominal ultrasonography and chest radiography. A complete colonoscopy was performed yearly.</p>	<p>Outcome: Overall survival at 5 years Laparoscopic 72.1% (95% CI 54.1% to 90.1%) Open 75.3% (95% CI 63.3% to 87.3%) p=0.980</p> <p>Outcome: CRM involved (not defined) Laparoscopic 4/101 Open 3/103</p> <p>Outcome: Distal margin involved (not defined) Laparoscopic 0/101 Open 0/103</p> <p>Outcome: Local recurrence at 5 years Laparoscopic 4.8% (95% CI 0% to 11.5%) Open 5.3% (0% to 11.2%) p=0.781</p> <p>Outcome: Length of hospital stay in days, mean±SD Laparoscopic 8.2±7.3</p>	<p>Selection bias Random sequence generation: low risk Allocation concealment: low risk</p> <p>Performance bias Blinding of participants and personnel: high risk (No blinding.)</p> <p>Detection bias Blinding of outcome assessment: low/high risk (No blinding. High risk of bias for subjective outcomes.)</p> <p>Attrition bias Incomplete outcome data: low risk (Intention-to-treat analysis done for most outcomes, for survival outcomes per-protocol analysis done.)</p> <p>Reporting bias Selective reporting: low risk</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b></p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Study dates</b> January 2002 to February 2007</p> <p><b>Source of funding</b> None reported.</p>	<p>Laparoscopic 11 (11) Open 15 (15) II Laparoscopic 35 (35) Open 39 (38) III Laparoscopic 45 (45) Open 44 (43) IV Laparoscopic 10 (10) Open 5 (5)</p> <p><b>Inclusion criteria</b> Patients with mid and low rectal adenocarcinoma.</p> <p><b>Exclusion criteria</b> Locally advanced disease (T4); familial adenomatous polyposis; those who underwent emergency surgery.</p>		<p>The primary endpoints were number of lymph nodes isolated, circumferential margin involvement, rate of complications and length of hospital stay. Secondary endpoints were local recurrence, disease-free and overall survival. (Only outcomes relevant for this review are reported here.)</p> <p>Local recurrence was defined as reappearance of tumour in the surgical field and it was confirmed by histological examination.</p> <p><b>Statistical analysis</b> Kaplan–Meier estimation method and survival curves were compared with the log rank test.</p>	<p>Open 9.9±6.8</p> <p>Outcome: Postoperative mortality (up to 30 days after surgery) Laparoscopic 2/101 Open 3/103</p> <p>Outcome: Anastomotic leak (in anterior resection only) Laparoscopic 5/77 Open 10/81</p> <p>Outcome: Surgical wound infection Laparoscopic 0/101 Open 2/103</p> <p>Outcome: Blood loss in ml, mean±SD Total Laparoscopic 127.8±113.3 Open 234.2±174.3 t-test p=&lt;0.001 Anterior resection Laparoscopic 109.6±117.3 Open 199.5±153.3</p>	None

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
				t-test p=0.001 Abdominoperineal resection Laparoscopic 187.5±74.9 Open 346.9±195.3 t-test p=0.006	
<p><b>Full citation</b> Ng, S. S. M., Leung, K. L., Lee, J. F. Y., Yiu, R. Y. C., Li, J. C. M., Teoh, A. Y. B., Leung, W. W., Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: A prospective randomized trial, <i>Annals of Surgical Oncology</i>, 15, 2418-2425, 2008</p> <p><b>Ref Id</b> 749447</p> <p><b>Country/ies where the study was carried out</b> Hong Kong</p>	<p><b>Sample size</b> N=99 randomised; n=51 allocated to laparoscopic surgery; n=48 allocated to open surgery</p> <p><b>Characteristics</b> Age in years, mean±SD Laparoscopic 63.7±11.8 Open 63.5±12.6</p> <p>Male sex, n/n Laparoscopic 31/51 Open 30/48</p> <p>AJCC staging, n/n I Laparoscopic 10/51 Open 8/48 II Laparoscopic 13/51 Open 8/48 III</p>	<p><b>Interventions</b> Laparoscopic-assisted abdominoperineal resection versus open abdominoperineal resection</p> <p>Laparoscopic surgery was performed with 3 ports.</p> <p>No one received preoperative (chemo)radiotherapy.</p>	<p><b>Details</b> Randomisation and allocation concealment Randomisation was performed on the day before surgery according to a computer-generated random sequence kept concealed by an independent operating theatre coordinator.</p> <p><b>Blinding</b> No blinding.</p> <p><b>Follow-up/outcomes</b> All patients were followed up regularly at 3-month intervals in the first 2 years and then every 6 months thereafter for clinical examination and CEA testing. The survival status was cross-checked with the networked computer</p>	<p><b>Results</b> Outcome: Overall survival after curative resection (stages I-III) (median 87 or 90 months of follow-up) Laparoscopic n=40, 12 events Open n=36, 17 events p=0.20</p> <p>Outcome: CRM involvement (not defined) Laparoscopic 3/40 Open 2/36</p> <p>Outcome: Local/peritoneal recurrence after curative resection (stages I-III) (median 87 or 90 months of follow-up) Laparoscopic 2/40</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: low risk Allocation concealment: unclear risk (No sufficient detail provided.)</p> <p>Performance bias Blinding of participants and personnel: high risk (No blinding.)</p> <p>Detection bias Blinding of outcome assessment: high risk (No blinding.)</p> <p>Attrition bias Incomplete outcome data: unclear risk (Not clear how many were lost to follow-up. Survival analysis not done on intention-to-treat</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Study type</b> RCT</p> <p><b>Aim of the study</b> To compare laparoscopic-assisted versus open abdominoperineal resection in patients with low rectal cancer.</p> <p><b>Study dates</b> September 1994 to February 2005</p> <p><b>Source of funding</b> None reported.</p>	<p>Laparoscopic 17/51 Open 20/48 IV Laparoscopic 11/51 Open 12/48</p> <p><b>Inclusion criteria</b> Patients diagnosed low rectal cancer within 5 cm from the anal verge.</p> <p><b>Exclusion criteria</b> Tumour &gt;6 cm; tumour infiltration to the adjacent organs on ultrasonography and/or computed tomography; recurrent disease; did not consent to randomisation; intestinal obstruction or perforation.</p>		<p>database of local hospital authority.</p> <p><b>Statistical analysis</b> Survival and disease-free interval were calculated by the Kaplan-Meier method, and differences between groups were compared with the log-rank test. The paper claims to have done intention-to-treat analysis but survival analysis was not done on all randomised patients.</p>	<p>Open 4/36</p> <p>Outcome: Length of hospital stay in days, mean (range) Laparoscopic 10.8 (5-27) Open 11.5 (5-38) p=0.55</p> <p>Outcome: Postoperative death (timeframe not provided) Laparoscopic 1/51 Open 1/48</p> <p>Outcome: Perineal wound infection Laparoscopic 10/51 Open 6/48</p> <p>Abdominal wound infection Laparoscopic - (not applicable) Open 4/48</p> <p>Outcome: Blood loss in ml, mean (range)* Laparoscopic 321.7 (0-3000)</p>	<p>population although the paper claims so.)</p> <p>Reporting bias Selective reporting: low risk</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
				Open 555.6 (0–4720) p=0.093	
<p><b>Full citation</b> Ng, S. S., Leung, K. L., Lee, J. F., Yiu, R. Y., Li, J. C., Hon, S. S., Long-term morbidity and oncologic outcomes of laparoscopic-assisted anterior resection for upper rectal cancer: ten-year results of a prospective, randomized trial, Dis Colon Rectum, 52, 558-66, 2009</p> <p><b>Ref Id</b> 809749</p> <p><b>Country/ies where the study was carried out</b> Hong Kong</p> <p><b>Study type</b> RCT</p>	<p><b>Sample size</b> N=153 randomised; n=76 allocated to laparoscopic anterior resection; n=77 allocated to open anterior resection</p> <p><b>Characteristics</b> Age in years, mean±SD Laparoscopic 66.5±11.9 Open 65.7±12.0</p> <p>Male sex, n/n Laparoscopic 37/76 Open 48/77</p> <p>AJCC stage, n/n I Laparoscopic 11/76 Open 13/77 II Laparoscopic 29/76 Open 29/77 III Laparoscopic 20/76 Open 28/77 IV Laparoscopic 16/76</p>	<p><b>Interventions</b> Laparoscopic anterior resection versus open anterior resection</p>	<p><b>Details</b> Randomisation and allocation concealment</p> <p>Blinding No blinding.</p> <p>Follow-up/outcomes After surgery, the patients were followed up regularly at 3-month intervals in the first 2 years and then every 6 months until year 5. Thereafter, patients were seen annually. Clinical examination, rigid sigmoidoscopy, and serum CEA testing were done at each visit. Colonoscopy was performed at one year after surgery, and thereafter every 3 years. If recurrence was suspected, computed tomography or positron emission tomography would be performed. Data regarding long-term morbidity, mortality, recurrence, and survival were prospectively recorded. The survival status was cross-checked</p>	<p>Results Outcome: Overall survival after curative resection (median 109 and 112.5 months of follow-up) Laparoscopic n=59, 22 events Open n=67, 26 events p=0.303</p> <p>Outcome: CRM involvement Laparoscopic 2/76 Open 1/77</p> <p>Outcome: Locoregional recurrence at 10 years Laparoscopic 7.1% Open 4.9% p=0.677</p> <p>Outcome: Length of hospital stay in days, mean (range) Laparoscopic 8.4 (2-32) (n=76)</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: low risk Allocation concealment: unclear risk (No sufficient detail provided.) Performance bias Blinding of participants and personnel: high risk (No blinding.) Detection bias Blinding of outcome assessment: high risk (No blinding.) Attrition bias Incomplete outcome data: low risk (No losses to follow-up. Survival analysis not done on intention-to-treat population although the paper claims so.) Reporting bias Selective reporting: low risk</p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Aim of the study</b> To compare laparoscopic and open resection in patients with upper rectal cancer.</p> <p><b>Study dates</b> September 1993 to October 2002</p> <p><b>Source of funding</b> None reported.</p>	<p>Open 7/77</p> <p><b>Inclusion criteria</b> Patients with upper rectal cancer (defined as adenocarcinoma in the rectum of which the lowest margin of the tumour was located between 12 and 15 cm from the anal verge as determined by rigid sigmoidoscopy). (The trial originally included rectosigmoid cancers and upper rectal cancers but this publication only reports outcomes for the subpopulation of people with upper rectal cancers.)</p> <p><b>Exclusion criteria</b> Distal tumour needing anastomosis within 5 cm of the dentate line; tumour &gt;6 cm; tumour infiltration to adjacent organs on sonography with or without computer tomography scan; previous abdominal operations near the region of the colorectal operation; individuals</p>		<p>with the networked computer database of the local hospital authority. Locoregional recurrence was defined as the presence of radiologically confirmed or histologically proven tumour restricted to the anastomosis or in the pelvis within the region of the primary surgery.</p> <p><b>Statistical analysis</b> Data were analysed by the intention-to-treat principle. Survival and recurrence were calculated by the Kaplan-Meier method, and differences between the groups were compared by the log-rank test.</p>	<p>Open 10.0 (3-39) (n=77) p=0.013</p> <p>Outcome: Operative mortality Laparoscopic 2/76 Open 4/77</p> <p>Outcome: Anastomotic leak Laparoscopic 1/76 Open 4/77</p> <p>Outcome: Wound infection Laparoscopic 5/76 Open 9/77</p> <p>Outcome: Blood loss in ml, mean (range) Laparoscopic 280.0 (0-3000) (n=76) Open 337.3 (0-2542) (n=77) p=0.338</p>	<p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	who did not consent to randomisation; those with intestinal obstruction or perforation.				
<p><b>Full citation</b> Ng, Ss, Lee, Jf, Yiu, Ry, Li, Jc, Hon, Ss, Mak, Tw, Ngo, Dk, Leung, Ww, Leung, Kl, Laparoscopic-assisted versus open total mesorectal excision with anal sphincter preservation for mid and low rectal cancer: a prospective, randomized trial, Surgical Endoscopy, 28, 297-306, 2014</p> <p><b>Ref Id</b> 749442</p> <p><b>Country/ies where the study was carried out</b> Hong Kong</p> <p><b>Study type</b> RCT</p>	<p><b>Sample size</b> N=80 randomised; n=40 allocated to laparoscopic TME; n=40 allocated to open TME</p> <p><b>Characteristics</b> Age in years, mean±SD Laparoscopic 60.2±11.3 Open 62.1±12.6</p> <p>Male sex, n/n Laparoscopic 24/40 Open 22/40</p> <p>BMI mean±SD Laparoscopic 23.1±3.4 Open 22.4±3.2</p> <p>Tumour location from the anal verge in cm, mean±SD Laparoscopic 6.9±1.7 Open 7.1±2</p> <p>AJCC staging, n/n I Laparoscopic 5/40</p>	<p><b>Interventions</b> Laparoscopic-assisted TME versus open TME</p> <p>All surgeries were done with anal sphincter preservation.</p> <p>Preoperative therapy was not given. (From September 2006 long-course preoperative chemoradiotherapy was offered to selected patients with radiologic T3 or T4 and/or N+ disease but those patients were excluded from this study.)</p>	<p><b>Details</b> Randomisation and allocation concealment Randomisation was performed on the day before surgery according to a computer-generated random sequence kept concealed by an independent operating theatre coordinator.</p> <p><b>Blinding</b> No blinding.</p> <p><b>Follow-up/outcomes</b> The patients were followed up regularly at 3-month intervals in the first 2 years and then every 6 months until year 5. Thereafter, patients were seen annually. Clinical examination, rigid sigmoidoscopy, and serum CEA testing were done at each visit. Colonoscopy was performed at one year after surgery, and thereafter every three years. Data</p>	<p><b>Results</b> Outcome: Overall survival after curative resection (stages I-III) (median 75.7 months of follow-up) Laparoscopic n=36, 6 events* Open n=36, 7 events* p=0.912</p> <p>Outcome: CRM involvement (not defined) Laparoscopic 3/40 Open 2/40</p> <p>Outcome: Locoregional recurrence after curative resection (stages I-III) (median 75.7 months of follow-up) Laparoscopic 1/36 Open 4/36</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: low risk Allocation concealment: unclear risk (No sufficient detail provided.)</p> <p>Performance bias Blinding of participants and personnel: high risk (No blinding.)</p> <p>Detection bias Blinding of outcome assessment: high risk (No blinding.)</p> <p>Attrition bias Incomplete outcome data: low risk (No losses to follow-up. Survival analysis not done on intention-to-treat population although the paper claims so.)</p> <p>Reporting bias</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Aim of the study</b> To compare laparoscopic-assisted and open TME with anal sphincter preservation in patients with mid and low rectal cancer.</p> <p><b>Study dates</b> August 2001 to August 2007</p> <p><b>Source of funding</b> This study was not supported by any grant.</p>	<p>Open 6/40 II Laparoscopic 15/40 Open 11/40 III Laparoscopic 16/40 Open 19/40 IV Laparoscopic 4/40 Open 4/40</p> <p><b>Inclusion criteria</b> Patients diagnosed with mid and low rectal cancer (lowest margin of the tumour was located between 5 and 12 cm from the anal verge as determined by rigid sigmoidoscopy).</p> <p><b>Exclusion criteria</b> Tumour larger than 6 cm; tumour infiltration to the adjacent organs on computed tomography; recurrent disease; synchronous colorectal tumours; intestinal obstruction or perforation; patients who required neoadjuvant therapy; patients who did</p>		<p>regarding perioperative outcome, long-term morbidity, recurrence, and survival were prospectively recorded. The survival status was cross-checked with the networked computer database of the local hospital authority. If recurrence was suspected, computed tomography or positron emission tomography would be performed.</p> <p>Primary endpoints were short-term clinical outcome, including postoperative recovery and short-term morbidity. Secondary endpoints were long-term morbidity and survival.</p> <p><b>Statistical analysis</b> Data were analysed by intention-to-treat principle. Recurrence and survival were calculated by the Kaplan-Meier method, and differences between the groups were compared with log-rank test.</p>	<p>Outcome: Length of hospital stay in says, mean (range) Laparoscopic 10.5 (5-35) Open 15 (6-167) p=0.071</p> <p>Outcome: Operative death Laparoscopic 0/40 Open 0/40</p> <p>Outcome: Anastomotic leak Laparoscopic 1/40 Open 0/40</p> <p>Outcome: Wound infection Laparoscopic 1/40 Open 7/40</p> <p>Outcome: Blood loss in ml, mean (range) Laparoscopic 142 (0-2,000) Open 361 (5-2,500) p&lt;0.001</p>	<p>Selective reporting: low risk</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	not consent to randomisation.			*Number of events calculated from the Kaplan-Meier curve	
<p><b>Full citation</b> Park, E. J., Cho, M. S., Baek, S. J., Hur, H., Min, B. S., Baik, S. H., Lee, K. Y., Kim, N. K., Long-term oncologic outcomes of robotic low anterior resection for rectal cancer, Annals of Surgery, 261, 129-137, 2015</p> <p><b>Ref Id</b> 749686</p> <p><b>Country/ies where the study was carried out</b> South Korea</p> <p><b>Study type</b> Prospective cohort study</p> <p><b>Aim of the study</b> To evaluate the long-term oncologic</p>	<p><b>Sample size</b> N=133 robotic lower anterior resection; N=84 laparoscopic lower anterior resection</p> <p><b>Characteristics</b> Age in years, mean±SD Robotic 59.2±11.4 Laparoscopic 63.5±11.2</p> <p>Male sex, n (%) Robotic 86 (65) Laparoscopic 60 (71)</p> <p>BMI, mean±SD Robotic 23.±2.9 Laparoscopic 22.9±2.8</p> <p>Tumour location from the anal verge, n (%) 0-5 cm Robotic 33 (25) Laparoscopic 16 (19) 5.1-10 cm Robotic 60 (45) Laparoscopic 37 (44) 10.1-15 cm</p>	<p><b>Interventions</b> Robotic versus laparoscopic lower anterior resection</p> <p>For robotic surgery, the da Vinci surgical system was used. All robotic-assisted lower anterior resections were performed by the hybrid technique.</p> <p>Chemoradiotherapy was given for stage T3-4N0 or N+ M0 low- and mid-rectal cancers. Majority of the patients underwent postoperative chemoradiotherapy due to the institute's treatment protocol at the time of the study. The regimen was based on 5-FU and leucovorin.</p> <p>Preoperative chemoradiotherapy, n (%) Robotic 15 (11) Laparoscopic 10 (12)</p>	<p><b>Details</b> Randomisation and allocation concealment This was not a randomised study. The groups were not matched.</p> <p>Blinding No blinding.</p> <p>Follow-up/outcomes Data were collected from the Yonsei Colorectal Cancer Database. The follow-up visits were at 1 month, 3 months, and every 3 months for the first 3 years and then 6 months until 5 years after surgery. Regular laboratory tests with CEA and a physical examination were performed. Colonoscopy was done 1 year after surgery and at 5 years. Chest and abdominopelvic computed tomography scans were obtained every 6 months to detect local recurrence or</p>	<p><b>Results</b> Outcome: Overall survival at 5 years Stages I-III Robotic 92.8% Laparoscopic 93.5% p=0.829 Stage II Robotic 94.2% Laparoscopic 100% p=0.221 Stage III Robotic 86.8% Laparoscopic 87.8% p=0.916</p>	<p><b>Limitations</b> ROBINS-I checklist for non-randomised studies of Interventions Pre-intervention Bias due to confounding: Moderate risk of bias (This is a non-randomised study, the groups were not matched by any characteristic but the study controlled for potential confounding or case-mix in the analysis.) Bias in selection of participants into the study: Low risk of bias</p> <p>At intervention Bias in classification of Interventions: Low risk of bias</p> <p>Post-intervention Bias due to deviations from intended Interventions: Low risk of bias Bias due to missing data: Low risk of bias</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>outcomes of robotic surgery for rectal cancer compared with conventional laparoscopic surgery.</p> <p><b>Study dates</b> April 2006 to August 2011</p> <p><b>Source of funding</b> None reported.</p>	<p>Robotic 40 (30) Laparoscopic 31 (37)</p> <p>Postoperative pathologic TNM stage, n (%)</p> <p>I Robotic 49 (37) Laparoscopic 22 (26)</p> <p>II Robotic 36 (27) Laparoscopic 28 (33)</p> <p>III Robotic 48 (36) Laparoscopic 34 (41)</p> <p><b>Inclusion criteria</b> People diagnosed with rectal adenocarcinoma; underwent low anterior resection by robotic or conventional laparoscopic approach.</p> <p><b>Exclusion criteria</b> Open surgery; stage IV disease; patients lost to follow-up.</p>		<p>systemic metastasis during the follow-up period.</p> <p><b>Statistical analysis</b> Survival was analysed using the Kaplan-Meier method and the groups were compared with the log-rank test. Univariate analysis of clinicopathological factors upon overall survival was performed using the log-rank test to determine the prognostic value of the surgical methods, all statistically significant factors determined by univariate analysis were conducted for multivariate analysis by the Cox proportional hazards regression model with a forward selection of variables.</p>		<p>Bias in measurement of outcomes: Low risk of bias Bias in selection of the reported result: Low risk of bias</p> <p><b>Other information</b> None</p>
<p><b>Full citation</b> van der Pas, M. H., Haglind, E., Cuesta, M. A., Furst, A., Lacy, A.</p>	<p><b>Sample size</b> See Bonjer 2015 (COLOR II trial).</p> <p><b>Characteristics</b></p>	<b>Interventions</b>	<b>Details</b>	<b>Results</b>	<p><b>Limitations</b></p> <p><b>Other information</b></p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>M., Hop, W. C., Bonjer, H. J., C. Olorectal cancer Laparoscopic or Open Resection II Study Group, Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial, Lancet Oncology, 14, 210-8, 2013</p> <p><b>Ref Id 751236</b></p> <p><b>Country/ies where the study was carried out</b></p> <p><b>Study type</b></p> <p><b>Aim of the study</b></p> <p><b>Study dates</b></p> <p><b>Source of funding</b></p>	<p><b>Inclusion criteria</b></p> <p><b>Exclusion criteria</b></p>				
<p><b>Full citation</b> Pontallier, A., Denost, Q., Van Geluwe, B., Adam, J. P.,</p>	<p><b>Sample size</b> See Denost 2017 (Bordeaux' trial).</p>	<p><b>Interventions</b></p>		<p>Results</p>	<p><b>Limitations</b></p> <p><b>Other information</b></p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Celerier, B., Rullier, E., Potential sexual function improvement by using transanal mesorectal approach for laparoscopic low rectal cancer excision, Surgical Endoscopy and Other Interventional Techniques, 30, 4924-4933, 2016</p> <p>Ref Id 749925</p> <p>Country/ies where the study was carried out</p> <p>Study type</p> <p>Aim of the study</p> <p>Study dates</p> <p>Source of funding</p>	<p>Characteristics</p> <p>Inclusion criteria</p> <p>Exclusion criteria</p>				
Full citation	Sample size	Interventions	Details	Results	Limitations

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Quah, H. M., Jayne, D. G., Eu, K. W., Seow-Choen, F., Bladder and sexual dysfunction following laparoscopically assisted and conventional open mesorectal resection for cancer, Br J Surg, 89, 1551-6, 2002</p> <p>Ref Id 809751</p> <p>Country/ies where the study was carried out</p> <p>Study type</p> <p>Aim of the study</p> <p>Study dates</p> <p>Source of funding</p>	<p>See Jayne 2010 (CLASICC trial).</p> <p><b>Characteristics</b></p> <p><b>Inclusion criteria</b></p> <p><b>Exclusion criteria</b></p>				Other information
<p><b>Full citation</b> Rouanet P, Bertrand MM,</p>	<p><b>Sample size</b> N=400</p>	<p><b>Interventions</b> N=400 R-TME (n=200)</p>	<p><b>Details</b> Prospectively collected records of 400 patients with</p>	<p><b>Results</b> Overall survival: Follow-up 4.1 years</p>	<p><b>Limitations</b></p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Jarlier M et al. Robotic Versus Laparoscopic Total Mesorectal Excision for Sphincter-Saving Surgery: Results of a Single-Center Series of 400 Consecutive Patients and Perspectives. Ann Surg Oncol. 2018 Nov;25(12):3572-3579.</p> <p><b>Ref Id</b> 982948</p> <p><b>Country/ies where the study was carried out</b> France</p> <p><b>Study type</b> Retrospective cohort study</p> <p><b>Aim of the study</b> To compare robotic total mesorectal excision (R-TME) with laparoscopic TME (L-TME) in a series of</p>	<p><b>Characteristics</b></p> <p>Male, n (%) 131 65.5% (R-TME); 136 (68.0%)</p> <p>Median age years (range) 64 (25, 85 (R-TME); 63.5 (35, 86) (L-TME)</p> <p>Tumour location, n (%)</p> <p>Upper <math>\geq</math> 11 cm 27 (13.6); middle 6-10 cm 83 (41.9); low (<math>\leq</math> 5 cm) 88 (44.4) (R-TME). Upper <math>\geq</math> 11 cm 39 (20.2); middle 6-10 cm 75 (38.9); low (<math>\leq</math> 5 cm) 79 (40.9) (L-TME)</p> <p><b>Inclusion criteria</b> Patients with histologically proven adenocarcinoma located <math>\geq</math> 12 cm from the anal verge who underwent minimally invasive surgery (laparoscopic or robotic TME), with no previous or concurrent malignancy and no evidence of distant metastasis at time of surgery.</p>	L-TME (n=200)	<p>mild or low rectal cancer who underwent curative conservative surgery</p> <p>Follow-up: NR</p> <p><b>Statistical analysis:</b> Patient Characteristics, and surgical and pathology results were described using frequency and percentage for categorical variables and median and range for continuous variables. Data were compared using the Pearson Chi square test or the nonparametric Kruskal–Wallis test for categorical or continuous variables. Analysis of the QLQC30 questionnaires was performed according to EORTC guidelines. 11 FSFI, IIEF, and IPSS scores are described as continuous variables, according to groups. Subgroup analyses were conducted to estimate the odds ratios (ORs) for conversion to laparotomy and CRM involvement between the groups. ORs and their 95% confidence intervals (95% CI) were</p>	<p>(R-TME 3.1 years [95% CI 2.9, 3.4 years]; L-TME 5.7 years [95% CI 5.3, 6.0 years])</p> <p>3 year survival rate was 84.1% (95% CI 77.3, 88.9%) (R-TME) vs 88.4% (95% CI 82.9, 92.2%) (L-TME)</p> <p>Quality of life: Sexual results were similar in the two groups, in both female (FSFI assessment) and male (IIEF score) patients. Quality of life was similar in the two groups in the overall population and for a high-risk subgroup of patients (n=61) including men with BMI <math>\geq</math> 28 kg/m<sup>2</sup> and low rectal tumour. A trend for better symptom scores was reported for the R-TME group in the high-risk</p>	<p>ROBINS-I checklist for non-randomised studies of Interventions Pre-intervention</p> <p>Bias due to confounding: Moderate risk of bias (This is a non-randomised study, the groups were not matched by any characteristic.)</p> <p>Bias in selection of participants into the study: Low risk of bias</p> <p>At intervention Bias in classification of Interventions: Low risk of bias</p> <p>Post-intervention Bias due to deviations from intended Interventions: Low risk of bias</p> <p>Bias due to missing data: Low risk of bias</p> <p>Bias in measurement of outcomes: Low risk of bias</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>consecutive rectal cancer patients</p> <p><b>Study dates</b> 2008 to 2012 and 2012 to 2015</p> <p><b>Source of funding</b> Financial support was provided by Intuitive Surgical, Aubonne, Switzerland.</p>	<p><b>Exclusion criteria</b> Not reported</p>		<p>estimated using a univariate logistic regression model. Overall survival was estimated using the Kaplan–Meier method, and survival curves were compared with the log-rank test. No imputation method was used in Laparoscopic Versus Robotic Proctectomy 3573 case of missing data. All tests were two-sided, and p value <math>\leq 0.05</math> was considered statistically significant. Statistical analyses were performed using STATA 13.0 (StataCorp, College Station, TX, USA).</p>	<p>patients although it was not significant</p>	<p>Bias in selection of the reported result: Low risk of bias</p> <p><b>Other information</b> None</p>
<p><b>Full citation</b> Stevenson, A. R. L., Solomon, M. J., Lumley, J. W., Hewett, P., Clouston, A. D., GebSKI, V. J., Davies, L., Wilson, K., Hague, W., Simes, J., Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal</p>	<p><b>Sample size</b> N=475 randomised; n=238 allocated to laparoscopic surgery; n=237 allocated to open surgery</p> <p><b>Characteristics</b> Age in years, median (IQR) Laparoscopic 65 (56-74) Open 65 (56-73)</p> <p>Male sex, n (%) Laparoscopic 160 (67)</p>	<p><b>Interventions</b> Laparoscopic surgery versus open surgery The open surgery was a hybrid operation in which the abdominal component (splenic flexure mobilization and vessel division) could be performed laparoscopically; however, the rectal mobilization had to be performed as an open procedure under direct vision via a laparotomy.</p>	<p><b>Details</b> Randomisation and allocation concealment Randomisation was conducted at the National Health and Medical Research Council Clinical Trials Centre via the Internet using the method of minimization and stratified by the location of the tumour from the anal verge, the registering surgeon, the planned operative procedure, body mass index, preoperative</p>	<p><b>Results</b> Outcome: Negative CRM (<math>\geq 1</math> mm) Laparoscopic 222/238 Open 228/235</p> <p>Outcome: Negative distal resection margin (<math>\geq 1</math> mm) Laparoscopic 236/238 Open 234/235</p>	<p><b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: unclear risk (Limited details reported.) Allocation concealment: unclear risk (Details not reported.)</p> <p>Performance bias Blinding of participants and personnel: high risk (No blinding.)</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>cancer: The ALaCaRT randomized clinical trial, JAMA - Journal of the American Medical Association, 314, 1356-1363, 2015</p> <p><b>Ref Id</b> 750805</p> <p><b>Country/ies where the study was carried out</b> Australia</p> <p><b>Study type</b> RCT (ALaCaRT trial)</p> <p><b>Aim of the study</b> To determine whether laparoscopic resection is noninferior to open rectal cancer resection for adequacy of cancer clearance.</p> <p><b>Study dates</b> March 2010 to November 2014</p>	<p>Open 151 (64)</p> <p>Tumour location from the anal verge, n/n &lt;5 cm</p> <p>Laparoscopic 82 (35)</p> <p>Open 83 (35)</p> <p>5-10 cm</p> <p>Laparoscopic 103 (43)</p> <p>Open 102 (44)</p> <p>10-15 cm</p> <p>Laparoscopic 53 (22)</p> <p>Open 50 (21)</p> <p>Tumour stage, n/n</p> <p>T1</p> <p>Laparoscopic 18 (8)</p> <p>Open 11 (5)</p> <p>T2</p> <p>Laparoscopic 68 (29)</p> <p>Open 68 (29)</p> <p>T3</p> <p>Laparoscopic 151 (63)</p> <p>Open 155 (66)</p> <p>Nodal status, n/n</p> <p>N0</p> <p>Laparoscopic 107 (45)</p> <p>Open 123 (53)</p> <p>N1</p> <p>Laparoscopic 92 (39)</p>	<p>Laparoscopic-assisted procedures could include the use of a hand port, but robotic surgery was excluded.</p> <p>Planned surgical approach, n (%)</p> <p>Low anterior resection</p> <p>Laparoscopic 220 (92)</p> <p>Open 218 (93)</p> <p>Abdominoperineal resection</p> <p>Laparoscopic 18 (8)</p> <p>Open 17 (7)</p> <p>Surgical approach performed, n (%)</p> <p>Low anterior resection</p> <p>Laparoscopic 143 (60)</p> <p>Open 153 (65)</p> <p>Low anterior resection and coloanal anastomosis</p> <p>Laparoscopic 69 (29)</p> <p>Open 58 (25)</p> <p>Abdominoperineal resection</p> <p>Laparoscopic 25 (11)</p> <p>Open 23 (10)</p>	<p>radiotherapy (yes or no), and distant metastasis (yes or no). No other details were provided.</p> <p>Blinding</p> <p>No blinding of participants. Pathologist blinded to allocation.</p> <p>Follow-up/outcomes</p> <p>A pathologist blinded to treatment allocation examined the surgical specimen. The specimens were photographed fresh and unopened to show the mesorectal dissection anteriorly and posteriorly before inking. The pathologist assessed the distal margin in the fresh and unstretched specimen. Other details not reported.</p> <p><b>Statistical analysis</b></p> <p>Wilcoxon rank sum test used to compare continuous data between groups.</p>	<p>Outcome: Length of hospital stay in days, median (IQR)</p> <p>Laparoscopic 8 (6-12)</p> <p>Open 8 (6-12)</p> <p>p=0.21</p> <p>Outcome: Blood loss in ml, median (IQR)</p> <p>Laparoscopic 100 (50-200)</p> <p>Open 150 (55-300)</p> <p>p=0.02</p>	<p>Detection bias</p> <p>Blinding of outcome assessment: low/high risk (Pathologist was blinded. Surgical team or patient was not blinded.)</p> <p>Attrition bias</p> <p>Incomplete outcome data: low risk</p> <p>Reporting bias</p> <p>Selective reporting: low risk</p> <p>Other bias</p> <p>Other sources of bias: -</p> <p><b>Other information</b></p> <p>None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Source of funding</b> The Colorectal Surgical Society of Australia and New Zealand Foundation and the National Health and Medical Research Council.</p>	<p>Open 80 (34) N2 Laparoscopic 37 (16) Open 30 (13)</p> <p>Distant metastases Laparoscopic 10 (4) Open 10 (4)</p> <p><b>Inclusion criteria</b> Aged 18 years or older; histological diagnosis of adenocarcinoma of the rectum within 15 cm of the anal verge; life expectancy of at least 12 weeks; adequate performance status (Eastern Cooperative Oncology Group Scale score of <math>\leq 2</math>); no comorbidity or condition that would preclude the use of either form of surgery.</p> <p><b>Exclusion criteria</b> T4 tumours or an involved CRM (determined by pretreatment pelvic MRI, or endorectal ultrasound if MRI was contraindicated); concurrent or previous invasive</p>	<p>Preoperative radiotherapy, n (%) Laparoscopic 119 (50) Open 116 (49)</p>			

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	pelvic malignant tumours (cervical, uterine, or rectal; excluding the prostate) within 5 years before study enrolment. (Distant metastases was not an exclusion criterion.)				
<p><b>Full citation</b> Stevenson ARL, Solomon MJ, Brown CSB et al. Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial. Ann Surg. 2019 Apr;269(4):596-602.</p> <p><b>Ref Id</b> 983031</p> <p><b>Country/ies where the study was carried out</b></p>	<p><b>Sample size</b> (See Stevenson, 2015 (ALaCaRT study))</p>	<p><b>Interventions</b></p>	<p><b>Details</b></p>	<p><b>Results</b> Median follow-up was 3.2 years (range: 0.1-5.4 yrs).  Outcome OS 28 deaths within 2 years and a 2-year survival estimate 94% for LAP and 93% for OPEN (difference, 0.9%, 95% CI, -3.6% to -5.4%). HR 1.08 (95% CI 0.63, 1.86) Outcome: LRR cumulative incidence at 2 years: LAP 5.4%; OPEN 3.1% [difference, 2.3%; 95% confidence interval (CI), -1.5% to 6.1%; hazard ratio (HR) 1.7; 95% CI, 0.74-3.9, p=0.21.</p>	<p><b>Limitations</b></p> <p><b>Other information</b></p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Australia</p> <p><b>Study type</b> RCT (ALaCaRT trial)</p> <p><b>Aim of the study</b> To determine whether laparoscopic resection is noninferior to open rectal cancer resection for adequacy of cancer clearance.</p> <p><b>Study dates</b> March 2010 to November 2014</p> <p><b>Source of funding</b> The Colorectal Surgical Society of Australia and New Zealand Foundation and the National Health and Medical Research Council.</p>					

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p><b>Full citation</b> Wang, G., Wang, Z., Jiang, Z., Liu, J., Zhao, J., and Li, J. (2017) Male urinary and sexual function after robotic pelvic autonomic nerve-preserving surgery for rectal cancer. <i>Int J Med Robotics Comput Assist Surg</i>, 13: e1725</p> <p><b>Ref Id</b> 1134546</p> <p><b>Country/ies where the study was carried out</b> China</p> <p><b>Study type</b> RCT</p> <p><b>Aim of the study</b> <b>Study dates</b> November 2010 to September 2013.</p> <p><b>Source of funding</b> National Natural Science</p>	<p><b>Sample size</b> N=137 (randomised) male patients with rectal adenocarcinoma within 12 cm from the anal verge.</p> <p>Laparoscopic n=66; robotic n=77.</p> <p>22% were T1-2N0M0.</p> <p><b>Characteristics</b> 336 consecutive male patients with medium-low rectal cancer.</p> <p>Mean age, years (range): Laparoscopic surgery 58.7 (36–71); robotic surgery 60.3 (36–68), <math>p = 0.561</math>.</p> <p>Mean BMI (kg/m<sup>2</sup>): Laparoscopic surgery 22.4 (18.3–30.6); robotic surgery 22.9 (19.1–30.1); <math>p = 0.752</math>.</p> <p>Tumour location: Medium - laparoscopic surgery n=26 (39.4%); robotic n=25 (35.2%).</p> <p>Low - laparoscopic surgery n=40 (60.6%);</p>	<p><b>Interventions</b> Laparoscopic surgery vs robotic pelvic autonomic nerve-preserving surgery.</p> <p>Perioperative radiotherapy: ~25%</p> <p>~96-97% LAR</p> <p>Operations performed by hospital surgical teams. Preservation of autonomic nerves achieved "... by identifying and saving the pre-aortic superior hypogastric plexus and hypogastric nerves, which join the parasympathetic nerves (nerves erigentes) to form the inferior hypogastric plexus, and are anterior and lateral in the pelvis bilaterally. At this point, the autonomic nerves branching off the inferior hypogastric plexus directly into the rectum require division, and damage to the inferior</p>	<p><b>Details</b> Randomisation Not reported.</p> <p>Allocation concealment Opaque sealed envelopes.</p> <p>Blinding Not reported</p> <p>Attrition Not reported</p> <p>Statistical analysis Mann-Whitney U-test, <math>\chi^2</math>. Statistical significance set at 5% level.</p> <p>Follow up 12 months from surgery (telephone interview).</p> <p>Outcomes Sexual function before and after surgery (International Prostate Symptom Score [IPSS] - frequency; nocturia; weak urinary stream; hesitancy; intermittence; incomplete emptying; and urgency).</p> <p>Urinary function before and after surgery (International Index of Erectile Function [IIEF] was used to assess</p>	<p><b>Results</b> Urinary function before and after surgery</p> <p>Total IPSS: Laparoscopic - pre-op 4.12±5.48, post-op 9.66±5.74*, <math>p = 0.031</math>; robotic - pre-op 4.04±5.26, post-op 6.79±5.69#, <math>p = 0.061</math>.</p> <p>Incomplete emptying: laparoscopic – pre-op 0.33±0.67, post-op 0.97±1.16, <math>p = 0.118</math>; robotic - pre-op 0.37±0.79, post-op 0.81±0.96, <math>p = 0.428</math>.</p> <p>Frequency: laparoscopic – pre-op 0.54±0.87, post-op 1.31±1.71*, <math>p = 0.043</math>; robotic pre-op 0.67±0.96; post-op 1.01±1.24, <math>p = 0.381</math>.</p> <p>Intermittency: laparoscopic – pre-op 0.47±0.91, post-op 1.14±1.06, <math>p = 0.082</math>; robotic - pre-op, 0.43±0.84, post-op 0.73±0.98#, <math>p = 0.152</math>.</p>	<p><b>Limitations</b> Risk of bias assessed using Cochrane risk of bias tool</p> <p>Selection bias Random sequence generation: Low risk of bias.</p> <p>Allocation concealment: Low risk of bias.</p> <p>Performance bias Blinding of participants and personnel: Unclear risk of bias. Details on participant and personnel blinding are not reported.</p> <p>Detection bias Blinding of outcome assessment: Unclear risk of bias. Details on outcome assessor blinding are not reported.</p> <p>Attrition bias Incomplete outcome data: Low risk of bias.</p> <p>Reporting bias Selective reporting: Low risk of bias.</p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
Foundation of China (Grant No. 81500417).	<p>robotic surgery 46 (64.8%), <math>p = 0.613</math>.</p> <p>Adjuvant radiotherapy: Before surgery laparoscopic surgery <math>n=11</math> (16.7%); robotic surgery <math>n=13</math> (18.3%).</p> <p>After surgery laparoscopic surgery <math>n=7</math> (10.6%); robotic surgery <math>n=5</math> (7.1%).</p> <p>None - laparoscopic surgery <math>n=48</math> (72.7%); robotic surgery <math>n=53</math> (74.6%), <math>p = 0.566</math>.</p> <p>Operation type – LAR - laparoscopic surgery <math>n=63</math> (95.5%); robotic surgery 69 (97.2%).</p> <p>Hartmann - laparoscopic surgery <math>n=3</math> (4.5%); robotic surgery <math>n=2</math> (2.8%), <math>p = 0.590</math>.</p> <p>Mean operating time, minutes (range): laparoscopic surgery 207.3 (170–230); robotic surgery 246.9 (210–330), <math>p = 0.002</math>.</p> <p>Mean retrieved nodes (range): laparoscopic surgery 16.3 (7–39); robotic surgery 16.4 (8–33), <math>p = 0.682</math>.</p>	<p>hypogastric plexus is avoided.”</p> <p>“All patients underwent peri-operative treatment with an enhanced recovery programme, as previously described. All patients underwent bladder catheterization before surgery; the catheter was removed on average 2 (range 1–5) days postoperatively.”</p>	<p>psychological male sexual function. IIEF domain scores computed by adding the scores of individual items in each domain. Complete erectile dysfunction was defined as an erectile function domain Score <math>&lt;10</math> and partial erectile dysfunction as a score <math>&lt;17</math> but <math>\geq 10</math>.</p>	<p>Urgency: laparoscopic – pre-op <math>0.48\pm 0.67</math>, post-op <math>0.91\pm 1.22</math>, <math>p = 0.351</math>; robotic - pre-op <math>0.31\pm 0.73</math>, post-op <math>0.84\pm 1.05</math>, <math>p = 0.417</math>.</p> <p>Weak stream: laparoscopic – pre-op <math>0.81\pm 1.21</math>, post-op <math>1.86\pm 1.73</math>, <math>p = 0.284</math>; robotic - pre-op <math>0.76\pm 1.24</math>, post-op <math>1.04\pm 1.26</math>, <math>p = 0.158</math>.</p> <p>Straining: laparoscopic – pre-op <math>0.66\pm 0.96</math>, post-op <math>1.17\pm 1.14</math>, <math>p = 0.117</math>; robotic - pre-op <math>0.61\pm 1.05</math>, post-op <math>0.97\pm 1.17</math>, <math>p = 0.331</math>.</p> <p>Nocturia: laparoscopic – pre-op <math>0.97\pm 1.14</math>, post-op <math>2.23\pm 2.05^*</math>, <math>p = 0.035</math>; robotic - pre-op <math>0.94\pm 1.27</math>, post-op <math>1.44\pm 2.11</math>, <math>p = 0.489</math>.</p> <p>* <math>p &lt; 0.05</math> for postoperative vs pre-operative values</p>	<p>Other bias:</p> <p><b>Other information</b> 22% were T1-2N0M0.</p>



Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	<p>Temporary diverting ileal stoma: laparoscopic surgery n=32 (48.5%), robotic surgery n=31 (43.7%), <math>p = 0.571</math>.</p> <p>TNM stage:            0/I – laparoscopic surgery n=8 (12.1%); robotic surgery n=9 (12.7%)            II laparoscopic surgery n=24 (36.4%); robotic surgery n=22 (30.9%)            III laparoscopic surgery n=34 (51.5%); robotic surgery n=40 (56.3%), <math>p = 0.798</math></p> <p><b>Inclusion criteria</b> Male patients with medium-low rectal cancer. Site of rectal neoplasm defined according to International Guidelines for Cancer Registrars "... as the lower (<math>\leq 7</math> cm from the anal verge) and middle rectum (7–12cm from the anal verge)."</p> <p><b>Exclusion criteria</b> "... pre-operative sexual dysfunction (n=61), a history of rectum or urinary tract surgery</p>			<p>#<math>p &lt; 0.05</math> for robotic vs laparoscopic operation.</p> <p>Male sexual function before and after surgery            Total IIEF:            laparoscopic – pre-op <math>57.9 \pm 23.7</math>, post-op <math>40.1 \pm 30.1^*</math>, <math>p = 0.011</math>; robotic - pre-op <math>56.4 \pm 25.3</math>, post-op <math>46.2 \pm 29.4^*\#</math>, <math>p = 0.034</math>.</p> <p>Erectile function:            laparoscopic – pre-op <math>22.6 \pm 12.2</math>, post-op <math>15.8 \pm 14.4^*</math>, <math>p = 0.035</math>; robotic - pre-op <math>23.7 \pm 11.6</math>, post-op <math>19.2 \pm 13.6^*\#</math>, <math>p = 0.042</math></p> <p>Orgasmic function:            laparoscopic – pre-op <math>7.4 \pm 5.1</math>, post-op <math>5.9 \pm 5.6^*</math>, <math>p = 0.041</math>; robotic - pre-op <math>7.6 \pm 4.2</math>, post-op <math>6.3 \pm 5.2</math>, <math>p = 0.151</math>.</p>	

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	(n=14), abdominal perineal resection (n=31), partial mesorectal resection (n=16), local or distant recurrence (n=41), death in 12 months (n=25) and incomplete follow-up data (n=11)."			<p>Sexual desire: laparoscopic – pre-op 7.5±2.6, post-op 6.2±3.4*, <math>p = 0.039</math>; robotic - pre-op 6.9±2.9, post-op 6.2±3.1, <math>p = 0.213</math>.</p> <p>Intercourse satisfaction: laparoscopic – pre-op 11.4±4.8, post-op 6.5±5.1, <math>p = 0.074</math>; robotic - pre-op 10.7±3.9, post-op 8.0±5.3*#, <math>p = 0.047</math>.</p> <p>Overall satisfaction: laparoscopic – pre-op 8.4±2.5, post-op 6.2±3.6*, <math>p = 0.043</math>, robotic - pre-op 8.0±1.9, post-op 6.9±3.3*, <math>p = 0.038</math>.</p> <p>*<math>p &lt; 0.05</math> for pre-operative vs postoperative values. #<math>p &lt; 0.05</math> for robotic vs laparoscopic operation.</p>	
<b>Full citation</b> Yoo, B. E., Cho, J. S., Shin, J. W.,	<b>Sample size</b> N=44 robotic intersphincteric	<b>Interventions</b> Robotic versus laparoscopic	<b>Details</b> Randomisation and allocation concealment	<b>Results</b> Outcome: Overall survival at 3 years	<b>Limitations</b>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>Lee, D. W., Kwak, J. M., Kim, J., Kim, S. H.,            Robotic Versus Laparoscopic Intersphincteric Resection for Low Rectal Cancer: Comparison of the Operative, Oncological, and Functional Outcomes, <i>Annals of Surgical Oncology</i>, 22, 1219-1225, 2015</p> <p><b>Ref Id</b> 751717</p> <p><b>Country/ies where the study was carried out</b>            South Korea</p> <p><b>Study type</b>            Retrospective cohort study</p> <p><b>Aim of the study</b>            To compare the operative, oncological, and functional outcomes of low</p>	<p>resection; N=26            laparoscopic intersphincteric resection</p> <p><b>Characteristics</b>            Age in years, mean±SD            Robotic 59.8±12.3            Laparoscopic 60.5±10.8            Male sex, n (%)            Robotic 35 (80)            Laparoscopic 19 (73)</p> <p>BMI, mean±SD            Robotic 24.13.3            Laparoscopic 21.4±3.1</p> <p>Tumour distance from the anal verge in cm, mean            Robotic 3.2±0.8            Laparoscopic 3.7±0.9</p> <p>Clinical T stage, n (%)            T1            Robotic 2 (5)            Laparoscopic 3 (12)            T2            Robotic 15 (34)            Laparoscopic 4 (15)            T3            Robotic 22 (50)            Laparoscopic 18 (69)</p>	<p>intersphincteric resection</p> <p>Robotic surgery was performed with the da Vinci Surgical System by a single surgeon.</p> <p>Preoperative chemoradiotherapy (5,080 cGy in 28 fractions and 5-fluorouracil) was given selectively to locally advanced cancers if the CRM was suspicious/threatened/positive or if lymph nodes that escaped the TME plane were detected using MRI or CT scan. Surgeries were performed 8 weeks after preoperative chemoradiotherapy.</p> <p>Preoperative chemoradiotherapy, n (%)            Robotic 24 (54)            Laparoscopic 7 (27)</p>	<p>This was not a randomised study. The groups were not matched.</p> <p>Blinding            No blinding.</p> <p>Follow-up/outcomes            Data was retrospectively obtained from a prospectively-collected database. No details about follow-up visits reported.</p> <p><b>Statistical analysis</b>            Survival was analysed using the Kaplan-Meier method, the differences between the groups were compared by log-rank test. The groups were not matched and the analysis did not control for potential confounding or case-mix.</p>	<p>Robotic 95.2%            Laparoscopic 88.5%            p=0.174</p>	<p>ROBINS-I checklist for non-randomised studies of <b>Interventions</b></p> <p>Pre-intervention            Bias due to confounding: Serious risk of bias (This is a non-randomised study, the groups were not matched by any characteristic. The study did not control for potential confounding or case-mix in the analysis.)            Bias in selection of participants into the study: Low risk of bias</p> <p>At intervention            Bias in classification of <b>Interventions</b>: Low risk of bias</p> <p>Post-intervention            Bias due to deviations from intended <b>Interventions</b>: Low risk of bias            Bias due to missing data: Low risk of bias            Bias in measurement of outcomes: Low risk of bias            Bias in selection of the reported result: Low risk of bias</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>rectal cancer patients who underwent robotic or laparoscopic intersphincteric resection.</p> <p><b>Study dates</b> September 2006 to August 2011</p> <p><b>Source of funding</b> None reported.</p>	<p>T4 Robotic 5 (11) Laparoscopic 1 (4)</p> <p>Clinical N stage, n (%) N0 Robotic 17 (39) Laparoscopic 14 (54) N1 Robotic 16 (36) Laparoscopic 2 (8) N2 Robotic 11 (25) Laparoscopic 10 (39)</p> <p>Clinical M stage, n (%) M0 Robotic 39 (89) Laparoscopic 24 (92) M1 Robotic 5 (11) Laparoscopic 2 (8)</p> <p><b>Inclusion criteria</b> Patients with low rectal cancer (&lt;5 cm from the anal verge) treated via laparoscopic or robotic intersphincteric resection.</p>				<p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	<b>Exclusion criteria</b> Patients with synchronous tumours or clinical T4 stage tumours that did not respond to neoadjuvant treatment.				
<b>Full citation</b> Zhou, Z. G., Hu, M., Li, Y., Lei, W. Z., Yu, Y. Y., Cheng, Z., Li, L., Shu, Y., Wang, T. C., Laparoscopic versus open total mesorectal excision with anal sphincter preservation for low rectal cancer, Surg Endosc, 18, 1211-5, 2004  <b>Ref Id</b> 809754  <b>Country/ies where the study was carried out</b> China  <b>Study type</b> RCT  <b>Aim of the study</b> To compare open versus	<b>Sample size</b> n=82 underwent laparoscopic surgery; n=89 underwent open surgery. How many were originally randomised and allocated to each group is not reported.  <b>Characteristics</b> Age in years, mean (range): Laparoscopic 44 (26-85); Open 45 (30-81)  Male sex, n/n: Laparoscopic 46/82 Open 43/89  Dukes stage, n/n: A Laparoscopic 5/82 Open 6/89 B Laparoscopic 10/82 Open 8/89 C1	<b>Interventions</b> Laparoscopic surgery versus open surgery  Open resection with TME.  Laparoscopic resection with TME and anal sphincter preservation.	<b>Details</b> Randomisation and allocation concealment No details reported.  Blinding No blinding.  Follow-up/outcomes Clinical data collected.  <b>Statistical analysis</b> Chi-square test and Student's t-test was performed to determine difference between the laparoscopic and open groups.	<b>Results</b> Outcome: Positive resection margin ("cancer cell found in the cut margins") Laparoscopic 0/82 Open 0/89  Outcome: Length of hospital stay in days, mean±SD Laparoscopic 8.1±3.1 (n=82) Open 13.3±3.4 (n=89) p=0.001  Outcome: Operative mortality (timeframe not reported) Laparoscopic 0/82 Open 0/89  Outcome: Anastomotic leak Laparoscopic 1/82 Open 3/89	<b>Limitations</b> Cochrane risk of bias tool Selection bias Random sequence generation: unclear risk (Details not reported.) Allocation concealment: unclear risk (Details not reported.)  Performance bias Blinding of participants and personnel: high risk (No blinding.)  Detection bias Blinding of outcome assessment: high risk (No blinding.)  Attrition bias Incomplete outcome data: unclear risk (The original number randomised not reported. Only outcomes immediate to surgery

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
<p>laparoscopic low and ultralow anterior resections, to assess the feasibility and efficacy of the laparoscopic approach of TME with anal sphincter preservation and to analyse the short-term results of patients with low rectal cancer.</p> <p><b>Study dates</b> June 2001 to September 2002</p> <p><b>Source of funding</b> National Outstanding Youth Foundation of China</p>	<p>Laparoscopic 33/82 Open 35/89 C2 Laparoscopic 30/82 Open 33/89 D Laparoscopic 4/82 Open 7/89</p> <p><b>Inclusion criteria</b> Patients diagnosed with rectal adenocarcinoma, with the lowest margin of tumour located under the peritoneal reflection and 1.5 cm above the dentate line.</p> <p><b>Exclusion criteria</b> Low rectal cancer of other pathological type (for example lymphoma); lowest margin of tumour within 1.5 cm above the dentate line; those in emergency situations (for example acute obstruction during enema, haemorrhage, and perforation); Dukes stage D with local infiltration affecting adjacent organs; those</p>			<p>Outcome: Postoperative infection Laparoscopic 2/82 Open 3/89</p> <p>Outcome: Blood loss in ml, mean (range) Laparoscopic 20 (5-120) (n=82) Open 92 (50-200) (n=89) p=0.025</p>	<p>reported, therefore, no losses to follow-up.)</p> <p>Reporting bias Selective reporting: unclear risk (Not clear which outcomes should be reported.)</p> <p>Other bias Other sources of bias: -</p> <p><b>Other information</b> None</p>

Study details	Participants	Interventions	Methods	Outcomes and Results	Comments
	unwilling to take part in the study.				

1 5-FU: 5-fluorouracil; AJCC: American Joint Committee on Cancer; ASA: American Society of Anestheologists; BMI: body mass index; c: clinical; CEA: carcinoembryonic antigen;  
2 cGy: centigray unit; CI: confidence interval; CRM: circumferential resection margin; CT: computed tomography; EORTC: European Organisation for Research and Treatment of  
3 Cancer; EQ-5D: EuroQol five dimensions questionnaire; EQ-VAS: EuroQol visual analogue scale; FSFI: Female Sexual Function Index; Gy: Gray unit; HR: hazard ratio; IIEF:  
4 International Index of Erectile Function; IQR: interquartile range; IPSS: International Prostate Symptom score; LAP: laparoscopic resection; LAR: low anterior resection; L-TME:  
5 laparoscopic total mesorectal excision; ml: millilitre; M0-1: distant metastasis stage; MRI: magnetic resonance imaging; N0-2: nodal stage; N: number; NR: not reported; p:  
6 pathological; OPEN: open resection; OR: odds ratio; PME: partial mesorectal excision; QLQ-C30: Quality of Life Questionnaire Core 30 Items; QLQ-CR38: Quality of Life  
7 Questionnaire colorectal cancer module (38 items); RCT: randomised controlled trial; ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions; R-  
8 TME: robotic total mesorectal excision; SD: standard deviation; SF-36: 36-Item Short Form Survey; T0-4: tumour stage; TME: total mesorectal excision; TNM: cancer classification  
9 system, standing for tumour, nodal and metastasis stages; VAS: visual analogue scale

10


1  
2



## 1 Appendix E – Forest plots

### 2 Forest plots for review question: What is the optimal surgery for rectal cancer?

3 **Figure 2: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Overall survival (median 3.2 to 9.2 years of follow-up,**  
4 **event is death from any cause)**



#### Footnotes

(1) Number of events not reported

(2) Number of events not reported


5

6 *CI: confidence interval; O-E: observed minus expected; V: variance*

7


8

1 **Figure 3: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - Global quality of life score (QLQ-C30;**  
2 **scale 0-100; better indicated by higher values)**




3  
4 *CI: confidence interval; IV: inverse variance; QLQ-C30: Quality of Life Questionnaire Core 30 Items; SE: standard error*

5 **Figure 4: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - Global health status (EQ-VAS; scale 0-**  
6 **100; better indicated by higher values)**




7  
8 *CI: confidence interval; EQ-VAS: EuroQol visual analogue scale; IV: inverse variance; SE: standard error*

1 **Figure 5: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - Sexual functioning (QLQ-CR38; scale 0-**  
2 **100; better indicated by higher values)**




3  
4 *CI: confidence interval; IV: inverse variance; QLQ-CR38: Quality of Life Questionnaire colorectal cancer module (38 items); SE: standard error*

1 **Figure 6: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - Sexual enjoyment (QLQ-CR38; scale 0-**  
 2 **100; better indicated by higher values)**




3  
 4 *CI: confidence interval; IV: inverse variance; QLQ-CR38: Quality of Life Questionnaire colorectal cancer module (38 items); SE: standard error*

5 **Figure 7: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - Female sexual problems (QLQ-CR38;**  
 6 **scale 0-100; better indicated by lower values)**




7  
 8 *CI: confidence interval; IV: inverse variance; QLQ-CR38: Quality of Life Questionnaire colorectal cancer module (38 items); SE: standard error*

1 **Figure 8: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - Overall level of sexual function decreased**  
 2 **‘quite a lot’ or ‘severely’ as a result of surgery in women (FSFI)**




3  
4 *CI: confidence interval; FSFI: Female Sexual Function Index; M-H: Mantel Haenszel method*

5 **Figure 9: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - Male sexual problems (QLQ-CR38; scale**  
 6 **0-100; better indicated by lower values)**




7  
8 *CI: confidence interval; IV: inverse variance; QLQ-CR38: Quality of Life Questionnaire colorectal cancer module (38 items); SE: standard error*

1 **Figure 10: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - Overall sexual dysfunction median 3**  
 2 **years after surgery among previously sexually active men (IIEF)**




3  
 4 *CI: confidence interval; IIEF: International Index of Erectile Function; M-H: Mantel Haenszel method*

5 **Figure 11: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - A severe change in overall level of**  
 6 **sexual function perceived in men (IIEF)**




7  
 8 *CI: confidence interval; IIEF: International Index of Erectile Function; M-H: Mantel Haenszel method*

1 **Figure 12: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Quality of life - Micturitional symptoms (QLQ-CR38;**  
2 **scale 0-100; better indicated by lower values)**



3  
4 *CI: confidence interval; IV: inverse variance; QLQ-CR38: Quality of Life Questionnaire colorectal cancer module (38 items); SE: standard error*

**Figure 13: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Positive resection margins**




**Footnotes**

- (1) Positive CRM not defined.
- (2) Positive CRM not defined.
- (3) Positive CRM not defined.

CI: confidence interval; CRM: circumferential resection margin; M-H: Mantel Haenszel method




**Figure 14: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Positive radial resection margin  $\leq 2$  mm**




CI: confidence interval

**Figure 15: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Positive resection margin (“cancer cell found in the cut margin”)**




CI: confidence interval; M-H: Mantel Haenszel method

**Figure 16: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Local recurrence (time to event outcome; median 3.2 to 4 years of follow-up)**




CI: confidence interval; O-E: observed minus expected; V: variance

**Figure 17: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Local or locoregional recurrence (median 3 to 7.5 years of follow-up)**



CI: confidence interval; M-H: Mantel Haenszel method


**Figure 18: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Length of hospital stay (days)**



**Footnotes**

- (1) Around 90% lower anterior resection.
- (2) SD not reported, range 2-32 versus 3-39, p=0.013. 100% anterior resection.
- (3) SD not reported, range 5-35 versus 6-167, p=0.071. 100% sphincter-preserving surgery.
- (4) 100% sphincter-preserving surgery.
- (5) SD not reported, range 5-27 versus 5-38, p=0.55. 100% abdominoperineal resection.


CI: confidence interval; IV: inverse variance; SD: standard deviation

**Figure 19: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Operative mortality****Footnotes**

- (1) 28-day mortality  
 (2) RR not estimable because no events.  
 (3) RR not estimable because no events.  
 (4) RR not estimable because no events.


CI: confidence interval; M-H: Mantel Haenszel method

Figure 20: Comparison 1: Laparoscopic versus open surgery for rectal cancer – 90-day operative mortality




CI: confidence interval; M-H: Mantel Haenszel method

Figure 21: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Anastomotic leak




CI: confidence interval; M-H: Mantel Haenszel method

**Figure 22: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Surgical site infection**



CI: confidence interval; M-H: Mantel Haenszel method

**Figure 23: Comparison 1: Laparoscopic versus open surgery for rectal cancer – Blood loss (ml)**




Test for subgroup differences: Chi<sup>2</sup> = 2.69, df = 1 (P = 0.10), I<sup>2</sup> = 62.9%

**Footnotes**

- (1) Around 90% lower anterior resection.
- (2) SD not reported, range 0-3,000 versus 0-2,542, p=0.338. 100% anterior resection.
- (3) SD not reported, range 0-2,000 versus 5-2,5000, p<0.001. 100% sphincter-preserving surgery.
- (4) SD not reported, p=0.025. 100% sphincter-preserving surgery.
- (5) SD not reported, range 0-3,000 versus 0-4,720, p=0.093. 100% abdominoperineal resection.

CI: confidence interval; IV: inverse variance; SD: standard deviation

**Figure 24: Comparison 2: Robotic versus open surgery for rectal cancer – overall survival (median follow-up 3 years)**




Footnotes

(1) Event rate not reported

CI: confidence interval; O-E: observed minus expected; V: variance


**Figure 25: Comparison 2: Robotic versus open surgery for rectal cancer – Quality of life - Sexual dysfunction in men ≤65 years**




CI: confidence interval; M-H: Mantel Haenszel method; VAS: visual analogue scale




**Figure 26: Comparison 2: Robotic versus open surgery for rectal cancer – Positive resection margins**



CI: confidence interval; CRM: circumferential resection margin; M-H: Mantel Haenszel method

**Figure 27: Comparison 2: Robotic versus open surgery for rectal cancer – positive resection margin (R1)**

CI: confidence interval


**Figure 28: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – overall survival (median follow-up 3 to 5 years )**

#### Footnotes

- (1) Number of events not reported
- (2) Number of events not reported
- (3) Number of events not reported
- (4) Number of events not reported
- (5) Number of events not reported


CI: confidence interval; O-E: observed minus expected; V: variance

**Figure 29: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Quality of life - Sexual function mean score at 12 months (QLQ-CR38; scale 0-100; better indicated by higher values)**




CI: confidence interval; IV: inverse variance; QLQ-CR38: Quality of Life Questionnaire colorectal cancer module (38 items); SD: standard deviation

**Figure 30: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Quality of life – Female sexual function adjusted mean score difference at 6 months (FSFI; scale 2-36; better indicated by higher values)**




CI: confidence interval; FSFI: Female Sexual Function Index; IV: inverse variance; SE: standard error

**Figure 31: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Quality of life – Male sexual function adjusted mean score difference at 6 months (IIEF; scale 5-75; better indicated by higher values)**




CI: confidence interval; IIEF: International Index of Erectile Function; IV: inverse variance; SE: standard error

**Figure 32: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Quality of life – Bladder function adjusted mean score difference at 6 months (IPSS; scale 0-35; better indicated by lower values)**




CI: confidence interval; IPSS: International Prostate Symptom Score; IV: inverse variance; SE: standard error

**Figure 33: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Positive resection margins**




CI: confidence interval; CRM: circumferential resection margin; M-H: Mantel Haenszel method

**Figure 34: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Positive proximal resection margin**




CI: confidence interval; M-H: Mantel Haenszel method

**Figure 35: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Positive distal resection margin**




CI: confidence interval

**Figure 36: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Length of hospital stay (days)**




CI: confidence interval; IV: inverse variance; SD: standard deviation

**Figure 37: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – 30-day operative mortality**




CI: confidence interval; M-H: Mantel Haenszel method

**Figure 38: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Anastomotic leak**




CI: confidence interval; M-H: Mantel Haenszel method

**Figure 39: Comparison 3: Robotic versus laparoscopic surgery for rectal cancer – Surgical site infection**




CI: confidence interval; M-H: Mantel Haenszel method

**Figure 40: Comparison 4: Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer – Overall survival (median 5 years of follow-up)**




CI: confidence interval; O-E: observed minus expected; TaTME: transanal total mesorectal excision; V: variance

**Figure 41: Comparison 4: Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer – Quality of life - Sexual activity maintained at median 3.2 years after treatment (in previously sexually active participants)**




CI: confidence interval; M-H: Mantel Haenszel method; TaTME: transanal total mesorectal excision

**Figure 42: Comparison 4: Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer – Quality of life - Sexual dysfunction at median 3.2 years after treatment (FSFI score ≤19) in previously sexually active women**



CI: confidence interval; FSFI: Female Sexual Function Index; M-H: Mantel Haenszel method; TaTME: transanal total mesorectal excision


**Figure 43: Comparison 4: Comparison 4: Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer – Quality of life - Normal ejaculatory function at median 3.2 years after treatment in previously sexually active men (IIEF)**



CI: confidence interval; IIEF: International Index of Erectile Function; M-H: Mantel Haenszel method; TaTME: transanal total mesorectal excision




**Figure 44: Comparison 4: Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer – Positive resection margins**




CI: confidence interval; CRM: circumferential resection margin; M-H: Mantel Haenszel method; TaTME: transanal total mesorectal excision

**Figure 45: Comparison 4: Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer – Postoperative mortality**



CI: confidence interval; TaTME: transanal total mesorectal excision

**Figure 46: Comparison 4: Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer – Anastomotic leak and/or abscess**



CI: confidence interval; M-H: Mantel Haenszel method; TaTME: transanal total mesorectal excision

## Appendix F – GRADE tables

GRADE tables for review question: What is the optimal surgery for rectal cancer?

Table 9: Clinical evidence profile for comparison 1: Laparoscopic versus open surgery for rectal cancer

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
<b>Overall survival (median 3.2 to 9.2 years of follow-up; event is death from any cause)</b>												
9	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	no serious imprecision	none	1,601	1,130	HR 0.83 (0.70 to 0.99)	At 5 years open 85% <sup>2</sup> , laparoscopic 87.4% (85.1% to 89.2%)	MODERATE	CRITICAL
<b>Quality of life - Global quality of life (QLQ-C30) - Change from baseline at 4 weeks (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	230	108	-	MD 0.3 higher (4.7 lower to 5.3 higher)	VERY LOW	CRITICAL
<b>Quality of life - Global quality of life (QLQ-C30) - Change from baseline at 6 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	221	106	-	MD 2.2 lower (6.8 lower to 2.4 higher)	VERY LOW	CRITICAL

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
<b>Quality of life - Global quality of life (QLQ-C30) - Change from baseline at 12 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	208	97	-	MD 1.8 lower (6.1 lower to 2.5 higher)	VERY LOW	CRITICAL
<b>Quality of life - Global health status (EQ-VAS) - Change from baseline at 4 weeks (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	232	104	-	MD 1.6 higher (3.3 lower to 6.5 higher)	VERY LOW	CRITICAL
<b>Quality of life - Global health status (EQ-VAS) - Change from baseline at 6 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	219	102	-	MD 1.7 higher (2.4 lower to 5.8 higher)	VERY LOW	CRITICAL
<b>Quality of life - Global health status (EQ-VAS) - Change from baseline at 12 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	206	91	-	MD 0.6 higher (3.4 lower to 4.6 higher)	VERY LOW	CRITICAL
<b>Quality of life - General health score (SF-36) - At 12 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	83	85	-	Laparoscopic: 74 Open 65 p=0.0001	VERY LOW	CRITICAL
<b>Quality of life - General health score (SF-36) - At 24 months after surgery (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	83	85	-	Laparoscopic: 72 Open: 65 Not significant (p-value not reported)	VERY LOW	CRITICAL

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
<b>Quality of life - Sexual functioning (QLQ-CR38) - Change from baseline at 4 weeks (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	207	98	-	MD 2.5 higher (0.3 lower to 5.3 higher)	VERY LOW	CRITICAL
<b>Quality of life - Sexual functioning (QLQ-CR38) - Change from baseline at 6 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	206	96	-	MD 0.8 lower (5.5 lower to 3.9 higher)	VERY LOW	CRITICAL
<b>Quality of life - Sexual functioning (QLQ-CR38) - Change from baseline at 12 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	197	89	-	MD 3.1 higher (1.7 lower to 7.9 higher)	VERY LOW	CRITICAL
<b>Quality of life - Sexual functioning (QLQ-CR38) - Change from baseline at 24 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	141	64	-	MD 4.6 higher (1.7 lower to 10.9 higher)	VERY LOW	CRITICAL
<b>Quality of life - Sexual enjoyment (QLQ-CR38) - Change from baseline at 6 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>7</sup>	none	72	37	-	MD 0.7 higher (13.6 lower to 15 higher)	VERY LOW	CRITICAL
<b>Quality of life - Sexual enjoyment (QLQ-CR38) - Change from baseline at 12 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>7</sup>	none	87	38	-	MD 8 higher (5 lower to 21 higher)	VERY LOW	CRITICAL
<b>Quality of life - Sexual enjoyment (QLQ-CR38) - Change from baseline at 24 months (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>7</sup>	none	41	21	-	MD 2.1 lower (17.2 lower to 13 higher)	VERY LOW	CRITICAL

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
<b>Quality of life - Female sexual problems (QLQ-CR38) - Change from baseline at 6 months (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>5</sup>	none	19	10	-	MD 5.1 higher (16.5 lower to 26.7 higher)	VERY LOW	CRITICAL
<b>Quality of life - Female sexual problems (QLQ-CR38) - Change from baseline at 12 months (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>7</sup>	none	19	14	-	MD 0.9 higher (20.8 lower to 22.6 higher)	VERY LOW	CRITICAL
<b>Quality of life - Female sexual problems (QLQ-CR38) - Change from baseline at 24 months (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>7</sup>	none	7	5	-	MD 11.8 higher (18.9 lower to 42.5 higher)	VERY LOW	CRITICAL
<b>Quality of life - Overall level of sexual function decreased 'quite a lot' or 'severely' as a result of surgery in women (FSFI)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	8/29 (27.6%)	3/17 (17.6%)	RR 1.56 (0.48 to 5.11)	99 more per 1000 (from 92 fewer to 725 more)	VERY LOW	CRITICAL
<b>Quality of life - Male sexual problems (QLQ-CR38) - Change from baseline at 4 weeks (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>7</sup>	none	91	41	-	MD 6.5 lower (19.9 lower to 6.9 higher)	VERY LOW	CRITICAL
<b>Quality of life - Male sexual problems (QLQ-CR38) - Change from baseline at 6 months (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>7</sup>	none	116	47	-	MD 6.9 lower (20.5 lower to 6.7 higher)	VERY LOW	CRITICAL
<b>Quality of life - Male sexual problems (QLQ-CR38) - Change from baseline at 12 months (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	117	50	-	MD 9.8 lower (22.3 lower to 2.7 higher)	VERY LOW	CRITICAL

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
<b>Quality of life - Male sexual problems (QLQ-CR38) - Change from baseline at 24 months (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	very serious <sup>7</sup>	none	78	37	-	MD 1.1 higher (12.2 lower to 14.4 higher)	VERY LOW	CRITICAL
<b>Quality of life - Overall sexual dysfunction median 3 years after surgery among previously sexually active men (IIEF)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	7/15 (46.7%)	1/22 (4.5%)	RR 10.27 (1.4 to 75.1)	421 more per 1000 (from 18 more to 1000 more)	VERY LOW	CRITICAL
<b>Quality of life - A severe change in overall level of sexual function perceived in men (IIEF)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	23/56 (41.1%)	6/26 (23.1%)	RR 1.78 (0.83 to 3.84)	180 more per 1000 (from 39 fewer to 655 more)	VERY LOW	CRITICAL
<b>Quality of life - Micturitional symptoms (QLQ-CR38) - Change from baseline at 4 weeks (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	219	103	-	MD 0.9 higher (4.4 lower to 6.2 higher)	VERY LOW	CRITICAL
<b>Quality of life - Micturitional symptoms (QLQ-CR38) - Change from baseline at 6 months (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	219	101	-	MD 1 lower (5 lower to 3 higher)	VERY LOW	CRITICAL
<b>Quality of life - Micturitional symptoms (QLQ-CR38) - Change from baseline at 12 months (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	209	95	-	MD 2.2 higher (2 lower to 6.4 higher)	VERY LOW	CRITICAL
<b>Quality of life - Micturitional symptoms (QLQ-CR38) - Change from baseline at 24 months (range of scores: 0-100; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>6</sup>	none	170	79	-	MD 2.4 higher (2.4)	VERY LOW	CRITICAL

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
										lower to 7.2 higher)		
<b>Quality of life - Bladder function at 2 weeks, 3, 6, and 18 months after surgery (IPSS and QLQ-CR38)</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	98	50	-	"No differences in bladder function were detected at any time point between the laparoscopic and open rectal groups."	VERY LOW	CRITICAL
<b>Positive CRM</b>												
9	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	93/1,181 (7.9%)	55/1,065 (5.2%)	RR 1.35 (0.98 to 1.86)	18 more per 1000 (from 1 fewer to 44 more)	MODERATE	CRITICAL
<b>Positive CRM (&lt;2 mm)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	56/588 (9.5%)	30/300 (10%)	RR 0.95 (0.63 to 1.45)	5 fewer per 1000 (from 37 fewer to 45 more)	LOW	CRITICAL
<b>Positive distal resection margin</b>												
5	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	8/682 (1.2%)	5/665 (0.75%)	RR 1.50 (0.50 to 4.54)	4 more per 1000 (from 4 fewer to 27 more)	MODERATE	CRITICAL
<b>Positive radial resection margin (≤1 mm)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	29/240 (12.1%)	17/222 (7.7%)	RR 1.58 (0.89 to 2.79)	44 more per 1000 (from 8 fewer to 137 more)	MODERATE	CRITICAL

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
<b>Positive radial resection margin (≤2 mm)</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	0/20 (0%)	4/20 (20%)	Peto odds ratio 0.11 (0.01, 0.88)	173 fewer per 1000 (from 198 fewer to 20 fewer)	VERY LOW	CRITICAL
<b>Positive resection margin ("cancer cell found in the cut margins")</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	0/82 (0%)	0/89 (0%)	RD 0.00 (-0.02, 0.02)	0 fewer per 1000 (from 20 fewer to 20 more)	LOW	CRITICAL
<b>Local recurrence (time to event outcome; median 3.2 to 4 years of follow-up)</b>												
3	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	7/350 (3.9%)	13/351 (3.1%)	HR 0.57 (0.25 to 1.26)	At 3 years open 4.9% <sup>8</sup> , laparoscopic 2.8% (1.2% to 6.6%)	MODERATE	IMPORTANT
<b>Local or locoregional recurrence (median 3 to 7.5 years of follow-up)</b>												
9	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	68/1,414 (4.8%)	46/1,106 (4.2%)	RR 1.13 (0.78 to 1.62)	5 more per 1000 (from 9 fewer to 26 more)	LOW	IMPORTANT
<b>Length of hospital stay (days) - Anterior resection or abdominoperineal resection</b>												
4	randomised trials	no serious risk of bias	very serious <sup>9</sup>	serious <sup>3</sup>	no serious imprecision	none	1,060	690	-	MD 0.25 lower (0.91 lower to 0.4 higher)	VERY LOW	IMPORTANT
1	randomised trials	no serious risk of bias	no serious inconsistency	serious	serious <sup>1</sup>	none	253	128	-	Laparoscopic: median 11 (IQR 9-15) Open: median 13 (IQR 9-18) No difference	LOW	IMPORTANT



Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
										between groups, narratively reported.		
<b>Length of hospital stay (days) - Sphincter-preserving surgery</b>												
4	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>3</sup>	no serious imprecision	none	281	291	-	MD 4.95 lower (5.89 to 4.01 lower)	LOW	IMPORTANT
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	no serious imprecision	none	238	237	-	Laparoscopic: median 8 (IQR 6-12) Open: median 8 (IQR 6-12) p=0.21	MODERATE	IMPORTANT
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	170	170	-	Laparoscopic: median 8 (IQR 7-12) Open: median 9 (IQR 8-12) p=0.056	MODERATE	IMPORTANT
<b>Length of hospital stay (days) - Abdominoperineal resection</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	51	48	-	Laparoscopic: mean 10.8 (range 5-27) Open: mean 11.5 (range 5-38) p=0.55	LOW	IMPORTANT
<b>30-day mortality</b>												
4	randomised trials	no serious	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	12/1,209 (0.99%)	11/844 (1.3%)	RR 0.71 (0.31 to 1.6)	4 fewer per 1000 (from 9)	LOW	IMPORTANT

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
		risk of bias								fewer to 8 more)		
<b>90-day mortality</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	0/170 (0%)	0/170 (0%)	RD 0.00 (-0.01, 0.01)	0 fewer per 1000 (from 10 fewer to 10 more)	MODERATE	IMPORTANT
<b>Operative mortality (timeframe not defined)</b>												
6	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	17/585 (2.9%)	27/823 (3.3%)	RR 1.03 (0.57 to 1.86)	1 fewer per 1000 (from 14 fewer to 28 more)	LOW	IMPORTANT
<b>Anastomotic leak</b>												
10	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	85/1,418 (6%)	64/1,198 (5.3%)	RR 0.94 (0.68 to 1.29)	3 fewer per 1000 (from 17 fewer to 15 more)	LOW	IMPORTANT
<b>Surgical site infection</b>												
10	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	97/1,572 (6.2%)	86/1,106 (7.8%)	RR 0.79 (0.6 to 1.05)	16 fewer per 1000 (from 31 fewer to 4 more)	LOW	IMPORTANT
<b>Blood loss (ml) - Anterior resection or abdominoperineal resection</b>												
3	randomised trials	no serious risk of bias	serious <sup>10</sup>	no serious indirectness	no serious imprecision	none	357	338	-	MD 100.71 lower (132.25 to 69.17 lower)	MODERATE	IMPORTANT
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	no serious imprecision	none	699	345	-	Laparoscopic: median 200 (IQR 100-400) Open: median 400 (IQR 200-700)	MODERATE	IMPORTANT

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Laparoscopic surgery	Open surgery	Relative (95% CI)	Absolute		
										p<0.0001		
<b>Blood loss (ml) - Sphincter-preserving surgery</b>												
4	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	no serious imprecision	none	281	291	-	MD 183 lower (276.09 to 89.91 lower)	MODERATE	IMPORTANT
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	no serious imprecision	none	238	237	-	Laparoscopic: median 100 (IQR 50-200) Open: median 150 (55-300) p=0.02	MODERATE	IMPORTANT
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	170	170	-	Laparoscopic: median 200 (IQR 100-300) Open: median 217.5 (IQR 150-400) p=0.006	MODERATE	IMPORTANT
<b>Blood loss (ml) - Abdominoperineal resection</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	serious <sup>1</sup>	none	51	48	-	Laparoscopic: mean 321.7 (range 0-3000) Open: mean 555.6 (range 0-4720) p=0.093	LOW	IMPORTANT

CI: confidence interval; CRM: circumferential resection margin; EQ-VAS: EuroQol visual analogue scale; FSFI: Female Sexual Function Index; HR: hazard ratio; IIEF: International Index of Erectile Function questionnaire; IPSS: International Prostate Symptom score; IQR: interquartile range; MD: mean difference; QLQ-C30: Quality of Life Questionnaire Core 30 Items; QLQ-CR38: Quality of Life Questionnaire colorectal cancer module (38 items); RD: risk difference; RR: relative risk; SF-36: 36-item Short Form health survey  
1 Quality of evidence downgraded by 1 because of imprecision of the effect estimate (<300 events for dichotomous outcomes or sample size <400 for continuous outcomes).

2 Survival percentage at 5 years in the control group estimated using 5-year survival data from Ng 2014 and Ng 2008, and 3-year survival data from COREAN trial (Jeong 2014) and 10-year survival data from Ng 2009.

3 Quality of evidence downgraded by 1 because a considerable proportion of the population had or likely had (not clearly reported) early (T1-2N0M0 or stage 0/I) rectal cancer.

4 Quality of evidence downgraded by 1 because of risk of selection bias (method of randomisation or allocation concealment were not reported).

5 Quality of evidence downgraded by 1 because of risk of detection bias (there was no blinding of intervention which might affect assessment of outcome).

6 Quality of evidence downgraded by 1 because the imprecision of the effect estimate (95% CI crosses 1 MID).

7 Quality of evidence downgraded by 2 because of the imprecision of the effect estimate (95% CI crosses 2 MIDs).

8 Local recurrence percentage at 3 years in the control group taken from COREAN trial (Jeong 2014).

9 Quality of evidence downgraded by 2 because of serious heterogeneity.

10 Quality of evidence downgraded by 1 because of heterogeneity.

**Table 10: Clinical evidence profile for comparison 2: Robotic versus open surgery for rectal cancer**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Robotic surgery	Open surgery	Relative (95% CI)	Absolute		
<b>Overall survival (median follow-up 3 years; event is death from any cause)</b>												
2	observational studies	serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	596	1,156	HR 0.98 (0.68 to 1.42)	At 3 years open 92%, robotic 92% (89% to 95%) <sup>5</sup>	VERY LOW	CRITICAL
<b>Quality of life - Moderate or severe sexual dysfunction in men ≤65 years (VAS 2-5)</b>												
1	observational studies	very serious <sup>1,4</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	27/141 (19.1%)	108/332 (32.5%)	RR 0.59 (0.41 to 0.85)	133 fewer per 1000 (from 49 fewer to 192 fewer)	VERY LOW	CRITICAL
<b>Quality of life - Severe sexual dysfunction in men ≤65 years (VAS 4-5)</b>												
1	observational studies	very serious <sup>1,4</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	13/141 (9.2%)	37/332 (11.1%)	RR 0.83 (0.45 to 1.51)	19 fewer per 1000 (from 61 fewer to 57 more)	VERY LOW	CRITICAL
<b>Quality of life - Moderate sexual dysfunction in men ≤65 years (VAS 2-3)</b>												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Robotic surgery	Open surgery	Relative (95% CI)	Absolute		
1	observational studies	very serious <sup>1,4</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	14/141 (9.9%)	71/332 (21.4%)	RR 0.46 (0.27 to 0.8)	115 fewer per 1000 (from 43 fewer to 156 fewer)	VERY LOW	CRITICAL
<b>Positive resection margin</b>												
1	observational studies	serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	no serious imprecision	none	106/1,937 (5.5%)	1,256/14,735 (8.5%)	RR 0.64 (0.53 to 0.78)	31 fewer per 1000 (from 19 fewer to 40 fewer)	VERY LOW	CRITICAL
<b>Positive CRM (≤1 mm)</b>												
1	observational studies	serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	8/533 (1.5%)	26/1,095 (2.4%)	RR 0.63 (0.29 to 1.39)	9 fewer per 1000 (from 17 fewer to 9 more)	VERY LOW	CRITICAL
<b>Positive resection margin (R1)</b>												
1	observational studies	serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	0/65 (0%)	2/55 (3.6%)	Peto odds ratio 0.11 (0.01, 1.81)	32 fewer per 1000 (from 36 fewer to 28 more)	VERY LOW	CRITICAL
<b>Positive distal resection margin (≤5 mm)</b>												
1	observational studies	serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	5/533 (0.94%)	13/1,095 (1.2%)	RR 0.79 (0.28 to 2.2)	2 fewer per 1000 (from 9 fewer to 14 more)	VERY LOW	CRITICAL
<b>Local recurrence</b>												
0	No RCT evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTANT

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Robotic surgery	Open surgery	Relative (95% CI)	Absolute		
<b>Length of hospital stay (days)</b>												
0	No RCT evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTANT
<b>Operative mortality</b>												
0	No RCT evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTANT
<b>Treatment-related complications</b>												
0	No RCT evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTANT

CI: confidence interval; CRM: circumferential resection margin; R1: positive resection margin; RCT: randomised controlled trial; RR relative risk; VAS: visual analogue scale

1 Quality of evidence downgraded by 1 because of risk of bias due to lack of adjustment for confounding or case mix.

2 Quality of evidence downgraded by 1 because a considerable proportion of the population had or likely had (not clearly reported) early (T1-2N0M0 or stage 0/I) rectal cancer.

3 Quality of evidence downgraded by 1 because of imprecision of the effect estimate (less than 300 events for dichotomous outcomes or sample size less than 400 for continuous outcomes).

4 Quality of evidence downgraded by 1 because of no blinding.

5 Estimated using the 3 year overall survival in the open surgery group from Kim 2016

**Table 11: Clinical evidence profile for comparison 3: Robotic versus laparoscopic surgery for rectal cancer**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Robotic surgery	Laparoscopic surgery	Relative (95% CI)	Absolute		
<b>Overall survival (median follow-up 3 to 5 years; event is death from any cause)</b>												
8	observational studies	serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	1,471	1,300	HR 1.07 (0.87 to 1.31)	At 3 years laparoscopic 94%,	VERY LOW	CRITICAL

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Robotic surgery	Laparoscopic surgery	Relative (95% CI)	Absolute		
										robotic 94% (92% to 95%) <sup>7</sup>		
<b>Quality of life - Global health status (QLQ-C30)</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	66	73	No difference between the two groups at 3 weeks, 3 months, and 12 months after surgery.	-	VERY LOW	CRITICAL
<b>Quality of life - Sexual function mean score at 12 months (QLQ-CR38) (range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	66	73	-	MD 12.2 higher (1.37 to 23.03 higher)	VERY LOW	CRITICAL
<b>Quality of life – Female sexual function at 6 months (FSFI) (range of scores: 2-36; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>4,5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	25	29	-	Adjusted <sup>6</sup> MD -1.23 (-6.00 to 3.54)	VERY LOW	CRITICAL
<b>Quality of life – Male sexual function at 6 months (IIEF) (range of scores: 5-75; Better indicated by lower values)</b>												
2	randomised trials	serious <sup>4,5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	168	8150	-	Adjusted <sup>6</sup> MD -1.83 (-6.23 to 2.57)	VERY LOW	CRITICAL
<b>Quality of life – Bladder function at 6 months (IPSS) (range of scores 0-35; Better indicated by lower values)</b>												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Robotic surgery	Laparoscopic surgery	Relative (95% CI)	Absolute		
2	randomised trials	serious <sup>4,5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	246	242	-	Adjusted <sup>6</sup> MD -1.69 (-3.76 to 0.39)	VERY LOW	CRITICAL
<b>Positive CRM (≤1 mm)</b>												
2	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	16/301 (5.3%)	18/297 (6.1%)	RR 0.88 (0.46 to 1.69)	7 fewer per 1000 (from 33 fewer to 42 more)	VERY LOW	CRITICAL
<b>Positive proximal resection margin</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	0/235 (0%)	0/224 (0%)	RD 0 .00 (-0.01., 0.01)	0 fewer per 1000 (from 10 fewer to 10 more)	VERY LOW	CRITICAL
<b>Positive distal resection margin</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	0/235 (0%)	1/224 (0.45%)	Peto odds ratio 0.13 (0.00, 6.50)	4 fewer per 1000 (from 0 fewer to 24more)	VERY LOW	CRITICAL
<b>Local recurrence</b>												
0	No RCT evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTANT
<b>Length of hospital stay (days)</b>												
3	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	321	323	-	MD -0.92 lower (-2.08 lower to 0.23 higher)	VERY LOW	IMPORTANT
<b>30-day operative mortality</b>												



Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Robotic surgery	Laparoscopic surgery	Relative (95% CI)	Absolute		
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	2/236 (0.85%)	2/230 (0.87%)	RR 0.97 (0.14 to 6.86)	0 fewer per 1000 (from 7 fewer to 51 more)	VERY LOW	IMPORTANT
<b>Anastomotic leak</b>												
2	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	30/246 (12.2%)	23/254 (9.1%)	RR 1.34 (0.8 to 2.24)	31 more per 1000 (from 18 fewer to 112 more)	VERY LOW	IMPORTANT
<b>Surgical site infection within 30 days</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	21/236 (8.9%)	19/230 (8.3%)	RR 1.08 (0.6 to 1.95)	7 more per 1000 (from 33 fewer to 78 more)	VERY LOW	IMPORTANT
<b>Surgical site infection between 30 days and 6 months after surgery</b>												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	4/236 (1.7%)	8/230 (3.5%)	RR 0.49 (0.15 to 1.6)	18 fewer per 1000 (from 30 fewer to 21 more)	VERY LOW	IMPORTANT
<b>Blood loss (ml)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	66	73	-	Robotic: median 100 (range 0-1,000) Laparoscopic: median 50 (range 0-300) p<0.0001	LOW	IMPORTANT

CI: confidence interval; CRM: circumferential resection margin; FSFI: Female Sexual Function Index; IIEF: International Index of Erectile Function; IPSS: International Prostate Symptom Score; MD: mean difference; QLQ-C30: Quality of Life Questionnaire Core 30 Items; QLQ-CR38: Quality of Life Questionnaire colorectal cancer module (38 items); RCT:

randomised controlled trial; RD: risk difference; RR: relative risk

1 Quality of evidence downgraded by 1 because of risk of bias due to lack of adjustment for confounding or case mix.

2 Quality of evidence downgraded by 1 because considerable proportion of the population had or likely had (not clear from the paper) early (T1-2N0M0 or stage 0-I) rectal cancer.

3 Quality of evidence downgraded by 1 because of imprecision of the effect estimate (less than 300 events for dichotomous outcomes or sample size less than 400 for continuous outcomes).

4 Quality of evidence downgraded by 1 because of no blinding.

5 Quality of evidence downgraded by 1 because details about randomisation and allocation concealment were not reported.

6 Adjusted for baseline scores and stratification factors (surgeon, sex, preoperative therapy, intended procedure and BMI).

7 Estimated using the 3 year overall survival in the laparoscopic surgery group from Kim 2016

**Table 12: Clinical evidence profile for comparison 4: Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	TaTME	Laparoscopic surgery	Relative (95% CI)	Absolute		
<b>Overall survival (median 5 years of follow-up; event is death from any cause)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	7/50 (14%)	13/50 (26%)	HR 0.50 (0.20 to 1.24)	At 5 years laparoscopic 74.4% <sup>3</sup> , TaTME 86.3% (69.3% to 94.3%)	LOW	CRITICAL
<b>Quality of life - Sexual activity maintained at median 3.2 years after treatment (in previously sexually active participants)</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	20/28 (71.4%)	9/23 (39.1%)	RR 1.83 (1.04 to 3.2)	325 more per 1000 (from 16 more to 861 more)	VERY LOW	CRITICAL
<b>Quality of life - Sexual dysfunction at median 3.2 years after treatment (FSFI score ≤19) in previously sexually active women</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	2/5 (40%)	2/3 (66.7%)	RR 0.6 (0.16 to 2.29)	267 fewer per 1000 (from 560 fewer to 860 more)	VERY LOW	CRITICAL
<b>Quality of life - Erectile function score at median 3.2 years after treatment (IIEF) (range of scores: 5-25; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	23	16	-	TaTME: median	VERY LOW	CRITICAL

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	TaTME	Laparoscopic surgery	Relative (95% CI)	Absolute		
										17.5 (range 5-25) Laparoscopic: median 7 (range 5-21) p=0.119		
<b>Quality of life - Normal ejaculatory function at median 3.2 years after treatment in previously sexually active men (IIEF)</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	14/21 (66.7%)	7/16 (43.8%)	RR 1.52 (0.81 to 2.87)	227 more per 1000 (from 83 fewer to 818 more)	VERY LOW	CRITICAL
<b>Quality of life - Urinary function quality of life score at median 3.2 years after treatment (IPSS) (range of scores: 0-6; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	38	34	-	TaTME: median 1 (range 0-6) Laparoscopic: median 1 (range 0-5) p=0.967	VERY LOW	CRITICAL
<b>Quality of life - Urinary function total score at median 3.2 years after treatment (IPSS) (range of scores: 0-35; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>4</sup>	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	38	34	-	TaTME: median 5.5 (range 0-23) Laparoscopic: median 3.5 (range 0-27) p=0.821	VERY LOW	CRITICAL
<b>R1 resection (positive CRM)</b>												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	TaTME	Laparoscopic surgery	Relative (95% CI)	Absolute		
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	2/50 (4%)	9/50 (18%)	RR 0.22 (0.05 to 0.98)	140 fewer per 1000 (from 4 fewer to 171 fewer)	LOW	CRITICAL
<b>Positive distal margin</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	1/50 (2%)	4/50 (8%)	RR 0.25 (0.03 to 2.16)	60 fewer per 1000 (from 78 fewer to 93 more)	LOW	CRITICAL
<b>Local recurrence</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	50	50	Insufficient data to calculate	At 5 years laparoscopic 4.8%, TaTME 2.6 (2.3% to 7.5%)	LOW	IMPORTANT
<b>Length of hospital stay (days)</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	50	50	-	TaTME: median 7 (range 3-54) Laparoscopic: median 8 (range 2-29) p=0.281	LOW	IMPORTANT
<b>Postoperative mortality</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	0/50 (0%)	1/50 (2%)	Peto odds ratio 0.14 (0.00, 6.82)	17 fewer per 1000 (from 0 fewer to 102 more)	LOW	IMPORTANT

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	TaTME	Laparoscopic surgery	Relative (95% CI)	Absolute		
<b>Anastomotic leak and/or abscess</b>												
1	randomised trials	no serious risk of bias	no serious inconsistency	serious <sup>1</sup>	serious <sup>2</sup>	none	1/50 (2%)	5/50 (10%)	RR 0.2 (0.02 to 1.65)	80 fewer per 1000 (from 98 fewer to 65 more)	LOW	IMPORTANT
<b>Surgical site infection</b>												
0	No evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTANT
<b>Blood loss (ml)</b>												
0	No evidence available	-	-	-	-	-	-	-	-	-	-	IMPORTANT

CI: confidence interval; CRM: circumferential resection margin; FSFI: Female Sexual Function Index; HR: hazard ratio; IIEF: International Index of Erectile Function questionnaire; IPSS: International Prostate Symptom score; MD: mean difference; R1: positive margin; RR: relative risk; TaTME: transanal total mesorectal excision

1 Quality of evidence downgraded by 1 because considerable proportion of the population likely had (not clear from the paper) early (T1-2N0M0 or stage 0-I) rectal cancer.

2 Quality of evidence downgraded by 1 because of imprecision of the effect estimate (less than 300 events for dichotomous outcomes or sample size less than 400 for continuous outcomes).

3 Survival percentage at 5 years in the control group taken from the Bordeaux' trial (Denost 2018).

4 Quality of evidence downgraded by 1 because of no blinding.

## 1 **Appendix G – Economic evidence study selection**

### 2 **Economic evidence study selection for review question: What is the optimal** 3 **surgical technique for rectal cancer?**

4 A global search of economic evidence was undertaken for all review questions in this  
5 guideline. See Supplement 2 for further information.  
6

1 **Appendix H – Economic evidence tables**

2 **Economic evidence study selection for review question: What is the optimal**  
3 **surgical technique for rectal cancer?**

4 No economic evidence was identified which was applicable to this review question.

5

1 **Appendix I – Economic evidence profiles**

2 **Economic evidence profiles for review question: What is the optimal surgical**  
3 **technique for rectal cancer?**

4 No economic evidence was identified which was applicable to this review question.



## 1 **Appendix J – Economic analysis**

### 2 **Economic evidence analysis for review question: What is the optimal surgical** 3 **technique for rectal cancer?**

4 An economic analysis was undertaken to estimate the cost-effectiveness of surgical  
5 techniques for rectal cancer.

#### 6 **Methods**

7 The analysis was developed in Microsoft Excel® and was conducted from the perspective of  
8 the NHS and Personal Social Services (PSS) as outlined in the NICE Reference Case (see  
9 [Developing NICE guidelines: the manual](#)). The model considered a lifetime horizon with  
10 future costs and benefits discounted at a rate of 3.5% (as recommended in the NICE  
11 reference case).

#### 12 ***Clinical data and model approach***

13 The economic analysis was based on clinical effectiveness data for each of the surgical  
14 techniques, which was sourced from the clinical evidence review. However, only the  
15 comparison between the open and laparoscopic approach provided sufficient data for all the  
16 key outcomes of interest for the economic analysis (overall survival, local recurrence and  
17 complications). As a result, a decision was made to separately consider two comparisons in  
18 the analysis. In the first, a comparison is made between the open and laparoscopic approach  
19 based on evidence from the clinical evidence review. In the second, all four surgical  
20 approaches are considered using available data from the clinical evidence review in  
21 combination with assumptions to fill in the missing data. The second analysis was therefore  
22 considered to be more speculative and the conclusions that can be drawn from the analysis  
23 were limited.

24 The clinical values applied in the analysis are detailed in the relevant sections below. In all  
25 cases it should be noted that there is considerable uncertainty around the estimates (as  
26 shown by the reported CIs). Furthermore, it should be noted that the four way comparison  
27 relies on making some assumptions where values were missing and also necessitates making  
28 indirect treatment comparisons which further increases uncertainty.


#### 29 ***Model Structure***

30 A partitioned survival analysis was developed to estimate the expected life expectancy,  
31 quality adjusted life years (QALYs) and costs associated with the approaches considered in  
32 this economic analysis. A partitioned survival analysis divides the model cohort between  
33 different health states based on survival curves derived for overall survival (OS) and  
34 recurrence free survival (RFS) derived from the accompanying clinical evidence review. The  
35 expected OS and RFS are then calculated from the area under the respective curves. For  
36 our model, 3 mutually exclusive health states were derived for the cohort to be partitioned  
37 into:

- 38 • alive without progressed disease (equal to the area under the RFS curve)
- 39 • alive with progressed disease (equal to the area between the RFS curve and the OS  
40 curve)
- 41 • death (area above the OS curve).

42 An illustrative example of the structure of the partitioned survival analysis is shown in Figure  
43 47.

**Figure 47: Illustrative example of partitioned survival analysis**



1 A partitioned survival analysis approach was chosen over other modelling approaches, for  
2 example, a state transition model as only absolute survival estimates at limited set time  
3 points were reported by the identified studies and these were the only survival estimates  
4 synthesised and reported by the meta-analyses in the accompanying clinical evidence  
5 review. Consequently all OS and RFS estimates in the model were derived from these  
6 outcomes. Given the scarcity of the time points at which these were reported it was difficult to  
7 estimate plausible transition probabilities for use in a state transition model. It was also  
8 possible to extrapolate survival beyond that reported by the studies in the accompanying  
9 clinical evidence review. This approach is widely used in models of the cost effectiveness of  
10 oncology interventions. A review of recent NICE technology appraisals in oncology found that  
11 this approach was used in 73% of submissions (Woods 2017).

12 While not a consideration in choosing the most appropriate modelling approach, a partitioned  
13 survival analysis is a more intuitive modelling approach for metastases in cancer than state  
14 transition models. Evidence from trials and observational studies where survival is a key  
15 outcome are almost exclusively reported as median overall and progression-free survival  
16 with accompanying hazard ratio and Kaplan Meier survival curves. As these are the primary  
17 inputs for partitioned survival analysis the inputs can be easily compared with those  
18 observed in the included trials and other external sources. The model can also be more  
19 easily compared, for validity, with any potential future study which consider the relevant  
20 interventions.

1 A partitioned survival analysis was performed for both interventions considered in the  
2 economic evaluation and for the two further interventions considered in the further  
3 speculative analysis and the total time spent in each health state for the model cohort was  
4 calculated. Each health state was assigned a quality of life weighting so that survival could  
5 be adjusted to QALYs.

6 The economic component of the model was built and run in Microsoft Excel 2013. The model  
7 had a cycle length of 1 year. The model had a time horizon of 36 years for which, based on  
8 Office of National Statistics (ONS) life tables, over 99.9% of a general population sample  
9 would have died. This percentage would be even higher for a population with rectal cancer.  
10 The model would therefore comfortably cover a sufficient time horizon to capture all  
11 outcomes, QALYs and costs. The model took a NHS and Personal Social Services  
12 perspective (PSS) and only outcomes relevant to either organisation were considered.

13 For the reporting of outcomes in the model the open approach was considered the  
14 comparator and laparoscopic approach the intervention. Costs and outcomes are reported  
15 on a per person basis.

### 16 **Overall survival**

17 Overall survival estimates for the comparison between the open and laparoscopic surgical  
18 approach were based upon values from the clinical evidence review. Absolute survival  
19 estimates showed that 85.0% of patients were alive at five years following treatment with the  
20 open surgical approach. The laparoscopic approach was found to reduce overall mortality in  
21 comparison to the open approach with an estimated HR of 0.83 (95% CI 0.70-0.99).

22 Overall survival estimates for the comparison between all four surgical approaches were also  
23 based upon values from the clinical evidence review. Overall survival values for the open and  
24 laparoscopic approach were based on the same methodology used in the two-way  
25 comparison between these approaches. Overall survival with the robotic approach was  
26 based on an estimated RR of 1.02. This value was estimated from absolute 3 year survival  
27 estimates obtained from 1 study (Rouanet 2018) the clinical evidence review which gave  
28 survival rates of 88.4% and 84.1% for the laparoscopic and robotic approach, respectively.  
29 Overall survival for the TaTME approach was based on the HR of 0.5 (95% CI 0.20-1.24)  
30 reported in the clinical evidence review for the comparison between TaTME and the  
31 laparoscopic approach. All calculations follow the usual proportional hazard assumptions.

### 32 **Local recurrence**

33 Local recurrence estimates for the comparison between the open and laparoscopic surgical  
34 approach were based upon values from the clinical evidence review. Absolute estimates  
35 from 1 study (Jeong 2014) identified in the accompanying clinical evidence review showed  
36 that 4.9% of patients had local recurrence at 3 years following treatment with the open  
37 surgical approach. From this study, the laparoscopic approach had lower local recurrence in  
38 comparison to the open approach and estimated a HR of 0.40 (95% CI 0.13-1.26). This  
39 estimate was chosen for use in the economic model over the pooled estimate from the  
40 clinical evidence review as this was the largest and most recent pooled study identified and was  
41 considered most applicable to technologies used today. The pooled estimate of 0.57 (95% CI  
42 0.25-1.26) would be less favourable to a laparoscopic approach however both estimates  
43 have 95% confidence intervals that pass the line of no effect.

44 Local recurrence estimates for the comparison between all four surgical approaches were  
45 also based upon values from the clinical evidence review. Local recurrence values for the  
46 open and laparoscopic approach were based on the same methodology used in the two-way  
47 comparison between these approaches. Local recurrence estimates were not available for  
48 the robotic approach. It was therefore assumed that it would be equivalent to local  
49 recurrence with the laparoscopic approach. A RR estimate of 1.00 was therefore applied.  
50 Local recurrence with the TaTME approach was based on an estimated RR of 0.54. This

1 value was estimated from absolute local recurrence estimates obtained from the clinical  
2 evidence review which gave local recurrence rates of 4.8% and 2.6% at 5 years for the  
3 laparoscopic and robotic approach, respectively. As with overall survival the usual  
4 proportional hazard assumptions apply.

## 5 **Complications**

6 The accompanying clinical evidence review found evidence for 3 types of surgical  
7 complications in this comparison: anastomotic leak, surgical site infection and excess blood  
8 loss. Excess blood loss is not an uncommon occurrence in surgery and it was likely that in all  
9 but rare severe cases there will be limited impact on quality of life and costs. This  
10 complication was therefore not included in the economic model. Other complications which  
11 were highlighted as important such as reduction in sexual function and bladder problems,  
12 even though they would have a significant impact upon quality of life were not included in the  
13 model. This is because the accompanying evidence review did not find any evidence around  
14 these outcomes and it is uncertain, from clinical opinion, whether these would be more  
15 favourable in either open or laparoscopic groups.

16 All complications were assumed to have only a short impact upon quality of life and  
17 morbidity. No longer-term morbidity was modelled. Whilst anastomotic leaks can lead to  
18 operative mortality this would be included in the perioperative mortality model inputs.

19 The proportion of treatment related complications were estimated for the comparison  
20 between the open and laparoscopic surgical approach using values from the clinical  
21 evidence review. Absolute estimates for patients treated with the open approach showed that  
22 5.3% had an anastomotic leak and 7.8% had a surgical site infection. Complications after the  
23 laparoscopic approach were estimated using RRs from the clinical evidence review which  
24 suggest that the laparoscopic approach reduces complications with RRs of 0.94 (95% CI  
25 0.68-1.29) and 0.79 (95% CI 0.60-1.05) for anastomotic leak and surgical site infection,  
26 respectively.

27 Complication estimates for the comparison between all four surgical approaches were also  
28 based upon values from the clinical evidence review. Complication estimates for the open  
29 and laparoscopic approach were based on the same methodology used in the two-way  
30 comparison between these approaches. The proportion of patients with an anastomotic leak  
31 after treatment with the robotic approach was based on a reported RR of 1.34 (95% CI 0.80-  
32 2.24) in comparison to the laparoscopic approach. There was no data on the proportion of  
33 patients with a surgical site infection after treatment with the robotic approach. Therefore this  
34 was assumed to be equivalent to laparoscopic approach (i.e. assuming RR of 1.00). The  
35 proportion of patients with an anastomotic leak after treatment with the TaTME approach was  
36 based on a reported RR of 0.20 (95% CI 0.02-1.65) in comparison to the laparoscopic  
37 approach. There was no data on the proportion of patients with a surgical site infection after  
38 treatment with the TaTME approach. Therefore this was assumed to be equivalent to  
39 laparoscopic approach (i.e. assuming RR of 1.00).

## 40 **Costs**

41 The costs considered in the model reflect the perspective of the analysis, thus only costs that  
42 are relevant to the UK NHS & PSS were included. Where possible, all costs were estimated  
43 in 2016/17 prices. All costs used in the model are presented in Table 13 with the exception of  
44 palliative care costs which are presented in Table 14.

45 The majority of costs were sourced from NHS reference costs 2016/17 by applying tariffs  
46 associated with the appropriate Healthcare Resource Groups (HRG) code. However, note  
47 that the cost of the surgical procedure in NHS reference costs (FF31: complex large intestine  
48 procedures, 19 years and over) is the same regardless of the approach taken. Therefore this  
49 cost was not estimated using the procedure code from NHS reference costs and an  
50 alternative approach was adopted in order to differentiate the various surgical techniques.

## 1 **Surgical equipment costs**

2 Surgical equipment costs were estimated using data from a cost-effectiveness analysis of  
3 surgical approaches in prostate cancer (Ramsay 2012), with costs inflated to 2016 prices.  
4 Equipment costs were estimated to be £1,502, £1,605, £4,628 and £1,815 for the open,  
5 laparoscopic, robotic, and TaTME approaches, respectively. Operative time costs were  
6 estimated using average theatre time estimates from the studies included in the clinical  
7 evidence review. A cost for an hour of operating theatre time was sourced the cost-  
8 effectiveness analysis from Ramsay 2012 and inflated to 2016 prices (£1,266). Length of  
9 stay costs were estimated using data on the number of days for each procedure from the  
10 studies included in the clinical evidence review combined with the cost of an excess bed day  
11 from NHS reference costs 2016/17. The length of hospital stay was meta-analysed by type of  
12 resection in the clinical evidence review given heterogeneity. This economic analysis does  
13 not investigate the cost effectiveness of the interventions by these subgroup so a pooled  
14 estimate of all length of stays was used in the economic model. This distribution was given a  
15 wide uniform distribution in the probabilistic sensitivity analysis given the considerations  
16 around heterogeneity.

## 17 **Complication costs**

18 Complication costs were estimated using the different costs associated with complication and  
19 co-morbidity (CC) scores for the surgical procedure from NHS reference costs. The  
20 difference between CC score 0-2 (used as a best estimate for no complications) and a  
21 weighted average of the other CC scores associated with complex large intestine procedures  
22 (FF31) was used as an estimate of complication costs.

## 23 **Systemic chemotherapy costs**

24 Systemic chemotherapy costs were estimated assuming that patients would be treated with 6  
25 cycles of FOLFIRI or FOLFOX. The chemotherapy delivery costs were sourced from NHS  
26 Reference Costs 2015/16 (assuming day case delivery) and drug costs were sourced from  
27 eMit.

## 28 **Inpatient and outpatient management costs**

29 The cost of palliative care was estimated using estimates from a costing report by the  
30 Nuffield Trust (Georghiou 2014). A cost of £7,287 was applied based on the average  
31 resource use of patients with cancer in the last three months of life.

## 32 **Table 13: Costs and cost weightings used in the economic model**

	Weight	Cost	Source
<b>Complex Large Intestine Procedures, 19 years and over</b>			
with CC Score 9+ (FF31A)	3%	£13,567.94	NHS Reference costs 2016/17
with CC Score 6-8 (FF31B)	6%	£10,626.33	NHS Reference costs 2016/17
with CC Score 3-5 (FF31C)	22%	£8,810.93	NHS Reference costs 2016/17
with CC Score 0-2 (FF31D)	70%	£7,370.66	NHS Reference costs 2016/17
<b>Weighted average</b>	100%	<b>£8,026.32</b>	
<b>Complex Large Intestine Procedures, 19 years and over-Excess bed days</b>			
with CC Score 9+ (FF31A)	6%	£247.57	NHS Reference costs 2016/17
with CC Score 6-8 (FF31B)	18%	£298.73	NHS Reference costs 2016/17

	Weight	Cost	Source
with CC Score 3-5 (FF31C)	23%	£354.04	NHS Reference costs 2016/17
with CC Score 0-2 (FF31D)	53%	£326.78	NHS Reference costs 2016/17
<b>Weighted average</b>	100%	<b>£323.36</b>	
<b>Operative and length of stay costs</b>			
Operative time cost per hour of surgery		£1,265.90	Ramsay 2012
LOS - cost per day		£323.36	Ramsay 2012
<i>Open approach</i>			
Equipment cost		£1,501.93	Ramsay 2012
Operative time		181 minutes	Ramsay 2012
Operative time cost		£3,813.41	
LOS - number of days		9.68 days	Ramsay 2012
LOS cost		£3,130.12	
<b>Total cost of open approach</b>		<b>£8,445.46</b>	
<i>Laparoscopic approach</i>			
Equipment cost		£1,605.41	Ramsay 2012
Operative time		225 minutes	Ramsay 2012
Operative time cost		£4,744.40	
LOS - number of days		8.27 days	Ramsay 2012
LOS cost		£2,674.18	
<b>Total cost of laparoscopic approach</b>		<b>£9,024.00</b>	
<i>Robotic approach</i>			
Equipment cost		£4,627.63	Ramsay 2012
Operative time		282 minutes	Ramsay 2012
Operative time cost		£5,950.57	
LOS - number of days		7.77 days	Ramsay 2012
LOS cost		£2,512.50	
<b>Total cost of robotic approach</b>		<b>£13,090.70</b>	
<i>TaTME approach</i>			
Equipment cost		£1,814.81	Ramsay 2012
Operative time		205 minutes	Ramsay 2012
Operative time cost		£4,329.50	
Surgeon cost per working hour		£107.00	Ramsay 2012
Cost for second surgeon		£365.95	Ramsay 2012
LOS - number of days		7.24 days	Ramsay 2012
LOS cost		£2,339.91	

	Weight	Cost	Source
<b>Total cost of TaTME approach</b>		<b>£8,850.16</b>	
<b>Systemic chemotherapy costs</b>			
<i>FOLFOX</i>			
Deliver complex chemotherapy at first attendance		£385.99	NHS Reference costs 2016/17
Dexamethasone 8mg		£1.52	eMit
Ondansetron 16mg		£0.17	eMit
Chlorphenamine 10mg		£3.01	eMit
Oxaliplatin 85mg/m2		£16.04	eMit
Folinic Acid 350mg		£10.42	eMit
Fluorouracil 400mg/m2		£3.94	eMit
Fluorouracil 2400mg/m2		£8.36	eMit
Cost per cycle		£429.45	
<b>Total cost for 6 cycles</b>		<b>£2,576.72</b>	
<i>FOLFIRI</i>			
Deliver complex chemotherapy at first attendance		£385.99	NHS Reference costs 2016/17
Atropine 250mcg		£0.12	eMit
Irinotecan 180mg/m2		£17.35	eMit
Folinic Acid 350mg		£10.42	eMit
Fluorouracil 400mg/m2		£3.94	eMit
Fluorouracil 2400mg/m2		£8.36	eMit
Cost per cycle		£426.18	
<b>Total cost for 6 cycles</b>		<b>£2,557.09</b>	
<b>Average cost of systemic chemotherapy regimens</b>		<b>£2,566.91</b>	

1 *FOLFIRI: folinic acid, fluorouracil and irinotecan; FOLFOX: folinic acid, fluorouracil and oxaliplatin; LOS: length of*  
2 *stay; CC: clinical complications; eMit: Drugs and pharmaceutical electronic market information tool*

### 3 **Cost of palliative care**

4 Given the life expectancy of the model cohort and that the majority of patients would die as a  
5 result of their disease a one off cost of palliative care was applied to the entirety of the cohort  
6 during their final year of life. This is to represent the increase in resource use experienced  
7 during the final months of a patient's life. This one off cost was taken from Georghiou 2014.  
8 The study used medical records of over 1,836 patients with cancer at multiple UK hospitals  
9 and hospices to estimate resource use and publically available UK costs to estimate a total  
10 cost for the final 90 days of life. An average cost for patients with cancer was used from the  
11 report. These costs are presented in Table 14.



1 **Table 14: Costs of palliative care for patients with cancer from Georghiou 2014**

Type of care	Cost
Cost of all hospital contacts	£5,890
Local authority-funded care	£444
District nursing care	£588
GP contacts	£365
<b>Total palliative care cost per patient</b>	<b>£7,287</b>

2 The above costs includes 'local authority-funded care'. The methods of calculation from the  
3 original report may include costs, such as personal contributions to care, which are not  
4 strictly covered by the NHS & PSS perspective used for this economic model. A deterministic  
5 sensitivity analysis was therefore undertaken which removed this cost from the total palliative  
6 care cost estimate.

7 ***Health-related quality of life***

8 As recommended in the NICE reference case, the model estimates effectiveness in terms of  
9 quality adjusted life years (QALYs). These are estimated by combining life year estimates  
10 with quality of life (QoL) values associated with being in a particular health state.

11 QoL data for all comparisons were sourced from Rao 2017, a cost-effectiveness analysis that  
12 estimated QoL for recurrences (0.78) and for being recurrence free (0.86).

13 **Sensitivity analysis**

14 Uncertainty was assessed in the economic model through deterministic and probabilistic  
15 sensitivity analysis. A series of deterministic sensitivity analyses were conducted, whereby  
16 an input parameter was changed, the model was re-run and the new cost-effectiveness  
17 result was recorded. This form of analysis is a useful way of estimating uncertainty and  
18 determining the key drivers of the model results.

19 Probabilistic sensitivity analysis (PSA) was conducted to assess the combined parameter  
20 uncertainty in the model. In this analysis, the mean values that were utilised in the base-case  
21 were replaced with values drawn from distributions around the mean values.


22 **Results**

23 ***Overall and recurrence free survival***

24 Overall (Figure 48) and recurrence free survival (Figure 49), based on the deterministic point  
25 estimates, were unsurprisingly in line with the HRs and RRs used as inputs. There is over a  
26 20 percentage point difference between TaTME and the open approach for both overall and  
27 recurrence free survival at the greatest point of difference although the uncertainty around  
28 the TaTME estimates of both types of survival should be noted.




1 **Figure 48: Overall survival estimated in the economic model**



2

3 **Figure 49: Recurrence free survival estimated in the economic model**



4

5 **Base-case results**

6 The base case results of the analysis, based on the point estimates of the model inputs, are  
7 shown in Table 15 and Table 16 for the two-way and four-way comparison respectively. The  
8 results of the two way comparison show the laparoscopic approach to be more effective  
9 (1.26 QALYs) and less costly than the open approach (£921) and it is therefore dominant.  
10 These results are driven by improvements in overall survival which are clinically significant.

1 In the four-way comparison, alternative approaches were compared using a net monetary  
2 benefit approach assuming a threshold of £20,000 per QALY. The results show the TaTME  
3 approach to be the least costly approach. All other strategies are found to be more costly and  
4 less effective than TaTME and are therefore dominated. Consequently, net monetary benefit  
5 was negative for all other interventions. However it should be noted for TaTME that the  
6 results are driven by improvements in overall survival and recurrence which were based on a  
7 hazard ratio for which the 95% confidence interval passed the line of no effect. It is therefore  
8 plausible that TaTME may result in lower QALYs and higher costs (through increased  
9 recurrence) compared to alternative approaches. These results should therefore be  
10 considered speculative.

11 **Table 15: Base case results for two-way comparison**

Strategy	Cost		QALYs		ICER (cost per QALY)
	Total	Incremental	Total	Incremental	
Open	£11,963	-	9.08	-	-
Laparoscopic	£11,042	-£921	10.34	1.26	<b>Dominant</b>

12 *ICER: incremental cost-effectiveness ratio; QALYs: quality adjusted life years*

13 **Table 16: Base case results for four-way comparison**

Strategy	Cost		QALYs		ICER (cost per QALY)	NMB
	Total	Incremental	Total	Incremental		
TaTME	£9,812	-	11.15	-	-	
Laparoscopic	£11,042	£1,230	10.34	-0.81	<b>Dominated</b>	-£17,395
Open	£11,963	£2,151	9.08	-2.07	<b>Dominated</b>	-£43,575
Robotic	£15,612	£5,800	9.92	-1.24	<b>Dominated</b>	-£30,503

14 *ICER: incremental cost-effectiveness ratio; QALYs: quality adjusted life years NMB Net monetary benefit*

15 Disaggregated costs are presented in Table 17. The majority of total costs (>60% of total  
16 costs) for all interventions is the upfront treatment cost of the surgical procedure. Systemic  
17 chemotherapy and palliative care costs are zero for both robotic and TaTME given the  
18 assumptions around disease specific mortality.

19 **Table 17: Disaggregated costs for four-way analysis**

	Upfront treatment costs	Complication costs	Recurrence costs	Systemic chemotherapy	Palliative care costs
TaTME	£8,850	£259	£1,154	£0	£0
Laparoscopic	£9,024	£404	£1,182	£319	£907
Open	£8,445	£475	£1,209	£805	£2,284
Robotic	£8,850	£259	£1,154	£0	£0

20

21 ***Deterministic sensitivity results***

22 A series of deterministic sensitivity analyses were conducted whereby an input parameter is  
23 changed, the model is re-run and the new cost-effectiveness result is recorded. This is a  
24 useful way of estimating uncertainty and determining the key drivers of the model result. The  
25 results of the deterministic sensitivity analyses are presented in Table 18 and Table 19 for  
26 the two-way and four-way comparison, respectively.

27 In the two-way comparison, it can again be seen that the conclusion of the analysis remains  
28 unchanged in the majority of modelled scenarios with the laparoscopic approach found to be  
29 cost effective. Notably this includes a scenario in which only statistically significant effects

1 are modelled. The conclusion of the analysis was found to change when the upper HR for  
2 overall survival was applied (meaning that overall survival is better with the open approach).

3 In the four-way comparison, it can again be seen that the conclusion of the analysis remains  
4 unchanged in the majority of modelled scenarios with TaTME found to be cost effective.  
5 However, notably, this does not include a scenario in which only statistically significant  
6 effects are modelled (in which the laparoscopic approach is found to be cost effective). The  
7 laparoscopic approach was also found to be cost effective when the upper HR for overall  
8 survival for TaTME was applied or when overall survival was assumed to be equivalent with  
9 laparoscopic and TaTME. The open approach was found to be cost effective when the upper  
10 HR for overall survival for TaTME and the laparoscopic approach was applied.

11 **Table 18: Deterministic sensitivity results for two-way comparison**

Modelled scenario	Optimal strategy
Base case	Laparoscopic
Overall survival – lower HR	Laparoscopic
Overall survival – upper HR	Laparoscopic
Local recurrence – lower RR	Laparoscopic
Local recurrence – upper RR	Laparoscopic
Complications – lower RR	Laparoscopic
Complications – upper RR	Laparoscopic
Statistically significant changes only	Laparoscopic
Number of robotic procedures per year = 50	Laparoscopic
Number of robotic procedures per year = 100	Laparoscopic
Number of robotic procedures per year = 200	Laparoscopic
Complication costs + 50%	Laparoscopic
Complication costs - 50%	Laparoscopic
No systemic chemotherapy costs	Laparoscopic
No palliative care costs	Laparoscopic
No recurrence disutility	Laparoscopic

12 *HR: hazard ratio; RR: relative risk*

13 **Table 19: Deterministic sensitivity results for four-way comparison**

Modelled scenario	Optimal strategy
Base case	TaTME
Overall survival – lower HR for laparoscopic	TaTME
Overall survival – upper HR for laparoscopic	TaTME
Overall survival – lower HR for TaTME	TaTME
Overall survival – upper HR for TaTME	<b>Laparoscopic</b>
Overall survival with TaTME equivalent to laparoscopic	<b>Laparoscopic</b>
Overall survival – upper HR for TaTME and laparoscopic	<b>Open</b>
Absolute overall survival with robotic 10% higher	TaTME
Absolute overall survival with robotic 10% lower	TaTME
Local recurrence – lower RR for laparoscopic	TaTME
Local recurrence – upper RR for laparoscopic	TaTME
Absolute local recurrence with TaTME 10% higher	TaTME
Absolute local recurrence with TaTME 10% lower	TaTME
Local recurrence with TaTME equivalent to laparoscopic	TaTME
Complications – lower RR	TaTME

Modelled scenario	Optimal strategy
Complications – upper RR	TaTME
Statistically significant changes only	<b>Laparoscopic</b>
Number of robotic procedures per year = 50	TaTME
Number of robotic procedures per year = 100	TaTME
Number of robotic procedures per year = 200	TaTME
Complication costs + 50%	TaTME
Complication costs - 50%	TaTME
No systemic chemotherapy costs	TaTME
No palliative care costs	TaTME
No recurrence disutility	TaTME

1 *HR: hazard ratio; RR: relative risk; TaTME: transanal total mesorectal excision; TME: total mesorectal excision*

## 2 **Probabilistic sensitivity results**


3 The results of 10,000 runs of the PSA are shown using ICER scatterplots and cost-  
4 effectiveness acceptability curves (CEAC). The ICER scatter plots show the incremental  
5 costs and QALYs associated with each of the 10,000 runs of the PSA along with the mean  
6 result. The CEAC graphs show the probability of each strategy being considered cost-  
7 effective at the various cost-effectiveness thresholds on the x axis.

8 Figure 50 shows the ICER scatterplot for the comparison between the open and laparoscopic  
9 surgical approach. It can be seen that, while the results are spread across all four domains of  
10 the scatterplot, the majority of the results reside on the East side of the graph. This indicates  
11 that in the majority of cases, the laparoscopic approach was found to be more effective.  
12 Furthermore, it can be seen that the majority of the cost effectiveness pairs reside below the  
13 cost-effectiveness threshold line (£20,000 per QALY) meaning that in the majority of cases,  
14 the laparoscopic strategy was found to be cost effective.

15 Figure 51 shows the CEAC for the comparison between the open and laparoscopic surgical  
16 approach. It can be seen that the likelihood of the laparoscopic approach being deemed  
17 cost-effective increases as the cost-effectiveness threshold increases. At the NICE threshold  
18 of £20,000 per QALY, the laparoscopic approach was found to have a 9% probability of  
19 being cost effective, while the open approach has a 2% probability of being cost effective.


20 Figure 52 shows the CEAC for the comparison between all four surgical approaches. It can  
21 be seen that the likelihood of the TaTME strategy being cost-effective increases as the cost-  
22 effectiveness threshold increases while the likelihood of all other strategies being cost-  
23 effective decrease. At the NICE threshold of £20,000 per QALY, the TaTME strategy was  
24 found to have an 86% probability of being cost effective, while the laparoscopic, open and  
25 robotic approach were found to have a 13%, 2% and 0% probability of being cost effective,  
26 respectively.

1 **Figure 50: ICER scatterplot for the comparison between the open and laparoscopic**  
2 **surgical approach**




3  
4 *CE: cost-effectiveness; QALYs: quality-adjusted live years*

5 **Figure 51: Cost-effectiveness acceptability curve (CEAC) for the comparison between**  
6 **the open and laparoscopic surgical approach**



7

1 **Figure 52: Cost-effectiveness acceptability curve (CEAC) for the comparison between**  
2 **all four surgical approaches**



3  
4 *TaTME: transanal total mesorectal excision*

## 5 Conclusions

6 The results of the analysis suggest that the laparoscopic approach may be cost effective for  
7 rectal cancer surgery. However, there is some uncertainty around the approach, largely  
8 driven by the uncertainty around some of the clinical effectiveness estimates especially  
9 around recurrence. A speculative analysis comparing the open, laparoscopic, robotic and  
10 TaTME approaches suggests that the TaTME may be cost-effective. However, the lack of  
11 clear data as well as the assumptions required to run this four-way comparison severely limit  
12 the conclusions that can be drawn from the analysis.

## Appendix K – Excluded studies

### Excluded clinical studies for review question: What is the optimal surgical technique for rectal cancer?

**Table 20: Excluded studies and reasons for their exclusion**

Study	Reason for exclusion
Anon. Short-term surgical outcomes and patient quality of life between robotic and laparoscopic extralevator abdominoperineal excision for adenocarcinoma of the rectum	A conference abstract
Abdujapparov A, Ten Y, Korakhadjaev B. The results of neoadjuvant chemoradiation therapy in combined treatment of rectal cancer. <i>European Journal of Cancer</i> . 2017;72:S50.	A conference abstract
Abraha I, Aristei C, Palumbo I, Lupattelli M, Trastulli S, Cirocchi R, et al. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. <i>Cochrane Database Syst Rev</i> . 2018;10:CD002102.	Wrong comparison: (comparison potentially relevant for review C1). A systematic review and meta-analysis of RCTs comparing preoperative radiotherapy and surgery versus surgery alone.
Agha, A., Benseler, V., Hornung, M., Gerken, M., Iesalnieks, I., Furst, A., Anthuber, M., Jauch, K. W., Schlitt, H. J., Long-term oncologic outcome after laparoscopic surgery for rectal cancer, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 28, 1119-1125, 2014	A non-randomised study comparing laparoscopic and open surgery.
Agha, A., Furst, A., Iesalnieks, I., Fichtner-Feigl, S., Ghali, N., Krenz, D., Anthuber, M., Jauch, K. W., Piso, P., Schlitt, H. J., Conversion rate in 300 laparoscopic rectal resections and its influence on morbidity and oncological outcome, <i>International Journal of Colorectal Disease</i> , 23, 409-417, 2008	A non-randomised study comparing laparoscopic and open surgery.
Ahmad, N. Z., Racheva, G., Elmusharaf, H., A systematic review and meta-analysis of randomized and non-randomized studies comparing laparoscopic and open abdominoperineal resection for rectal cancer, <i>Colorectal Disease</i> , 15, 269-277, 2013	Systematic review of laparoscopic versus open rectal surgery including both RCTs and non-RCTs and studies published pre-2000. Included RCTs checked for relevance.
Alecu, L., Stanciulea, O., Poesina, D., Tomulescu, V., Vasilescu, C., Popescu, I., Robotically performed total mesorectal excision for rectal cancer, <i>Chirurgia (Bucuresti)</i> , 110, 137-43, 2015	No comparison group.
Ali, S., Taylor, B. M., Schlachta, C. M., Evaluation of pilot experience with robotic-assisted proctectomy and coloanal anastomosis for rectal cancer, <i>Canadian journal of surgery, Journal canadien de chirurgie</i> . 58, 188-192, 2015	Insufficient number of participants to get meaningful data. (Robot group included a total of 3 participants.)
Allaix, M. E., Giraudo, G., Ferrarese, A., Arezzo, A., Rebecchi, F., Morino, M., 10-Year Oncologic Outcomes After Laparoscopic or Open Total Mesorectal Excision for Rectal Cancer, <i>World Journal of Surgery</i> , 40, 3052-3062, 2016	A non-randomised study comparing laparoscopic and open surgery.

Alvim, Rg, Queiroz, Fld, Lacerda-Filho, A, Silva, Rg, Male sexual function after total mesorectal excision: a comparison between laparoscopic and open surgery during the learning curve period, <i>Surgical Laparoscopy, Endoscopy &amp; Percutaneous Techniques</i> , 25, e51-e56, 2015	A non-randomised study comparing laparoscopic and open surgery.
Aly, E. H., Laparoscopic colorectal surgery: Summary of the current evidence, <i>Annals of the Royal College of Surgeons of England</i> , 91, 541-544, 2009	A non-randomised study comparing laparoscopic and open surgery.
Anderson, C, Uman, G, Pigazzi, A, Oncologic outcomes of laparoscopic surgery for rectal cancer: a systematic review and meta-analysis of the literature (Structured abstract), <i>European Journal of Surgical Oncology</i> , 34, 1135-1142, 2008	Systematic review of laparoscopic versus open rectal surgery including both RCTs and non-RCTs and studies published pre-2000. Included RCTs checked for relevance.
Anthuber, M., Fuerst, A., Elser, F., Berger, R., Jauch, K. W., Outcome of laparoscopic surgery for rectal cancer in 101 patients, <i>Diseases of the Colon and Rectum</i> , 46, 1047-1053, 2003	A non-randomised study comparing laparoscopic and open surgery.
Araujo, S. E. A., Seid, V. E., Bertoncini, A., Campos, F. G., Sousa Jr, A., Nahas, S. C., Ceconello, I., Laparoscopic total mesorectal excision for rectal cancer after neoadjuvant treatment: Targeting sphincter-preserving surgery, <i>Hepato-Gastroenterology</i> , 58, 1545-1554, 2011	A non-randomised study comparing laparoscopic and open surgery.
Araujo, S. E., da Silva e Sousa, A. H., Jr., de Campos, F. G., Habr-Gama, A., Dumarco, R. B., Caravatto, P. P., Nahas, S. C., da Silva, J., Kiss, D. R., Gama-Rodrigues, J. J., Conventional approach x laparoscopic abdominoperineal resection for rectal cancer treatment after neoadjuvant chemoradiation: results of a prospective randomized trial, <i>Revista do Hospital das Clinicas; Faculdade de Medicina Da Universidade de Sao Paulo</i> , 58, 133-40, 2003	Population not relevant (more than half of the population with early rectal cancer).
Arezzo, A., Passera, R., Salvai, A., Arolfo, S., Allaix, M. E., Schwarzer, G., Morino, M., Laparoscopy for rectal cancer is oncologically adequate: A systematic review and meta-analysis of the literature, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 29, 334-348, 2015	Systematic review of laparoscopic versus open rectal surgery, includes non-RCTs. Included RCTs checked for relevance.
Aziz, O., Constantinides, V., Tekkis, P. P., Athanasiou, T., Purkayastha, S., Paraskeva, P., Darzi, A. W., Heriot, A. G., Laparoscopic versus open surgery for rectal cancer: A meta-analysis, <i>Annals of Surgical Oncology</i> , 13, 413-424, 2006	Systematic review of laparoscopic versus open rectal surgery including both RCTs and non-RCTs and studies published pre-2000. Included RCTs checked for relevance.
Baek, J. H., Pastor, C., Pigazzi, A., Robotic and laparoscopic total mesorectal excision for rectal cancer: A case-matched study, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 25, 521-525, 2011	Population not according to protocol :almost half of the participants with TNM stage 0 or I cancer.
Baek, S. J., Al-Asari, S., Jeong, D. H., Hur, H., Min, B. S., Baik, S. H., Kim, N. K., Robotic versus laparoscopic coloanal anastomosis with	Non-randomised study comparing robotic versus laparoscopic surgery. RCT evidence is available for critical outcomes, apart from overall survival, therefore, data from non-randomised studies will



or without intersphincteric resection for rectal cancer, <i>Surgical Endoscopy</i> , 27, 4157-63, 2013	only be considered for overall survival. This study does not report overall survival.
Baek, S. J., Kim, S. H., Cho, J. S., Shin, J. W., Kim, J., Robotic versus conventional laparoscopic surgery for rectal cancer: a cost analysis from a single institute in Korea, <i>World Journal of Surgery</i> , 36, 2722-9, 2012	A non-randomised study comparing robotic versus laparoscopic surgery but no critical outcomes of interest reported.
Baik, S. H., Kwon, H. Y., Kim, J. S., Hur, H., Sohn, S. K., Cho, C. H., Kim, H., Robotic versus laparoscopic low anterior resection of rectal cancer: Short-term outcome of a prospective comparative study, <i>Annals of Surgical Oncology</i> , 16, 1480-1487, 2009	Non-randomised study comparing robotic versus laparoscopic surgery. RCT evidence is available for critical outcomes, apart from overall survival, therefore, data from non-randomised studies will only be considered for overall survival. This study does not report overall survival.
Baik, Sh, Gincherman, M, Mutch, Mg, Birnbaum, Eh, Fleshman, Jw, Laparoscopic vs open resection for patients with rectal cancer: comparison of perioperative outcomes and long-term survival, <i>Diseases of the Colon and Rectum</i> , 54, 6-14, 2011	A non-randomised study comparing laparoscopic and open surgery.
Baker, R. P., White, E. E., Titu, L., Duthie, G. S., Lee, P. W. R., Monson, J. R. T., Does laparoscopic abdominoperineal resection of the rectum compromise long-term survival?, <i>Diseases of the Colon and Rectum</i> , 45, 1481-1485, 2002	A non-randomised study comparing laparoscopic and open surgery.
Barendse RM, Musters GD, de Graaf EJR, van den Broek FJC, Consten ECJ, Doornebosch PG, et al. Randomised controlled trial of transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal adenomas (TREND Study). <i>Gut</i> . 2018;67(5):837-46.	A systematic review of RCTs and non-RCTs; included RCTs checked
Bianchi, P. P., Ceriani, C., Locatelli, A., Spinoglio, G., Zampino, M. G., Sonzogni, A., Crosta, C., Andreoni, B., Robotic versus laparoscopic total mesorectal excision for rectal cancer: a comparative analysis of oncological safety and short-term outcomes, <i>Surg Endosc</i> , 24, 2888-94, 2010	Non-randomised study comparing robotic versus laparoscopic surgery. RCT evidence is available for critical outcomes, apart from overall survival, therefore, data from non-randomised studies will only be considered for overall survival. This study does not report overall survival.
Boller, A. M., Nelson, H., Colon and rectal cancer: Laparoscopic or open?, <i>Clinical Cancer Research</i> , 13, 6894S-6896S, 2007	A non-randomised study comparing laparoscopic and open surgery.
Boutros, M., Hippalgaonkar, N., Silva, E., Allende, D., Wexner, S. D., Berho, M., Laparoscopic resection of rectal cancer results in higher lymph node yield and better short-term outcomes than open surgery: A large single-center comparative study, <i>Diseases of the Colon and Rectum</i> , 56, 679-688, 2013	A non-randomised study comparing laparoscopic and open surgery.
Breukink, S., Pierie, J., Wiggers, T., Laparoscopic versus open total mesorectal excision for rectal cancer, <i>Cochrane Database of Systematic Reviews</i> , (4) (no pagination), 2006	A non-randomised study comparing laparoscopic and open surgery.
Capussotti, L., Massucco, P., Muratore, A., Amisano, M., Bima, C., Zorzi, D., Laparoscopy as a prognostic factor in curative resection for node positive colorectal cancer: results for a	A non-randomised study comparing laparoscopic and open surgery.

single-institution nonrandomized prospective trial, <i>Surgical Endoscopy</i> , 18, 1130-5, 2004	
Chen K, Xie G, Zhang Q, Shen Y, Zhou T. Comparison of short-course with long-course preoperative neoadjuvant therapy for rectal cancer: A meta-analysis. <i>J Cancer Res Ther</i> . 2018;14(Supplement):S224-S31.	Wrong comparison: (comparison relevant for review question ): Systematic review and meta-analysis of studies comparing preoperative CRT with or without additional CT.
Chen, C. C., Lai, Y. L., Jiang, J. K., Chu, C. H., Huang, I. P., Chen, W. S., Cheng, A. Y. M., Yang, S. H., Transanal Total Mesorectal Excision Versus Laparoscopic Surgery for Rectal Cancer Receiving Neoadjuvant Chemoradiation: A Matched Case-Control Study, <i>Annals of Surgical Oncology</i> , 23, 1169-1176, 2016	Non-randomised study comparing TaTME to laparoscopic surgery. Evidence on critical outcomes already available from a RCT.
Chen, H., Zhao, L., An, S., Wu, J., Zou, Z., Liu, H., Li, G., Laparoscopic Versus Open Surgery Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Meta-analysis, <i>Journal of Gastrointestinal Surgery</i> , 18, 617-626, 2014	Systematic review of laparoscopic versus open rectal surgery including both RCTs and non-RCTs. Included RCTs checked for relevance.
Chen, K., Cao, G., Chen, B., Wang, M., Xu, X., Cai, W., Xu, Y., Xiong, M., Laparoscopic versus open surgery for rectal cancer: A meta-analysis of classic randomized controlled trials and high-quality Nonrandomized Studies in the last 5 years, <i>International Journal of Surgery</i> , 39, 1-10, 2017	Systematic review of laparoscopic versus open rectal surgery including both RCTs and non-RCTs. Included RCTs checked for relevance.
Chen, W., Li, Q., Qiu, P., Jiang, L., Fu, Z., Fan, Y., Li, D., Liu, P., Tang, L., Comparison of perioperative outcomes between laparoscopic and open surgery for mid-low rectal cancer with total mesorectal excision following neoadjuvant chemoradiotherapy, <i>Journal of Cancer Research and Therapeutics</i> , 12, C199-C204, 2016	A non-randomised study comparing laparoscopic and open surgery.
Chen, Y., Guo, R., Xie, J., Liu, Z., Shi, P., Ming, Q., Laparoscopy combined with transanal endoscopic microsurgery for rectal cancer: A prospective, single-blinded, randomized clinical trial, <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 25, 399-402, 2015	Population not relevant. More than half of the participants with early rectal cancer (Duke's A).
Chi, P., Huang, S. H., Lin, H. M., Lu, X. R., Huang, Y., Jiang, W. Z., Xu, Z. B., Chen, Z. F., Sun, Y. W., Ye, D. X., Laparoscopic Transabdominal Approach Partial Intersphincteric Resection for Low Rectal Cancer: Surgical Feasibility and Intermediate-Term Outcome, <i>Annals of Surgical Oncology</i> , 22, 944-951, 2015	A non-randomised study comparing laparoscopic and open surgery.
Chiu, H. H., Chen, J. B., Wang, H. M., Tsai, C. Y., Laparoscopic abdominoperineal resection for low rectal cancer, <i>Formosan Journal of Surgery</i> , 35, 23-27, 2002	A non-randomised study comparing laparoscopic and open surgery.
Cho, M. S., Baek, S. J., Hur, H., Min, B. S., Baik, S. H., Lee, K. Y., Kim, N. K., Short and long-term outcomes of robotic versus laparoscopic total mesorectal excision for rectal cancer: a case-matched retrospective study, <i>Medicine</i> , 94, e522, 2015	Population not according to the protocol: >40% of the population with TNM stage 0 or I cancer.

Cleary RK, Morris AM, Chang GJ, Halverson AL. Controversies in Surgical Oncology: Does the Minimally Invasive Approach for Rectal Cancer Provide Equivalent Oncologic Outcomes Compared with the Open Approach? <i>Ann Surg Oncol</i> . 2018;25(12):3587-95.	Systematic review of RCTs. All included studies are either included in our review or are too old for inclusion in our review.
Collinson, F. J., Jayne, D. G., Pigazzi, A., Tsang, C., Barrie, J. M., Edlin, R., Garbett, C., Guillou, P., Holloway, I., Howard, H., Marshall, H., McCabe, C., Pavitt, S., Quirke, P., Rivers, C. S., Brown, J. M., An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer, <i>International Journal of Colorectal Disease</i> , 27, 233-41, 2012	The summary of the ROLARR trial protocol. No results presented.
Cui, Z. L., Sun, X., Song, X. L., Zhang, Y. D. Feasibility study of neoadjuvant XELOX for local advanced lower rectal cancer. <i>Chinese journal of cancer prevention and treatment</i> . 2017; 1091-1093.	Wrong comparison; study does not compare surgical techniques
Da Luz Moreira, A., Mor, I., Geisler, D. P., Remzi, F. H., Kiran, R. P., Laparoscopic resection for rectal cancer: A case-matched study, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 25, 278-283, 2011	A non-randomised study comparing laparoscopic and open surgery.
D'Ambrosio G, Picchetto A, Campo S, Palma R, Panetta C, De Laurentis F, et al. Quality of life in patients with loco-regional rectal cancer after ELRR by TEM versus VLS TME after nChRT: long-term results. <i>Surg Endosc</i> . 2019;33(3):941-8.	Wrong comparison: (comparison relevant for review question what is the most effective treatment for early rectal cancer?)
D'Annibale, A., Morpurgo, E., Fiscon, V., Trevisan, P., Sovernigo, G., Orsini, C., Guidolin, D., Robotic and laparoscopic surgery for treatment of colorectal diseases, <i>Dis Colon Rectum</i> , 47, 2162-8, 2004	Population includes people with both colonic and rectal tumours as well as benign and malignant tumours and results are not stratified.
D'Annibale, A., Pernazza, G., Monsellato, I., Pende, V., Lucandri, G., Mazzocchi, P., Alfano, G., Total mesorectal excision: A comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 27, 1887-1895, 2013	Not clear if population is according to the protocol: >50% T0-2 and 70% N0 most assumed to be outside the population of interest.
Dat, Anthony D, Poon, Flora, Robotic surgery for rectal cancer, <i>Cochrane Database of Systematic Reviews</i> , 2011	A protocol for a Cochrane systematic review. No full text has been published.
Day, W., Lau, P. Y. Y., Li, K. M., Kwok, S. Y., Yip, A. W. C., Clinical outcome of open and laparoscopic surgery in Dukes'B and C rectal cancer: Experience from a regional hospital in Hong Kong, <i>Hong Kong Medical Journal</i> , 17, 26-32, 2011	A non-randomised study comparing laparoscopic and open surgery.
de'Angelis, N., Portigliotti, L., Azoulay, D., Brunetti, F., Transanal total mesorectal excision for rectal cancer: a single center experience and systematic review of the literature, <i>Langenbeck's Archives of Surgery</i> , 400, 945-959, 2015	Non-randomised study comparing TaTME to laparoscopic surgery. Evidence on critical outcomes already available from a RCT.

Deijen, C. L., Velthuis, S., Tsai, A., Mavroveli, S., de Lange-de Klerk, E. S., Sietses, C., Tuynman, J. B., Lacy, A. M., Hanna, G. B., Bonjer, H. J., COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer, <i>Surgical Endoscopy</i> , 30, 3210-5, 2016	A protocol of the COLOR III trial. This trial is still recruiting and no results have been published yet.
Delaney, C.P., Lynch, A.C., Senagore, A.J., Fazio, V.W., Comparison of robotically performed and traditional laparoscopic colorectal surgery, <i>Diseases of the Colon and Rectum</i> , 46, 1633-1639, 2003	A case-series of 6 robotic surgeries and 6 laparoscopic surgeries of both colon and rectum tumours.
Denost, Q., Adam, J. P., Rullier, A., Buscail, E., Laurent, C., Rullier, E., Perineal transanal approach: A new standard for laparoscopic sphincter-saving resection in low rectal cancer, a randomized trial, <i>Annals of Surgery</i> , 260, 993-999, 2014	The Bordeaux' trial is included in the review, however, this publication does not report any additional outcomes.
Denost Q, Loughlin P, Chevalier R et al. (2017) Transanal versus abdominal low rectal dissection for rectal cancer: long-term results of the Bordeaux' randomized trial. <i>Surgical Endoscopy and Other Interventional Techniques</i> 1-9	This publication is a duplicate of the included trial: Denost et al., 2018. This publication record the EPub record..
Denoya, P., Wang, H., Sands, D., Nogueras, J., Weiss, E., Wexner, S. D., Short-term outcomes of laparoscopic total mesorectal excision following neoadjuvant chemoradiotherapy, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 24, 933-938, 2010	A non-randomised study comparing laparoscopic and open surgery.
DeSouza, A. L., Prasad, L. M., Ricci, J., Park, J. J., Marecik, S. J., Zimmern, A., Blumetti, J., Abcarian, H., A comparison of open and robotic total mesorectal excision for rectal adenocarcinoma, <i>Diseases of the Colon and Rectum</i> , 54, 275-282, 2011	Non-randomised study comparing robotic versus laparoscopic surgery. RCT evidence is available for critical outcomes, apart from overall survival, therefore, data from non-randomised studies will only be considered for overall survival. This study does not report overall survival.
Ding, K. F., Chen, R., Zhang, J. L., Li, J., Xu, Y. Q., Lv, L., Wang, X. C., Sun, L. F., Wang, J. W., Zheng, S., Zhang, S. Z., Laparoscopic surgery for the curative treatment of rectal cancer: Results of a Chinese three-center case-control study, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 23, 854-861, 2009	A non-randomised study comparing laparoscopic and open surgery.
Draeger T, Volkel V, Gerken M, Klinkhammer-Schalke M, Furst A. Long-term oncologic outcomes after laparoscopic versus open rectal cancer resection: a high-quality population-based analysis in a Southern German district. <i>Surg Endosc</i> . 2018;32(10):4096-104.	A non-randomised study comparing laparoscopic and open surgery.
Dural, A. C., Keskin, M., Balik, E., Akici, M., Kunduz, E., Yamaner, S., Asoglu, O., Gulluoglu, M., Bugra, D., The role of the laparoscopy on circumferential resection margin positivity in patients with rectal cancer: Long-term outcomes at a single high-volume institution, <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 25, 129-137, 2015	A non-randomised study comparing laparoscopic and open surgery.

Ellis-Clark, J. M., Lumley, J. W., Stevenson, A. R. L., Stitz, R. W., Laparoscopic restorative proctectomy - hybrid approach or totally laparoscopic?, ANZ journal of surgery, 80, 807-812, 2010	A non-randomised study comparing laparoscopic and open surgery.
Feliciotti, F., Guerrieri, M., Paganini, A. M., De Sanctis, A., Campagnacci, R., Perretta, S., D'Ambrosio, G., Lezoche, G., Lezoche, E., Long-term results of laparoscopic vs open resections for rectal cancer for 124 unselected patients, Surgical Endoscopy and Other Interventional Techniques, 17, 1530-1535, 2003	A non-randomised study comparing laparoscopic and open surgery.
Feng B, Lu J, Zhang S, Yan X, Li J, Xue P, et al. Laparoscopic abdominoperineal excision with trans-abdominal individualized levator transection: interim analysis of a randomized controlled trial. Colorectal Dis. 2017;19(7):O246-O52.	Wrong comparison (compares laparoscopic APE vs trans-abdominal individualised levator transection)
Feroci, F., Vannucchi, A., Bianchi, P. P., Cantafio, S., Garzi, A., Formisano, G., Scatizzi, M., Total mesorectal excision for mid and low rectal cancer: Laparoscopic vs robotic surgery, World Journal of Gastroenterology, 22, 3602-3610, 2016	Population not according to protocol: >40% with stage I cancer.
Formisano, G., Marano, A., Bianchi, P. P., Spinoglio, G., Challenges with robotic low anterior resection, Minerva chirurgica, 70, 341-354, 2015	A review of literature on robotic rectal surgery. No additional data/references.
Franks, P. J., Bosanquet, N., Thorpe, H., Brown, J. M., Copeland, J., Smith, A. M., Quirke, P., Guillou, P. J., Clasicc trial participants, Short-term costs of conventional vs laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial), Br J Cancer, 95, 6-12, 2006	Population is people with colorectal cancer, results are not stratified by colon/rectum.
Fujii, S, Inomata, M, Akagi, T, Katayama, H, Mizusawa, J, Saito, S, Saida, Y, Munakata, Y, Sato, T, Bandou, H, Sekimoto, M, Yamamoto, H, Shimada, Y, Kitano, S, Transitional impact of short and long-term outcomes of a randomized controlled trial to evaluate laparoscopic versus open surgery for colorectal cancer from Japan clinical oncology group study JCOG0404, European journal of cancer., 51, S139, 2015	A conference abstract. This trial is on colon cancer.
Fujimoto, Y., Akiyoshi, T., Kuroyanagi, H., Konishi, T., Ueno, M., Oya, M., Yamaguchi, T., Safety and feasibility of laparoscopic intersphincteric resection for very low rectal cancer, Journal of Gastrointestinal Surgery, 14, 645-650, 2010	A non-randomised study comparing laparoscopic and open surgery.
Ge, L, Wang, H, Zhao, Z, Yang, X, Zhao, W, Hati, P, Liu, L, Evaluation of short-term efficacy and safety after laparoscopic resection for mid-low rectal cancer, Zhonghua yi xue za zhi, 92, 98-101, 2012	A non-randomised study comparing laparoscopic and open surgery.
Gezen, C., Altuntas, Y. E., Kement, M., Aksakal, N., Okkabaz, N., Vural, S., Oncel, M., Laparoscopic and conventional resections for low rectal cancers: A retrospective analysis on	A non-randomised study comparing laparoscopic and open surgery.

perioperative outcomes, sphincter preservation, and oncological results, <i>Journal of Laparoendoscopic and Advanced Surgical Techniques</i> , 22, 625-630, 2012	
Gezen, C., Altuntas, Y. E., Kement, M., Vural, S., Civil, O., Okkabaz, N., Aksakal, N., Oncel, M., Complete versus partial mobilization of splenic flexure during laparoscopic low anterior resection for rectal tumors: a comparative study, <i>Journal of Laparoendoscopic &amp; Advanced Surgical Techniques. Part A</i> , 22, 392-6, 2012	A non-randomised study comparing laparoscopic and open surgery.
Ghezzi, T. L., Luca, F., Valvo, M., Corleta, O. C., Zuccaro, M., Cenciarelli, S., Biffi, R., Robotic versus open total mesorectal excision for rectal cancer: Comparative study of short and long-term outcomes, <i>European Journal of Surgical Oncology</i> , 40, 1072-1079, 2014	Population not according to protocol: >40% with stage 0 or I cancer.
Gijn, W, Marijnen, Ca, Nagtegaal, Id, Kranenbarg, Em, Putter, H, Wiggers, T, Rutten, Hj, Pählman, L, Glimelius, B, Velde, Cj, Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial, <i>The lancet. Oncology</i> , 12, 575-582, 2011	A non-randomised study comparing laparoscopic and open surgery.
Gleeson, F. C., Clain, J. E., Rajan, E., Topazian, M., Wang, K. K., Levy, M. J., Surveillance EUS FNA following transanal excision of primary rectal cancer facilitates early detection of local recurrence, <i>Gastrointestinal Endoscopy</i> , 1), AB170, 2011	A non-randomised study comparing laparoscopic and open surgery.
Gong, J., Shi, D. B., Li, X. X., Cai, S. J., Guan, Z. Q., Xu, Y., Short-term outcomes of laparoscopic total mesorectal excision compared to open surgery, <i>World Journal of Gastroenterology</i> , 18, 7308-7313, 2012	Population not according to protocol: people with cT3-4 and cTxN tumours were excluded.
Gonzalez, Q. H., Rodriguez-Zentner, H. A., Moreno-Berber, J. M., Vergara-Fernandez, O., de Leon, H. T. C., Lopez, R. F., Jonguitud, L. A., Ramos, R., Castaneda-Argaiz, R., Laparoscopic vs. open total mesorectal excision for treatment of rectal cancer, <i>Revista de Investigacion Clinica</i> , 60, 205-211, 2008	A non-randomised study comparing laparoscopic and open surgery.
Gonzalez, Q. H., Rodriguez-Zentner, H. A., Moreno-Berber, J. M., Vergara-Fernandez, O., Tapia-Cid de Leon, H., Jonguitud, L. A., Ramos, R., Moreno-Lopez, J. A., Laparoscopic versus open total mesorectal excision: a nonrandomized comparative prospective trial in a tertiary center in Mexico City, <i>American Surgeon</i> , 75, 33-8, 2009	A non-randomised study comparing laparoscopic and open surgery.
Gouvas, N., Tsiaoussis, J., Pechlivanides, G., Zervakis, N., Tzortzinis, A., Avgerinos, C., Dervenis, C., Xynos, E., Laparoscopic or open surgery for the cancer of the middle and lower rectum short-term outcomes of a comparative non-randomised study, <i>International Journal of Colorectal Disease</i> , 24, 761-769, 2009	A non-randomised study comparing laparoscopic and open surgery.

Gresham, G., Cheung, W. Y., Speers, C., Woods, R., Kennecke, H., Time to adjuvant chemotherapy and survival outcomes among patients with stage 2 to 3 rectal cancer treated with preoperative chemoradiation, <i>Clinical Colorectal Cancer</i> , 14, 41-5, 2015	A non-randomised study comparing laparoscopic and open surgery.
Guillermé, F., Kurtz, J. E., Clavier, J. B., Schumacher, C., Brigand, C., Noel, G., A retrospective outcome study in the elder patient with locally advanced rectal cancer treated with hypofractionated or conventional preoperative radiotherapy, <i>Journal of Solid Tumors</i> , 3, 25-34, 2013	A non-randomised study comparing laparoscopic and open surgery.
Gunka, I., Dostalík, J., Martinek, L., Gunkova, P., Mazur, M., Vavra, P., Long-term results of laparoscopic versus open surgery for nonmetastatic colorectal cancer, <i>Acta chirurgica Belgica</i> , 112, 139-147, 2012	A non-randomised study comparing laparoscopic and open surgery.
Haddock, M. G., Gunderson, L. L., Nelson, H., Cha, S. S., Devine, R. M., Dozois, R. R., Wolff, B. G., Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients, <i>International journal of radiation oncology, biology, physics</i> , 49, 1267-74, 2001	A non-randomised study comparing laparoscopic and open surgery.
Hall, N. R., Finan, P. J., al-Jaberi, T., Tsang, C. S., Brown, S. R., Dixon, M. F., Quirke, P., Circumferential margin involvement after mesorectal excision of rectal cancer with curative intent. Predictor of survival but not local recurrence?, <i>Diseases of the Colon &amp; Rectum</i> , 41, 979-83, 1998	A non-randomised study comparing laparoscopic and open surgery.
Hamel, C. T., Metzger, J., Curti, G., Degen, L., Harder, F., von Flue, M. O., Ileocecal reservoir reconstruction after total mesorectal excision: functional results of the long-term follow-up, <i>International Journal of Colorectal Disease</i> , 19, 574-9, 2004	A non-randomised study comparing laparoscopic and open surgery.
Han, K. S., Sohn, D. K., Kim, D. Y., Kim, B. C., Hong, C. W., Chang, H. J., Kim, S. Y., Baek, J. Y., Park, S. C., Kim, M. J., Oh, J. H., Endoscopic criteria for evaluating tumor stage after preoperative chemoradiation therapy in locally advanced rectal cancer, <i>Cancer Research and Treatment</i> , 48, 567-573, 2016	A non-randomised study comparing laparoscopic and open surgery.
Han, S. L., Zeng, Q. Q., Shen, X., Zheng, X. F., Guo, S. C., Yan, J. Y., The indication and surgical results of local excision following radiotherapy for low rectal cancer, <i>Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland</i> , 12, 1094-1098, 2010	A non-randomised study comparing laparoscopic and open surgery.
Hartley, J. E., Mehigan, B. J., Qureshi, A. E., Duthie, G. S., Lee, P. W., Monson, J. R., Total mesorectal excision: assessment of the laparoscopic approach, <i>Diseases of the Colon &amp; Rectum</i> , 44, 315-21, 2001	A non-randomised study comparing laparoscopic and open surgery.
Hida K, Okamura R, Sakai Y, Konishi T, Akagi T, Yamaguchi T, et al. Open versus	A non-randomised study comparing laparoscopic and open surgery.

Laparoscopic Surgery for Advanced Low Rectal Cancer: A Large, Multicenter, Propensity Score Matched Cohort Study in Japan. <i>Annals of surgery</i> . 2018;268(2):318-24.	
Hida, K., Okamura, R., Sakai, Y., Konishi, T., Akagi, T., Yamaguchi, T., Akiyoshi, T., Fukuda, M., Yamamoto, S., Yamamoto, M., Nishigori, T., Kawada, K., Hasegawa, S., Morita, S., Watanabe, M., Open versus Laparoscopic Surgery for Advanced Low Rectal Cancer: A Large, Multicenter, Propensity Score Matched Cohort Study in Japan, <i>Annals of Surgery.</i> , 16, 2017	A non-randomised study comparing laparoscopic and open surgery.
Holmer C, Kreis ME. Systematic review of robotic low anterior resection for rectal cancer. <i>Surg Endosc</i> . 2018;32(2):569-81.	A systematic review of studies evaluating robotic surgery (included studies checked and accounted for)
Hong, D, Tabet, J, Anvari, M, Laparoscopic vs. open resection for colorectal adenocarcinoma, <i>Diseases of the Colon and Rectum</i> , 44, 10-8; discussion 18-9, 2001	A non-randomised study comparing laparoscopic and open surgery.
Hu, J. J., Liang, J. W., Wang, Z., Zhang, X. M., Zhou, H. T., Hou, H. R., Zhou, Z. X., Short-term outcomes of laparoscopically assisted surgery for rectal cancer following neoadjuvant chemoradiotherapy: A single-center experience, <i>Journal of Surgical Research</i> , 187, 438-444, 2014	A non-randomised study comparing laparoscopic and open surgery.
Huang, Mj, Liang, Ji, Wang, H, Kang, L, Deng, Yh, Wang, Jp, Laparoscopic-assisted versus open surgery for rectal cancer: a meta-analysis of randomized controlled trials on oncologic adequacy of resection and long-term oncologic outcomes (Structured abstract), <i>International Journal of Colorectal Disease</i> <i>Int J Colorectal Dis</i> , 26, 415-421, 2011	Systematic review of laparoscopic versus open rectal surgery, not all studies are relevant to our review according to PICO in protocol.
Huang, Y. M., Huang, Y. J., Wei, P. L., Outcomes of robotic versus laparoscopic surgery for mid and low rectal cancer after neoadjuvant chemoradiation therapy and the effect of learning curve, <i>Medicine (United States)</i> , 96 (40) (no pagination), 2017	Non-randomised study comparing robotic versus laparoscopic surgery. RCT evidence is available for critical outcomes, apart from overall survival, therefore, data from non-randomised studies will only be considered for overall survival. This study does not report overall survival.
Ishihara, S., Watanabe, T., Fukushima, Y., Akahane, T., Horiuchi, A., Shimada, R., Nakamura, K., Hayama, T., Yamada, H., Nozawa, K., Matsuda, K., Hashiguchi, Y., Safety and factors contributing to the difficulty of laparoscopic surgery for rectal cancer treated with preoperative chemoradiotherapy, <i>Techniques in Coloproctology</i> , 18, 247-55, 2014	A non-randomised study comparing laparoscopic and open surgery.
Jackson, T D, Kaplan, G G, Arena, G, Page, J H, Rogers, S O, Laparoscopic versus open resection for colorectal cancer: a metaanalysis of oncologic outcomes (Structured abstract), <i>Journal of the American College of Surgeons</i> , 204, 439-446, 2007	Systematic review of laparoscopic versus open colorectal surgery, includes both colon and rectal cancers, included RCTs checked for relevance.
Jayne, D. G., Guillou, P. J., Thorpe, H., Quirke, P., Copeland, J., Smith, A. M. H., Heath, R. M., Brown, J. M., Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-	This trial (CLASICC) is included in this review, however, this paper does not report any additional outcomes.



Year results of the UK MRC CLASICC trial group, <i>Journal of Clinical Oncology</i> , 25, 3061-3068, 2007	
Jefferies, M. T., Evans, M. D., Hilton, J., Chandrasekaran, T. V., Beynon, J., Khot, U., Oncological outcome after laparoscopic abdominoperineal excision of the rectum, <i>Colorectal Disease</i> , 14, 967-971, 2012	A non-randomised study comparing laparoscopic and open surgery.
Jeong, W. K., Park, J. W., Choi, H. S., Jeong, S. Y., Oh, J. H., Comparison of peristomal adhesion formation between laparoscopic and open low anterior resection of rectal cancer, <i>World Journal of Surgery</i> , 37, 2683-2687, 2013	A non-randomised study comparing laparoscopic and open surgery.
Jiang, J. B., Jiang, K., Wang, J. J., Dai, Y., Xie, F. B., Li, X. M., Short-term and Long-term Outcomes Regarding Laparoscopic Versus Open Surgery for Low Rectal Cancer: A Systematic Review and Meta-Analysis, <i>Surgical Laparoscopy, Endoscopy &amp; Percutaneous Techniques</i> , 25, 286-96, 2015	Systematic review of laparoscopic versus open rectal surgery including both RCTs and non-RCTs. Included RCTs checked for relevance.
Jimenez Rodriguez, R. M., Diaz Pavon, J. M., de La Portilla de Juan, F., Prendes Sillero, E., Hisnard Cadet Dussort, J. M., Padillo, J., [Prospective randomised study: robotic-assisted versus conventional laparoscopic surgery in colorectal cancer resection], <i>Cir Esp</i> , 89, 432-8, 2011	Full text in Spanish.
Jimenez-Rodriguez, R., Quezada, F., Lynn, P., Strombon, P., Paty, P. S., Martin, W. R., Garcia Aguilar, J. Similar short-term oncological outcomes for robotic and open total mesorectal excision in patients with rectal cancer. 2018 American Society of Colon and Rectal Surgeons Annual Meeting, ASCRS 2018. United States	A conference abstract
Jones K, Qassem MG, Sains P, Baig MK, Sajid MS. Robotic total meso-rectal excision for rectal cancer: A systematic review following the publication of the ROLARR trial. <i>World J Gastrointest Oncol</i> . 2018;10(11):449-64.	Systematic review evaluating the effectiveness of robotic TME. Included studies checked for relevance.
Kang, J., Yoon, K. J., Min, B. S., Hur, H., Baik, S. H., Kim, N. K., Lee, K. Y., The impact of robotic surgery for mid and low rectal cancer: a case-matched analysis of a 3-arm comparison--open, laparoscopic, and robotic surgery, <i>Annals of Surgery</i> , 257, 95-101, 2013	Population not according to protocol, the exact proportion are unclear but T3-4 or TxN appear to be less than half of the population.
Katsuno, H., Shiomi, A., Ito, M., Koide, Y., Maeda, K., Yatsuka, T., Hase, K., Komori, K., Minami, K., Sakamoto, K., Saida, Y., Saito, N., Comparison of symptomatic anastomotic leakage following laparoscopic and open low anterior resection for rectal cancer: a propensity score matching analysis of 1014 consecutive patients, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 30, 2848-2856, 2016	A non-randomised study comparing laparoscopic and open surgery.
Keller, D. S., Champagne, B. J., Reynolds, H. L., Stein, S. L., Delaney, C. P., Cost-effectiveness of laparoscopy in rectal cancer, <i>Diseases of the Colon and Rectum</i> , 57, 564-569, 2014	A non-randomised study comparing laparoscopic and open surgery.

Keller, D. S., Khorgami, Z., Swendseid, B., Champagne, B. J., Reynolds, H. L., Jr., Stein, S. L., Delaney, C. P., Laparoscopic and converted approaches to rectal cancer resection have superior long-term outcomes: a comparative study by operative approach, <i>Surgical Endoscopy</i> , 28, 1940-8, 2014	A non-randomised study comparing laparoscopic and open surgery.
Keller, D. S., Park, K. J., Augestad, K. M., Delaney, C. P., Integration of open and laparoscopic approaches for rectal cancer resection: Oncologic and short-term outcomes, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 28, 2129-2136, 2014	A non-randomised study comparing laparoscopic and open surgery.
Kellokumpu, I. H., Kairaluoma, M. I., Nuorva, K. P., Kautiainen, H. J., Jantunen, I. T., Short - and long-term outcome following laparoscopic versus open resection for carcinoma of the rectum in the multimodal setting, <i>Diseases of the Colon and Rectum</i> , 55, 854-863, 2012	A non-randomised study comparing laparoscopic and open surgery.
Keskin, M., Akici, M., Agcaoglu, O., Yegen, G., Saglam, E., Bugra, D., Bulut, M. T., Balik, E., Open Versus Laparoscopic Surgery for Rectal Cancer: Single-Center Results of 587 Cases, <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 26, e62-e68, 2016	A non-randomised study comparing laparoscopic and open surgery.
Khaikin, M., Bashankaev, B., Person, B., Cera, S., Sands, D., Weiss, E., Nogueras, J., Vernava, Iii A., Wexner, S. D., Laparoscopic versus open proctectomy for rectal cancer: Patients' outcome and oncologic adequacy, <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 19, 118-122, 2009	A non-randomised study comparing laparoscopic and open surgery.
Kim HJ, Choi GS, Park JS, Park SY, Yang CS, Lee HJ. The impact of robotic surgery on quality of life, urinary and sexual function following total mesorectal excision for rectal cancer: a propensity score-matched analysis with laparoscopic surgery. <i>Colorectal Dis</i> . 2018;20(5):O103-O13.	A non-randomised study comparing laparoscopic and robotic surgery.
Kim MJ, Park SC, Park JW, Chang HJ, Kim DY, Nam BH, et al. Robot-assisted Versus Laparoscopic Surgery for Rectal Cancer: A Phase II Open Label Prospective Randomized Controlled Trial. <i>Annals of surgery</i> . 2018;267(2):243-51.	Outcomes
Kim, J. C., Lim, S. B., Yoon, Y. S., Park, I. J., Kim, C. W., Kim, C. N., Completely abdominal intersphincteric resection for lower rectal cancer: Feasibility and comparison of robot-assisted and open surgery, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 28, 2734-2744, 2014	The cohort in this study is included in another bigger cohort study from the same hospital (see Kim 2016).
Kim, J. G., Heo, Y. J., Son, G. M., Lee, Y. S., Lee, I. K., Suh, Y. J., Cho, H. M., Chun, C. S., Impact of laparoscopic surgery on the long-term outcomes for patients with rectal cancer, <i>ANZ journal of surgery</i> , 79, 817-823, 2009	A non-randomised study comparing laparoscopic and open surgery.
Kim, J. H., Ahn, B. K., Park, S. J., Park, M. I., Kim, S. E., Baek, S. U., Lee, S. H., Park, S. S., Long-term Outcomes of Laparoscopic versus	A non-randomised study comparing laparoscopic and open surgery.

Open Surgery for Rectal Cancer: A Single-center Retrospective Analysis, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 65, 273-282, 2015	
Kim, K. Y., Hwang, D. W., Park, Y. K., Lee, H. S., A single surgeon's experience with 54 consecutive cases of multivisceral resection for locally advanced primary colorectal cancer: can the laparoscopic approach be performed safely?, Surgical Endoscopy, 26, 493-500, 2012	A non-randomised study comparing laparoscopic and open surgery.
King, P. M., Blazeby, J. M., Ewings, P., Franks, P. J., Longman, R. J., Kendrick, A. H., Kipling, R. M., Kennedy, R. H., Randomized clinical trial comparing laparoscopic and open surgery for colorectal cancer within an enhanced recovery programme, Br J Surg, 93, 300-8, 2006	Population is people with colorectal cancer, only a few rectal cancers and results are not stratified by colon/rectum.
King, P. M., Blazeby, J. M., Ewings, P., Kennedy, R. H., Detailed evaluation of functional recovery following laparoscopic or open surgery for colorectal cancer within an enhanced recovery programme, International Journal of Colorectal Disease, 23, 795-800, 2008	Population is people with colorectal cancer, no stratification of results by colon/rectum.
Kitano, S., Inomata, M., Sato, A., Yoshimura, K., Moriya, Y., Japan Clinical Oncology Group, Study, Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404, Japanese Journal of Clinical Oncology, 35, 475-7, 2005	A protocol for the JCOG 0404 trial (population with colon cancer).
Koedam TWA, Veltcamp Helbach M, Penna M, Wijsmuller A, Doornebosch P, van Westreenen HL, et al. Short-term outcomes of transanal completion total mesorectal excision (cTaTME) for rectal cancer: a case-matched analysis. Surg Endosc. 2019;33(1):103-9.	Wrong comparison (a non-randomised study comparing TaTME vs cTaTME)
Koedam, T. W. A., Deijen, C. L., Velthuis, S., Tsai, A., Mavrouveli, S., De Lange-De Klerk, E. S. M., Sietses, C., Tuynman, J. B., Lacy, A. M., Hanna, G. B., Bonjer, H. J., COLOR III trial, Surgical Endoscopy and Other Interventional Techniques, 31 (2 Supplement 1), S376, 2017	A conference abstract. This trial is still recruiting and no results have been published.
Koh, F., Tan, K. K., Lieske, B., Tsang, M., Tsang, C., Koh, D., Endowrist versus wrist: A case-controlled study comparing robotic versus hand-assisted laparoscopic surgery for rectal cancer, Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 24, 452-456, 2014	A non-randomised study comparing robotic versus laparoscopic surgery but no critical outcomes of interest reported.
Koulas, S. G., Pappas-Gogos, G., Spirou, S., Roustanis, E., Tsimogiannis, K. E., Tsirves, G., Tsimoyiannis, E. C., Evaluations of laparoscopic proctocolectomy versus traditional technique in patients with rectal cancer, Journal of the Society of Laparoendoscopic Surgeons, 13, 564-573, 2009	A non-randomised study comparing laparoscopic and open surgery.
Kusano, T., Inomata, M., Hiratsuka, T., Akagi, T., Ueda, Y., Tojigamori, M., Shiroshta, H., Etoh, T., Shiraishi, N., Kitano, S., A comparison of laparoscopic and open surgery following pre-operative chemoradiation therapy for locally	A non-randomised study comparing laparoscopic and open surgery.

advanced lower rectal cancer, Japanese Journal of Clinical Oncology, 44, 305-310, 2014	
Kwak, J. M., Kim, S. H., Kim, J., Son, D. N., Baek, S. J., Cho, J. S., Robotic vs laparoscopic resection of rectal cancer: Short-term outcomes of a case-control study, Diseases of the Colon and Rectum, 54, 151-156, 2011	Non-randomised study comparing robotic versus laparoscopic surgery. RCT evidence is available for critical outcomes, apart from overall survival, therefore, data from non-randomised studies will only be considered for overall survival. This study does not report overall survival.
Lacy, Fb, Fernandez-Hevia, M, Delgado, S, Bravo, R, Tasende, M, Jimenez, M, Diaz, Del Gobbo G, Castells, A, Lacy, Am, Transanal versus laparoscopic total mesorectal excision for rectal cancer: comparison of the 2-year follow-up, Surgical endoscopy and other interventional techniques., 30, S26, 2016	A conference abstract.
Lai, Yi, Chu, Cc, Huang, Ip, Chen, Cc, Cheng, Ts, Chen, Cm, Comparison of laparoscopic versus conventional surgery for rectal cancer after neoadjuvant chemoradiation-a matched case-controlled study, Surgical endoscopy and other interventional techniques., 29, S155, 2015	A non-randomised study comparing laparoscopic and open surgery.
Lam, H. D., Stefano, M., Tran-Ba, T., Tinton, N., Cambier, E., Navez, B., Laparoscopic versus open techniques in rectal cancer surgery: A retrospective analysis of 121 sphincter-saving procedures in a single institution, Surgical Endoscopy and Other Interventional Techniques, 25, 454-462, 2011	A non-randomised study comparing laparoscopic and open surgery.
Larson, D. W., Boostrom, S. Y., Cima, R. R., Pemberton, J. H., Larson, D. R., Dozois, E. J., Laparoscopic surgery for rectal cancer: Short-term benefits and oncologic outcomes using more than one technique, Techniques in Coloproctology, 14, 125-131, 2010	A non-randomised study comparing laparoscopic and open surgery.
Laurent, C., Leblanc, F., Wutrich, P., Scheffler, M., Rullier, E., Laparoscopic versus open surgery for rectal cancer: long-term oncologic results, Annals of Surgery, 250, 54-61, 2009	A non-randomised study comparing laparoscopic and open surgery.
Laurent, C., Paumet, T., Leblanc, F., Denost, Q., Rullier, E., Intersphincteric resection for low rectal cancer: laparoscopic vs open surgery approach, Colorectal Disease, 14, 35-41; discussion 42-3, 2012	A non-randomised study comparing laparoscopic and open surgery.
Law WL, Foo DCC. Comparison of early experience of robotic and transanal total mesorectal excision using propensity score matching. Surg Endosc. 2019;33(3):757-63.	A non-randomised study comparing robotic and TaTME surgery.
Law, W. L., Poon, J. T. C., Fan, J. K. M., Lo, S. H., Comparison of outcome of open and laparoscopic resection for stage II and stage III rectal cancer, Annals of Surgical Oncology, 16, 1488-1493, 2009	A non-randomised study comparing laparoscopic and open surgery.
Lee SH, Kim DH, Lim SW. Robotic versus laparoscopic intersphincteric resection for low rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2018;33(12):1741-53.	A systematic review evaluating studies comparing robotic with laparoscopic. Included studies checked

Lelong, B., Bege, T., Esterni, B., Guiramand, J., Turrini, O., Moutardier, V., Magnin, V., Monges, G., Pernoud, N., Blache, J. L., Giovannini, M., Delpero, J. R., Short-term outcome after laparoscopic or open restorative mesorectal excision for rectal cancer: A comparative cohort study, <i>Diseases of the Colon and Rectum</i> , 50, 176-183, 2007	A non-randomised study comparing laparoscopic and open surgery.
Leung, K. L., Kwok, S. P., Lam, S. C., Lee, J. F., Yiu, R. Y., Ng, S. S., Lai, P. B., Lau, W. Y., Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial, <i>Lancet</i> , 363, 1187-92, 2004	This study is among people with rectosigmoid cancer, therefore, not the right population.
Leung, K. L., Lai, P. B., Ho, R. L., Meng, W. C., Yiu, R. Y., Lee, J. F., Lau, W. Y., Systemic cytokine response after laparoscopic-assisted resection of rectosigmoid carcinoma: A prospective randomized trial, <i>Ann Surg</i> , 231, 506-11, 2000	This study is among people with rectosigmoid cancer, therefore, not the right population.
Leung, Kl, Yiu, Ry, Lai, Pb, Lee, Jf, Thung, Kh, Lau, Wy, Laparoscopic-assisted resection of colorectal carcinoma: five-year audit, <i>Diseases of the Colon and Rectum</i> , 42, 327-32; discussion 332-3, 1999	A non-randomised study comparing laparoscopic and open surgery.
Levic, K., Donatsky, A. M., Bulut, O., Rosenberg, J., A Comparative Study of Single-Port Laparoscopic Surgery Versus Robotic-Assisted Laparoscopic Surgery for Rectal Cancer, <i>Surgical Innovation</i> , 22, 368-375, 2015	Non-randomised study comparing robotic versus laparoscopic surgery. RCT evidence is available for critical outcomes, apart from overall survival, therefore, data from non-randomised studies will only be considered for overall survival. This study does not report overall survival.
Lezoche, E., Guerrieri, M., De Sanctis, A., Campagnacci, R., Baldarelli, M., Lezoche, G., Paganini, A. M., Long-term results of laparoscopic versus open colorectal resections for cancer in 235 patients with a minimum follow-up of 5 years, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 20, 546-553, 2006	A non-randomised study comparing laparoscopic and open surgery.
Li, S., Chi, P., Lin, H., Lu, X., Huang, Y., Long-term outcomes of laparoscopic surgery versus open resection for middle and lower rectal cancer: An NTCLES study, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 25, 3175-3182, 2011	A non-randomised study comparing laparoscopic and open surgery.
Li, S., Jiang, F., Tu, J., Zheng, X., Long-term oncologic outcomes of laparoscopic versus open surgery for middle and lower rectal cancer, <i>PLoS ONE</i> , 10 (9) (no pagination), 2015	A non-randomised study comparing laparoscopic and open surgery.
Lim, D. R., Bae, S. U., Hur, H., Min, B. S., Baik, S. H., Lee, K. Y., Kim, N. K., Long-term oncological outcomes of robotic versus laparoscopic total mesorectal excision of mid-low rectal cancer following neoadjuvant chemoradiation therapy, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 31, 1728-1737, 2017	Population not according to protocol: 45% of participants in one arm with stage 0-I rectal cancer.
Lin Y, Lin H, Xu Z, Zhou S, Chi P. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy	Wrong comparison (compares preoperative chemoradiotherapy with/without postoperative chemotherapy)

in Clinical Stage T3N0 Low and Mid Rectal Cancer. <i>J Invest Surg.</i> 2018:1-9.	
Liu, F. L., Lin, J. J., Ye, F., Teng, L. S., Hand-assisted laparoscopic surgery versus the open approach in curative resection of rectal cancer, <i>Journal of International Medical Research</i> , 38, 916-922, 2010	Hand-assisted laparoscopic colorectal surgery is rarely performed in England and therefore not relevant for this review.
Liu, L., Cao, Y., Zhang, G., Zhang, L., Wang, P., Gong, J., Long-term outcomes after laparoscopic total mesorectal excision for advanced rectal cancer, <i>South African Journal of Surgery</i> , 49, 186-189, 2011	A non-randomised study comparing laparoscopic and open surgery.
Liu, Y., Lu, X. M., Niu, Y. F., Tao, K. X., Wang, G. B., Application of laparoscopic total mesorectal excision combined with sphincter-preserving surgery in low or ultralow rectal cancer, <i>Journal of Innovative Optical Health Sciences</i> , 9 (5) (no pagination), 2016	A non-randomised study comparing laparoscopic and open surgery.
Liu, Z., Kang, L., Huang, M., Luo, Y., Wang, L., Lan, P., Cui, J., Wang, J., Open surgery against laparoscopic surgery for mid-rectal or low-rectal cancer of male patients: Better postoperative genital function of laparoscopic surgery, <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 25, 444-448, 2015	A non-randomised study comparing laparoscopic and open surgery.
Lujan, J., Parrila, P., Authors' reply: Randomized clinical trial comparing laparoscopic and open surgery in patients with rectal cancer ( <i>Br J Surg</i> 2009; 96: 982-989), <i>British Journal of Surgery</i> , 96, 1496, 2009	Author's reply. The trial this comment refers to is included in the review.
Lujan, J., Valero, G., Biondo, S., Espin, E., Parrilla, P., Ortiz, H., Laparoscopic versus open surgery for rectal cancer: Results of a prospective multicentre analysis of 4,970 patients, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 27, 295-302, 2013	A non-randomised study comparing laparoscopic and open surgery.
Marks, J. H., Montenegro, G. A., Salem, J. F., Shields, M. V., Marks, G. J., Transanal TATA/TME: a case-matched study of taTME versus laparoscopic TME surgery for rectal cancer, <i>Techniques in Coloproctology</i> , 20, 467-473, 2016	Non-randomised study comparing TaTME to laparoscopic surgery. Evidence on critical outcomes already available from a RCT.
Matsuhashi, N., Takahashi, T., Tanahashi, T., Matsui, S., Imai, H., Tanaka, Y., Yamaguchi, K., Osada, S., Yoshida, K., Safety and feasibility of laparoscopic intersphincteric resection for a lower rectal tumor, <i>Oncology Letters</i> , 14, 4142-4150, 2017	A non-randomised study comparing laparoscopic and open surgery.
Matsumoto, A, Arita, K, Tashiro, M, Haruki, S, Usui, S, Laparoscopic versus open resection for rectal cancer (RA and RB) based on 10 year data: results of our hospital study in 217 rectal cancer patients, <i>Surgical endoscopy and other interventional techniques.</i> , 29, S102, 2015	A non-randomised study comparing laparoscopic and open surgery.
Milsom, Jw, Böhm, B, Hammerhofer, Ka, Fazio, V, Steiger, E, Elson, P, A prospective, randomized trial comparing laparoscopic versus conventional techniques in colorectal cancer	Published 1998. Includes both colon and rectal tumours and results are not stratified according to tumour location.

surgery: a preliminary report, Journal of the American College of Surgeons, 187, 46-54; discussion 54-5, 1998	
Mirza, M. S., Longman, R. J., Farrokhyar, F., Sheffield, J. P., Kennedy, R. H., Long-term outcomes for laparoscopic versus open resection of nonmetastatic colorectal cancer, Journal of Laparoendoscopic and Advanced Surgical Techniques, 18, 679-685, 2008	A non-randomised study comparing laparoscopic and open surgery.
Mohamed, Z. K., Law, W. L., Outcome of tumor-specific mesorectal excision for rectal cancer: the impact of laparoscopic resection, World Journal of Surgery, 38, 2168-2174, 2014	A non-randomised study comparing laparoscopic and open surgery.
Morelli, L., Guadagni, S., Lorenzoni, V., Di Franco, G., Cobuccio, L., Palmeri, M., Caprili, G., D'Isidoro, C., Moglia, A., Ferrari, V., Di Candio, G., Mosca, F., Turchetti, G., Robot-assisted versus laparoscopic rectal resection for cancer in a single surgeon's experience: a cost analysis covering the initial 50 robotic cases with the da Vinci Si, International Journal of Colorectal Disease, 31, 1639-48, 2016	Population not according to protocol: only around 40% of population with T3 or N cancer, T4 were excluded.
Morino, M., Allaix, M., Giraudo, G., Corno, F., Garrone, C., Laparoscopic versus open surgery for extraperitoneal rectal cancer: a prospective comparative study, Surgical Endoscopy and Other Interventional Techniques, 19, 1460-1467, 2005	A non-randomised study comparing laparoscopic and open surgery.
Morino, M., Allaix, M. E., Giraudo, G., Corno, F., Garrone, C., Laparoscopic versus open surgery for extraperitoneal rectal cancer: A prospective comparative study, Surgical Endoscopy and Other Interventional Techniques, 19, 1460-1467, 2005	A non-randomised study comparing laparoscopic and open surgery.
Nagasaki, T., Akiyoshi, T., Ueno, M., Fukunaga, Y., Nagayama, S., Fujimoto, Y., Konishi, T., Yamaguchi, T., Laparoscopic salvage surgery for locally recurrent rectal cancer, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 18, 1319-1326, 2014	A non-randomised study comparing laparoscopic and open surgery.
Nakamura, H., Uehara, K., Arimoto, A., Kato, T., Ebata, T., Nagino, M., The feasibility of laparoscopic extended pelvic surgery for rectal cancer, Surgery Today, 46, 950-956, 2016	A non-randomised study comparing laparoscopic and open surgery.
Nakamura, T., Kokuba, Y., Mitomi, H., Onozato, W., Hatate, K., Satoh, T., Ozawa, H., Ihara, A., Watanabe, M., Comparison between the oncologic outcome of laparoscopic surgery and open surgery for T1 and T2 rectosigmoidal and rectal carcinoma: Matched case-control study, Hepato-Gastroenterology, 54, 1094-1097, 2007	A non-randomised study comparing laparoscopic and open surgery.
NCT. Laparoscopic Surgery or Robotic-Assisted Laparoscopic Surgery in Treating Patients With Rectal Cancer That Can Be Removed By Surgery. 2010	A clinical trial record; no results (no data)
NCT. Optimisation of Response for Organ Preservation in Rectal Cancer : neoadjuvant	A clinical trial record; no results (no data)

Chemotherapy and Radiochemotherapy vs. Radiochemotherapy. 2015	
NCT. Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer. 2013	A clinical trial record; no results (no data)
NCT. Preoperative Chemoradiotherapy for Rectal Cancer. 2009	Wrong comparison for this research question. A clinical trial record; no results (no data) (linked to Park et al., 2012 [evidence review C1])
Neijenhuis, Pa, Buurma, M, Reimers, M, Kroon, Hm, Laparoscopic colorectal surgery leads to increased overall survival when compared to a conventional open approach, Surgical endoscopy and other interventional techniques., 29, S104, 2015	A non-randomised study comparing laparoscopic and open surgery.
Ng, S. S. M., Lee, J. F. Y., Yiu, R. Y. C., Li, J. C. M., Hon, S. S. F., Mak, T. W. C., Leung, W. W., Leung, K. L., Long-term oncologic outcomes of laparoscopic versus open surgery for rectal cancer: A pooled analysis of 3 randomized controlled trials, Annals of Surgery, 259, 139-147, 2014	This is a pooled analysis of 3 randomised trials from the same hospital in Hong Kong. The three trials focused on different rectal tumour locations (lower, middle, upper), and the type of surgery was therefore different (APR or AR). All of these trials have been included in this review.
Nienhuser H, Heger P, Schmitz R, Kulu Y, Diener MK, Klose J, et al. Short- and Long-Term Oncological Outcome After Rectal Cancer Surgery: a Systematic Review and Meta-Analysis Comparing Open Versus Laparoscopic Rectal Cancer Surgery. J Gastrointest Surg. 2018;22(8):1418-33.	A systematic review and meta-analysis comparing laparoscopic and open surgery. Included studies checked.
Nonaka, T., Fukuda, A., Maekawa, K., Nagayoshi, S., Tokunaga, T., Takatsuki, M., Kitajima, T., Taniguchi, K., Fujioka, H., Clinical and oncological outcomes of laparoscopic versus open surgery for advanced rectal cancer, Anticancer Research, 36, 5419-5424, 2016	A non-randomised study comparing laparoscopic and open surgery.
Odermatt, M., Flashman, K., Khan, J., Parvaiz, A., Laparoscopic-assisted abdominoperineal resection for low rectal cancer provides a shorter length of hospital stay while not affecting the recurrence or survival: a propensity score-matched analysis, Surgery Today, 46, 798-806, 2016	A non-randomised study comparing laparoscopic and open surgery.
Ohtani H, Maeda K, Nomura S, Shinto O, Mizuyama Y, Nakagawa H, et al. Meta-analysis of Robot-assisted Versus Laparoscopic Surgery for Rectal Cancer. In Vivo. 2018;32(3):611-23.	A systematic review and meta-analysis comparing robotic and laparoscopic surgery. Included studies checked.
Ohtani, H., Tamamori, Y., Azuma, T., Mori, Y., Nishiguchi, Y., Maeda, K., Hirakawa, K., A Meta-analysis of the Short- and Long-Term Results of Randomized Controlled Trials That Compared Laparoscopy-Assisted and Conventional Open Surgery for Rectal Cancer, Journal of Gastrointestinal Surgery, 15, 1375-1385, 2011	Systematic review of laparoscopic versus open rectal surgery, all included studies checked for relevance but not all studies are relevant to our review according to protocol.
Pai, A., Marecik, S. J., Park, J. J., Melich, G., Sulo, S., Prasad, L. M., Oncologic and Clinicopathologic Outcomes of Robot-Assisted	No comparison group.



Total Mesorectal Excision for Rectal Cancer, Diseases of the Colon & Rectum/Dis Colon Rectum, 58, 659-67, 2015	
Pan, R., Zheng, S., Cai, W., Wang, Z., Zheng, M., Retrospective study on the effect of laparoscopic and open total mesorectal excision for middle/low T3 rectal cancer, International Journal of Clinical and Experimental Medicine, 9, 21708-21715, 2016	A non-randomised study comparing laparoscopic and open surgery.
Pan, Yf, Zhang, Xh, Jia, Xj, Qu, Jm, Xiang, Yq, Yang, K, Lin, Br, Zheng, Xf, Zheng, J, Laparoscopic abdominoperineal resection for low rectal cancer, Zhonghua wei chang wai ke za zhi [Chinese journal of gastrointestinal surgery], 10, 253-256, 2007	Full text in Chinese.
Park, I. J., Choi, G. S., Lim, K. H., Kang, B. M., Jun, S. H., Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection, Surgical Endoscopy, 23, 1818-24, 2009	A non-randomised study comparing laparoscopic and open surgery.
Park, J. S., Choi, G. S., Jun, S. H., Hasegawa, S., Sakai, Y., Laparoscopic versus open intersphincteric resection and coloanal anastomosis for low rectal cancer: Intermediate-term oncologic outcomes, Annals of Surgery, 254, 941-946, 2011	A non-randomised study comparing laparoscopic and open surgery.
Park, J. S., Choi, G. S., Jun, S. H., Park, S. Y., Kim, H. J., Long-term outcomes after laparoscopic surgery versus open surgery for rectal cancer: A propensity score analysis, Annals of Surgical Oncology, 20, 2633-2640, 2013	A non-randomised study comparing laparoscopic and open surgery.
Park, J. S., Choi, G. S., Lim, K. H., Jang, Y. S., Jun, S. H., S052: a comparison of robot-assisted, laparoscopic, and open surgery in the treatment of rectal cancer, Surgical Endoscopy, 25, 240-8, 2011	Population not according to protocol: people with T3-4 or TxN cancer are a minority in this study.
Park, J. S., Kang, S. B., Kim, D. W., Lee, K. H., Kim, Y. H., Laparoscopic versus open resection without splenic flexure mobilization for the treatment of rectum and sigmoid cancer: a study from a single institution that selectively used splenic flexure mobilization, Surgical Laparoscopy, Endoscopy & Percutaneous Techniques, 19, 62-8, 2009	A non-randomised study comparing laparoscopic and open surgery.
Park, J. S., Kim, N. K., Kim, S. H., Lee, K. Y., Lee, K. Y., Shin, J. Y., Kim, C. N., Choi, G. S., Korean Laparoscopic Colorectal Surgery Study, Group, Multicentre study of robotic intersphincteric resection for low rectal cancer, British Journal of Surgery, 102, 1567-73, 2015	Population not according to the protocol: >40% of people in one arm outside the population defined in the protocol (T3-4 or N , M0).
Park, Js, Kim, Nk, Kim, Sh, Lee, Ky, Sin, Jy, Kim, Cn, Choi, Gs, Kim, Hj, Long-term results: of robotic intersphincteric resection with coloanal anastomosis for low rectal cancer-the Korean laparoscopic colorectal surgery study group, Surgical endoscopy and other interventional techniques., 30, S33, 2016	A conference abstract.

Pasupathy, S., Eu, K. W., Ho, Y. H., Seow-Choen, F., A comparison between open versus laparoscopic assisted colonic pouches for rectal cancer, <i>Techniques in Coloproctology</i> , 5, 19-22, 2001	A non-randomised study comparing laparoscopic and open surgery.
Patankar, S. K., Larach, S. W., Ferrara, A., Williamson, P. R., Gallagher, J. T., DeJesus, S., Narayanan, S., Prospective comparison of laparoscopic vs. open resections for colorectal adenocarcinoma over a ten-year period, <i>Diseases of the Colon and Rectum</i> , 46, 601-611, 2003	A non-randomised study comparing laparoscopic and open surgery.
Patel, C. B., Ragupathi, M., Ramos-Valadez, D. I., Haas, E. M., A three-arm (laparoscopic, hand-assisted, and robotic) matched-case analysis of intraoperative and postoperative outcomes in minimally invasive colorectal surgery, <i>Dis Colon Rectum</i> , 54, 144-50, 2011	Population not relevant: mostly people with benign rectosigmoid tumours.
Patriti, A., Ceccarelli, G., Bartoli, A., Spaziani, A., Biancafarina, A., Casciola, L., Short- and medium-term outcome of robot-assisted and traditional laparoscopic rectal resection, <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 13, 176-83, 2009	Non-randomised study comparing robotic versus laparoscopic surgery. RCT evidence is available for critical outcomes, apart from overall survival, therefore, data from non-randomised studies will only be considered for overall survival. This study does not report overall survival. Population not according to protocol: 46% in one arm with stage I rectal cancer.
Pechlivanides, G., Gouvas, N., Tsiaoussis, J., Tzortzinis, A., Tzardi, M., Moutafidis, M., Dervenis, C., Xynos, E., Lymph node clearance after total mesorectal excision for rectal cancer: laparoscopic versus open approach, <i>Digestive Diseases</i> , 25, 94-9, 2007	No relevant outcomes.
Pedziwiatr, M., Malczak, P., Mizera, M., Witowski, J., Torbicz, G., Major, P., Pisarska, M., Wysocki, M., Budzynski, A., There is no difference in outcome between laparoscopic and open surgery for rectal cancer: a systematic review and meta-analysis on short- and long-term oncologic outcomes, <i>Techniques in Coloproctology</i> , 21, 595-604, 2017	Systematic review and meta-analysis comparing laparoscopic and open rectal surgery. More studies are included in our review.
Perdawood, S. K., Al Khefagie, G. A. A., Transanal vs laparoscopic total mesorectal excision for rectal cancer: Initial experience from Denmark, <i>Colorectal Disease</i> , 18, 51-58, 2016	Non-randomised study comparing TaTME to laparoscopic surgery. Evidence on critical outcomes already available from a RCT.
Popescu, I., Vasilescu, C., Tomulescu, V., Vasile, S., Sgarbura, O., The minimally invasive approach, laparoscopic and robotic, in rectal resection for cancer. A single center experience, <i>Acta chirurgica Iugoslavica</i> , 57, 29-35, 2010	Population not according to protocol: around 40% of participants with stage 0-I rectal cancer.
Prytz M, Ledebø A, Angenete E, Bock D, Haglind E. Association between operative technique and intrusive thoughts on health-related Quality of Life 3 years after APE/ELAPE for rectal cancer: results from a national Swedish cohort with comparison with normative Swedish data. <i>Cancer Med.</i> 2018;7(6):2727-35.	Wrong comparison
Rasulov, Ao, Mamedli, Zz, Dzhumabaev, Ke, Kulushev, Vm, Kozlov, Na, Total mesorectal excision in rectal cancer management:	Full text not in English.

laparoscopic or transanal?, <i>Khirurgiia</i> , 37-44, 2016	
Rickert, A., Herrle, F., Doyon, F., Post, S., Kienle, P., Influence of conversion on the perioperative and oncologic outcomes of laparoscopic resection for rectal cancer compared with primarily open resection, <i>Surgical Endoscopy and Other Interventional Techniques</i> , 27, 4675-4683, 2013	A non-randomised study comparing laparoscopic and open surgery.
Sajid, M. S., Ahamd, A., Miles, W. F., Baig, M. K., Systematic review of oncological outcomes following laparoscopic vs open total mesorectal excision, <i>World Journal of Gastrointestinal Endoscopy</i> , 6, 209-19, 2014	Systematic review of laparoscopic versus open rectal surgery, all included studies checked for relevance but not all studies are relevant to our review according to protocol.
Saklani, A. P., Lim, D. R., Hur, H., Min, B. S., Baik, S. H., Lee, K. Y., Kim, N. K., Robotic versus laparoscopic surgery for mid-low rectal cancer after neoadjuvant chemoradiation therapy: Comparison of oncologic outcomes, <i>International Journal of Colorectal Disease</i> , 28, 1689-1698, 2013	Population not according to protocol: 46% in one arm with stage 0-I rectal cancer.
Sambasivan, C. N., Deveney, K. E., Morris, K. T., Oncologic outcomes after resection of rectal cancer: Laparoscopic versus open approach, <i>American Journal of Surgery</i> , 199, 599-603, 2010	A non-randomised study comparing laparoscopic and open surgery.
Schmidt, C. E., Bestmann, B., Kuchler, T., Longo, W. E., Kremer, B., Ten-year historic cohort of quality of life and sexuality in patients with rectal cancer, <i>Diseases of the Colon and Rectum</i> , 48, 483-492, 2005	A non-randomised study comparing laparoscopic and open surgery.
Schwandner, O., Schiedeck, T. H. K., Killaitis, C., Bruch, H. P., A case-control-study comparing laparoscopic versus open surgery for rectosigmoidal and rectal cancer, <i>International Journal of Colorectal Disease</i> , 14, 158-163, 1999	A non-randomised study comparing laparoscopic and open surgery.
Serin, K. R., Gultekin, F. A., Batman, B., Ay, S., Kapran, Y., Saglam, S., Asoglu, O., Robotic versus laparoscopic surgery for mid or low rectal cancer in male patients after neoadjuvant chemoradiation therapy: comparison of short-term outcomes, <i>Journal of robotic surgery</i> , 9, 187-194, 2015	Non-randomised study comparing robotic versus laparoscopic surgery. RCT evidence is available for critical outcomes, apart from overall survival, therefore, data from non-randomised studies will only be considered for overall survival. This study does not report overall survival.
Serra-Aracil X, Pericay C, Golda T, Mora L, Targarona E, Delgado S, et al. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2-T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME). <i>Int J Colorectal Dis.</i> 2018;33(2):241-9.	Wrong comparison (compares local excision with total mesorectal excision)
Seshadri RA, Swaminathan R, Srinivasan A. Laparoscopic versus open surgery for rectal cancer after neoadjuvant chemoradiation: Long-term outcomes of a propensity score matched study. <i>J Surg Oncol.</i> 2018;117(3):506-13.	A non-randomised study comparing laparoscopic and open surgery.
Seshadri, R. A., Srinivasan, A., Tapkire, R., Swaminathan, R., Laparoscopic versus open	A non-randomised study comparing laparoscopic and open surgery.

surgery for rectal cancer after neoadjuvant chemoradiation: a matched case-control study of short-term outcomes, <i>Surgical Endoscopy</i> , 26, 154-61, 2012	
Shiomi, A., Kinugasa, Y., Yamaguchi, T., Kagawa, H., Yamakawa, Y., Robot-assisted versus laparoscopic surgery for lower rectal cancer: the impact of visceral obesity on surgical outcomes, <i>International Journal of Colorectal Disease</i> , 31, 1701-1710, 2016	Population not according to protocol: only 25-30% with T3-4 tumour and <20% with N .
Sikorszki, L., Temesi, R., Liptay-Wagner, P., Bezsilla, J., Botos, A., Vereczkei, A., Horvath, O. P., Case-matched comparison of short and middle term survival after laparoscopic versus open rectal and rectosigmoid cancer surgery, <i>European Surgery - Acta Chirurgica Austriaca</i> , 47, 303-311, 2015	A non-randomised study comparing laparoscopic and open surgery.
Simillis C, Lal N, Thoukididou SN, Kontovounisios C, Smith JJ, Hompes R, et al. Open Versus Laparoscopic Versus Robotic Versus Transanal Mesorectal Excision for Rectal Cancer: A Systematic Review and Network Meta-analysis. <i>Annals of surgery</i> . 2019.	A systematic review comparing laparoscopic and open surgery. Included studies checked
Sindhu, R. S. N., Natesh, B., Rajan, R., Shanavas, K., Sukumaran, G., Gayathri, L. K., Low-tie IMA and selective D3 lymph node sampling in laparoscopic rectal resection for carcinoma rectum: Comparison of surgical and oncological outcomes with the open technique, <i>Journal of Gastrointestinal Oncology</i> , 8, 850-857, 2017	A non-randomised study comparing laparoscopic and open surgery.
Sinukumar, S., Mehta, S., Ostwal, V., Jatal, S., Saklani, A., Impact of type of surgery (laparoscopic versus open) on the time to initiation of adjuvant chemotherapy in operable rectal cancers, <i>Indian Journal of Gastroenterology</i> , 34, 310-3, 2015	A non-randomised study comparing laparoscopic and open surgery.
Spiegel DY, Boyer MJ, Hong JC, Williams CD, Kelley MJ, Moore H, et al. Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration. <i>Int J Radiat Oncol Biol Phys</i> . 2019;103(3):565-73.	Wrong comparison (non-operative management)
Spinoglio, G., Summa, M., Priora, F., Quarati, R., Testa, S., Robotic colorectal surgery: First 50 cases experience, <i>Diseases of the Colon and Rectum</i> , 51, 1627-1632, 2008	Population includes both colonic and rectal tumours and results are not stratified. Large proportion of participants with stage I cancer.
Stamopoulos, P., Theodoropoulos, G. E., Papailiou, J., Savidis, D., Golemati, C., Bramis, K., Panoussopoulos, S. G., Leandros, E., Prospective evaluation of sexual function after open and laparoscopic surgery for rectal cancer, <i>Surgical Endoscopy</i> , 23, 2665-74, 2009	A non-randomised study comparing laparoscopic and open surgery.
Steele, S. R., Randomized clinical trial comparing laparoscopic and open surgery in patients with rectal cancer, <i>Diseases of the Colon and Rectum</i> , 53, 369, 2010	A conference abstract.

Stewart, D. B., Hollenbeak, C., Boltz, M., Laparoscopic and Open Abdominoperineal Resection for Cancer: How Patient Selection and Complications Differ by Approach, <i>Journal of Gastrointestinal Surgery</i> , 15, 1928-1938, 2011	A non-randomised study comparing laparoscopic and open surgery.
Strohlein, M. A., Grutzner, K. U., Jauch, K. W., Heiss, M. M., Comparison of laparoscopic vs. open access surgery in patients with rectal cancer: A prospective analysis, <i>Diseases of the Colon and Rectum</i> , 51, 385-391, 2008	A non-randomised study comparing laparoscopic and open surgery.
Tajima, T., Mukai, M., Noguchi, W., Higami, S., Uda, S., Yamamoto, S., Hasegawa, S., Nomura, E., Sadahiro, S., Yasuda, S., Makuuchi, H., Comparison of hand-assisted laparoscopic surgery and conventional laparotomy for rectal cancer: Interim results from a single center, <i>Molecular and Clinical Oncology</i> , 3, 533-538, 2015	A non-randomised study comparing laparoscopic and open surgery.
Takiyama H, Kawai K, Ishihara S, Yasuda K, Otani K, Nishikawa T, et al. Different Impacts of Preoperative Radiotherapy and Chemoradiotherapy on Oncological Outcomes in Patients with Stages II and III Lower Rectal Cancer: A Propensity Score Analysis. <i>Dig Surg</i> . 2018;35(3):212-9.	Wrong comparison (compares preoperative radiotherapy and chemoradiotherapy)
Tan, K. K., Chong, C. S., Tsang, C. B., Koh, D. C., Outcomes following surgery for distal rectal cancers: A comparison between laparoscopic and open abdomino-perineal resection, <i>Medical Journal of Malaysia</i> , 68, 348-352, 2013	A non-randomised study comparing laparoscopic and open surgery.
Tang, C. L., Eu, K. W., Tai, B. C., Soh, J. G., MacHin, D., Seow-Choen, F., Randomized clinical trial of the effect of open versus laparoscopically assisted colectomy on systemic immunity in patients with colorectal cancer, <i>Br J Surg</i> , 88, 801-7, 2001	This trial includes both colon and rectal cancers. No relevant outcomes reported stratified by colon/rectum.
Taylor, G. W., Jayne, D. G., Brown, S. R., Thorpe, H., Brown, J. M., Dewberry, S. C., Parker, M. C., Guillou, P. J., Adhesions and incisional hernias following laparoscopic versus open surgery for colorectal cancer in the CLASICC trial, <i>Br J Surg</i> , 97, 70-8, 2010	No relevant outcomes presented.
Tjandra, J. J., Chan, M. K. Y., Yeh, C. H., Laparoscopic- vs. hand-assisted ultralow anterior resection: A prospective study, <i>Diseases of the Colon and Rectum</i> , 51, 26-31, 2008	A non-randomised study comparing laparoscopic and open surgery.
Vaughan-Shaw, P. G., Cheung, T., Knight, J. S., Nichols, P. H., Pilkington, S. A., Mirnezami, A. H., A prospective case-control study of extralevator abdominoperineal excision (ELAPE) of the rectum versus conventional laparoscopic and open abdominoperineal excision: Comparative analysis of short-term outcomes and quality of life, <i>Techniques in Coloproctology</i> , 16, 355-362, 2012	A non-randomised study comparing laparoscopic and open surgery.
Veenhof, A. A. F. A., Engel, A. F., Craanen, M. E., Meijer, S., De Lange-De Klerk, E. S. M., Van	A non-randomised study comparing laparoscopic and open surgery.

Der Peet, D. L., Meijerink, W. J. H. J., Cuesta, M. A., Laparoscopic versus open total mesorectal excision: A comparative study on short-term outcomes: A single-institution experience regarding anterior resections and abdominoperineal resections, <i>Digestive Surgery</i> , 24, 367-374, 2007	
Veenhof, A. A. F. A., Sietses, C., Von Blomberg, B. M. E., Van Hoogstraten, I. M. W., Vd Pas, M. H. G. M., Meijerink, W. J. H. J., Vd Peet, D. L., Vd Tol, M. P., Bonjer, H. J., Cuesta, M. A., The surgical stress response and postoperative immune function after laparoscopic or conventional total mesorectal excision in rectal cancer: A randomized trial, <i>International Journal of Colorectal Disease</i> , 26, 53-59, 2011	A sub-study of the COLOR II trial. No relevant outcomes reported.
Veltcamp Helbach M, Koedam TWA, Knol JJ, Velthuis S, Bonjer HJ, Tuynman JB, et al. Quality of life after rectal cancer surgery: differences between laparoscopic and transanal total mesorectal excision. <i>Surg Endosc</i> . 2019;33(1):79-87.	A non-randomised study comparing laparoscopic and transanal total mesorectal excision.
Velthuis, S., Nieuwenhuis, D. H., Ruijter, T. E., Cuesta, M. A., Bonjer, H. J., Sietses, C., Transanal versus traditional laparoscopic total mesorectal excision for rectal carcinoma, <i>Surgical Endoscopy</i> , 28, 3494-9, 2014	Non-randomised study comparing TaTME to laparoscopic surgery. Evidence on critical outcomes already available from a RCT. Population not according to protocol: Around half of participants with T1-2 and more than half with N0, T4 were excluded.
Vennix, S., Pelzers, L., Bouvy, N., Beets, G. L., Pierie, J. P., Wiggers, T., Breukink, S., Laparoscopic versus open total mesorectal excision for rectal cancer, <i>The Cochrane database of systematic reviews</i> , 4, CD005200, 2014	Systematic review of laparoscopic versus open rectal surgery, all included studies checked for relevance but not all studies are relevant to our review according to protocol.
Wang F, Fan W, Peng J, Lu Z, Pan Z, Li L, et al. Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial. <i>Cancer Commun (Lond)</i> . 2018;38(1):73.	Wrong comparison (compares any preoperative therapy with surgery alone)
Wang X, Zheng B, Lu X, Bai R, Feng L, Wang Q, et al. Preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer: Meta-analysis with trial sequential analysis of long-term survival data. <i>PLoS One</i> . 2018;13(7):e0200142.	Wrong comparison (a systematic review of short course radiotherapy with long course radiotherapy)
Wang, Y. W., Huang, L. Y., Song, C. L., Zhuo, C. H., Shi, D. B., Cai, G. X., Xu, Y., Cai, S. J., Li, X. X., Laparoscopic vs open abdominoperineal resection in the multimodality management of low rectal cancers, <i>World Journal of Gastroenterology</i> , 21, 10174-10183, 2015	A non-randomised study comparing laparoscopic and open surgery.
Wang, Z., Zhang, X. M., Liang, J. W., Hu, J. J., Zeng, W. G., Zhou, Z. X., Evaluation of short-term outcomes after laparoscopically assisted abdominoperineal resection for low rectal cancer, <i>ANZ journal of surgery</i> , 84, 842-846, 2014	A non-randomised study comparing laparoscopic and open surgery.

Westerholm, J., Garcia-Osogobio, S., Farrokhyar, F., Cadeddu, M., Anvari, M., Midterm outcomes of laparoscopic surgery for rectal cancer, <i>Surgical Innovation</i> , 19, 81-88, 2012	A non-randomised study comparing laparoscopic and open surgery.
Wu QB, Deng XB, Zhang XB, Kong LH, Zhou ZG. & Wang ZQ. Short-Term and Long-Term Outcomes of Laparoscopic Versus Open Surgery for Low Rectal Cancer. <i>J Laparoendosc Adv Surg Tech A</i> , 2018, 28, 637-644.	A non-randomised study comparing laparoscopic and open surgery.
Wu, Y., Sun, X., Qi, J., Wei, G., Cui, F., Gao, Q., Yu, J., Wang, K., Zheng, J., Comparative study of short-and long-term outcomes of laparoscopic-assisted versus open rectal cancer resection during and after the learning curve period, <i>Medicine (United States)</i> , 96 (19) (no pagination), 2017	A non-randomised study comparing laparoscopic and open surgery.
Xanthis A, Greenberg D, Jha B, Olafimihan O, Miller R, Fearnhead N, et al. Local recurrence after 'standard' abdominoperineal resection: do we really need ELAPE? <i>Ann R Coll Surg Engl</i> . 2018;100(2):111-5.	Wrong intervention
Xiao, J., Teng, W. H., Liu, S., Wei, C., Liu, W. J., Chen, S., Zang, W. D. Short-course radiotherapy with delayed surgery versus conventional chemoradiotherapy: Comparison of short-term outcomes in patients with rectal cancer. 2018	Wrong comparison
Xiong, B., Ma, L., Huang, W., Zhao, Q., Cheng, Y., Liu, J., Robotic versus laparoscopic total mesorectal excision for rectal cancer: a meta-analysis of eight studies, <i>Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract</i> , 19, 516-526, 2015	Systematic review of robotic versus laparoscopic rectal surgery, not all studies are relevant to our review according protocol.
Xiong, B., Ma, L., Zhang, C., Cheng, Y., Robotic versus laparoscopic total mesorectal excision for rectal cancer: A meta-analysis, <i>Journal of Surgical Research</i> , 188, 404-414, 2014	Systematic review of robotic versus laparoscopic rectal surgery, not all studies are relevant to our review according protocol.
Xu J, Wei Y, Ren L, Feng Q, Chen J, Zhu D, et al. 482PD Robot-assisted vs laparoscopic vs open abdominoperineal resections for low rectal cancer: Short-term outcomes of a single-center prospective randomized controlled trial. <i>Annals of Oncology</i> . 2017;28(suppl_5).	A conference abstract
Yang, Y., Wang, F., Zhang, P., Shi, C., Zou, Y., Qin, H., Ma, Y., Robot-assisted versus conventional laparoscopic surgery for colorectal disease, focusing on rectal cancer: A meta-analysis, <i>Annals of Surgical Oncology</i> , 19, 3727-3736, 2012	Systematic review of TaTME versus laparoscopic rectal surgery, not all studies are relevant to our review according protocol.
Yu, J, Zhang, C, Wang, Yn, Hu, Yf, Cheng, X, Li, Gx, Laparoscopic versus open total mesorectal excision for the middle-lower rectal cancer: a clinical comparative study, <i>Zhonghua wei chang wai ke za zhi [Chinese journal of gastrointestinal surgery]</i> , 12, 573-576, 2009	A non-randomised study comparing laparoscopic and open surgery.

Zhang X, Gao Y, Dai X, Zhang H, Shang Z, Cai X, et al. Short- and long-term outcomes of transanal versus laparoscopic total mesorectal excision for mid-to-low rectal cancer: a meta-analysis. <i>Surg Endosc.</i> 2019;33(3):972-85.	Meta-analysis of transanal versus laparoscopic rectal surgery, not all studies are relevant to our review according to protocol.
Zhang X, Wu Q, Hu T, Gu C, Bi L, Wang Z. Laparoscopic Versus Conventional Open Abdominoperineal Resection for Rectal Cancer: An Updated Systematic Review and Meta-Analysis. <i>J Laparoendosc Adv Surg Tech A.</i> 2018;28(5):526-39.	Systematic review of laparoscopic versus open rectal surgery, not all studies are relevant to our review according to protocol.
Zhang, F. W., Zhou, Z. Y., Wang, H. L., Zhang, J. X., Di, B. S., Huang, W. H., Yang, K. H., Laparoscopic versus open surgery for rectal cancer: a systematic review and meta-analysis of randomized controlled trials, <i>Asian Pacific journal of cancer prevention : APJCP</i> , 15, 9985-9996, 2014	Systematic review of laparoscopic versus open rectal surgery, all included studies checked for relevance but not all studies are relevant to our review according to protocol.
Zhang, X. M., Wang, Z., Ma, S. H., Zhou, Z. X., Advantages of laparoscopic abdominoperineal resection for anastomotic recurrence of rectal cancer, <i>Asian Pacific journal of cancer prevention : APJCP</i> , 15, 4295-4299, 2014	A non-randomised study comparing laparoscopic and open surgery.
Zhao, J. K., Chen, N. Z., Zheng, J. B., He, S., Sun, X. J., Laparoscopic versus open surgery for rectal cancer: Results of a systematic review and meta-analysis on clinical efficacy, <i>Molecular and Clinical Oncology</i> , 2, 1097-1102, 2014	Systematic review of laparoscopic versus open rectal surgery, all included studies checked for relevance but not all studies are relevant to our review according to protocol.
Zheng, J., Feng, X., Yang, Z., Hu, W., Luo, Y., Li, Y., The comprehensive therapeutic effects of rectal surgery are better in laparoscopy: A systematic review and meta-analysis, <i>Oncotarget</i> , 8, 12717-12729, 2017	Systematic review of laparoscopic versus open rectal surgery including both RCTs and non-RCTs. Included RCTs checked for relevance.
Zheng, M. H., Feng, B., Hu, C. Y., Lu, A. G., Wang, M. L., Li, J. W., Hu, W. G., Zang, L., Mao, Z. H., Dong, T. T., Dong, F., Cai, W., Ma, J. J., Zong, Y. P., Li, M. K. W., Long-term outcome of laparoscopic total mesorectal excision for middle and low rectal cancer, <i>Minimally Invasive Therapy and Allied Technologies</i> , 19, 329-339, 2010	A non-randomised study comparing laparoscopic and open surgery.
Zhou, T., Zhang, G., Tian, H., Liu, Z., Xia, S., Laparoscopic rectal resection versus open rectal resection with minilaparotomy for invasive rectal cancer, <i>Journal of Gastrointestinal Oncology</i> , 5, 36-45, 2014	A non-randomised study comparing laparoscopic and open surgery.
Zhou, X., Liu, F., Lin, C., You, Q., Yang, J., Chen, W., Xu, J., Lin, J., Xu, X., Hand-assisted laparoscopic surgery compared with open resection for mid and low rectal cancer: A case-matched study with long-term follow-up, <i>World Journal of Surgical Oncology</i> , 13 (1) (no pagination), 2015	A non-randomised study comparing laparoscopic and open surgery.
Zhou, Z. X., Zhao, L. Y., Lin, T., Liu, H., Deng, H. J., Zhu, H. L., Yan, J., Li, G. X., Long-term oncologic outcomes of laparoscopic vs open surgery for stages II and III rectal cancer: A retrospective cohort study, <i>World Journal of Gastroenterology</i> , 21, 5505-5512, 2015	A non-randomised study comparing laparoscopic and open surgery.



Zhou, Z; Li, L; Shu, Y; Yu, Y; Cheng, Z; Lei, W;;  
[Laparoscopic total mesorectal excision for low  
or ultralow anterior resection of rectal cancer  
with anal sphincter preservation], Zhonghua wai  
ke za zhi [Chinese journal of surgery], 40, 899-  
901, 2007

Full text in Chinese.

## **Appendix L – Research recommendations**

### **Research recommendations for review question: What is the optimal surgical technique for rectal cancer?**

No research recommendations were made for this review question.